{"title": "Eric Winer", "author": "Eric Winer", "url": "https://www.yalemedicine.org/specialists/eric-winer", "hostname": "yalemedicine.org", "description": "Eric Winer, MD, is the Director of Yale Cancer Center, as well as President and Physician-in-Chief of the Smilow Cancer Hospital Yale New Haven Health System. An internationally renowned medical oncologist and expert in breast cancer, he has conducted clinical trials that have changed the face of the disease. His work has impacted almost all aspects of breast cancer. \"First and foremost, I'm a clinician,\" Dr. Winer says. \"I am fortunate to have been able to spend a great deal of time taking care of patients over the years. Patient care ultimately drives everything that I do professionally, and my patients have been my greatest teachers.\" Dr. Winer has long been an advocate of building teams of scientists and clinicians to accelerate progress in cancer care and research, and appreciates the wealth of experts and resources at Yale involved in this work. \"Our mission at Yale is to deliver the best cancer care today and investigate approaches to improve care in the years ahead,\" he says. Dr. Winer is the Alfred Gilman Professor of Medicine and Pharmacology and Deputy Dean of Cancer Research at Yale School of Medicine. His is also Chair of the Board for the American Society of Clinical Oncology (ASCO). For over a decade, he served as chief scientific advisor and chair of the scientific advisory board for Susan G. Komen for the Cure and is now on the scientific advisory board of the Breast Cancer Research Foundation. For the past six years he has co-led the National Cancer Institute breast cancer steering committee. Dr. Winer has published over 350 research articles, mentored many trainees, and received numerous awards for his breast cancer research. He has served as the principal investigator of a National Institutes of Health-funded SPORE in breast cancer for the last 10 years. \"I have seen the transformation of cancer care over the past three decades and look forward to even more remarkable advances over the next decade. I believe Yale will play a prominent role in cancer care and research in the coming years.\"", "sitename": "Yale Medicine", "date": "2023-08-28", "cleaned_text": "- Breast CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 1st, suite ANew Haven, CT 06511 Eric Winer, MD [Learn more about telehealth](/patient-tools/telehealth) Biography Eric Winer, MD, is the Director of Yale Cancer Center, as well as President and Physician-in-Chief of the Smilow Cancer Hospital Yale New Haven Health System. An internationally renowned medical oncologist and expert in breast cancer, he has conducted clinical trials that have changed the face of the disease. His work has impacted almost all aspects of breast cancer. \"First and foremost, I'm a clinician,\" Dr. Winer says. \"I am fortunate to have been able to spend a great deal of time taking care of patients over the years. Patient care ultimately drives everything that I do professionally, and my patients have been my greatest teachers.\" Dr. Winer has long been an advocate of building teams of scientists and clinicians to accelerate progress in cancer care and research, and appreciates the wealth of experts and resources at Yale involved in this work. \"Our mission at Yale is to deliver the best cancer care today and investigate approaches to improve care in the years ahead,\" he says. Dr. Winer is the Alfred Gilman Professor of Medicine and Pharmacology and Deputy Dean of Cancer Research at Yale School of Medicine. His is also Chair of the Board for the American Society of Clinical Oncology (ASCO). For over a decade, he served as chief scientific advisor and chair of the scientific advisory board for Susan G. Komen for the Cure and is now on the scientific advisory board of the Breast Cancer Research Foundation. For the past six years he has co-led the National Cancer Institute breast cancer steering committee. Dr. Winer has published over 350 research articles, mentored many trainees, and received numerous awards for his breast cancer research. He has served as the principal investigator of a National Institutes of Health-funded SPORE in breast cancer for the last 10 years. \"I have seen the transformation of cancer care over the past three decades and look forward to even more remarkable advances over the next decade. I believe Yale will play a prominent role in cancer care and research in the coming years.\" Titles - Alfred Gilman Professor of Pharmacology and Professor of Medicine (Medical Oncology) - Director, Yale Cancer Center - President and Physician-in-Chief, Smilow Cancer Hospital - Deputy Dean for Cancer Research, Yale School of Medicine Education & Training - Chief ResidentYale School of Medicine (1987) - InternYale School of Medicine (1984) - MDYale School of Medicine - ResidentYale School of Medicine Additional Information - William Silen Lifetime Achievement in Mentoring Award: Harvard Medical School (2022) - Jill Rose Award for Scientific Excellence: Breast Cancer Research Foundation (2019) - Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research: San Antonio Breast Cancer Symposium (2018) - AB of Internal Medicine, Medical Oncology (1989) - AB of Internal Medicine, Internal Medicine (1987) [Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Treated Trastuzumab, O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, Tung N, Krop I, Parker J, Perou C, Prat A, Winer E, Tolaney S, Mittendorf E. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. tool](http://www.ncbi.nlm.nih.gov/pubmed/37356327)Leone J, Graham B, Freedman R, Hassett M, Vallejo C, Winer E, Lin N, Tayob N. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.](https://doi.org/10.1200/jco.2023.41.16_suppl.12001)Ligibel J, Ballman K, McCall L, Goodwin P, Weiss A, Delahanty L, Alfano C, Crane T, Neuhouser M, Spears P, Hershman D, Paskett E, Hopkins J, Bernstein V, Stearns V, White J, Wadden T, Winer E, Partridge A, Carey L. Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial. Journal Of Clinical Oncology 2023, 41: 12001-12001. [DOI: 10.1200/jco.2023.41.16_suppl.12001](https://doi.org/10.1200/jco.2023.41.16_suppl.12001). - Brastianos P, Kim A, Giobbie-Hurder A, Lee E, Lin N, Overmoyer B, Wen P, Nayak L, Cohen J, Dietrich J, Heist R, Krop I, Lawrence D, Mayer E, Winer E, Shih H, Oh K, Cahill D, Gerstner E, Sullivan R. Phase II trial of pembrolizumab in patients with brain metastases. Journal Of of Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.](http://www.ncbi.nlm.nih.gov/pubmed/37194964)Weiss A, Li T, Desai N, Tung N, Poorvu P, Partridge A, Nakhlis F, Dominici L, Sinclair N, Spring L, Faggen M, Constantine M, Krop I, DeMeo M, Wrabel E, Alberti J, Chikarmane T, Tolaney S, E, Mittendorf E, Waks A. Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. Journal Of The American College Of Surgeons 2023, Publish Ahead of Print [PMID: 37194964](https://pubmed.ncbi.nlm.nih.gov/37194964), [DOI: 10.1097/xcs.0000000000000761](https://doi.org/10.1097/xcs.0000000000000761). - Tarantino P, Villacampa G, Graham Waks A, Gonzalez P, Bras\u00f3-Maristany F, Torres E, Galv\u00e1n P, Brunet L, Demeo E, S. 6P Combined analysis of the HER2DX genomic tool in adjuvant APT and 8: of 18-Gene expression with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119](https://doi.org/10.1016/j.esmoop.2023.101379)Cort\u00e9s J, Lipatov O, Im S, Gon\u00e7alves A, Lee K, Schmid P, Tamura K, Testa L, Ohtani S, Harbeck N, Loi S, Salgado R, Lunceford J, Karantza V, Mejia J, Cristescu R, Nebozhyn M, Jelinic P, Huang L, Winer E. 190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) A correlative analysis from a phase II clinical trial](https://doi.org/10.1016/j.esmoop.2023.101236)Lynce F, Bras\u00f3-Maristany F, Waks A, Gonzalez P, Villacampa G, Torres E, Galv\u00e1n P, Brunet L, Anderson L, Perou C, Parker J, Vivancos A, Dilullo M, Simon S, Winer E, inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial ESMO Open 2023, 8: 101236. [DOI: 10.1016/j.esmoop.2023.101236](https://doi.org/10.1016/j.esmoop.2023.101236). - Sella Gelber S, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Carey L, Winer E, Partridge A. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors Npj Breast Cancer D, E, D, H, De Laurentiis M, Nanda R, Iwata H, Awada A, Tan A, Sun Y, Karantza V, Wang A, Huang L, Saadatpour A, Cristescu R, Yearley J, Lunceford J, Jelinic P, Adams S. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Triple-Negative clinical T1-T2N0 human epidermal growth factor receptorpositive breast cancer: Results from two international cohorts](http://www.ncbi.nlm.nih.gov/pubmed/36951169)Weiss A, Mart\u00ednezS\u00e1ez O, Waks A, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia A, Partridge A, S, Cejalvo J, Mittendorf E, King T. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptorpositive breast cancer: Results from 1836-1845. [PMID: 36951169](https://pubmed.ncbi.nlm.nih.gov/36951169), [DOI: 10.1002/cncr.34750](https://doi.org/10.1002/cncr.34750). [Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040823)Pichardo M, Sanft A, Fayanju O, Winer E, Irwin M. Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review 10.3389/fonc.2023.1079293](https://doi.org/10.3389/fonc.2023.1079293). [Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review](http://www.ncbi.nlm.nih.gov/pubmed/36994212)Pichardo M, Sanft A, Fayanju O, Winer E, Irwin M. Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review open-label, single-arm, phase 2 APT trial](http://www.ncbi.nlm.nih.gov/pubmed/36858723)Tolaney S, Tarantino P, Graham N, Tayob N, Par\u00e8 L, Villacampa G, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo C, final 10-year analysis of the open-label, single-arm, phase 2 and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019](https://doi.org/10.1158/1538-7445.sabcs22-pd12-01)Puklin L, Li F, Cartmel B, Sanft T, Lisevick E, M, L. Abstract PD12-01: PD12-01 Impact of obesity and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019 Cancer Research 2023, 83: pd12-01-pd12-01. [DOI: 10.1158/1538-7445.sabcs22-pd12-01](https://doi.org/10.1158/1538-7445.sabcs22-pd12-01). - Tarantino P, Gupta H, Hughes M, Files J, Strauss S, Kirkner G, Feeney A, Li Y, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, MacConaill L, Lindeman N, Johnson B, Meyerson M, Kabraji S, Jeselsohn R, Qiu X, Li R, Long H, Winer E, Dillon D, Curigliano G, Cherniack A, Tolaney S, Lin N. Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast 2023, 83: her2-05-her2-05. [DOI: 10.1158/1538-7445.sabcs22-her2-05](https://doi.org/10.1158/1538-7445.sabcs22-her2-05). - Garrido-Castro A, Ngo L, Richardson Frangieh A, Mohammed-Abreu A, Hughes M, Zanudo J, Navarro J, Tarantino P, Mittendorf E, Tolaney S, King T, Winer E, Lin N, Wagle N. Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in 2023, 83: her2-10-her2-10. [DOI: 10.1158/1538-7445.sabcs22-her2-10](https://doi.org/10.1158/1538-7445.sabcs22-her2-10). [Abstract OT1-12-02: Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer](https://doi.org/10.1158/1538-7445.sabcs22-ot1-12-02)Braunstein L, Wong J, Dillon D, Chen Y, Catalano P, Cahlon O, El-Tamer M, Jimenez R, Khan A, Perez C, Punglia R, Shiloh R, Warren L, Wazer D, Wright J, Buckley E, King T, Powell S, Winer E, Bellon J. Abstract OT1-12-02: Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast and pertuzumab (THP): a correlative II trial](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-05)Waks A, Ogayo E, Par\u00e9 L, Mar\u00edn-Aguilera M, Bras\u00f3-Maristany O, Mart\u00ednez-S\u00e1ez O, Vivancos A, Villagrasa P, Tarantino P, Desai N, Guerriero J, Metzger O, Tung N, Krop I, Parker J, Perou C, Prat A, Winer E, Tolaney S, validation of the HER2DX genomic in and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial Cancer Research 2023, 83: p1-04-05-p1-04-05. [DOI: 10.1158/1538-7445.sabcs22-p1-04-05](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-05). - Gupta H, Freedman R, Hughes M, Li Y, Kirkner G, Files J, Strauss S, Garrido-Castro A, Buckley L, Barroso-Sousa R, Bychkovsky B, Tolaney S, MacConaill L, Lindeman N, Johnson B, Meyerson M, Winer E, Dillon D, Cherniack A, Lin N. Abstract P5-14-06: Tumor Genomic Landscape in Older Women with Metastatic Breast [Abstract P6-05-05: Patient-reported outcomes, perceptions, and about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC)](https://doi.org/10.1158/1538-7445.sabcs22-p6-05-05)Rosenberg S, Zheng Y, Santos K, Riley E, Meadows H, Snow C, Hughes M, Frank E, Lin N, Partridge A, Winer E, Parsons H. Abstract P6-05-05: Patient-reported outcomes, perceptions, and knowledge about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC) 10.1158/1538-7445.sabcs22-p6-05-05](https://doi.org/10.1158/1538-7445.sabcs22-p6-05-05). [Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030](https://doi.org/10.1158/1538-7445.sabcs22-pd11-06)Parsons H, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson V, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina T, Carey L, Rimawi M, Elkhanany A, Stearns V, Specht J, Burstein H, Wolff A, Winer E, Tayob N, Krop I, Golub T, Mayer E, Adalsteinsson V. Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030 Cancer Research and correlative analyses from P, Tayob N, Dang C, Yardley D, Isakoff Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Garrett A, Marcom P, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz R, Rimawi M, Abramson V, Pohlmann P, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Barroso-Sousa R, Waks A, DeMeo A, Winer E, Viale G, Hui W, Mittendorf E, Schneider B, Prat A, Krop I, Tolaney PD18-01: Adjuvant 5-year results and (HER2+) Breast 10-year analysis](https://doi.org/10.1158/1538-7445.sabcs22-pd18-02)Tolaney S, Tarantino Tayob Dang Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Barroso-Sousa R, DeMeo M, DiLullo M, Partridge E. PD18-02: Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Growth Factor Receptor 2-Positive (HER2+) Breast [Abstract PD6-08: PD6-08 Mortality risks in men with stage I-III hormone receptor-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs22-pd6-08)Leone J, Hassett M, Freedman R, Tolaney S, Graham N, Tayob N, Vallejo C, Winer E, Lin N, Leone J. Abstract PD6-08: PD6-08 Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)](https://doi.org/10.1158/1538-7445.sabcs22-pd7-03)Freedman R, Ren S, Tayob N, Gelman R, Smith K, Davis R, Pereslete A, Attaya V, Cotter C, Chen W, Santa-Maria C, Van Poznak C, Moy B, Brufsky A, Melisko O'Sullivan N, Rauf Y, Nangia J, Trapani D, Savoie J, Burns R, Wolff A, Winer E, Rimawi M, Krop I, Lin N. Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast alterations in of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis](https://doi.org/10.1158/1538-7445.sabcs22-pd7-07)Kabraji S, Li Y, Hughes M, Gupta H, Buckley L, Files J, Mohammed-Abreu A, Feeney A, Kirkner G, Patel A, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, Meyerson M, Tolaney S, Dillon D, Johnson B, Winer E, Cherniack A, Lin N. Abstract PD7-07: Somatic alterations in primary tumors of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis Cancer Research 2023, 83: pd7-07-pd7-07. [DOI: 10.1158/1538-7445.sabcs22-pd7-07](https://doi.org/10.1158/1538-7445.sabcs22-pd7-07). [Tucatinib vs Placebo, Both in and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/36454580)Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Vallejo C, Leone B, Winer E, Lin N, Hassett M. Survival in male breast cancer over the past 3 decades. Journal Of The National Cancer capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases overall survival analysis\" G, Mueller Hamilton Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Corrigendum to \"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases overall survival analysis\" Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials](http://www.ncbi.nlm.nih.gov/pubmed/36521078)Pagani O, Walley B, Fleming G, Colleoni M, L\u00e1ng I, Gomez H, Tondini C, Burstein H, Goetz M, Ciruelos E, Stearns S, Ruhstaller T, Winer E, Ruepp B, Loi S, Coates A, Gelber R, Goldhirsch A, Regan M, Francis P, Group F. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials Oncology 2022, 41: 1376-1382. Bonnefoi H, Bellet M, Bernardo A, Climent M, Martino S, Bermejo B, Burstein H, Davidson N, Geyer C, Walley B, Ingle J, Coleman R, M\u00fcller B, Le Du F, Loibl S, Winer E, Ruepp B, Loi S, Colleoni M, Coates A, Gelber R, Goldhirsch A, Regan M, Group F. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results and Immune Checkpoint Inhibitor Benefit.](http://www.ncbi.nlm.nih.gov/pubmed/35797509)Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen (ATEMPT)](http://www.ncbi.nlm.nih.gov/pubmed/36450763)Sella T, Zheng Y, Tayob N, Ruddy K, Freedman R, Dang C, Yardley D, Isakoff S, Valero V, DeMeo M, Burstein H, Winer E, Wolff A, Krop I, A, Tolaney S. Treatment discontinuation, patient-reported ) advanced/metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/36401732)Bardia A, Mayer I, Winer E, Linden H, Ma C, Parker B, Bellet M, Arteaga C, Cheeti S, Gates M, Chang C, Fredrickson J, Spoerke J, Moore H, Giltnane J, Friedman L, Chow Maneval E, Chan I, Jhaveri K. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) + /HER2 ) advanced/metastatic breast Colleoni Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart M, Wolff AC, Viale G, Gelber RD. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for metastatic HER2-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/36252998)Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET, Attaya B, Tolaney Ib study pembrolizumab in combination with emtansine for metastatic HER2-positive in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/36215125)Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, EP, Getz G, Jeselsohn R. Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, RK, Winer EP, Anders CK, NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain NU. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers](http://www.ncbi.nlm.nih.gov/pubmed/36048535)Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, HP, Park PJ, Wulf GM. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers Clinical HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up](https://doi.org/10.1016/j.annonc.2022.06.009)Loibl Bergh J, Gelber R, Restuccia E, Im Y, Huang C, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Moreno H, Bliss J, Viale G, Bines J, Piccart M. VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in Correlation of early standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)](https://doi.org/10.1016/j.annonc.2022.07.226)Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Cimino-Mathews A, Wahl R, Stearns V, Connolly R. 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026) Nagy Z, Feiglin A, Feit A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, Cornwell M, Liu W, Ors A, Mohammed H, Cejas P, Brock JB, Freedman ML, Metzger Filho O, Jeselsohn R. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast treated with a hypomethylating agent and venetoclax.](http://www.ncbi.nlm.nih.gov/pubmed/35289704)Chen EC, Liu Y, Harris CE, M, Lane AA, Vedula RS, Lindsley Copson KM, Charles A, Marty F, Neuberg D, DeAngelo DJ, Stone RM, Luskin MR, Issa NC, Garcia JS. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx](http://www.ncbi.nlm.nih.gov/pubmed/35902504)Kantor O, Burstein HJ, King TA, Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in Positive Breast Cancer Patients Enrolled in TAILORx](http://www.ncbi.nlm.nih.gov/pubmed/35900648)Kantor O, Burstein HJ, King TA, Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in AE, Ni W, Garg S, Sattler M, Azab AK, Sun J, Muz B, Sanchez D, Toure A, Stone RM, Galinsky I, Winer E, Gleim S, Gkountela S, Kedves A, Harrington E, Abrams T, Zoller T, Vaupel A, Manley P, Faller M, Chung B, Chen X, Busenhart P, Stephan C, Calkins K, Bonenfant D, W, Griffin JD. BRD9 degraders as chemosensitizers in acute leukemia and The 'ESTIMATE' tool](http://www.ncbi.nlm.nih.gov/pubmed/35841843)Leone JP, EP, Lin NU, N. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial](https://doi.org/10.1158/1538-7445.am2022-ct026)Ellis M, Anurag M, Hoog Fernandez-Martinez A, Fan C, Gibbs R, Sanati S, Vij K, Watson M, Dockter T, Hahn O, Guenther J, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Leitch A, Unzeitig G, Winer E, Weiss A, Hunt K, Partridge A, Perou C, Suman V, Ma C, Carey L. Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE Cancer Research 2022, 10.1158/1538-7445.am2022-ct026](https://doi.org/10.1158/1538-7445.am2022-ct026). Isakoff S, Winer E, Schrag D, Manz C. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/35658506)Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson Patel Howarth K, Winer EP, Lin NU, Parsons HA. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast in high-risk, hormone receptor-positive, HER2-negative breast cancer (CHiRP).](https://doi.org/10.1200/jco.2022.40.16_suppl.103)Lipsyc-Sharf M, De Bruin E, Santos K, McEwen R, Stetson D, Patel A, Kirkner G, Hughes M, Tolaney S, Krop I, Knape C, Feger U, Marsico G, Howarth K, Winer E, Lin N, Parsons H. Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast models of breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/35641483)Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ. STING agonism reprograms and overcomes resistance to PARP inhibition paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/35538105)Waks PD, Partridge AH, Sinclair N, Spring LM, Faggen M, M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, of in HER2-positive autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/35482127)Anderson KS, Erick TK, Chen M, H, Campbell M, Colson Y, Mihm M, Zakka LR, Hopper M, Barry W, Winer EP, Dranoff G, Overmoyer B. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers Breast Cancer for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust\" [Annals of Oncology 32 (2021) 1077-1082]](http://www.ncbi.nlm.nih.gov/pubmed/35487836)Piccart M, Kalinsky Barlow Poncet Cardoso F, Winer E, Sparano J. Erratum to \"Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust\" [Annals V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz M, Paplomata E, Pegram M, Slamon D, A, J, Feng W, Winer E. Aktualisierte Ergebnisse von Tucatinib versus Placebo of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial](https://doi.org/10.1200/jco.2022.40.36_suppl.360922)Chen W, Ballman K, Winer E, Openshaw T, Hahn O, Briccetti F, Irvin W, Pohlmann P, Carey L, Partridge A, Weiss A, McCall L, Matyka C, Carvan M, Holmes M. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial Journal Of Clinical Oncology 2022, 40: 360922-360922. [DOI: 10.1200/jco.2022.40.36_suppl.360922](https://doi.org/10.1200/jco.2022.40.36_suppl.360922). A, Winer in HER2+ breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/35304445)Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Leone JP, Long HW, Brown MA, Winer EP, Dillon DAR, Lin NU, Zhao JJ. p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in Dai Y, Verma A, Wang S, Mills CE, Chung M, Bergholz JS, Coy S, Lin JR, Jeselsohn R, Metzger EP, Dillon DA, Zhao JJ, Sorger PK, Santagata S. Temporal and spatial topography of cell proliferation in cancer Nature CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer New England 386: 942-950. [PMID: emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial](http://www.ncbi.nlm.nih.gov/pubmed/35173164)Barroso-Sousa SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman R, RC, M, Abramson V, Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa EP, Krop subjects adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial](https://doi.org/10.1158/1538-7445.sabcs21-gs1-07)Gnant M, Dueck A, Frantal S, Martin M, Burstein H, Greil R, Fox P, Wolff A, Chan A, Winer E, Singer C, Miller K, Colleoni M, Naughton M, Rubovszky G, Bliss J, Mayer I, Steger G, Nowecki Z, Hahn O, Wolmark N, Rugo G, Fohler H, Metzger K, Lu D, Tenner K, Fesl C, DeMichele A, Mayer E. Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS Overall survival by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal J, Stemmer S, Burris H, Yap L, Campone M, Petrakova K, Winer E, Janni W, Conte P, Cameron D, Andr\u00e9 F, Arteaga C, Zarate J, Chakravartty A, Taran T, Gac F, Serra P, Hortobagyi G. Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials](https://doi.org/10.1158/1538-7445.sabcs21-gs2-05)Regan M, Walley B, Fleming G, Francis P, Colleoni M, L\u00e1ng I, G\u00f3mez H, Tondini C, Burstein S, Ruhstaller T, Winer E, Ruepp B, Loi S, Coates A, Goldhirsch A, Gelber R, Pagani O. Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials 2022, 82: gs2-05-gs2-05. [DOI: for patients with hypermutated her2-negative metastatic breast (MBC)](https://doi.org/10.1158/1538-7445.sabcs21-gs2-10)Barroso-Sousa Li L, Overmoyer B, Lange P, Dilullo J, E, Tayob N, Tolaney S. Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated of expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with Hether J, Tolaney S, Krop I, Divakar P, Metzger O, O'Donnell M, Church S, Winer E, Guerriero J, Mittendorf E. Abstract P2-07-03: Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients and non-BCSM in patients with triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p2-10-01)Leone J, Graham N, Leone J, Tolaney S, Leone B, Freedman R, Hassett M, Vallejo C, Winer E, Lin N, Tayob N. Abstract P2-10-01: Estimating risk of breast cancer-specific mortality (BCSM) and non-BCSM in patients with patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis](https://doi.org/10.1158/1538-7445.sabcs21-p2-13-02)Weiss A, Waks A, Laws A, Tolaney S, Winer E, E, Partridge A, King T. Abstract P2-13-02: Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution p2-13-02-p2-13-02. [DOI: or without nivolumab in metastatic triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p2-14-18)Garrido-Castro A, Graham N, Bi K, Park J, Fu J, Keenan T, Richardson E, Pastorello R, Lange P, Attaya V, Wesolowski R, Sinclair N, Lucas Z, Lo S, Tung N, Faggen M, Kaufman P, Block C, Briccetti F, Toke M, Chen W, Wucherpfennig K, Marx S, Tian Y, Agudo J, Guerriero J, Schnitt S, Lin N, Winer E, Mittendorf E, Tayob N, Van Allen E, Tolaney S. Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic in metastatic triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p3-08-01)Santos K, Jin Q, Miller P, Patel A, Kirkner G, Files J, Hughes M, Stokes S, Tayob N, Stover D, Gibson C, Winer E, Lin N, Garber J, Parsons H. Abstract P3-08-01: Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple Cancer Research breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial](https://doi.org/10.1158/1538-7445.sabcs21-p3-18-05)Weiss A, Li T, Desai N, Tung N, Tayob N, King T, Winer E, Mittendorf E, Waks A. Abstract P3-18-05: Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (CDK4/6i)](https://doi.org/10.1158/1538-7445.sabcs21-p4-01-06)Zanudo J, Barroso-Sousa Jain Tayob N, Rees R, Pereslete A, Ferreira A, Abravanel A, S. Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) dimensional flow cytometric analysis or the peripheral immune profile and response to HER2-targeted antibody therapy](https://doi.org/10.1158/1538-7445.sabcs21-p5-13-15)Ogayo E, Waks A, Rogers W, Ionita M, Adigwe K, Alberti J, Kadel S, Moore J, King T, Krop I, Tolaney S, Winer E, Guerriero J, Mittendorf E. Abstract P5-13-15: High dimensional flow cytometric analysis or the peripheral immune profile and response to HER2-targeted antibody therapy Cancer Research PD13-10: Extended adjuvant endocrine in a longitudinal cohort of young breast cancer survivors](https://doi.org/10.1158/1538-7445.sabcs21-pd13-10)Sella T, Zheng Y, Rosenberg S, Ruddy K, Gelber S, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Carey L, Winer E, Partridge A. Abstract PD13-10: Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors Cancer Research 2022, 82: pd13-10-pd13-10. [DOI: 10.1158/1538-7445.sabcs21-pd13-10](https://doi.org/10.1158/1538-7445.sabcs21-pd13-10). [Abstract placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)](https://doi.org/10.1158/1538-7445.sabcs21-pd4-04)Lin N, Murthy Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer deruxtecan in breast cancer brain metastases (BCBM)](https://doi.org/10.1158/1538-7445.sabcs21-pd4-05)Kabraji S, Ni J, Sammons S, Van Swearingen A, Wang Y, Pereslete A, Hsu L, Lascola C, Moore H, Hughes M, Raghavendra A, Gule-Monroe M, Murthy R, Winer E, Anders C, Zhao J, Lin N. Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast patients enrolled the TAILORx trial](https://doi.org/10.1158/1538-7445.sabcs21-pd9-01)Kantor O, Burstein H, King T, Shak S, Russell Giuliano A, Hortobagyi G, Winer E, L, Sparano hormone-receptor positive patients of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)](https://doi.org/10.1158/1538-7445.sabcs21-pd9-03)Ma C, Anurag M, Dockter T, Hoog J, Fernandez-Martinez A, Fan C, Gibbs R, Sanati S, Vij K, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Leitch A, Unzeitig G, Weiss A, Winer E, Hunt K, Partridge A, Carey L, Perou C, Ellis M, Suman V. Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial Research 2022, with Advanced Triple-Negative Breast CancerAlpelisib plus Olaparib for Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/35149538)Batalini UA, GM, Mayer EL. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerAlpelisib plus Olaparib for Triple-Negative oncologists toward biospecimen donation in the setting of abnormal breast imaging findings](http://www.ncbi.nlm.nih.gov/pubmed/35066788)Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Winer EP, Silverman SG, Come SE, Lin NU. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings Breast Cancer Research And Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Combination with Fulvestrant HER2-Mutated, Breast CancerNeratinib and Fulvestrant C, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant HER2-Mutated, Non-amplified Metastatic Breast CancerNeratinib and CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).](http://www.ncbi.nlm.nih.gov/pubmed/34995105)Mayer Fesl C, Hlauschek D, N, Wette V, KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz Lu DR, Dueck A, Gnant M, DeMichele A. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34990776)Bellon JR, Tayob N, Yang SM. and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer International Journal Of Radiation for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis](http://www.ncbi.nlm.nih.gov/pubmed/34954044)Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention](http://www.ncbi.nlm.nih.gov/pubmed/34932888)Delahanty LM, Wadden TA, Goodwin PJ, Alfano CM, Thomson CA, Irwin ML, Neuhouser ML, Crane TE, Frank E, Spears PA, Gillis BP, Hershman DL, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hudis C, Winer EP, Carey L, Partridge AH, Ligibel JA. The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle Winer E, Schnitt S, Hamilton E, Hurvitz S, Rugo H, Curigliano G, Tolaney S. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study](http://www.ncbi.nlm.nih.gov/pubmed/34890214)Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Pertuzumab Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, JM, Mayer Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, HS, KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Chemotherapy Response in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34849445)Collier KA, Asad S, Tallman D, ER, Parsons Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer](https://doi.org/10.1016/j.ijrobp.2021.07.103)Bellon J, Tayob N, Burstein H, Partridge A, Demeo M, Tralins J, Yang D, Dang C, Isakoff S, Yardley D, Valero V, Winer E, Krop I, Tolaney S. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer International Journal Of Radiation Oncology Biology Physics 2021, 111: s34. of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery](http://www.ncbi.nlm.nih.gov/pubmed/34648061)Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, the impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery Supportive Care In Cancer 2021, 30: 2027-2036. Regimen in Patients with Early Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34472667)BarrosoSousa R, VazLuis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early metastatic N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn A, EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM)](https://doi.org/10.1093/noajnl/vdab112.034)Leone J, Tayob N, Pereslete A, Ligibel J, Parsons H, Bi W, Zhao J, Winer E, Lin N. SYST-06. PHASE II TRIAL OF PAXALISIB (GDC-0084) IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE IE. Reply to the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2) advanced breast cancer (ABC) treated with endocrine therapy (ET) \u00b1 ribociclib (RIB)](https://doi.org/10.1016/j.annonc.2021.08.2090)Hortobagyi G, Stemmer L, Campone M, Petrakova K, Winer E, Janni W, Conte P, Cameron D, Andr\u00e9 F, Arteaga C, Zarate J, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2) advanced breast cancer (ABC) treated with endocrine therapy (ET) cancer: a phase II and biomarker study](http://www.ncbi.nlm.nih.gov/pubmed/34433812)Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson III cancer: a phase II metastatic breast cancer patients with and without BRCA1/2 mutations](http://www.ncbi.nlm.nih.gov/pubmed/34417675)Xu J, Keenan TE, Overmoyer B, Tung NM, trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations Breast Cancer Research A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago Fraser Hilbers Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, C, IT, Ruddy KJ, van Asperen C, Van Weyngaert van C, van Leeuwen-Stok E, Vermeij J, Winer E, Giordano SH, Cardoso F, Bartlett JMS. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer Npj risks of breast cancerspecific mortality in the SEER registry](http://www.ncbi.nlm.nih.gov/pubmed/34231078)Leone JP, Vallejo CT, Hassett Leone BA, Winer EP, Lin NU. Correction to: Factors associated with late risks of breast cancerspecific mortality in the SEER registry Breast Cancer Research for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021](http://www.ncbi.nlm.nih.gov/pubmed/34242744)Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant Bergh J, Bonnefoi H, Morales D, Brucker S, Burstein H, Cameron D, Cardoso F, Carey L, Chua B, Ciruelos E, Colleoni M, Curigliano G, Delaloge S, Denkert P, Ejlertsen B, Fitzal F, Francis P, Galimberti V, Mahmoud H, Garber J, Gnant M, Gradishar W, Gulluoglu B, Harbeck N, Huang C, Huober J, Ilbawi A, Jiang Z, Johnston S, Lee E, Loibl S, Morrow M, Partridge A, Piccart M, Poortmans P, Prat A, Regan M, Rubio I, Rugo H, Rutgers E, Sedlmayer F, Semiglazov V, Senn H, Shao Z, Spanic T, Tesarova P, Th\u00fcrlimann B, Tjulandin S, Toi M, Trudeau M, Turner N, Luis I, Viale G, Watanabe T, Weber W, Winer E, Xu B. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer breast cancer: Barrios Di\u00e9ras V, A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. First-line metastatic triple-negative breast cancer: a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119](https://doi.org/10.1016/j.pathol.2021.06.099)Emancipator Winer E, Lipatov O, Im S, Goncalves A, Mu\u00f1oz-Couselo E, Lee K, Nowecki Z, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Hund S, Kulangara K, Karantza V, Mejia J, Ma J, Jelinic P, Huang L, Cortes J. Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative in triple-negative breast cancer and high-grade serous cancer](https://doi.org/10.1158/1538-7445.am2021-156)Batalini F, Gulhan D, Mao V, Polak M, Winer E, Mayer E, Matulonis U, Konstantinopoulos P, Park P, Wulf G. Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and inhibition in HER2+ breast cancer brain metastases](https://doi.org/10.1158/1538-7445.am2021-337)Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Long H, Brown M, Winer E, Dillon D, Lin N, Zhao J. Abstract 337: p16INK4A-deficiency predicts for response to combined HER2 and CDK4/6 inhibition in HER2+ Dai Y, Bergholz J, Coy S, Lin J, Winer E, Dillon D, Zhao J, Sorger P, Santagata S. Abstract 4: Temporal and spatial topography of cell proliferation in cancer Cancer Research 2021, 81: 4-4. [DOI: 10.1158/1538-7445.am2021-4](https://doi.org/10.1158/1538-7445.am2021-4). [Abstract CT026: A (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER](https://doi.org/10.1158/1538-7445.am2021-ct026)Ma C, Luo J, Freedman R, Pluard T, Nangia J, Lu J, Valdez-Albini F, Cobleigh M, Jones J, Lin N, Winer E, Marcom P, Thomas S, Anderson J, Haas B, Hamann K, Bryce R, Lalani A, Carey L, Goetz M, Gao F, Kimmick G, Pegram M, Ellis M, Bose R. Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic ATEMPT Trial)](http://www.ncbi.nlm.nih.gov/pubmed/34120223)Ruddy Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34097070)Rugo HS, Loi G, L, Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer Journal Of Breast Cancer (ATEMPT): A Randomized Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman R, RC, M, Abramson V, PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, in With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust](http://www.ncbi.nlm.nih.gov/pubmed/34082017)Piccart M, Kalinsky K, Gray R, Barlow W, Poncet C, Cardoso F, Winer E, Sparano J. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).](https://doi.org/10.1200/jco.2021.39.15_suppl.1043)Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Zhang C, Winer E. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without D, Dai Y, Wang S, Bergholz J, Coy S, Lin J, Jeselsohn R, Metzger O, Winer E, Dillon D, Zhao J, Sorger P, Santagata S. Temporal and spatial topography of cell proliferation in cancer. Journal Of Clinical Oncology 2021, 39: 3122-3122. Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Survival in male breast cancer (MaBC) over the past three decades. Journal (MBC).](https://doi.org/10.1200/jco.2021.39.15_suppl.tps1102)Garrido-Castro Keenan Li T, Lange P, Callahan C, Guerriero J, Tayob N, Anderson L, Stover D, Gogineni K, Carey L, E, PD-L1- metastatic Li T, Lange P, Callahan C, Guerriero J, Tayob N, Anderson L, Yam C, Daniel B, Carey L, Nanda R, Winer E, Mittendorf E, Tolaney [DOI: 10.1200/jco.2021.39.15_suppl.tps1106](https://doi.org/10.1200/jco.2021.39.15_suppl.tps1106). [ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.](https://doi.org/10.1200/jco.2021.39.15_suppl.tps597)Saji S, McArthur Ignatiadis M, Bailey El-Abed S, Brandao M, Metzger O, Lai C, Guillaume E, Gelber R, Piccart-Gebhart M. ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast 10.1200/jco.2021.39.15_suppl.tps597](https://doi.org/10.1200/jco.2021.39.15_suppl.tps597). Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. Journal Of The National S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai ST, Verschraegen DG. Genomic features of rapid versus late relapse in for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0](http://www.ncbi.nlm.nih.gov/pubmed/34003702)Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0 Journal Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33999652)Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Rosovsky R, PiperVallillo A, Gao R, Freeman H, Kirkner Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab](http://www.ncbi.nlm.nih.gov/pubmed/33941592)Filho OM, Viale G, Stein S, Trippa L, Yardley F, Winer EP, Krop IE. of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)](https://doi.org/10.1016/j.annonc.2021.03.056)Metzger O, Lambertini C, Krop I, Phillips G, Perou C, Symmans F, Melero I, Harbeck N, Winer E, Im S, Barrios C, Bonnefoi H, Gralow J, Ellis P, Gianni L, Toi M, Swain S, Boulet T, Song C, de Haas S. 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast SM, Leone BA, Winer EP, Lin NU. Factors associated with late risks of breast cancer-specific mortality in the SEER registry Breast Cancer Research heterogeneity on treatment responses in HER2-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/33886505)Janiszewska M, Stein S, Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alekovi M, Trinh A, Murphy Marangoni EP, Krop I, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/33981951)Ligibel JA, Huebner L, Rugo HS, LA, Partridge AH, Hudis CA, Winer EP. Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance) Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33507222)Freedman RA, Minami CA, Winer EP, Morrow Ruddy Jagsi Lin NU, Canin Schonberg MA, Keating NL. Individualizing Surveillance Mammography for Older Patients Adjuvant endocrine therapy for pre- and postmenopausal women The Breast 2021, 56: s4-s5. [DOI: subtypes and survival in male breast cancer Breast Cancer Research Treatment 2021, of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33713742)Bellon JR, Chen YH, Rees R, Taghian JS, Punglia RS, Shiloh Warren LEG, Krishnan MS, Phillips J, Pretz J, Jimenez SM. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer International Journal Of Radiation Mu\u00f1oz-Couselo Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J, investigators K. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry](http://www.ncbi.nlm.nih.gov/pubmed/33590387)Leone JP, Leone BA, Tayob NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry Breast Cancer Research And Treatment 2021, AD, P, MR, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Jain E, Files J, Mohammed-Abreu A, Krevalin M, MacKichan C, Barry WT, Guo H, Xia D, Cerami E, Rollins BJ, MacConaill LE, Lindeman NI, Krop IE, Johnson BE, Wagle N, Winer EP, Dillon DA, Lin NU. Genomic Characterization of de novo Metastatic Breast Cancer the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Vallius B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, EM, Shapiro GI, Tolaney SM. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)](https://doi.org/10.1158/1538-7445.sabcs20-gs4-05)Ma C, Suman V, Leitch A, Sanati S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Maluf H, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Dockter T, Zujewski J, Weiss A, Hunt K, Hudis C, Winer E, Ellis M, Carey L, Partridge A. Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance 2021, 81: patients with localized (NeoSTAR)](https://doi.org/10.1158/1538-7445.sabcs20-ot-03-06)Spring L, Tolaney S, Desai N, Comander Mulvey I, E, Mittendorf E, Ellisen L, of neoadjuvant sacituzumab govitecan (IMMU-132) in patients of cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119](https://doi.org/10.1158/1538-7445.sabcs20-pd14-04)Winer E, Lipatov O, Im S, Goncalves A, Mu\u00f1oz-Couselo E, Lee K, Nowecki Z, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Hund S, Kulangara K, Karantza V, Mejia J, Ma J, Jelinic P, Huang L, Emancipator K, Cortes J. Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer and nab -paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial](https://doi.org/10.1158/1538-7445.sabcs20-pd14-05)Emens L, Molinero L, Adams S, Rugo Di\u00e9ras V, Iwata H, Barrios C, Winer E, Chang C, Chui S, Schmid P, Loi S. Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab and nab -paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 Research in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086](https://doi.org/10.1158/1538-7445.sabcs20-pd14-07)Loi S, Schmid P, Cortes J, Cescon D, Winer E, D, H, De Laurentiis Nanda Iwata Awada A, Tan A, Salgado R, Karantza V, Jelinic P, Wang A, Huang L, Cristescu R, Annamalai L, Yearley J, Yearley J, Adams S. Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)](https://doi.org/10.1158/1538-7445.sabcs20-pd2-10)Ellis M, Suman V, Leitch A, Sanati S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Maluf H, Dowsett M, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Dockter T, Zujewski J, Weiss A, Hudis C, Winer E, Hunt K, Partridge A, Ma C, Carey L. Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-pd3-05)Waks A, Desai N, Li T, Poorvu P, Partridge A, Sinclair N, Spring L, Faggen M, Constantine M, Alberti J, Deane J, Rosenberg S, Tolaney S, Krop I, Tung N, Tayob N, King T, Mittendorf E, Winer E. Abstract PD3-05: The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) samples and in cellular models](https://doi.org/10.1158/1538-7445.sabcs20-pd7-08)Wander S, Mao P, Lloyd M, Johnson G, Kowalski K, Nayar U, Guenther L, Stegmaier K, mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor 2021, 81: pd7-08-pd7-08. [DOI: metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases](https://doi.org/10.1158/1538-7445.sabcs20-ps12-01)Winer E, Lipatov O, Im S, Goncalves A, Lee K, Schmid P, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Lin J, Karantza V, Mejia J, Cortes J. Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs20-ps4-25)Barroso-Sousa R, Forman J, Weber Z, Collier K, Kao K, Richardson E, Keenan T, Cohen O, Manos M, Brennick R, Ott P, Hodi F, Dillon D, Lin N, Van Allen E, Rodig S, Winer E, Mittendorf E, Wu C, Stover D, N, Shukla S, Tolaney S. Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast tool risks of breast cancer specific mortality (BCSM) and non-BCSM](https://doi.org/10.1158/1538-7445.sabcs20-ps6-13)Leone J, Tolaney S, Leone B, Freedman R, Hassett M, Leone J, Vallejo C, Winer E, Lin N, Tayob N. Abstract PS6-13: Population-based tool to estimate residual risks of breast cancer specific mortality (BCSM) and non-BCSM Cancer Research for the treatment of metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/33585999)Lynce F, Williams JT, Regan MM, Bunnell Freedman RA, Mayer EL, Partridge AH, study of JAK1/2 inhibitor with weekly paclitaxel for the treatment of P, Winer E, Mittendorf E, King T. Utility of the 21-Gene Recurrence Score the Study](http://www.ncbi.nlm.nih.gov/pubmed/33523233)Emens V, H, Barrios EP, Adams S, Schmid nab-Paclitaxel Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study Journal Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. The global landscape of treatment standards for breast cancer Journal Of The National Cancer Institute 2021, cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study](http://www.ncbi.nlm.nih.gov/pubmed/33460574)Mayer EL, Dueck AC, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff A, Gnant M. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, EP, Come SE, Lin NU. Perceptions of patients with early stage breast cancer toward research biopsies Cancer in Breast and Colorectal Cancer: A Randomized Trial](http://www.ncbi.nlm.nih.gov/pubmed/32859615)Brown JC, Zhang S, PS, Hu FB, Fuchs CS, Meyerhardt JA. Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32988969)Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, O'Brien T, Kelly C, Winer E, Yardley D. A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer Clinical Cancer 2020, 26: 6149-6157. [PMID: 32988969](https://pubmed.ncbi.nlm.nih.gov/32988969), [DOI: 10.1158/1078-0432.ccr-20-1693](https://doi.org/10.1158/1078-0432.ccr-20-1693). - Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop Sohl J, Hu J, Kasparian E, Winer EP, Lin NU. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases Breast Cancer Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32723837)Mao Cohen MS, Exman P, Wander SA, Waks AG, Nayar U, Chung J, Freeman S, Rozenblatt-Rosen O, Miller VA, Piccioni F, Root DE, Regev A, EP, Lin NU, Wagle N. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, Meyer O, KD, Giambartolomei C, Pasaniuc C, Ellis MJ, Krop I, Winer E, Letai A, Brown M, Dawson Long HW, Zhao JJ, Goel S. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/33150547)Sella T, Gelber SI, Poorvu Borges VF, Come SE, Warner E, Snow C, Jakubowski DM, Russell CA, Winer EP, Rosenberg SM, Partridge AH. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer Breast Cancer Research 186: 157-165. AC, Saura C, Barroso-Sousa R, Guo Ciruelos E, Bermejo B, Gavil\u00e1 J, Serra V, Prat A, Par\u00e9 L, C\u00e9liz P, buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation](https://doi.org/10.1016/j.annonc.2020.10.064)Im O, Goncalves Lee K, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Zambelli S, Harbeck N, Andre F, Dent R, Lin J, Karantza V, Mejia J, Winer E. 44O Pembrolizumab (pembro) vs chemotherapy (chemo) IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer](https://doi.org/10.1016/j.annonc.2020.10.069)Iwata H, Emens L, Adams S, Barrios Di\u00e9ras V, Loi S, Rugo H, Schneeweiss A, Winer E, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Chui S, Schmid P. 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast of Cancer and Mutations in Homologous Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/33095682)Fernandez-Martinez JS, L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. of Systemic Adjuvant Therapy for Solid Tumors.](http://www.ncbi.nlm.nih.gov/pubmed/33052755)Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Na\u00eft Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber RD, Davidson NE, Norton L, Winer EP. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal Of Clinical Oncology Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32880602)Tolaney SM, Barroso-Sousa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer Krop Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone resistance to cyclin-dependent kinase 4/6 inhibitors](https://doi.org/10.1158/1557-3125.pi3k-mtor18-b23)Wander S, Cohen O, Johnson G, Buendia J, Luo F, Geradts J, Winer E, Lin N, driving resistance to cyclin-dependent kinase B24: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation](https://doi.org/10.1158/1557-3125.pi3k-mtor18-b24)Xing Y, Lin N, Mauer M, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abraham V, Litton J, Chavez-McGregor M, Valero V, Piha-Paul S, Hong D, Do K, Tarco E, Riall D, Eterovic K, Cantley L, Mills G, Doyle L, Winer E, Hortobagyi G, Gonzalez-Angulo A, Meric-Bernstam F. Abstract B24: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Molecular Cancer 2020, Saghir N, Elzayat M, Eniu A, Fallowfield PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim S, Lin NU, Mertz C, Vorobiof DA, T, B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Annals Of the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506448)Emens L, Adams S, Barrios C, Dieras Iwata H, Loi S, Rugo H, Schneeweiss A, Winer E, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Chui S, Schmid P. IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center](http://www.ncbi.nlm.nih.gov/pubmed/32939592)Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center Breast Cancer Research And Treatment 2020, 185: 215-227. [PMID: 32939592](https://pubmed.ncbi.nlm.nih.gov/32939592), [DOI: 10.1007/s10549-020-05931-9](https://doi.org/10.1007/s10549-020-05931-9). Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole MJM, Savenkov A, Carey LA, Winer EP, Rugo HS. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab Clinical outcomes among hospitalized COVID-19 patients: A case-control analysis](https://doi.org/10.1158/1557-3265.covid-19-po-063)Klein I, Rosenberg S, Kotton C, Reynolds K, Zubiri L, Gaither R, Freeman H, Kirkner G, Rhee C, Klompas M, Baker M, Wadleigh M, Winer E, Partridge A. Abstract PO-063: Impact of cancer history on outcomes among hospitalized COVID-19 patients: A case-control analysis Clinical Cancer Research 2020, 26: po-063-po-063. and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial](https://doi.org/10.1016/j.annonc.2020.08.398)Emens L, Molinero L, Adams S, Rugo V, Iwata H, Barrios C, Nechaeva M, Winer E, Chang C, Chui S, Schmid P, Loi S. Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 Annals Oncology 2020, 31: s360-s361. [DOI: adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1016/j.annonc.2020.08.2240)Mayer E, Gnant M, DeMichele A, Martin M, Burstein H, Prat A, Rubovszky G, Miller K, Pfeiler G, Winer E, Zdenkowski N, Anderson D, Nowecki C, Dueck A. PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast Annals 2020, 31: s1145. [DOI: 10.1016/j.annonc.2020.08.2240](https://doi.org/10.1016/j.annonc.2020.08.2240). [Impact of free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases](https://doi.org/10.1016/j.annonc.2020.08.395)Bachelot T, Lin N, Murthy R, Hurvitz S, Borges V, Oliveira M, Oakman C, Khan S, Lynch C, Westbrook K, Doyle C, Reinisch M, Colleoni M, Slamon D, Hortobagyi G, Winer E, McGoldrick S, An X, Loibl S. Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain Of Oncology 2020, 31: s359-s360. [DOI: 10.1016/j.annonc.2020.08.395](https://doi.org/10.1016/j.annonc.2020.08.395). [A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials](http://www.ncbi.nlm.nih.gov/pubmed/32866625)Amiri-Kordestani L, Xie D, Tolaney SM, Bloomquist E, Tang S, Ibrahim A, Goldberg KB, Theoret MR, Pazdur R, Sridhara R, Winer EP, Beaver JA. A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials Annals Of for radiotherapy omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer](https://doi.org/10.1158/1538-7445.am2020-ct271)Patel M, Dillon D, Digiovanni G, Chen Y, Catalano P, Perez C, Wazer D, Wright J, Jimenez R, Winer E, Wong J, Bellon J, Braunstein L. Abstract CT271: PRECISION (Profiling early breast cancer for radiotherapy omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast 2020, 80: ct271-ct271. versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker](http://www.ncbi.nlm.nih.gov/pubmed/32798689)Mayer Abramson V, Jankowitz R, Falkson Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski AC, versus paclitaxel in triple-negative breast cancer: evaluating the Cancer Receiving First-Line Dirix L, C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy Journal Of The National CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC CANCER WITH R, Anders Borges Loi S, Abramson V, Bedard P, Oliveira M, Zelnack A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, Mueller V, Carey L, McGoldrick S, An X, Winer E. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ CANCER (MBC) WITH Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32404308)Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu SG, Wagle N. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Reply. New Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32019858)Barroso-Sousa R, Keenan TE, Pernas S, Exman Jain E, Garrido-Castro AC, Hughes JL, Lindeman NI, EP, EA, Tolaney SM. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins Trippa DeFelice Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson VA. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Clinical Cancer Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the Borges Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial NU, Wulf GM. Response of Brain Metastases From PIK3CA-Mutant Breast Cancer Block CC, Lin NU, King TA, Muss HB, Winer EP. Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond Journal Of The National Cancer Institute combination with trastuzumab in patients with HER2-positive breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/32461105)Filho O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, Younger J, Lawler E, L, Freedman RA, Tolaney SM, Krop I, Winer EP, Lin NU. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).](https://doi.org/10.1200/jco.2020.38.15_suppl.1002)Tung N, Robson M, Ventz C, Marcom Nanda R, Shah P, Ballinger T, Yang E, Melisko M, Brufsky A, Vinayak S, Demeo M, Jenkins C, Domchek S, Wulf G, Krop I, Wolff A, Winer E, Garber J. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). Journal Of Clinical Oncology 2020, 1002-1002. [Tucatinib versus placebo added capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).](https://doi.org/10.1200/jco.2020.38.15_suppl.1005)Lin N, Murthy R, Anders C, Borges V, Hurvitz Loi S, Abramson V, Bedard P, Oliveira M, Zelnak A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, M\u00fcller V, Carey L, McGoldrick S, An G, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.](https://doi.org/10.1200/jco.2020.38.15_suppl.1013)Winer E, Lipatov O, Im S, Goncalves A, Mu\u00f1oz-Couselo E, Lee K, Schmid P, Testa L, Witzel I, Ohtani S, Lunceford J, Karantza V, Mejia J, Cristescu R, Aurora-Garg D, Jelinic P, Huang L, Cortes J. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from A, Keenan T, Li T, Tayob N, Wulf G, Richardson E, Mittendorf E, Overmoyer B, Krop I, Winer E, Van Allen E, Agudo J, Tolaney S. A Ib [DOI: 10.1200/jco.2020.38.15_suppl.1046](https://doi.org/10.1200/jco.2020.38.15_suppl.1046). Kabraji Li Y, Leone J, Garrido-Castro A, Barroso-Sousa R, Files J, Kirkner G, Johnson B, Winer E, Cherniack A, Lin N. Genomic profiling of breast cancer brain metastases reveals targetable alterations. Of Clinical [DOI: 10.1200/jco.2020.38.15_suppl.2525](https://doi.org/10.1200/jco.2020.38.15_suppl.2525). [Primary (T-DM1) versus trastuzumab + pertuzumab after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).](https://doi.org/10.1200/jco.2020.38.15_suppl.500)Harbeck N, Im S, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis P, Gianni L, Swain S, Im Y, De Laurentiis M, Nowecki Z, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer E, Krop I. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) versus trastuzumab + pertuzumab after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). Journal Neoadjuvant endocrine or III estrogen receptor-positive HER2-negative breast cancer (ER+ S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Dockter T, Korde L, Weiss A, Hunt K, Hudis C, Winer E, Partridge A, Carey L, Ellis M. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) to neoadjuvant chemotherapy and the breast recurrence score in young women with estrogen receptor-positive early breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.514)Sella T, Gelber S, Poorvu P, Kim H, Guzman Arocho Y, Collins L, Ruddy K, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Warner E, Snow C, Jakubowski D, Russell C, Winer E, Rosenberg S, Partridge A. Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer. Journal Of Clinical Oncology 2020, 514-514. [DOI: 10.1200/jco.2020.38.15_suppl.514](https://doi.org/10.1200/jco.2020.38.15_suppl.514). - Kantor Giuliano A, Hortobagyi G, Burstein H, Winer E, Sparano J, Mittendorf E. Expanding criteria for prognostic stage IA disease in HR+ breast cancer. Journal Of Oncology 2020, 38: 550-550. [DOI: 10.1200/jco.2020.38.15_suppl.550](https://doi.org/10.1200/jco.2020.38.15_suppl.550). [Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.](https://doi.org/10.1200/jco.2020.38.15_suppl.587)Leone J, Freedman R, Hassett M, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. Journal Of placebo-controlled trial of aspirin as adjuvant therapy breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.tps600)Chen W, Winer E, Ballman K, Partridge A, Carey M, Matyka C, Openshaw T, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2020, 38: tps600-tps600. Savoie Agarwal A, Guo H, Hu J, Fell G, Lederman R, Hughes ME, Winer EP, Lin NU, Tolaney SM. Barriers to Clinical Trial Accrual: Perspectives of Community-Based on health-related quality of life in patients with metastatic triple negative breast cancer](https://doi.org/10.1016/j.annonc.2020.03.242)Schmid P, Haiderali A, Mejia J, Guo Z, Zhou X, Martin-Nguyen A, Cort\u00e9s J, Winer E. 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer Annals Of Oncology 2020, 31: [DOI: capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)](https://doi.org/10.1016/j.annonc.2020.03.238)Curigliano G, Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Cameron D, Borges V, Bedard P, Oliveira M, Jakobsen E, Bachelot T, Shachar S, Mueller V, Carey L, Loibl S, Feng W, Walker L, Winer E. 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain Regimen: A Prospective Study](http://www.ncbi.nlm.nih.gov/pubmed/32330102)Vaz-Luis I, Meglio Hu J, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, O'Neil K, Partridge of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A P, Leo Viale G, Senn H, M, Curigliano G. The legacy of Professor G, Hylton N. in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).](http://www.ncbi.nlm.nih.gov/pubmed/32097092)Tung N, Arun B, Hacker Hofstatter AC, Marcom PK, Mayer EL, Lange PB, AJ, Jenkins SJ, in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/32245699)Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso NU, Shapiro GI, Wagle N. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic plus nab-paclitaxel Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)](https://doi.org/10.1158/1538-7445.sabcs19-gs1-01)Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Lin N, Borges V, Abramson V, Anders C, Bedard P, Oliveira V, Braga S, Duhoux F, Greil R, Cameron D, Carey L, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels M, Walker L, Feng W, Winer E. Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)](https://doi.org/10.1158/1538-7445.sabcs19-gs1-05)Tolaney S, Trippa L, Barry W, Hu J, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett M, Marcom K, Albain K, DeFusco P, Tung N, Ardman M, GS1-05: of adjuvant emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) Research 2020, 80: in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state](https://doi.org/10.1158/1538-7445.sabcs19-gs2-02)Cohen O, Mao P, Nayar U, Buendia-Bue J, Kim D, Jain E, Helvie K, Abravanel D, Kowalski K, Kapstad C, Freeman S, Adalsteinsson V, Wander S, Waks A, Getz G, Regev A, Winer E, Lin N, Wagle N. Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell ( BRCA carriers) with HER2-negative breast Results from the INFORM trial (TBCRC 031)](https://doi.org/10.1158/1538-7445.sabcs19-gs6-03)Tung N, Arun B, Hofstatter E, Hacker Isakoff S, Borges V, Legare R, Isaacs C, Wolff A, Marcom P, Mayer E, Lange P, Goss A, Krop I, Winer E, Schnitt S, Garber J. Abstract versus treatment ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC Research 2020, 80: gs6-03-gs6-03. [DOI: 10.1158/1538-7445.sabcs19-gs6-03](https://doi.org/10.1158/1538-7445.sabcs19-gs6-03). RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment](https://doi.org/10.1158/1538-7445.sabcs19-gs6-05)Cohen O, Abravanel D, Slyper M, Klughammer L, Frangieh A, Vigneau S, Wu J, Mayorga A, Waldman J, Nguyen L, Dionne D, Ashenberg O, Hofree M, Cuoco M, Rodman C, Winer E, Lin N, Johnson B, Rotem A, Rozenblatt-Rosen O, Regev A, Wagle N. Abstract GS6-05: A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the Research 2020, 80: gs6-05-gs6-05. [DOI: 10.1158/1538-7445.sabcs19-gs6-05](https://doi.org/10.1158/1538-7445.sabcs19-gs6-05). [Abstract II trial in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases (BCBM)](https://doi.org/10.1158/1538-7445.sabcs19-ot1-08-05)Leone J, Trippa L, Milisits L, Andrews C, Ligibel J, Parsons H, Bi W, Zhao J, Winer E, Lin N. Abstract OT1-08-05: Phase II trial of GDC-0084 in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases [DOI: 10.1158/1538-7445.sabcs19-ot1-08-05](https://doi.org/10.1158/1538-7445.sabcs19-ot1-08-05). A, Spoerke J, Zhou Guan J, Ingalla E, Young A, Hafner M, Aimi J, Chang C, Giltnane J, Gates M, Mayer I, Azaro A, Winer E, Loi S, Jhaveri K, Lauchle J, Gendreau S, Humke E, Metcalfe C. Abstract P2-11-05: ER pathway activity signature as a biomarker for (TBCRC033: ATEMPT trial)](https://doi.org/10.1158/1538-7445.sabcs19-p2-13-02)Ruddy K, Trippa L, Hu J, Barry W, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett A, Marcom P, Albain K, DeFusco P, Tung N, Ardman in combination with Clonal heterogeneity and treatment resistance in a patient with HER2+ breast cancer](https://doi.org/10.1158/1538-7445.sabcs19-p3-01-09)Buendia-Buendia J, Pernas S, Cohen O, Mao P, Kowalski K, Lin N, Winer E, Wagle N. Abstract P3-01-09: Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer Cancer Research 2020, 80: p3-01-09-p3-01-09. [DOI: 10.1158/1538-7445.sabcs19-p3-01-09](https://doi.org/10.1158/1538-7445.sabcs19-p3-01-09). [Abstract P3-09-10: A phase combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-10)Barroso-Sousa R, Trippa L, Li T, Keenan T, Winship G, Andrews C, Osmani W, Overmoyer B, Winer E, Mittendorf E, Duda D, Tolaney S. Abstract P3-09-10: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative [Abstract P3-09-16: Fecal microbiome and among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-16)de Sousa R, Ajami N, Keenan T, Andrews C, Pittenger J, Wulf G, Spring L, Krop I, Winer E, Mittendorf E, Tolaney S. Abstract P3-09-16: Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) [Abstract adavosertib Guerriero J, Tahara R, Winship G, Osmani W, Andrews C, Conway J, He M, Pastorello R, Tracy A, Godin R, Overmoyer B, Winer E, Mittendorf E, Shapiro G, Van Allen E, Tolaney S. Abstract P3-10-08: A phase II study of cisplatin and the Wee1 inhibitor adavosertib in in combination with PD-1 inhibitor hormone receptor-positive MBC) and metastatic ovarian cancer (MOC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-14-03)Herold C, Trippa L, Li T, Do K, Bardia A, Anderson L, Montazeri K, Pittenger J, Andrews C, Mittendorf E, Goel S, Winer E, Shapiro G, Tolaney S. Abstract P3-14-03: A phase 1b study of the inhibitor ribociclib in combination with PD-1 inhibitor hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic Cancer Research 2020, 80: p3-14-03-p3-14-03. [DOI: 10.1158/1538-7445.sabcs19-p3-14-03](https://doi.org/10.1158/1538-7445.sabcs19-p3-14-03). - Zhang Y, Nock W, Wyse M, Weber Z, Adams E, Sarah A, Stockard S, Tallman D, Singh J, Bae J, Winer E, Lin N, Jiang Y, Ma D, Wang P, Shi L, Huang W, Shao Z, Verschraegen C, Cherian M, Lustberg M, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Robert W, Stover D. Abstract P4-05-02: Machine learning predicts rapid relapse in triple negative breast cancer Cancer Research 2020, 80: p4-05-02-p4-05-02. [DOI: 10.1158/1538-7445.sabcs19-p4-05-02](https://doi.org/10.1158/1538-7445.sabcs19-p4-05-02). [Abstract P4-06-01: Using multi-omic complexity of triple-negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p4-06-01)Goel S, Brauer H, Ren Y, Gorman K, Osmani W, Pittenger J, Andrews C, Richardson E, Mittendorf E, PhD M, Winer E, Schnitt S, Tolaney S. Abstract P4-06-01: Using multi-omic profiling to unravel the complexity of triple-negative breast cancer Cancer [Abstract P4-10-03: genomic cancers using the oncomine comprehensive assay for actionable mutations](https://doi.org/10.1158/1538-7445.sabcs19-p4-10-03)Bayani J, Poncet C, Crozier C, Trinh Q, Hopkins M, Uwimana A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, C, Rubio I, Ruddy K, van Asperen C, Weyngaert van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Stein L, Giordano S, Cardoso F, Bartlett J. Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations Cancer Research 2020, [DOI: 10.1158/1538-7445.sabcs19-p4-10-03](https://doi.org/10.1158/1538-7445.sabcs19-p4-10-03). [Abstract P5-06-13: Factors breast cancer-specific mortality (BCSM) for locally-advanced breast cancer (LABC) in the surveillance, epidemiology, and end results (SEER) registry](https://doi.org/10.1158/1538-7445.sabcs19-p5-06-13)Leone J, Leone B, Hassett M, Leone J, Freedman R, Tolaney S, Winer E, Vallejo C, Lin N. Abstract P5-06-13: Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) for locally-advanced breast cancer (LABC) in the surveillance, epidemiology, and end results (SEER) registry Cancer Research 2020, 80: p5-06-13-p5-06-13. [DOI: and in hormone-receptor positive (HR+)/HER2- metastatic cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study](https://doi.org/10.1158/1538-7445.sabcs19-p5-11-04)Barroso-Sousa R, Li T, Trippa L, Rees R, Andrews C, Ferreira A, Helvie K, Partridge A, Overmoyer B, Winer E, Wagle N, phase study of palbociclib (PALBO) plus and in hormone-receptor positive (HR+)/HER2- metastatic cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II 80: p5-11-04-p5-11-04. breast cancer: A retrospective substudy of IMpassion130](https://doi.org/10.1158/1538-7445.sabcs19-pd1-07)Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios C, Iwata H, Di\u00e9ras V, Winer E, Kockx M, Peeters D, Chui S, Lin J, Duc A, Viale G, Molinero L, Emens L. Abstract PD1-07: breast [DOI: paclitaxel + trastuzumab (TH) A, Zheng Y, Rosenberg S, Gelber R, Gelber S, Barry W, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett M, Marcom P, Albain K, Defusco P, Tung N, Ardman M, E, Krop I, Tolaney S. Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab [Abstract PD2-09: The resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs19-pd2-09)Wander S, Cohen O, Gong X, Johnson G, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, Ye X, Yu C, Jansen V, Garraway L, Winer E, Tolaney S, Lin N, Buchanan S, Wagle N. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone 10.1158/1538-7445.sabcs19-pd2-09](https://doi.org/10.1158/1538-7445.sabcs19-pd2-09). [Abstract PD4-08: An FDA analysis of survival outcomes comparing adjuvant paclitaxel and trastuzumab trial (APT) to an external control from historical clinical trials](https://doi.org/10.1158/1538-7445.sabcs19-pd4-08)Amiri-Kordestani L, Xie D, Bloomquist E, Tang S, Pazdur R, Sridhara R, Tolaney S, Winer E, Beaver J. Abstract PD4-08: An FDA analysis of survival outcomes comparing adjuvant paclitaxel and trastuzumab trial (APT) to an external control from historical clinical trials Cancer Research 2020, 80: in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs19-pd5-03)Loi S, Winer E, Lipatov O, Im S, Goncalves A, Cortes J, Lee K, Schmid P, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Huang L, Mejia J, Karantza V, Salgado R. Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast [Abstract PD7-05: A first-in-human phase oral selective estrogen receptor degrader Fidalgo J, Bellet M, Mayer I, Boni V, Patel J, Bardia A, Garcia J, Kabos P, Gates M, Chen Y, Fredrickson J, Wang X, Friedman L, Spoerke J, Gendreau S, Metcalfe C, Liu L, Chang C, Monemi S, Gonzalez M, McCurry U, Milan S, Humke E, Loi S. Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader Morrow M, Radiotherapy for Hormone Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32113750)Barroso-Sousa Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic [DOI: 10.1016/j.clbc.2020.01.012](https://doi.org/10.1016/j.clbc.2020.01.012). Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney S, Wagle N. Prevalence and mutational determinants of high tumor mutation burden in breast cancer Of Oncology E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira Hortobagyi G, Capecitabine for HER2-Positive Metastatic [PMID: 31825569](https://pubmed.ncbi.nlm.nih.gov/31825569), With Node-Negative Borges VF, Come SE, Warner Jakubowski DM, Russell C, Winer EP, Partridge AH. Prognostic Impact of the 21-Gene Recurrence Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Reported Outcome: CALGB 40502 (Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/31802506)Sharma MR, Mehrotra S, C, Winer EP, Lyss AP, Toppmeyer B, HS, MJ, Gobburu JV. Personalized Management on a Patient Reported Outcome: CALGB 40502 (Alliance) advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial](http://www.ncbi.nlm.nih.gov/pubmed/31786121)Schmid V, Husain A, Winer EP, Loi S, Emens LA, Investigators I. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase or both on metabolic biomarkers in colorectal and breast cancer survivors](http://www.ncbi.nlm.nih.gov/pubmed/32090192)Meyerhardt JA, Irwin ML, Jones LW, Zhang S, Campbell N, Brown JC, Pollak M, Sorrentino Cartmel B, Harrigan K, Abrams T, Fuchs CS, Sanft T, Douglas PS, Hu F, Ligibel JA. Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.](http://www.ncbi.nlm.nih.gov/pubmed/32923853)Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, SM, Krop CX, DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries](https://doi.org/10.1093/annonc/mdz418)Iwata H, Im S, Sohn J, Jung K, Im Y, Lee K, Inoue K, Tamura K, Wong A, Emens L, Barrios C, Adams S, Schneeweiss A, Di\u00e9ras V, Winer E, Chui S, Henschel V, Rugo H, Loi S, Schmid P. 37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries Annals Of Oncology 30: ix13-ix14. [DOI: 10.1093/annonc/mdz418](https://doi.org/10.1093/annonc/mdz418). - Freedman RA, Winer EP. Adjuvant chemotherapy for older patients with breast cancer: When is the pain worth the gain? Journal Of The National Cancer early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019](http://www.ncbi.nlm.nih.gov/pubmed/31373601)Burstein H, Curigliano G, Loibl S, Dubsky M, Regan M, Senn H, Winer E, Thurlimann B, 2019 M. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 Annals Of phase study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer](https://doi.org/10.1093/annonc/mdz240.112)Ignatiadis M, McArthur H, Bailey A, Martinez J, de Azambuja E, Metzger O, Lai C, Franzoi M, Goulioti T, Daly F, Bouhlel A, Balta V, Maetens M, Viale G, Andr\u00e9 R, Piccart M, Winer E. 289TiP ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer Annals Of Oncology 2019, 30: v97. versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)](https://doi.org/10.1093/annonc/mdz394.010)Cort\u00e9s J, Lipatov O, Im S, Gon\u00e7alves A, Lee K, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Zambelli S, Harbeck N, Andr\u00e9 F, Dent R, Zhou X, Karantza V, Mejia J, Winer E. LBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative Of cancer (mTNBC): Post-hoc analysis of IMpassion130](https://doi.org/10.1093/annonc/mdz394.009)Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios C, Iwata H, Dieras V, Winer E, Kockx M, Peeters D, Chui S, Lin J, Duc A, Viale G, Molinero L, Emens 10.1093/annonc/mdz394.009](https://doi.org/10.1093/annonc/mdz394.009). [PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor Forero-Torres A, imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic 10.1038/s41523-019-0126-6](https://doi.org/10.1038/s41523-019-0126-6). [A phase cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/31541381)Leone JP, Duda DG, Hu J, Barry EP, NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases Breast Cancer Research And Treatment Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study](http://www.ncbi.nlm.nih.gov/pubmed/31018921)Ligibel JA, Dillon D, Giobbie-Hurder A, McTiernan A, Frank E, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney S, Chagpar AB, Yung RA, Dominici LS, Golshan M, Rhei E, Taneja K, Huang Y, Brown M, Winer EP, Jeselsohn R, Irwin ML. Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study 5398-5406. [PMID: 10.1158/1078-0432.ccr-18-3143](https://doi.org/10.1158/1078-0432.ccr-18-3143). [A phase of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/31250880)Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma 31250880](https://pubmed.ncbi.nlm.nih.gov/31250880), I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC)](https://doi.org/10.1016/j.ijrobp.2019.06.466)Bellon J, Chen Y, Rees R, Taghian A, Wong J, Punglia R, Shiloh R, Krishnan M, Andrews C, Isakoff S, Winer E, Tolaney S. A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC) International Journal Of Radiation Oncology Metastases: Translational Breast Research Consortium 022](http://www.ncbi.nlm.nih.gov/pubmed/31558424)Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Lopez B, Connolly RM, IF, Van Poznak CH, SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, Consortium T. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium of first-line ribociclib plus letrozole versus placebo plus P, Arteaga Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213424)Leone J, Trippa L, Milisits L, Andrews C, Ligibel J, Parsons H, Bi W, Zhao J, Winer E, Lin N. TRLS-03. PHASE II TRIAL OF GDC-0084 IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN Preoperative Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy Clinical PMC6677598](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677598), Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, EP, NU, DG. Aggressive Subsets of Metastatic Triple Negative 20: e20-e26. [PMID: 31631016](https://pubmed.ncbi.nlm.nih.gov/31631016), [DOI: Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast the CALGB Kornblith AB, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation](http://www.ncbi.nlm.nih.gov/pubmed/31277699)Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Breast first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA and CALGB 40503 (Alliance) trials](http://www.ncbi.nlm.nih.gov/pubmed/31276981)Mart\u00edn M, Loibl J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Ja\u00f1ez N, Hahn O, Winer MN, G, Oncology A. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials European to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-314)Mao P, Cohen O, Kowalski K, Kusiel Buendia J, Exman P, Wander S, Waks A, Winer E, Lin N, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer 2019, 314-314. [DOI: 10.1158/1538-7445.sabcs18-314](https://doi.org/10.1158/1538-7445.sabcs18-314). [Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations](https://doi.org/10.1158/1538-7445.sabcs18-ct050)Keenan T, Liu D, Elmarakeby H, Stover D, Kochupurakkal B, Tracy A, Danielczyk E, Anderson L, Andrews C, Reardon B, Overmoyer B, Winer E, Zheleva D, Chiao J, Blake D, Allen E, Shapiro G, Tolaney S. Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast BRCA1/2 mutations 2019, ct050-ct050. [DOI: 10.1158/1538-7445.sabcs18-ct050](https://doi.org/10.1158/1538-7445.sabcs18-ct050). [Abstract LB-225: RNA as predictive response to monotherapy pembrolizumab in patients M, Nanda R, Iwata H, Awada A, Tan A, Zhang C, Loboda A, Albright A, Cristescu R, Lane M, Wang A, Lunceford J, Aktan G, Karantza V, Adams S. Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in alterations to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer](https://doi.org/10.1158/1538-7445.am2019-314)Mao P, Cohen O, Kowalski K, Kusiel Buendia J, Exman P, Wander S, Waks A, Winer E, Lin N, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast Research 2019, 79: 314-314. [DOI: 10.1158/1538-7445.am2019-314](https://doi.org/10.1158/1538-7445.am2019-314). [Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations](https://doi.org/10.1158/1538-7445.am2019-ct050)Keenan T, Liu D, Elmarakeby H, Stover D, Kochupurakkal B, Tracy A, Danielczyk E, Anderson L, Andrews C, Reardon B, Overmoyer B, Winer E, Zheleva D, Chiao J, Blake D, Allen E, Shapiro G, Tolaney S. Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 Research 2019, 79: ct050-ct050. [DOI: 10.1158/1538-7445.am2019-ct050](https://doi.org/10.1158/1538-7445.am2019-ct050). [Abstract LB-225: RNA response to monotherapy pembrolizumab in patients M, Nanda R, Iwata H, Awada A, Tan A, Zhang C, Loboda A, Albright A, Cristescu R, Lane M, Wang A, Lunceford J, Aktan G, Karantza V, Adams S. Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with Breast Cancer: Results of a Phase 1b/2 Trial 19: 399-404. [PMID: 31235441](https://pubmed.ncbi.nlm.nih.gov/31235441), [DOI: 10.1016/j.clbc.2019.05.010](https://doi.org/10.1016/j.clbc.2019.05.010). randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab- paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1003)Schmid P, Adams S, Rugo Barrios C, Iwata H, Dieras V, Henschel V, Molinero L, Chui S, Husain A, Winer E, Loi S, Emens L. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab- paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). phase eribulin or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1004)Tolaney S, Barroso-Sousa R, Keenan T, Trippa L, Hu J, Luis I, Wulf G, Spring L, Sinclair N, Andrews C, Pittenger J, Richardson E, Dillon D, Lin N, Overmoyer B, Partridge A, VanAllen E, Mittendorf E, Winer I. Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast 1004-1004. [DOI: 10.1200/jco.2019.37.15_suppl.1004](https://doi.org/10.1200/jco.2019.37.15_suppl.1004). Buendia-Buendia J, Cohen Kim D, Jain E, Winer E, Lin N, Wagle N. Characterization of mutational processes in ER+ metastatic breast Journal [DOI: 10.1200/jco.2019.37.15_suppl.1019](https://doi.org/10.1200/jco.2019.37.15_suppl.1019). - Garrido-Castro Y, Cherniack A, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Files Kumari P, Cerami E, Krop I, MacConaill L, Lindeman N, Rollins B, Johnson B, Wagle N, Winer E, Dillon D, Lin N. Genomic landscape of de novo stage IV breast cancer. Journal Of Clinical Oncology 2019, 37: 1022-1022. [DOI: 10.1200/jco.2019.37.15_suppl.1022](https://doi.org/10.1200/jco.2019.37.15_suppl.1022). [A palliative radiotherapy (RT) for hormone Krop I, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson E, Winer E, Mittendorf E, Schoenfeld J, Tolaney S. A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic [DOI: 10.1200/jco.2019.37.15_suppl.1047](https://doi.org/10.1200/jco.2019.37.15_suppl.1047). hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients Scott J, Park J, Dickler M, Partridge A, Carey L, Winer E, Rugo H. Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients or Let plus bevacizumab (Bev): CALGB 10.1200/jco.2019.37.15_suppl.1049](https://doi.org/10.1200/jco.2019.37.15_suppl.1049). [Patient-reported outcomes of atezolizumab (atezo) plus nabpaclitaxel (nP) Barrios C, Winer E, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui S, Rugo H, Emens L, Schmid P. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic [DOI: 10.1200/jco.2019.37.15_suppl.1067](https://doi.org/10.1200/jco.2019.37.15_suppl.1067). Expanded safety a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-na\u00efve, locally advanced or metastatic triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1068)Schneeweiss H, Winer C, Iwata H, Dieras V, Loi S, Maiya V, Bond J, Lei G, Chui S, Adams S, Emens L, Schmid P. IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-na\u00efve, locally advanced or metastatic triple-negative breast cancer receptor-positive (HR+), HER2- breast cancer (ABC): MONALEESA-2 long-term J, Campone M, Andre F, Nusch A, Grischke E, Villanueva C, Marschner N, Winer E, Paluch-Shimon S, Rodriguez-Lorenc K, Hilliard Hortobagyi First-line (1L) ribociclib (RIB) receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term 1078-1078. [DOI: 10.1200/jco.2019.37.15_suppl.1078](https://doi.org/10.1200/jco.2019.37.15_suppl.1078). PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2 -mutant metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1085)Waks A, Cohen O, Kochupurakkal B, Kim D, Wander S, Buendia-Buendia J, Helvie K, Matulonis U, Krop I, Tolaney S, Winer E, D'Andrea A, Shapiro G, Lin N, Wagle N. Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2 -mutant metastatic breast [DOI: to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.](https://doi.org/10.1200/jco.2019.37.15_suppl.502)Metzger Filho O, Viale G, Trippa L, Li T, Yardley D, Mayer I, Abramson V, Arteaga C, Spring L, Waks A, Janiszewska M, Wrabel E, Demeo M, Bardia K, Winer E, Krop I. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. Clinical 2019, 37: 502-502. [DOI: paclitaxel in TNBC\u2014Evaluating the homologous recombination deficiency biomarker.](https://doi.org/10.1200/jco.2019.37.15_suppl.507)Mayer E, Abramson V, Jankowitz R, Falkson C, Marcom P, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Perou C, Richardson A, Tung N, Barry W, Tan-Wasielewski Z, Timms K, Hartman A, Wolff A, Winer E. 030: randomized II study of preoperative cisplatin paclitaxel in TNBC\u2014Evaluating the homologous recombination (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.](https://doi.org/10.1200/jco.2019.37.15_suppl.517)Barroso-Sousa R, Luis I, Di Meglio A, Hu J, Rees R, Sinclair N, Milisits L, Leone J, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein A, Trippa L, Tolaney N. Avoiding peg-filgrastim (Peg-F) prophylaxis during the (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective 517-517. [DOI: 10.1200/jco.2019.37.15_suppl.517](https://doi.org/10.1200/jco.2019.37.15_suppl.517). [Factors risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.](https://doi.org/10.1200/jco.2019.37.15_suppl.540)Leone J, Vallejo C, Hassett M, Leone J, Freedman R, Tolaney S, Leone B, Lin N, Winer E. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal Of Clinical Oncology 2019, 37: 540-540. W, Polley M, Twohy E, Perou C, Singh B, Berry D, Tolaney S, Somlo G, Port E, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Hudis C, Winer E, Partridge A, Carey L. CALGB 37: [DOI: hypermutated HER2-negative L, Winer E, Mittendorf E, Tolaney S. Nimbus: A of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.](https://doi.org/10.1200/jco.2019.37.15_suppl.tps599)Chen W, Winer E, Ballman K, Partridge A, Carey L, Carvan M, Matyka C, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2019, 37: tps599-tps599. for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Breast Cancer EP, Singer CF, Hurvitz S, Est\u00e9vez LG, van Dam PA, K\u00fcmmel S, Mundhenke C, Holmes Babbar Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)](http://www.ncbi.nlm.nih.gov/pubmed/31004299)Bellon JR, Guo H, Barry Overmoyer BA, Partridge AH, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) Breast Cancer Research And 176: 303-310. Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30939096)Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay Overmoyer B, for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Tan YB, Fuhrman K, Osmani W, Getz A, of small HER2-positive breast cancers: a secondary analysis from the APT trial dose-expansion phase Birrer Westin SN, Cadoo Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills cancer: dose-escalation and dose-expansion phase Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/30860945)Freedman RA, Gelman RS, Anders CK, Melisko ME, SL, Jankowitz Smith N, Moynihan TJ, O'Sullivan C, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, . TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases cohort B of the phase KEYNOTE-086 study](http://www.ncbi.nlm.nih.gov/pubmed/30475947)Adams S, Loi S, Toppmeyer H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase A of the phase G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cort\u00e9s J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II therapy in patients with early breast cancer: Principles and practical considerations](https://doi.org/10.1016/s0960-9776(19)30093-1)Winer E. SL 2.1 Adjuvant and neoadjuvant therapy in patients with early breast cancer: Principles and practical considerations The Breast 2019, 44: s11. [DOI: 10.1016/s0960-9776(19)30093-1](https://doi.org/10.1016/s0960-9776(19)30093-1). [P246 nodenegative (N0) and node-positive (N+) breast cancer (BC) real-world G. (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials](http://www.ncbi.nlm.nih.gov/pubmed/30770494)Wang Y, Ayres KL, Goldman DA, Dickler PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials Clinical Cancer global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-na\u00efve, locally advanced or metastatic triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-gs1-04)Emens L, Loi Rugo V, Iwata H, Barrios C, Nechaeva M, Molinero L, Nguyen Duc A, Funke R, Chui S, Husain A, Winer E, Adams S, Schmid P. Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-na\u00efve, locally advanced or metastatic triple-negative OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs18-ot3-02-07)Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, Loi S, Krop I, Gianni I, A. Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast [Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-ot3-05-02)Ignatiadis M, McArthur H, Bailey A, Martinez J, De Azambuja E, Metzger O, Lai C, Ponde N, Goulioti T, Daly F, Bouhlel A, Balta V, Van Dooren V, Viale G, Maetens M, Dufrane C, Nguyen Duc Winer E, Gelber R, Piccart M. Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer Cancer Research 2019, 79: ot3-05-02-ot3-05-02. [DOI: 10.1158/1538-7445.sabcs18-ot3-05-02](https://doi.org/10.1158/1538-7445.sabcs18-ot3-05-02). young women with node-negative and node-positive ER+/HER2- breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p2-08-07)Poorvu P, Gelber S, Rosenberg Ruddy Tamimi R, Collins L, Peppercorn J, Schapira L, Borges V, Come S, Warner E, Jakubowski D, Russell C, Winer E, Partridge A. Abstract P2-08-07: Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER+/HER2- [DOI: [Abstract P3-08-04: Transient state change, subtype change, after HER2-targeted therapy for HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p3-08-04)Tanioka M, Parker J, Henry L, Tolaney S, Dang C, Krop I, Harris L, Polley M, Berry D, Winer E, Carey L, Perou C. Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast node-negative (N0) and node-positive (N+) breast cancer N. Abstract P3-11-02: cancer-specific patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: breast cancer: Inflammatory breast cancer and young patients in the Dana-Farber cell-free DNA cohort](https://doi.org/10.1158/1538-7445.sabcs18-p4-01-17)Singh J, Asad S, Nock W, Zhang Y, Adams E, Damicis A, Parsons H, Adalsteinsson V, Winer E, Lin N, Partridge A, Overmoyer B, Stover D. Abstract P4-01-17: Aggressive subgroups of metastatic triple-negative breast cancer: Inflammatory breast cancer and young patients in the Dana-Farber cell-free DNA cohort Cancer in HER2 negative tumors for clinical trials - Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice](https://doi.org/10.1158/1538-7445.sabcs18-p4-04-02)Exman P, Garrido-Castro A, Hughes M, Freedman R, Ma C, Bose R, Cerami E, Wagle N, Barroso-Sousa R, Fitz C, Kumari P, Tolaney S, Krop I, Winer E, Dillon D, Lin N. Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials - Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice Cancer Research 2019, 79: p4-04-02-p4-04-02. [DOI: 10.1158/1538-7445.sabcs18-p4-04-02](https://doi.org/10.1158/1538-7445.sabcs18-p4-04-02). [Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD)](https://doi.org/10.1158/1538-7445.sabcs18-p5-11-01)Spoerke C, Dickler M, Bardia A, Perez Fidalgo J, Mayer I, Boni V, Winer E, Hamilton E, Bellet M, Urruticoechea A, Gonzalez Martin A, Cortes J, Martin M, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman L, Liu L, Li R, Chan I, Mueller L, Milan S, Lauchle J, Humke E, Lackner M. Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs18-p5-12-02)Barroso-Sousa R, Tyekucheva S, Pernas-Simon P, Jain E, A, Hughes M, Bychkovsky B, Di Lascio S, Umeton R, Files J, Lindeman N, MacConaill L, Hodi F, Krop I, Dillon D, Winer E, Wagle N, Lin N, Mittendorf E, Tolaney S. Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer for the treatment of advanced, treatment-refractory HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10)Goel S, Spring L, Rees R, Andrews C, Tahara R, Mayer E, Bardia A, Winer E, Tolaney S. Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer Cancer Research 2019, 79: p6-18-10-p6-18-10. [DOI: 10.1158/1538-7445.sabcs18-p6-18-10](https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10). - Bayani J, Poncet C, Yao C, Crozier C, Anouk N, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago Fraser Hilbers Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schr\u00f6der C, Rubio I, Ruddy K, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Boutros P, Giordano S, Cardoso F, Bartlett J. Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer Cancer Research 2019, 79: p6-19-01-p6-19-01. [DOI: 10.1158/1538-7445.sabcs18-p6-19-01](https://doi.org/10.1158/1538-7445.sabcs18-p6-19-01). - Leone J, Freedman Tolaney S, Vallejo C, Leone B, Winer E, Leone J. Abstract P6-19-02: Tumor subtypes and survival in male breast cancer: 2019, 79: clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-pd1-05)Jeselsohn R, Guo H, Rees R, Barry W, Barlett C, Tung N, Krop I, Brown M, Winer E. Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast 79: pd1-05-pd1-05. [DOI: 10.1158/1538-7445.sabcs18-pd1-05](https://doi.org/10.1158/1538-7445.sabcs18-pd1-05). [Abstract PD9-01: Genomic alterations of HR expression in metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-pd9-01)Garrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Di Lascio S, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, MacConaill L, Dillon D, Winer E, Lin N. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research 2019, 79: pd9-01-pd9-01. [DOI: 10.1158/1538-7445.sabcs18-pd9-01](https://doi.org/10.1158/1538-7445.sabcs18-pd9-01). [Abstract PD9-02: Evolutionary analysis of from 208 patients with estrogen receptor-positive Buendia-Buendia J, Wander S, Nayar U, Mao P, Waks A, Kim D, Freeman S, Adalsteinsson V, Helvie K, Livitz D, Rosebrock L, Krop I, Garraway L, Getz G, Winer E, Lin N, Wagle N. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) [DOI: 10.1158/1538-7445.sabcs18-pd9-02](https://doi.org/10.1158/1538-7445.sabcs18-pd9-02). Phase II Trial Correlating Standardized Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30721110)Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer 10.1001/jama.2018.19323](https://doi.org/10.1001/jama.2018.19323). checkpoint triple negative breast cancer: Comment on the IMpassion130 study](http://www.ncbi.nlm.nih.gov/pubmed/30351400)Kok M, Winer EP, Loi S. Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)](https://doi.org/10.29289/259453942019v29s1g04)Sousa R, Tyekucheva S, Exman R, Hodi F, E, Lin N, Tolaney S. TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER estrogen receptor-directed therapies](http://www.ncbi.nlm.nih.gov/pubmed/30531871)Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, A, Winer EP, N. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to Breast: Prognosis and the Importance of Histologic Grade](http://www.ncbi.nlm.nih.gov/pubmed/30518616)MetzgerFilho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, VazLuis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Cancer: ASCO Clinical Practice Guideline Focused Update](http://www.ncbi.nlm.nih.gov/pubmed/30452337)Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update Glass B, Beck AH, Hazra A, Rosner Eliassen Hankinson SE, Winer EP, Brown M, Tamimi RM. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. Journal Of The National Cancer from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy HER2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30037817)Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang ER, Winer EP, Hudis CA, Carey LA, Perou CM. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast CH, Iwata H, Di\u00e9ras V, R, Im SA, Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain EP, S, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer New England breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](http://www.ncbi.nlm.nih.gov/pubmed/29733336)Curigliano G, Burstein HJ, Winer EP, Gnant L, E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Annals clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance)](https://doi.org/10.1093/annonc/mdy373)Tanioka M, Parker J, Henry L, Tolaney S, Dang C, Krop I, Harris L, Hillman D, Polley M, Berry D, Winer E, Carey L, Perou C. SPS-3 A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)](https://doi.org/10.1093/annonc/mdy272.357)Loibl S, Metzger O, Mandrekar S, Mundhenke C, Seiler S, Valagussa P, DeMichele A, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, Loi S, Krop I, Gianni L, Ciruelos E. 369TiP PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P locally advanced or metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1093/annonc/mdy424.008)Schmid P, Adams S, Rugo A, Barrios C, Iwata H, Dieras V, Hegg R, Im S, Wright G, Henschel V, Molinero L, Chui S, Funke R, Husain A, Winer E, Loi S, Emens L. LBA1_PR IMpassion130: Results from a global, randomised, III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P locally advanced or metastatic triple-negative capecitabine and with T, C, Loibl E. A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/30185228)Sch\u00f6ffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, VW, of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer Breast Cancer 2018, BrinJones H, Sceneay J, Li B, Khan N, Ubellacker J, Xie S, Metzger-Filho O, Hoog J, Ellis M, Ma C, Ramm S, Krop I, Winer E, Roberts T, Kim H, Zhao J, McAllister S. Abstract B04: CDK4/6 inhibition triggers an b04-b04. [DOI: [Unraveling the ESR1 mutations in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/30083595)Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, EP, Brown M, Jeselsohn R. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer Npj Breast 10.1038/s41523-018-0075-5](https://doi.org/10.1038/s41523-018-0075-5). [4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO).](http://www.ncbi.nlm.nih.gov/pubmed/30032243)Cardoso F, Senkus E, Costa A, Papadopoulos E, N, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop GW, Spence D, C, DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical of first-line ribociclib plus letrozole versus placebo plus P, Arteaga Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab](https://doi.org/10.1158/1538-7445.am2018-4564)Waks A, Stover D, Barry W, Dillon D, Gjini E, Rodig S, Brock J, Baltay M, I, S. Abstract 4564: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus Cancer confer resistance to ER-directed therapies](https://doi.org/10.1158/1538-7445.am2018-4952)Nayar U, Cohen O, Kapstad C, Waks A, Wander S, Painter C, Freeman S, Ram P, Persky N, Marini L, Helvie K, Oliver N, Ma C, Winer E, Lin N, Wagle N. Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to therapies Cancer Research 2018, 78: 4952-4952. [DOI: 10.1158/1538-7445.am2018-4952](https://doi.org/10.1158/1538-7445.am2018-4952). [Systemic Therapy for Patients With Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update](http://www.ncbi.nlm.nih.gov/pubmed/29939838)Giordano SH, Temin Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update jco.2018.79.269. [PMID: 29939838](https://pubmed.ncbi.nlm.nih.gov/29939838), [DOI: 10.1200/jco.2018.79.2697](https://doi.org/10.1200/jco.2018.79.2697). Management Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update](http://www.ncbi.nlm.nih.gov/pubmed/29939840)Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, S, Patt DA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Journal jco.2018.79.271. [PMID: S, Climent MA, Pavesi L, Ruhstaller T, Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer New England Journal for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study](http://www.ncbi.nlm.nih.gov/pubmed/29789969)Li W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study 29789969](https://pubmed.ncbi.nlm.nih.gov/29789969), Sepucha K, Miller K, Dang C, Northfelt D, Winer E, Sledge G, Schneider B, Partridge A. Symptom burden and employment status in breast cancer (BC) survivors. Journal Of Clinical Oncology 2018, 36: 10073-10073. [DOI: 10.1200/jco.2018.36.15_suppl.10073](https://doi.org/10.1200/jco.2018.36.15_suppl.10073). [A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).](https://doi.org/10.1200/jco.2018.36.15_suppl.1026)Leone J, Hu J, Barry W, Duda D, Gerstner E, Jain R, Tan S, Lawler E, Winer E, Lin N, Tolaney S. A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM). Journal (met) tumors and prior treatment (tx) received.](https://doi.org/10.1200/jco.2018.36.15_suppl.1054)Waks A, Tolaney S, Schnitt S, Dillon Abdelrahman S, Marino-Enriquez A, Helvie K, Marini L, Cohen O, Kim D, Wander S, Stover D, Rodig S, Krop I, Winer E, HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received. Journal Of Clinical Oncology 2018, 36: and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic cancer safety, tolerability and pharmacokinetic (PK) analysis.](https://doi.org/10.1200/jco.2018.36.15_suppl.1068)Barroso-Sousa Barry W, Ferreira A, Rees R, Winer E, Wagle N, Tolaney S. A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic cancer (CDK4/6i): safety, tolerability resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).](https://doi.org/10.1200/jco.2018.36.15_suppl.12016)Wander S, Cohen O, Johnson G, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway L, Winer E, Lin N, Wagle exome (WES) in hormone-receptor positive (HR+) metastatic breast resistance cyclin-dependent kinase with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2018.36.15_suppl.tps1100)Barroso-Sousa R, Barry W, Kumthekar Guo H, Silvestri K, Krop I, Winer E, Tolaney S, Lin N. A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic pre-treated Regan DeMichele A, Forero-Torres A, Rimawi M, Ma C, Cristofanilli M, Anders C, Bartlett C, Winer E, Burstein after CDK and endocrine for pre-treated 10.1200/jco.2018.36.15_suppl.tps1104](https://doi.org/10.1200/jco.2018.36.15_suppl.tps1104). [A nivolumab in first- or second-line metastatic TNBC.](https://doi.org/10.1200/jco.2018.36.15_suppl.tps1118)Garrido-Castro A, Barry W, Traina T, Wesolowski R, Tung N, Keenan T, Van Allen E, Lin N, Winer E, Krop I, Tolaney S. A randomized phase II trial of carboplatin with or without nivolumab in first- or trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer.](https://doi.org/10.1200/jco.2018.36.15_suppl.tps597)Chen W, Winer E, Barry W, Partridge A, Carey L, Carvan M, Matyka C, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer. Journal Of Clinical Oncology 2018, 36: tps597-tps597. (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).](https://doi.org/10.1200/jco.2018.36.15_suppl.tps598)Ligibel J, Barry W, Alfano C, Hershman D, Irwin M, Neuhouser M, Thomson C, Delahanty L, Frank E, Spears P, Paskett E, Hopkins J, Bernstein V, Stearns V, White J, Wadden T, Goodwin P, Carey L, Partridge A, Winer E. The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401). Journal Garrido-Castro AC, Winer L, Sledge GW, Winer EP. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer Breast Cancer Research 2018, 171: [PMID: 29736741](https://pubmed.ncbi.nlm.nih.gov/29736741), with cancer](http://www.ncbi.nlm.nih.gov/pubmed/29761158)Stover Alcazar CR, Brock Guo H, B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer [PMCID: PMC5935675](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935675), [DOI: 10.1038/s41523-018-0060-z](https://doi.org/10.1038/s41523-018-0060-z). - Lin NU, Xie S, Winer EP, Zhao JJ. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clinical EP, VazLuis I, Lii J, Exman P, Barry WT. Breast cancerspecific survival by age: Worse outcomes for the in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab](https://doi.org/10.1158/1538-7445.sabcs17-gs3-02)Krop I, Hillman D, Polley M, Tanioka M, Parker J, Huebner L, Henry N, Tolaney S, Dang C, Harris L, Berry D, Perou C, Partridge A, Winer E, Carey L. Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs17-gs3-06)Rugo H, Barry W, Moreno-Aspitia A, Lyss A, Huebner L, Mayer E, Naughton M, Layman R, Carey L, Somer R, Toppmeyer D, Velasco M, Perez E, Hudis C, A randomized phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic cancer from cell-free DNA](https://doi.org/10.1158/1538-7445.sabcs17-gs3-07)Stover D, Parsons H, Ha G, Freeman S, Barry B, Guo H, Choudhury A, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Dillon D, Partridge A, Wagle N, Krop I, Getz G, Golub T, Love J, Winer E, Tolaney S, Lin N, Adalsteinsson V. copy analysis of chemotherapy-resistant metastatic triple-negative evaluating exemestane \u00b1 enzalutamide in patients with hormone receptor-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-gs4-07)Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Gucalp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Tudor I, Markova D, Barry E, Tarazi J, Stewart R, Winer E, Yardley D. Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane \u00b1 enzalutamide in patients with hormone receptor-positive 78: GS5-05: ductal carcinoma in ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-01)Overmoyer B, Regan M, Polyak K, Brock J, Van Poznak C, King T, Haddad T, Stearns V, Hwang S, Winer E. Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast Research 78: ot3-05-01-ot3-05-01. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-01](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-01). [Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-07)Metzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A. Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-08)Mayer E, DeMichele A, Gnant M, Barry W, Pfeiler G, Metzger O, Burstein H, Miller K, Rastogi T, Zardavas D, Fesl M, Huang-Bartlett C, Huang X, OT3-05-08: PALLAS: PALbociclib Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer II study of fulvestrant versus palbociclib DeMichele A, Forero A, Rimawi M, Ma C, Cristofanilli M, Anders C, Huang Bartlett C, Koehler M, II study of fulvestrant versus palbociclib 10.1158/1538-7445.sabcs17-ot3-05-11](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-11). [Abstract P1-07-04: Physical activity, weight and in patients receiving first-line chemotherapy for metastatic breast cancer: Results Anders C, Ma C, Hudis C, Winer E, Barry W. Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from in chemotherapy-treated metastatic breast cancer (Alliance)/NCCTG E, Hudis C, Toppmeyer D, Burnstein H, Qadir M, Ma C, Scott J, Park J, Rugo H. Abstract P2-01-01: Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p4-10-04)Hughes M, Frank E, Merrill M, Santiago R, Kuhnly N, Crowley L, Gupta G, Winer E, Lin N. Abstract P4-10-04: EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer Cancer Research 2018, 78: p4-10-04-p4-10-04. [DOI: 10.1158/1538-7445.sabcs17-p4-10-04](https://doi.org/10.1158/1538-7445.sabcs17-p4-10-04). P5-21-10: Phase a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative cancer](https://doi.org/10.1158/1538-7445.sabcs17-p5-21-10)Stover D, Gil Del Alcazar C, Tolaney S, Bardia A, Guo H, Balko J, Overmoyer B, Gelman R, Lloyd M, Wang V, Brock J, Winer E, Polyak K, Lin N. Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, HER2 positive inflammatory breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p6-15-11)Overmoyer B, Regan M, Hu J, Nakhlis F, Dominici L, Lin N, Freedman R, Morganstern D, Partridge A, Schlosnagle E, Hirshfield-Bartek J, Bellon J, and trastuzumab (TPH) neoadjuvant therapy for Research 2018, 78: p6-15-11-p6-15-11. [DOI: 10.1158/1538-7445.sabcs17-p6-15-11](https://doi.org/10.1158/1538-7445.sabcs17-p6-15-11). - Tolaney S, Barry W, Guo H, Dillon D, Tan Y, Fuhrman K, Osmani W, Getz A, Baltay M, Dang D, B, Marcom K, Krop I, Winer E. Abstract PD3-01: Immune profile of small HER2+ tumors in the APT trial Cancer Research 2018, [DOI: 10.1158/1538-7445.sabcs17-pd3-01](https://doi.org/10.1158/1538-7445.sabcs17-pd3-01). [Abstract hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study](https://doi.org/10.1158/1538-7445.sabcs17-pd5-06)Mayer E, DeMichele A, Guo H, Miller K, Rugo H, Schneider B, Waks A, Come S, Mulvey T, Huang Bartlett C, Koehler M, Barry W, Winer E, Burstein H. Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study Cancer 2018, 78: pd5-06-pd5-06. [DOI: 10.1158/1538-7445.sabcs17-pd5-06](https://doi.org/10.1158/1538-7445.sabcs17-pd5-06). [Abstract PD5-10: A first-in-human phase oral selective estrogen receptor degrader (SERD), GDC-0927, metastatic breast cancer (BC)](https://doi.org/10.1158/1538-7445.sabcs17-pd5-10)Dickler M, Villanueva R, Perez Fidalgo J, Mayer I, Boni V, Winer E, Hamilton E, Bellet M, Urruticoechea A, Gonzalez-Martin A, Cortes J, Martin M, Giltnane J, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman L, Spoerke J, Metcalfe C, Liu L, Li R, Morley R, McCurry U, Chan I, Mueller L, Milan S, Lauchle J, Humke E, Bardia A. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, positive [Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab](https://doi.org/10.1158/1538-7445.sabcs17-pd6-09)Waks A, Stover D, Barry W, Dillon D, Gjini E, Rodig S, Brock J, Baltay M, I, S. Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab S, Loi S, Toppmeyer D, D, De Laurentiis M, Nanda R, Winer E, Mukai H, Tamura K, Armstrong A, Liu M, Iwata H, Ryvo L, Wimberger P, Rugo H, Tan A, D'Aquanno C, Ding Y, [Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC Weerd V, Slaets L, Piper T, van Deurzen C, Schroder C, Stangle C, Kloosterman W, van Leeuwen-Stok Nilsson Goulioti M, Aebi S, Rubio I, Kelly C, Bayani J, Porter P, Murray M, Hudis C, Middleton L, Korde L, Ruddy K, Winer E, Bogler O, van den Weyngaert D, dal Lago L, Fraser J, Benstead K, van Asperen C, Linderholm B, Hedenfalk I, Tryfonidis K, Giordano S, Bartlett J, Cardoso F. Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program](http://www.ncbi.nlm.nih.gov/pubmed/29092024)Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schr\u00f6der C, Martens J, Bayani J, Asperen Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio I, Aebi S, Kelly C, Ruddy K, E, C, Lago K, Poncet C, Tryfonidis K, Giordano S. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer LS, O'Shaughnessy J, Gradishar C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast metastatic breast cancer in the United States](http://www.ncbi.nlm.nih.gov/pubmed/29332137)Poorvu PD, Vaz-Luis I, RA, Lin EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States Breast Cancer Research And Treatment 2018, 168: 727-737. [PMID: 29332137](https://pubmed.ncbi.nlm.nih.gov/29332137), Alterations With Survival in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/29298117)Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.](http://www.ncbi.nlm.nih.gov/pubmed/29045519)Dubsky L, E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. breast cancer: current practice and future directions Therapeutic Advances In Therapy for ER+ Breast Cancer: A Sea Change is Underway. Journal Of The National Institute 2017, chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](http://www.ncbi.nlm.nih.gov/pubmed/29242041)Group E, Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordstr\u00f6m E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G, Bradley R, Brain E, Braybrooke J, Broet P, Bryant J, Burrett J, Cameron D, Clarke M, Coates A, Coleman R, Coombes R, Correa C, Costantino J, Cuzick J, Danforth D, Davidson N, Davies C, Davies L, Di Leo A, Dodwell D, Dowsett M, Duane F, Evans V, Ewertz M, Fisher B, Forbes J, Ford L, Gazet J, Gelber R, Gettins L, Gianni L, Gnant M, Godwin J, Goldhirsch A, Goodwin P, Gray R, Hayes D, Hill C, Ingle J, Jagsi R, Jakesz R, James S, Janni W, Liu H, Liu Z, Lohrisch C, Loibl S, MacKinnon L, Makris L, McGale P, McHugh T, Morris P, Mukai H, Norton L, Ohashi Y, Olivotto I, Paik S, Pan H, Peto R, Piccart M, Pierce L, Poortmans P, Powles T, Pritchard K, Ragaz J, Raina V, Ravdin P, Read S, Regan M, Robertson J, Rutgers E, Scholl S, Slamon D, S\u00f6lkner L, Sparano J, Steinberg S, Sutcliffe R, Swain S, Taylor C, Tutt A, Valagussa P, van de Velde C, van der Hage J, Viale G, von Minckwitz G, Wang Y, Wang Z, Wang X, Whelan T, Wilcken N, Winer E, Wolmark N, Wood W, Zambetti M, Zujewski J. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten Stover DG, Parsons HA, Gydush Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor E, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang L, Golub JS, JC, Meyerson M. Scalable sequencing of cell-free DNA reveals Mutations in HER2 Nonamplified Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/28679771)X. C, Bose Gao Telli ML, Kimmick G, Winer E, Naughton M, Goetz M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, K, Bedard PL, Al-Kateb H, Ellis MJC. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial)](https://doi.org/10.1016/j.ijrobp.2017.06.141)Bellon J, Tolaney S, Guo H, Barry W, Burstein H, Winer E, Harris J. Local-Regional Recurrence in Women with N0/N1mi, HER2-Positive Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial) International Journal Of Radiation Oncology Biology Physics 2017, 99: s56. [DOI: 10.1016/j.ijrobp.2017.06.141](https://doi.org/10.1016/j.ijrobp.2017.06.141). [Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design](http://www.ncbi.nlm.nih.gov/pubmed/28948213)Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design Npj Breast and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results Adams Schmid P, Cort\u00e9s J, Cescon D, E, Laurentiis M, Nanda R, Iwata H, Awada A, Tan A, Wang A, Aktan G, Karantza V, Salgado R. LBA13 Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer](https://doi.org/10.1093/annonc/mdx365.087)Metzger Mandrekar S, Ciruelos P, Demichele A, Lim E, Tripathy D, Winer E, Huang C, Khoeler M, Carey L, Francis P, Miller K, Goel S, Goetz M, Prat A, Loi S, Krop I, Gianni L. 324TiP PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1093/annonc/mdx362.064)Mayer E, Demichele A, Pfeiler G, Barry W, Metzger O, Rastogi P, Symmans F, Burstein H, Miller S, Goulioti T, Zardavas D, Fesl C, Koehler M, Bartlett C, 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast 10.1093/annonc/mdx362.064](https://doi.org/10.1093/annonc/mdx362.064). [Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)](http://www.ncbi.nlm.nih.gov/pubmed/28825227)Hopkins JO, Allred J, Hurria A, Jatoi Carey L, Muss HB. Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302) Breast Cancer Research N, Ubellacker JM, Ramm IE, Winer EP, McAllister SS, an important agent in the history of breast cancer management Nature breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](http://www.ncbi.nlm.nih.gov/pubmed/28838210)Curigliano G, Burstein HJ, Winer EP, Gnant F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K, Pagani O, Partridge A, Pritchard K, Ro J, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 aromatase inhibitor and fulvestrant therapy](https://doi.org/10.1158/1538-7445.am2017-4950)Kuang Y, Siddiqui B, Hu J, Barry W, Lin N, Wagle N, Kirschmeier P, J\u00e4nne P, Paweletz C, Krop I, Winer E, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort](https://doi.org/10.1158/1538-7445.am2017-ct008)Konstantinopoulos P, Barry W, Birrer M, Westin S, Farooq S, Cadoo K, Whalen C, Luo W, Liu H, Aghajanian C, Solit D, Mills G, Taylor B, Won H, Berger M, Palakurthi S, Liu J, Cantley L, Kaufmann S, Swisher E, A, Winer E, Wulf G, Matulonis U. Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort Cancer Research 2017, 77: ( HER2 mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.am2017-ct011)Ma C, Bose R, Gao F, Freedman R, Telli M, Kimmick G, Winer E, Naughton M, Goetz D, Cobleigh M, Forero A, Pluard T, Anders C, Thomas S, Anderson J, Bumb C, Banks K, Lanman R, Bryce R, Lalani A, Pfeifer J, Hays D, Pegram M, Blackwell K, Bedard P, Al-Kateb H, Ellis M. Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for HER2 mutation ( HER2 mut) screening and response monitoring to neratinib in placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated metastatic breast carcinoma (MBC) (HER2CLIMB)](https://doi.org/10.1158/1538-7445.am2017-ct055)Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, M\u00fcller V, Curigliano G, Gelmon K, Hortobagyi G, Krop S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated locally or Ixabepilone: CALGB 40502 (Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/28620884)Mehrotra C, Winer EP, Lyss Cancer Treated Paclitaxel, Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials](http://www.ncbi.nlm.nih.gov/pubmed/28011460)Wang Y, Ayres KL, Goldman DA, Dickler PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials Clinical TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER](https://doi.org/10.1158/1557-3265.ovcasymp16-ntoc-112)Wang Z, Birkbak N, Barry W, Roberts T, Winer E, Iglehart J, Matulonis U, Ivy S, Liu J. Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER 23: ntoc-112-ntoc-112. [DOI: 10.1158/1557-3265.ovcasymp16-ntoc-112](https://doi.org/10.1158/1557-3265.ovcasymp16-ntoc-112). [Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.](https://doi.org/10.1200/jco.2017.35.15_suppl.10059)Meyerhardt J, Irwin M, Jones L, Zhang S, Campbell N, Brown J, Pollak M, Sorrentino A, Cartmel B, Harrigan M, West M, Tolaney S, Yung R, Winer E, Ng K, Abrams T, Fuchs C, Sanft T, Douglas P, Ligibel J. Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast 35: + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).](https://doi.org/10.1200/jco.2017.35.15_suppl.1005)Freedman R, Gelman R, Melisko M, Anders C, Moy B, Blackwell K, Connolly R, Niravath P, Van Poznak C, Puhalla S, Farooq S, Cropp A, Cotter C, Liu M, Krop I, Nangia J, Tung N, Wolff A, Winer E, Lin N. TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Card D, Zhao J, Karantza V, Cortes J. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): from CALGB 40503 Loibl Haba-Rodriguez J, Aktas B, Cirrincione C, Carrasco E, Mehta K, Barry W, Morales S, Carey L, Garcia Saenz J, Partridge A, Martinez N, Hahn O, Winer E, Guerrero A, Hudis C, Casas M, Dickler M. Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB with TDM1 in advanced HER2-positive breast cancer (MBC).](https://doi.org/10.1200/jco.2017.35.15_suppl.1030)Metzger Filho O, Goel S, Barry W, Hamilton E, Tolaney S, Yardley D, Rees R, Demeo M, Mills C, Hafner M, Winer E, Zhao J, Krop I. A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2017.35.15_suppl.1034)Luis I, Guo H, Barry W, Krop I, Wagle N, Lowe A, Gore D, Andrews C, Osmani W, Isakoff S, Tung N, Winer E, Lin N, Freedman R. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic + letrozole hormone Y, Sonke K, Blackwell K, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, Xuan F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.](https://doi.org/10.1200/jco.2017.35.15_suppl.1088)Adams S, Loi S, Toppmeyer D, Cescon D, Laurentiis M, Nanda R, Winer E, Mukai H, Tamura K, Armstrong A, Liu M, Iwata H, Ryvo L, Wimberger P, Card D, Ding Y, Karantza V, Schmid P. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from with chemotherapy-resistant metastatic triple-negative breast cancer.](https://doi.org/10.1200/jco.2017.35.15_suppl.1092)Stover D, Parsons H, Ha G, Freeman S, Barry W, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Krop I, Tolaney S, Wagle N, Getz G, Meyerson M, Love J, Winer E, Lin N, Adalsteinsson V. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).](https://doi.org/10.1200/jco.2017.35.15_suppl.511)Tolaney S, Barry W, Guo H, Dillon D, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Partridge A, Hudis C, Krop I, (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).](https://doi.org/10.1200/jco.2017.35.15_suppl.e12134)Waks A, Barry W, Gjini E, Dillon D, Rodig Brock J, Baltay J, I, Tolaney S. biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated metastatic breast carcinoma (mBC) (HER2CLIMB).](https://doi.org/10.1200/jco.2017.35.15_suppl.tps1107)Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, M\u00fcller V, Curigliano G, Gelmon K, Hortobagyi G, Krop S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated locally advanced phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer.](https://doi.org/10.1200/jco.2017.35.15_suppl.tps586)Chen W, Winer E, Barry W, Hudis C, Openshaw T, Visvanathan K, Symington B, Matyka C, Holmes M. ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer. Journal Of Clinical Oncology 2017, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance) Breast Survival benefit needed to undergo chemotherapy: Patient and Can Tumor Biology Guide Locoregional Therapy? Journal Of The in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)](http://www.ncbi.nlm.nih.gov/pubmed/28283904)Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin JM, Hopkins J, Winer H, H, Jatoi A, A, Mandelblatt J. Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503) Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/28275032)Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: A, Older Cancer\u2014Can pathway inhibitor BKM120 and the oral poly (ADP olaparib for the serous ovarian and breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/27993796)Matulonis U, Wulf G, Barry W, Birrer M, Westin S, Farooq S, Bell-McGuinn K, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok R, Aghajanian C, Solit D, Mills G, Taylor B, Won H, Berger M, Palakurthi S, Liu J, Cantley L, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP olaparib for the treatment of with De Novo Metastatic Breast Cancer: A PopulationBased Study](http://www.ncbi.nlm.nih.gov/pubmed/28242790)VazLuis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Correction to: 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-ot1-01-07)Overmoyer B, Goel S, Regan M, Hirshfield-Bartek J, Schlosnagel E, Yeh E, Qin L, Bellon J, Nakhlis F, Jacene H, Winer E. Abstract OT1-01-07: A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for ot1-01-07-ot1-01-07. colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen](https://doi.org/10.1158/1538-7445.sabcs16-ot1-01-09)Barroso-Sousa R, Vaz-Luis I, Guo H, Barry W, Brackett A, Brock V, Roche K, Kasparian E, Winer E, Lin N. Abstract OT1-01-09: Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced metastatic E, Borges V, Murthy R, Anders C, Cameron Carey L, M\u00fcller V, Curigliano G, Gelmon K, Hortobagy M, D, Hurvitz S, Tsai M, Winer E. Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced direct patient engagement](https://doi.org/10.1158/1538-7445.sabcs16-p1-05-13)Painter C, Anastasio E, Krevalin M, Kim D, Larken K, Lennon N, Frank E, Winer E, Lander E, Golub T. Abstract P1-05-13: The metastatic breast cancer project: Translational 10.1158/1538-7445.sabcs16-p1-05-13](https://doi.org/10.1158/1538-7445.sabcs16-p1-05-13). paradox': High proliferation, chemosensitivity, and poor prognosis](https://doi.org/10.1158/1538-7445.sabcs16-p1-07-05)Stover D, Selfors L, Winer E, Partridge A, Barry W. Abstract P1-07-05: Integrated transcriptional analysis of the triple negative 'proliferation paradox': High proliferation, chemosensitivity, and in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases](https://doi.org/10.1158/1538-7445.sabcs16-p1-12-04)Metzger O, Barry W, Krop I, Guo H, Younger J, Lawler E, Walker L, Freedman R, Tolaney S, Winer E, Lin N. Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer evaluating exemestane \u00b1 enzalutamide in patients with hormone receptor-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-p2-08-01)Krop I, Abramson V, Colleoni M, Holmes F, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly C, Uppal H, Tudor I, Peterson A, Winer E, Yardley D. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane \u00b1 enzalutamide in patients with hormone cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial](https://doi.org/10.1158/1538-7445.sabcs16-p4-22-16)Burris H, Chan A, Campone M, Blackwell K, Winer E, Janni W, Verma S, Burdaeva O, Alba E, Favret A, Mondal S, Miller M, C, Y. letrozole in patients with HR+, HER2- cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-p5-11-02)Ligibel J, Giobbie-Hurder A, Dillion D, Shockro L, Campbell N, Rhei E, Troyan S, Dominici L, Golshan M, Chagpar A, Yung R, Freedman R, Tolaney S, Winer E, Frank E, McTiernan A, Irwin M. Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer Cancer Research 2017, 77: p5-11-02-p5-11-02. [DOI: 10.1158/1538-7445.sabcs16-p5-11-02](https://doi.org/10.1158/1538-7445.sabcs16-p5-11-02). [Abstract JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs16-p6-12-12)Overmoyer B, Regan M, Schlosnagle E, Bunnell C, Freedman R, Tolaney S, Chen W, Mayer E, Partridge A, Silver D, Winer E. Abstract P6-12-12: Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 Cancer Research 2017, 77: p6-12-12-p6-12-12. [DOI: 10.1158/1538-7445.sabcs16-p6-12-12](https://doi.org/10.1158/1538-7445.sabcs16-p6-12-12). - Cohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, Tamayo P, Johannessen C, Krop I, L, E, N. exome and transcriptome sequencing 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-s3-05)Tanioka M, Fan C, Carey L, Hyslop T, Pitcher B, Parker J, Hoadley K, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Mardis E, Perou C, Winer E, Hudis C. Abstract analysis data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast Cancer [DOI: 10.1158/1538-7445.sabcs16-s3-05](https://doi.org/10.1158/1538-7445.sabcs16-s3-05). Ligibel J, Irwin Barry W, Giobbie-Hurder A, Frank E, Winer E, McTiernan A, Cornwell M, Pun M, Brown M, Jeselsohn R. Abstract S5-05: Impact of pre-operative exercise on breast cancer gene expression s5-05-s5-05. [DOI: 10.1158/1538-7445.sabcs16-s5-05](https://doi.org/10.1158/1538-7445.sabcs16-s5-05). [Corrigendum to \"3rd breast cancer (ABC 3)\" [Breast 31 (February 2017) 244-259]](http://www.ncbi.nlm.nih.gov/pubmed/28109648)Cardoso F, Costa C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, B, Norton L, Winer E. Corrigendum to \"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)\" [Breast 31 Cancer in Patients Treated with Neoadjuvant Systemic Golshan M. Axillary Management Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic of CALGB 40601 (HER2-Positive) and CALGB for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, X. C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) MV, ME, Juric HH, Li LC, with Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527](http://www.ncbi.nlm.nih.gov/pubmed/27992272)Freedman RA, Foster JC, Seisler A, Kimmick G, Jatoi A, Hurria A. Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527 Journal Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: of in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) The Breast 2016, 31: 244-259. [PMID: 27927580](https://pubmed.ncbi.nlm.nih.gov/27927580), C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Annals Of versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC](https://doi.org/10.1093/annonc/mdw577.019)Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V, de la Haba-Rodriguez J, L, Kusuma N, Chui S, Schmid P. IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive Of Oncology 2016, III versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC](https://doi.org/10.1016/s0923-7534(21)00294-5)Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V, de la Haba-Rodriguez J, L, Kusuma N, Chui S, Schmid P. IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in ix40. [DOI: 10.1016/s0923-7534(21)00294-5](https://doi.org/10.1016/s0923-7534(21)00294-5). [TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/27185372)Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, J, C, Bonechi M, Laing N, Winer EP, Brown M, Di Leo A, Malorni L. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer Clinical myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)](http://www.ncbi.nlm.nih.gov/pubmed/27866278)Freedman RA, Seisler DK, Foster JC, Sloan JA, AH, Carey LA, Jatoi A, Klepin HD, Citron M, DA, Shulman LN, AU, Suman VJ, Muss HB. Risk of acute leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) Breast Cancer Research And HJ. Perils of the Pathologic Complete Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer New England Journal Medicine randomized study](http://www.ncbi.nlm.nih.gov/pubmed/27714541)Tolaney Nechushtan H, Ron Awada A, Laird AD, O'Keeffe GI, Winer EP. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study Breast Cancer Research granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study](http://www.ncbi.nlm.nih.gov/pubmed/27721193)Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study The Breast [PMID: 27721193](https://pubmed.ncbi.nlm.nih.gov/27721193), [DOI: 10.1016/j.breast.2016.09.013](https://doi.org/10.1016/j.breast.2016.09.013). [Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW, for the Alliance for Clinical Trials in Oncology. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) Yap Y, Sonke K, Andr\u00e9 F, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, Xuan F, Souami F, Miller M, Germa C, O'Shaughnessy J. LBA1_PR breast cancer, locally advanced and metastatic First-line HER2-negative (HER2-), 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab](http://www.ncbi.nlm.nih.gov/pubmed/27484879)Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab Breast Cancer Research And [PMID: 27484879](https://pubmed.ncbi.nlm.nih.gov/27484879), [DOI: 10.1007/s10549-016-3927-4](https://doi.org/10.1007/s10549-016-3927-4). - Partridge AH, RM. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival Journal Of Clinical Oncology 2016, Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26957554)Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Z, V, JT, JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer matched biopsies enables genomic discovery in metastatic cancer](https://doi.org/10.1158/1538-7445.am2016-lb-136)Adalsteinsson V, Ha G, Freeman S, Choudhury A, Stover D, Parsons H, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Cohen O, Oh C, Kim J, Stewart C, Rosenberg M, Ding H, Lloyd M, Mahmud S, Helvie K, Merrill M, Santiago R, O'Connor E, Jeong S, Kramkowski J, Lohr J, Polacek L, Oliver N, Marini L, Francis J, Harshman L, Van Allen E, Winer E, Lin N, Nakabayashi M, Taplin M, Garraway L, Golub T, Boehm J, Wagle N, Getz G, Meyerson M, Love C. Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer Cancer Research 2016, 10.1158/1538-7445.am2016-lb-136](https://doi.org/10.1158/1538-7445.am2016-lb-136). - Carey LA, Winer EP. I-SPY 2 \u2014 Toward More Rapid Progress in Breast Cancer Treatment New England Journal Of Medicine 2016, 375: 83-84. [PMID: 27406352](https://pubmed.ncbi.nlm.nih.gov/27406352), Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26842237)Varadan V, Gilmore H, Miskimen KL, G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris L. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer Clinical adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.](https://doi.org/10.1200/jco.2016.34.18_suppl.lba1)Goss P, Ingle Pritchard Robert H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff A, Winer E, Hudis C, Stopeck A, Beck J, Kaur J, Whelan K, Tu D, Parulekar W. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. to accelerate genomics research.](https://doi.org/10.1200/jco.2016.34.18_suppl.lba1519)Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer E, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. orthotopic xenografts of HER2-positive breast cancer brain Xie S, Goel S, Stover DG, Guo H, Luu V, Marco LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Zhao JJ. Combination inhibition of PI3K and remissions in mice orthotopic patient-derived xenografts of HER2-positive incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis](http://www.ncbi.nlm.nih.gov/pubmed/27271765)Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis Breast Cancer Research And Treatment K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, C, Stopeck D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years New England Journal Of in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab A CALGB 40503 (Alliance) correlative study.](https://doi.org/10.1200/jco.2016.34.15_suppl.10047)Li D, Dickler M, McCall L, Hahn O, Hudis C, Cohen H, Muss H, Ballman K, Winer E, Tripathy D, Schneider B, Cirrincione C, Barry W, Hurria A. Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) 2016, 10047-10047. [DOI: 10.1200/jco.2016.34.15_suppl.10047](https://doi.org/10.1200/jco.2016.34.15_suppl.10047). - King T, Lyman J, Gonen M, Reyes S, Hwang E, Rugo H, Liu M, Boughey J, Jacobs L, McGuire K, Storniolo A, Isaacs C, Meszoely I, Van Poznak C, Babiera G, Norton L, Morrow M, Wolff A, Winer E, Hudis C. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). Journal Of Clinical Oncology 2016, 34: 1006-1006. [DOI: 10.1200/jco.2016.34.15_suppl.1006](https://doi.org/10.1200/jco.2016.34.15_suppl.1006). [Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.](https://doi.org/10.1200/jco.2016.34.15_suppl.1024)Freedman R, Seisler D, Foster J, Lafky J, Kimmick Jatoi A, Muss H, Cohen E, Hudis C, Cirrincione C, Moreno-Aspitia A, Hurria A. Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527. Journal Of [Effect of cabozantinib treatment circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.1093)Duda D, Ziehr D, Guo H, Ng M, Barry W, Higgins M, Isakoff S, Brock J, Ivanova E, Paweletz R, Winer E, Tolaney S. Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). 1093-1093. [DOI: 10.1200/jco.2016.34.15_suppl.1093](https://doi.org/10.1200/jco.2016.34.15_suppl.1093). cancer from metastatic biopsies (bx) in Helvie K, Lloyd M, Marini L, Waks A, Cohen O, Oh C, Sougnez C, Oliver N, Quartey Q, Rotem A, Shah P, Lindeman N, Krop I, Garraway L, Winer E, Lin N. A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.](https://doi.org/10.1200/jco.2016.34.15_suppl.538)Innocenti F, Owzar K, Jiang C, Sibley A, Mulkey F, Carey L, Tripathy D, Schneider B, Barry W, Winer E, Hudis C, McLeod H, Dickler M. A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 538-538. [DOI: [Mechanisms of resistance DNA therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.542)Waks A, Cohen O, Helvie K, Lloyd M, Marini L, Oh C, Oliver N, Lindeman N, Matulonis U, Krop I, Garraway L, Winer E, Lin N, Wagle N. Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer 34: 542-542. [DOI: 10.1200/jco.2016.34.15_suppl.542](https://doi.org/10.1200/jco.2016.34.15_suppl.542). - Vaz Luis I, Lin N, Keating N, Barry W, Lii J, Burstein H, Winer E, Freedman R. Factors associated with non use of adjuvant trastuzumab in older patients with HER2+ breast cancer. Journal Of Clinical Oncology 2016, 34: 601-601. [DOI: 10.1200/jco.2016.34.15_suppl.601](https://doi.org/10.1200/jco.2016.34.15_suppl.601). - Vaz Luis I, Lin N, Freedman R, Barry W, Winer E, Hassett M. Quality of care for metastatic breast cancer (MBC). Of Clinical Oncology 2016, 34: e18031-e18031. [DOI: 10.1200/jco.2016.34.15_suppl.e18031](https://doi.org/10.1200/jco.2016.34.15_suppl.e18031). [Patterns of utilization of imaging and tumor markers (TM) among metastatic breast cancer (MBC) patients (pts).](https://doi.org/10.1200/jco.2016.34.15_suppl.e18224)Di Meglio A, Lin N, Freedman R, Barry W, Winer E, Vaz Luis I. Patterns of utilization of imaging and tumor markers (TM) among metastatic breast cancer (MBC) patients (pts). Journal extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.](https://doi.org/10.1200/jco.2016.34.15_suppl.lba1)Goss K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff A, Winer E, Hudis C, Stopeck A, Beck J, Kaur J, Whelan K, Tu D, Parulekar W. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. to accelerate genomics research.](https://doi.org/10.1200/jco.2016.34.15_suppl.lba1519)Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer E, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. 34: lba1519-lba1519. single-agent per physician's choice triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.tps1102)Winer E, Dang T, Karantza V, Su S. KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab single-agent per physician's choice nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.tps1104)Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V, de la Haba-Rodriguez J, Gianni L, Chui S, Schmid P. IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.](https://doi.org/10.1200/jco.2016.34.15_suppl.tps629)Freedman R, Polley M, Dueck A, Hurria A, Muss H, Ruddy K, Hubbard J, Liu H, Rogak L, Basch E, Dakhil S, Huff J, Bajaj M, Wilkinson M, Al Baghadadi T, Benjamin S, Mowat R, Hudis C, Rugo H, Winer E. Academic and Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Journal Of phase 2 trial](http://www.ncbi.nlm.nih.gov/pubmed/27155741)Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, J, Schmid P. Pictilisib for oestrogen receptor-positive, Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women Hurria Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26976419)Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer Journal Of AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors in Breast Cancer Treatment\u2014The Sooner, Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression](http://www.ncbi.nlm.nih.gov/pubmed/26884586)Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Journal Of of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs15-ot1-01-06)Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, Chui S, Winer E. Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-21)Mayer E, DeMichele A, Dubsky P, Barry W, Metzger O, Symmans W, Burstein H, Miller K, Wolff A, Rastogi P, Loibl S, von Minckwitz G, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang Bartlett C, Chen L, Piccart Winer Gnant phase of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast Cancer 76: direct-to-patient research initiative to accelerate genomics research](https://doi.org/10.1158/1538-7445.sabcs15-ot2-05-03)Wagle N, Painter C, Ilzarbe M, Van Allen E, Frank E, Oh C, Krevalin M, Lloyd M, Anderka K, Kryukov G, Boehm J, Winer E, Lander E, Golub T. Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics Research 2016, 76: ot2-05-03-ot2-05-03. [DOI: 10.1158/1538-7445.sabcs15-ot2-05-03](https://doi.org/10.1158/1538-7445.sabcs15-ot2-05-03). [Abstract P1-07-08: Time trends in incidence rates and survival for women with de novo metastatic lobular vs. ductal carcinoma, a population-based study](https://doi.org/10.1158/1538-7445.sabcs15-p1-07-08)Di Meglio A, Freedman R, Lin N, Barry W, Metzger-Filho O, Keating N, Winer E, Vaz-Luis I. Abstract P1-07-08: Time trends in incidence rates and survival for women with de novo metastatic lobular vs. ductal carcinoma, a population-based study Cancer Research 2016, 76: p1-07-08-p1-07-08. [DOI: 10.1158/1538-7445.sabcs15-p1-07-08](https://doi.org/10.1158/1538-7445.sabcs15-p1-07-08). - Garber J, Tung N, Elkin E, Allen B, Singh N, Wenstrup R, Hartman A, Winer E, Lin N. Abstract P1-08-07: Predisposing germline mutations in a clinic based breast cancer (BC) population Cancer Research 2016, 76: p1-08-07-p1-08-07. [DOI: 10.1158/1538-7445.sabcs15-p1-08-07](https://doi.org/10.1158/1538-7445.sabcs15-p1-08-07). [Abstract P3-07-31: Immune activation signatures subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy](https://doi.org/10.1158/1538-7445.sabcs15-p3-07-31)Stover D, Waks A, Erica M, Brugge J, Winer E, Selfors L. Abstract P3-07-31: Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant Cancer Research 2016, 76: p3-07-31-p3-07-31. [DOI: 10.1158/1538-7445.sabcs15-p3-07-31](https://doi.org/10.1158/1538-7445.sabcs15-p3-07-31). [Abstract P5-11-02: Survival benefit needed to undergo chemotherapy: Patients and physicians preferences](https://doi.org/10.1158/1538-7445.sabcs15-p5-11-02)Vaz Luis I, O'Neill A, Sepucha K, Miller K, Baker E, Dang C, Northfelt D, Winer E, Sledge G, Schneider B, Partridge A. Abstract P5-11-02: Survival benefit needed to undergo chemotherapy: Patients and physicians preferences Cancer Research 2016, 76: p5-11-02-p5-11-02. [DOI: 10.1158/1538-7445.sabcs15-p5-11-02](https://doi.org/10.1158/1538-7445.sabcs15-p5-11-02). [Abstract P6-09-10: All-cause survival estimates compared to observed survival in older women with breast cancer in CALGB 49907 and 369901 (Alliance A151503)](https://doi.org/10.1158/1538-7445.sabcs15-p6-09-10)Kimmick G, Pitcher B, Mandelblatt J, Clapp J, Ballman K, Barginear M, Freedman R, Artz A, Klepin H, Lafky J, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A. Abstract P6-09-10: All-cause survival estimates compared to observed survival in older women with breast cancer in CALGB 49907 and 369901 +/- (Alliance)](https://doi.org/10.1158/1538-7445.sabcs15-s2-05)Sikov Berry Perou C, Singh B, Cirrincione C, Tolaney S, Somlo G, Port E, Qamar K, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E. Abstract S2-05: Event-free and overall +/- SM, Lin NU, Winer EP. Randomized trial of a physical activity intervention in women with metastatic breast cancer Cancer 2016, 122: 1169-1177. [PMID: 26872302](https://pubmed.ncbi.nlm.nih.gov/26872302), [DOI: 10.1002/cncr.29899](https://doi.org/10.1002/cncr.29899). [Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers](http://www.ncbi.nlm.nih.gov/pubmed/26868124)Vaz-Luis I, Hughes ME, Cronin A, EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers Breast Cancer Research And Treatment 2016, 155: 569-578. [PMID: 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/26834058)Freedman RA, Gelman RS, Wefel JS, Melisko ME, RM, Van Puhalla SL, N, Blackwell Herold C, Liu MC, Lowe A, Agar Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases RM, Tabassum DP, Roberts JM, Janiszewska M, Jin Huh S, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop I, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao P, Duarte M, Wu S, Chiang C, Anders L, Young R, Winer E, Letai A, Barry W, Carroll J, Long H, Brown M, Shirley Liu X, Meyer C, Bradner J, Polyak K. Response and resistance to BET bromodomain inhibitors in triple-negative breast and taxane-based Gradishar WJ, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26539793)Dang Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, EP, SM. Outcomes Adjuvant and Trastuzumab for Node-Negative, compensatory activation of MEK-ERK signaling](http://www.ncbi.nlm.nih.gov/pubmed/26640141)Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, NU, Krop and Her2-initiated escape PI3K dependency by compensatory CA, Barry WT. Response Journal Of The National Cancer Institute 2015, 108 [PMID: 26719886](https://pubmed.ncbi.nlm.nih.gov/26719886), [DOI: 10.1093/jnci/djv334](https://doi.org/10.1093/jnci/djv334). [Molecular Heterogeneity and Response to Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](http://www.ncbi.nlm.nih.gov/pubmed/26527775)Carey LA, Berry Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/26578779)Tolaney RK. density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients Proceedings Of The National Academy Of Sciences Of The United States Of America Evolution and Potential Therapeutic Targets](http://www.ncbi.nlm.nih.gov/pubmed/26410082)Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG, Gill CM, Van Hummelen Thorner Hoang MP, Choueiri TK, EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Cancer Discovery 2015, 5: 1164-1177. 29: 797-8, 802. [PMID: 26573058](https://pubmed.ncbi.nlm.nih.gov/26573058). - Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ. PI3K-p110 mediates resistance to and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors](http://www.ncbi.nlm.nih.gov/pubmed/26420402)Waks AG, Tolaney SM, A, SP, LR. Pneumocystis pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors Breast Cancer Research And Treatment 154: 359-367. [PMID: II-III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates](http://www.ncbi.nlm.nih.gov/pubmed/26222764)Golshan M, of Neoadjuvant Chemotherapy in Stage II-III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates Annals Of that targets leukemia.](https://doi.org/10.1158/1557-3265.hemmal14-a14)Reagan J, Fast L, Nevola M, Schumacher A, Rosati K, Safran H, Quesenberry M, E, generate an allogeneic leukemia. Clinical [DOI: chemotherapy regimens for patients with triple negative breast cancer The Breast 2015, 24: s132-s135. [PMID: 26255198](https://pubmed.ncbi.nlm.nih.gov/26255198), [DOI: 10.1016/j.breast.2015.07.032](https://doi.org/10.1016/j.breast.2015.07.032). [Variation in the Attitudes Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26240134)Seah DS, Scott S, Guo H, Najita J, Lederman R, Frank E, Sohl J, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin NU. Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies](https://doi.org/10.1158/1538-7445.am2015-2399)Wilson T, Savage H, Aimi J, Jin J, Parmar H, Hsu J, Krop I, Saura C, Cervantes A, Sachdev J, Patel M, Cejalvo J, Oliveira M, Winer E, Von Hoff D, Baselga J, Juric D. Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K discovery and validation set of breast cancer preoperative clinical trials show an increase in immune score upon brief-exposure to trastuzumab (T) and the HER2-enriched subtype predict response to combination chemotherapy and T](https://doi.org/10.1158/1538-7445.am2015-2836)Varadan V, Miskimen K, Parsai S, Krop I, Winer E, V, Abu-Khalaf M, Sikov W, Harris L. Abstract 2836: A discovery and validation set of breast cancer preoperative clinical trials show an increase in immune score upon brief-exposure to trastuzumab (T) and the HER2-enriched subtype predict response to combination chemotherapy and T 2015, 2836-2836. [DOI: 10.1158/1538-7445.am2015-2836](https://doi.org/10.1158/1538-7445.am2015-2836). [Abstract CT231: A first-in-human phase I oral selective estrogen receptor degrader M, Bardia A, Mayer I, Winer E, Rix P, Hager J, Chen M, Chan I, Chow-Maneval E, Arteaga C, Baselga J. Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader ER+/HER2-metastatic V, Balko J, Sanders M, Juric D, Solit D, Li Y, Cantley L, Winer E, Arteaga C. for high-grade serous ovarian cancer or triple-negative cancer: results of the BKM120 plus olaparib cohort](https://doi.org/10.1158/1538-7445.am2015-ct324)Matulonis U, Wulf G, Barry W, Birrer Westin Spagnoletti T, Bell-McGuinn K, Obermayer E, Whalen C, Aghajanian C, D, Mills G, Cantley L, Winer E. Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results BKM120 plus 2015, [DOI: 10.1158/1538-7445.am2015-ct324](https://doi.org/10.1158/1538-7445.am2015-ct324). [Relative Letrozole Compared With Tamoxifen With Lobular Carcinoma in the BIG 1-98 Filho M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Journal J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, G, M, C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno Etten Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs Mayo Clinic Proceedings Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)](http://www.ncbi.nlm.nih.gov/pubmed/26169615)Lin Mayer Falkson Hobday TJ, Dees Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, B, Wright JJ, Shapiro GI, Winer EP, Krop IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer treatment of triple-negative breast cancer](https://doi.org/10.1158/1538-8514.pi3k14-ia21)Wulf G, Juvekar A, Lyssiotis C, Hu H, Baek K, Yadegarynia S, Scully R, Winer E, Asara J, Cantley L, Matulonis U. Abstract IA21: Combination treatments that include PI3K-inhibitors for the treatment of triple-negative breast cancer Molecular Cancer Sikov Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance) Journal Of The [PMID: 26113580](https://pubmed.ncbi.nlm.nih.gov/26113580), [PMCID: PMC4651106](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651106), [DOI: 10.1093/jnci/djv179](https://doi.org/10.1093/jnci/djv179). [Randomized Phase Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype Breast Cancer Research [DOI: 10.1007/s10549-015-3432-1](https://doi.org/10.1007/s10549-015-3432-1). [Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women](http://www.ncbi.nlm.nih.gov/pubmed/26025931)Collins LC, Gelber Borges T, Tamimi RM, Winer EP, Partridge AH. Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women The rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40601 (Alliance).](https://doi.org/10.1200/jco.2015.33.15_suppl.1007)Golshan M, Cirrincione C, Carey L, Sikov W, Berry D, Burstein H, Overmoyer B, Henry N, Somlo G, Port E, Winer E, Hudis C, Ollila D. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 [DOI: 10.1200/jco.2015.33.15_suppl.1007](https://doi.org/10.1200/jco.2015.33.15_suppl.1007). [Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907.](https://doi.org/10.1200/jco.2015.33.15_suppl.1022)Muss H, Berry D, Cirrincione C, Theodoulou M, Hurria A, Cohen H, Partridge A, Norton L, Hudis C, Winer E. Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. neurotoxic chemotherapy for metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2015.33.15_suppl.1041)Sharma M, Gray E, Mehrotra S, Wu K, Barry W, Hudis C, Winer E, Lyss A, Toppmeyer D, H, Ratain M, Gobburu J. A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). Journal [DOI: 10.1200/jco.2015.33.15_suppl.1041](https://doi.org/10.1200/jco.2015.33.15_suppl.1041). - Tolaney S, Ziehr Guo Barry W, Higgins M, Isakoff S, Brock J, Ivanova E, Paweletz B, Jain R, Duda D, Winer E. A Phase II study of cabozantinib for metastatic triple-negative breast cancer 2015, 33: 1080-1080. [DOI: 10.1200/jco.2015.33.15_suppl.1080](https://doi.org/10.1200/jco.2015.33.15_suppl.1080). - Garber J, Tung N, Elkin E, Allen B, Hartman A, Singh N, Wenstrup R, Winer E, Lin N. Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed (Dx). Journal Of Clinical Oncology 2015, 33: 1503-1503. [DOI: 10.1200/jco.2015.33.15_suppl.1503](https://doi.org/10.1200/jco.2015.33.15_suppl.1503). [Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort.](https://doi.org/10.1200/jco.2015.33.15_suppl.1577)Luis I, Lin N, Keating N, Lii J, Barry W, Winer E, Freedman R. Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort. Journal Of Clinical Oncology 2015, 33: 1577-1577. [DOI: 10.1200/jco.2015.33.15_suppl.1577](https://doi.org/10.1200/jco.2015.33.15_suppl.1577). [Variation in the granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study.](https://doi.org/10.1200/jco.2015.33.15_suppl.561)Paes F, Luis I, Costa R, Metzger Filho O, Hughes M, Losk K, Camuso K, Bunnell C, Golshan M, Winer E, Lin N. Variation in the use of granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study. Journal Of Clinical Oncology 2015, 33: 561-561. with HER2+ metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2015.33.15_suppl.608)Jhaveri K, Hamilton E, Miller K, Roche M, Berger M, Winer E, Lin N. A phase 1b HER2+ metastatic breast cancer patients (pts) with extraordinary responses to trastuzumab (T).](https://doi.org/10.1200/jco.2015.33.15_suppl.611)Luis I, Oh C, Wang Z, Dipiro P, Macrae E, Painter C, Kryukov G, Krop I, Winer E, Lin N, Wagle N. exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). Journal Of Clinical Oncology 2015, 33: 611-611. [DOI: 10.1200/jco.2015.33.15_suppl.611](https://doi.org/10.1200/jco.2015.33.15_suppl.611). - Calip G, Law E, Winer E, Ko N. Racial and ethnic differences in risk of second primary cancers among breast cancer survivors. Journal Of Clinical Oncology 2015, 33: e12592-e12592. [DOI: 10.1200/jco.2015.33.15_suppl.e12592](https://doi.org/10.1200/jco.2015.33.15_suppl.e12592). [A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or cancer.](https://doi.org/10.1200/jco.2015.33.15_suppl.tps640)Trudeau Winer E, Steinberg J, Liosatos M, Poondru S, Dydo M, Peterson A, Gradishar W. A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or locally Oncology 2015, 33: tps640-tps640. [DOI: 10.1200/jco.2015.33.15_suppl.tps640](https://doi.org/10.1200/jco.2015.33.15_suppl.tps640). [Phase III bevacizumab to letrozole as first-line endocrine therapy for positive breast cancer: CALGB 40503 (Alliance).](https://doi.org/10.1200/jco.2015.33.15_suppl.501)Dickler M, Barry Cirrincione Moynahan M, Innocenti F, Hurria A, Rugo H, Lake D, Hahn O, Schneider B, Tripathy D, Winer E, Hudis C. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 [DOI: 10.1200/jco.2015.33.15_suppl.501](https://doi.org/10.1200/jco.2015.33.15_suppl.501). [Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance.](https://doi.org/10.1200/jco.2015.33.15_suppl.509)Stover D, Selfors L, Coloff J, Brugge J, Winer E. Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance. Journal Of Clinical Oncology 2015, 33: 509-509. [DOI: 10.1200/jco.2015.33.15_suppl.509](https://doi.org/10.1200/jco.2015.33.15_suppl.509). [Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study.](https://doi.org/10.1200/jco.2015.33.15_suppl.515)Rosenberg S, Ruddy K, Tamimi R, Gelber S, Schapira L, Borges V, Come S, Meyer M, Winer E, Partridge A. Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study. Journal Of Clinical Oncology 2015, 33: 515-515. [DOI: 10.1200/jco.2015.33.15_suppl.515](https://doi.org/10.1200/jco.2015.33.15_suppl.515). adjuvant Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors](http://www.ncbi.nlm.nih.gov/pubmed/25964252)Warner ET, Tamimi RM, Hughes ME, Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors Journal Of breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015](http://www.ncbi.nlm.nih.gov/pubmed/25939896)Coates AS, Winer EP, Goldhirsch J, Bonnefoi H, Burstein F, Castiglione-Gertsch M, Coates A, Colleoni M, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Galimberti V, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Harbeck N, Hayes D, Huober J, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne C, Partridge A, de la Pe\u00f1a L, Piccart-Gebhart M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Th\u00fcrlimann B, Toi M, Tutt A, Viale G, von Minckwitz G, Watanabe T, Whelan T, Winer E, Xu B. Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Annals Of T, Forbes JF, von Minckwitz Robertson J, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow L, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov DY, Klimberg VS. Personalization of loco-regional care for primary breast cancer patients (part Future Oncology 2015, 11: T, Forbes JF, von Minckwitz Robertson J, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow L, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov DY, Klimberg VS. Personalization of loco-regional care for primary breast cancer patients (part Borges VF, Golshan M, AH. Local Therapy and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer es9-3-es9-3. [DOI: 10.1158/1538-7445.sabcs14-es9-3](https://doi.org/10.1158/1538-7445.sabcs14-es9-3). [Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study](https://doi.org/10.1158/1538-7445.sabcs14-ot2-1-04)Ma Suman Sanati S, DeSchryver K, Unzeitig G, Haluska P, Watson M, Hahn O, Zujewski J, Hunt K, Winer E, Hudis C, Ellis M. Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study ot2-1-04-ot2-1-04. [DOI: 10.1158/1538-7445.sabcs14-ot2-1-04](https://doi.org/10.1158/1538-7445.sabcs14-ot2-1-04). [Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-ot3-1-06)Trudeau M, Winer E, Steinberg J, Liosatos M, Poondru S, Dydo M, Zhou Y, Westphal M, Peterson A, Gradishar W. Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer 2015, ot3-1-06-ot3-1-06. [DOI: 10.1158/1538-7445.sabcs14-ot3-1-06](https://doi.org/10.1158/1538-7445.sabcs14-ot3-1-06). [Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with Mayer I, Winer E, Mahmood U, Ulaner G, Manning H, Rix P, Hager J, Roychowdhury D, Chow Maneval E, Arteaga C, Baselga J. Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival](https://doi.org/10.1158/1538-7445.sabcs14-p1-13-04)Overmoyer B, Sanz-Altimira P, Partridge A, Extermann M, Liu J, Winer E, Lin N, Hassett M, Parker L, Taylor R, Hancock M, Small S, Johnston M. Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival 2015, p1-13-04-p1-13-04. [DOI: 10.1158/1538-7445.sabcs14-p1-13-04](https://doi.org/10.1158/1538-7445.sabcs14-p1-13-04). [Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy](https://doi.org/10.1158/1538-7445.sabcs14-p1-16-01)Sagara Y, Barry W, Vaz-Luis Aydogan F, Winer E, Golshan M, Metzger-Filho O. Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy 2015, p1-16-01-p1-16-01. [DOI: 10.1158/1538-7445.sabcs14-p1-16-01](https://doi.org/10.1158/1538-7445.sabcs14-p1-16-01). [Abstract P2-13-03: Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions](https://doi.org/10.1158/1538-7445.sabcs14-p2-13-03)Vaz Luis I, Hughes M, Cronin A, Rugo H, Edge S, Moy B, Theriault R, Hassett M, Winer E, Lin N. Abstract P2-13-03: Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions 2015, p2-13-03-p2-13-03. [DOI: 10.1158/1538-7445.sabcs14-p2-13-03](https://doi.org/10.1158/1538-7445.sabcs14-p2-13-03). - Anderson K, Overmoyer B, Canning C, J, Wallstrom G, Winer E, Dranoff G. Abstract P2-15-03: A Phase Ib Study of an adjuvant GM-CSF-Secreting Breast Cancer Vaccine 2015, [DOI: 10.1158/1538-7445.sabcs14-p2-15-03](https://doi.org/10.1158/1538-7445.sabcs14-p2-15-03). [Abstract response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-11)Richardson A, Silver D, Szallasi Z, Birkbak N, Wang Z, Iglehart J, Mayer E, Winer E, Tung N, Ryan P, Isakoff S, Barry W, Greene-Collozi A, Gutin A, Reid J, Neff C, Jones J, Timms K, Hartman A, Garber J. Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer 2015, p3-06-11-p3-06-11. [DOI: 10.1158/1538-7445.sabcs14-p3-06-11](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-11). [Abstract P3-06-24: Brief exposure to trastuzumab chemotherapy confirms predictors of response to treatment](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-24)Vadodkar A, Varadan Miskimen K, Bossuyt V, Abu-khalaf M, Krop I, Winer E, Harris L. Abstract P3-06-24: Brief exposure to trastuzumab prior to preoperative chemotherapy confirms predictors of response to treatment 2015, p3-06-24-p3-06-24. [DOI: 10.1158/1538-7445.sabcs14-p3-06-24](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-24). [Abstract P4-01-02: Prospective characterization of HER2-positive in patients with HER2-negative metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p4-01-02)Krop I, Macrae E, Galler S, Bischoff Fauni R, Sales E, Huynh L, Mitchell C, Clarin-Tamayo T, Anderson M, Abad L, Winer E. Abstract P4-01-02: Prospective characterization of HER2-positive circulating tumor cells in patients with HER2-negative metastatic breast cancer 2015, p4-01-02-p4-01-02. [DOI: 10.1158/1538-7445.sabcs14-p4-01-02](https://doi.org/10.1158/1538-7445.sabcs14-p4-01-02). [Abstract P4-17-01: Attitudes of medical oncologists towards research breast biopsies in patients with newly diagnosed stage I-III breast cancer not enrolled in a clinical trial](https://doi.org/10.1158/1538-7445.sabcs14-p4-17-01)Seah D, Scott S, Guo H, Najita J, Lederman R, Frank E, Sohl J, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin N. Abstract P4-17-01: Attitudes of medical oncologists towards research breast biopsies in patients with newly diagnosed stage I-III breast cancer not enrolled in a clinical trial 2015, p4-17-01-p4-17-01. [DOI: 10.1158/1538-7445.sabcs14-p4-17-01](https://doi.org/10.1158/1538-7445.sabcs14-p4-17-01). [Abstract P5-19-09: Preliminary results from a phase single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in AR+ cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs14-p5-19-09)Traina T, O'Shaughnessy J, Nanda R, Schwartzberg L, Abramson V, Cortes J, Peterson A, Tudor I, Blaney M, Steinberg J, Kelly C, Trudeau M, Awada A, Winer E, Hudis C, Schmid P, Yardley D. Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p5-19-10)Sch\u00f6ffski P, Cresta S, Mayer I, Wildiers H, Rooney I, Apt D, Gendreau S, Morrissey K, Lackner M, Spoerke J, Winer E. Abstract P5-19-10: activity the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603](https://doi.org/10.1158/1538-7445.sabcs14-pd1-2)Iglesia M, Vincent B, Serody J, Carey L, Barry W, Sikov W, Hudis C, Winer E, Perou C. Abstract PD1-2: of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003](https://doi.org/10.1158/1538-7445.sabcs14-pd3-5)Wagle N, Lin N, Richardson A, Leshchiner I, Mayer I, Forero-Torres A, Hobday T, Dees E, Nanda R, Rimawi M, Guo H, Barry W, Bose R, Shen W, Wolff A, Gabriel S, Garraway L, Winer E, Krop I. Abstract PD3-5: (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): combination with letrozole in patients with hormone receptor-positive advanced breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-pd5-2)Saura C, Sachdev J, Patel M, Cervantes A, Juric D, Infante J, Richards D, Sanabria S, Lu X, Ware J, Wilson T, Parmar H, Hsu J, Oliveira M, Winer E, Von Hoff D, Baselga J, inhibitor taselisib (GDC-0032) in combination with letrozole in patients advanced breast cancer 2015, pd5-2-pd5-2. [DOI: 10.1158/1538-7445.sabcs14-pd5-2](https://doi.org/10.1158/1538-7445.sabcs14-pd5-2). plus fulvestrant in patients with PIK3CA -altered wild type ER+/HER2- locally advanced or metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-pd5-5)Janku F, Juric D, Cortes J, Rugo H, Burris H, Schuler M, Deschler-Baier B, Middleton M, Gil-Martin M, Berlin J, Winer L, D, Coughlin C, Quadt C, Baselga J. PD5-5: I study of the PI3K inhibitor BYL719 plus fulvestrant in patients with PIK3CA -altered and wild type ER+/HER2- locally advanced [Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant](https://doi.org/10.1158/1538-7445.sabcs14-s1-01)Jeselsohn R, Barry W, Zhao J, Buchwalter G, Guarducci Migliaccio I, Biagioni C, Bonechi M, Laing N, Rukazenkov Y, Winer E, Brown M, Di Leo A, Malorni L. Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant 2015, s1-01-s1-01. [DOI: 10.1158/1538-7445.sabcs14-s1-01](https://doi.org/10.1158/1538-7445.sabcs14-s1-01). pictilisib (GDC-0941) plus fulvestrant ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer - Part I results](https://doi.org/10.1158/1538-7445.sabcs14-s2-02)Krop I, Johnston S, Mayer I, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S, de Boer R, Gendreau S, Derynck M, Lackner M, Spoerke J, Yeh R, Levy G, Ng V, O'Brien C, Savage H, Xiao Y, Wilson T, Lee S, Petrakova K, Vallentin S, Yardley D, Ellis M, Piccart M, Perez E, Winer E, Schmid P. Abstract S2-02: The FERGI phase PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-s3-06)Hoadley K, Barry W, Pitcher B, Parker J, Wilkerson M, Irvin W, Henry N, Tolaney S, Dang C, Krop I, Berry D, Mardis E, Perou C, Winer E, Hudis C, Carey L. S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) HER2-positive breast cancer 2015, s3-06-s3-06. S4-05: Impact of intrinsic subtype by and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer Hoadley Singh B, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Berry D, Hahn O, Carey L, Perou C, Hudis C, Winer E. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program](https://doi.org/10.1158/1538-7445.sabcs14-s6-05)Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leewen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Peeters S, Fraser J, Nowaczyk M, Rubio I, Aebi S, Kelly C, Ruddy K, E, Nilsson C, Dal Lago L, Korde Benstead Van Den Weyngaert D, Bogler O, Goulioti T, Dif N, Messina C, Tryfonidis K, Bogaerts J, Giordano S. Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program 2015, s6-05-s6-05. [DOI: 10.1158/1538-7445.sabcs14-s6-05](https://doi.org/10.1158/1538-7445.sabcs14-s6-05). [Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast](http://www.ncbi.nlm.nih.gov/pubmed/25893416)Sagara Y, Barry WT, Mallory JE, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast Annals Of With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25847936)Isakoff SJ, L, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, PE, Ellisen LW. Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast of adjuvant chemotherapy received among patients with stage I breast cancer: A multiinstitutional study](http://www.ncbi.nlm.nih.gov/pubmed/25757412)Vaz-Luis I, Hughes ME, EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multiinstitutional 12.01 Tailoring the chemotherapy regimen in patients with triple negative subtypes The Breast 2015, 24: s22. [DOI: 10.1016/s0960-9776(15)70045-7](https://doi.org/10.1016/s0960-9776(15)70045-7). - Gonzalez-Angulo AM, Krop I, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer Journal Of The National Cancer Institute 2015, 107 [PMID: 25688104](https://pubmed.ncbi.nlm.nih.gov/25688104), [PMCID: PMC4342675](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342675), [DOI: 10.1093/jnci/dju493](https://doi.org/10.1093/jnci/dju493). [Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial](http://www.ncbi.nlm.nih.gov/pubmed/25605861)Perez Gralow JR, Reinholz MM. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial Journal I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Trastuzumab for Node-Negative, HER2-Positive Breast Response to Platinum in the breast: Case report and review of the literature](https://doi.org/10.1016/j.ctrc.2015.04.001)Tahara R, Keraliya A, Ramaiya N, Ritterhouse L, Winer E, Tolaney S. Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature Cancer Treatment And Research Communications 2015, 4: 41-45. [DOI: 10.1016/j.ctrc.2015.04.001](https://doi.org/10.1016/j.ctrc.2015.04.001). [Phase I/II HER2-positive metastatic E, Mayer IA, Saura C, Maurer M, Ciruelos E, Garcia AA, Campana F, Wu B, Xu Y, Jiang J, Winer E, Krop I. Phase I/II study of pilaralisib (SAR245408) plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast 151-161. [PMID: Winer EP. Reply to V. 2014, 33: 291-291. [PMID: 25512457](https://pubmed.ncbi.nlm.nih.gov/25512457), I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada Burstein HJ, Martino S, Davidson NE, Geyer CE, M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer New England Journal Of E. Heterogeneity, Genome Complexity of TNBC MD Conference Express 2014, 14: 23-24. [DOI: 10.1177/1559897715571080](https://doi.org/10.1177/1559897715571080). - Emblem Gerstner E, Stufflebeam S, Sorenson G, Harris G, Freedman R, Sohl J, Younger J, Krop I, Winer E, Lin N. NI-23BRAIN BREAST METASTASES RESPOND TO ANTI-ANGIOGENIC THERAPY BY of PST on Pathologic Response and Survival in Breast Cancer MD Conference Express 2014, 14: 21-22. [DOI: 10.1177/155989771431020](https://doi.org/10.1177/155989771431020). [Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Blackwell KL, Winer EP, CA. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer\u2014CALGB and Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, RW, Finn RS, Charpentier Winer EP. Phase Study Plus Gemcitabine and Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival Wolmark N. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations](https://doi.org/10.1158/1538-7445.am2014-ng03)Brastianos P, Carter S, Santagata S, Taylor-Weiner A, Jones R, Horowitz P, Ligon K, Seaone J, Martinez-Saez E, Tabernero J, Cahill D, Paek S, Dunn I, Johnson B, Choueiri T, Rabin M, Winer E, Lin N, Hummelen P, Stemmer-Rachamimov A, Beroukhim R, Louis D, Batchelor T, Baselga J, Getz G, Hahn W. Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations 2014, ng03-ng03. [DOI: 10.1158/1538-7445.am2014-ng03](https://doi.org/10.1158/1538-7445.am2014-ng03). - Cardoso F, Costa A, Norton Aapro M, Andr\u00e9 F, Barrios C, Bergh M, Cufer T, Saghir N, Fallowfield L, Fenech J, Goldhirsch A, Harbeck N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin U, Mayer M, Merjaver S, Nordstr\u00f6m E, Pagani O, Partridge G, Thomssen C, Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) The Breast 2014, 23: 489-502. [PMID: 25244983](https://pubmed.ncbi.nlm.nih.gov/25244983), Aapro M, Andr\u00e9 F, Barrios C, Bergh M, Cufer T, Saghir N, Fallowfield L, Fenech J, Goldhirsch A, Harbeck N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin U, Mayer M, Merjaver S, Nordstr\u00f6m E, Pagani O, Partridge G, Thomssen C, Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) platinum-sensitive ovarian a randomised phase Obermayer L, Lee H, Winer EP, EC, SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 in Breast [DOI: [Long-Term Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25205424)Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast ML, Liu R, Carrasco E, Mart\u00edn M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer British Journal and Cyclophosphamide on Pathologic Complete Response Rates in to III Triple-Negative Breast Cancer: CALGB 40603 Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the Addition of and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 GG. Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/25001612)Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases Breast Cancer Research And of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib recurrent platinum-sensitive ovarian cancer.](https://doi.org/10.1200/jco.2014.32.18_suppl.lba5500)Liu J, Barry W, Birrer M, Lee J, Buckanovich R, Fleming G, Rimel B, Buss M, Nattam S, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer E, Kohn E, Ivy S, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian Clinical Oncology 2014, 32: lba5500-lba5500. [DOI: 10.1200/jco.2014.32.18_suppl.lba5500](https://doi.org/10.1200/jco.2014.32.18_suppl.lba5500). [Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901](http://www.ncbi.nlm.nih.gov/pubmed/24934786)Sheppard VB, Faul JS. Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901 Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 Schneider of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901](http://www.ncbi.nlm.nih.gov/pubmed/24917307)Faul LA, Luta G, Sheppard V, R, Clapp JD, Winer E, Wang J, Barry WT, Mandelblatt JS. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study](http://www.ncbi.nlm.nih.gov/pubmed/24888816)Vaz-Luis I, Ottesen RL, Winer EP, Lin NU. Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG Premenopausal Patients With Breast Cancer After Tamoxifen](http://www.ncbi.nlm.nih.gov/pubmed/24970714)Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, V, Winer EP, Partridge AH. Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen Clinical Breast 14: 413-416. M, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer New England Journal Of Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update](http://www.ncbi.nlm.nih.gov/pubmed/24868023)Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update Journal Of chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009.](https://doi.org/10.1200/jco.2014.32.15_suppl.1020)Isakoff S, He L, Mayer E, Goss P, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Ryan P, Finkelstein D, Hartman A, Garber J, Timms K, Winer E, Ellisen L. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative 1020-1020. [DOI: 10.1200/jco.2014.32.15_suppl.1020](https://doi.org/10.1200/jco.2014.32.15_suppl.1020). Tolaney Barry W, Larrabee K, Brock J, Wagle N, Van Allen E, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright J, Shapiro G, Winer E, Krop I. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast [DOI: 10.1200/jco.2014.32.15_suppl.1106](https://doi.org/10.1200/jco.2014.32.15_suppl.1106). [Phase for high-grade serous ovarian cancer triple-negative breast (TNBC).](https://doi.org/10.1200/jco.2014.32.15_suppl.2510)Matulonis Wulf G, Birrer Westin Quy K, Lasonde B, Whalen C, Aghajanian C, Solit D, Mills G, Cantley L, Winer E. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative 32: specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).](https://doi.org/10.1200/jco.2014.32.15_suppl.506)Carey L, Barry W, Pitcher B, Hoadley K, Cheang M, Anders C, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Perou C, Winer E, Hudis C. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast [DOI: 10.1200/jco.2014.32.15_suppl.506](https://doi.org/10.1200/jco.2014.32.15_suppl.506). [Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.](https://doi.org/10.1200/jco.2014.32.15_suppl.509)Perez E, Thompson E, Anderson Asmann Y, Kalari K, Eckel-Passow J, Dueck A, Tenner K, Jen J, Fan J, Geiger X, McCullough A, Chen B, Zschunke M, Jenkins R, Sledge G, Winer E, Gralow J, Reinholz M, Ballman K. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. metastatic breast I, Abramson V, Balko J, Sanders M, Juric D, Li Y, Cantley L, Winer E, Arteaga [DOI: 10.1200/jco.2014.32.15_suppl.516](https://doi.org/10.1200/jco.2014.32.15_suppl.516). [Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).](https://doi.org/10.1200/jco.2014.32.15_suppl.522)Luis I, Hughes M, Cronin A, Rugo H, Edge S, Moy B, Theriault R, Winer E, Lin N. Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC). Journal Of Clinical Oncology 2014, 32: 522-522. [DOI: 10.1200/jco.2014.32.15_suppl.522](https://doi.org/10.1200/jco.2014.32.15_suppl.522). [TBCRC 022: Phase of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).](https://doi.org/10.1200/jco.2014.32.15_suppl.528)Freedman R, Gelman R, Wefel J, Krop I, Melisko M, Lowe A, Agar N, Blackwell K, Connolly R, Niravath P, Van Poznak C, Puhalla S, Ryabin N, Lawler E, Ibrahim N, Liu M, Wolff A, Winer E, Lin N. TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.](https://doi.org/10.1200/jco.2014.32.15_suppl.536)Wagle N, Lin N, Richardson A, Leshchiner I, Mayer I, Forero-Torres A, Hobday T, Dees E, Nanda R, Rimawi M, Guo H, Barry W, Wolff A, Gabriel S, Garraway L, Winer E, Krop I. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of 32: 536-536. [DOI: 10.1200/jco.2014.32.15_suppl.536](https://doi.org/10.1200/jco.2014.32.15_suppl.536). [Disparities among older women with de novo stage IV breast cancer treated with trastuzumab from 1999 to 2009.](https://doi.org/10.1200/jco.2014.32.15_suppl.646)Luis I, Keating N, Lin N, Lii J, Winer E, Freedman R. Disparities among older women with de novo stage IV breast cancer treated with trastuzumab from 1999 to 2009. Journal Of Clinical Oncology 2014, 32: 646-646. [DOI: 10.1200/jco.2014.32.15_suppl.646](https://doi.org/10.1200/jco.2014.32.15_suppl.646). [A randomized phase 2 of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib recurrent platinum-sensitive ovarian cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.lba5500)Liu J, Barry W, Birrer M, Lee J, Buckanovich R, Fleming G, Rimel B, Buss M, Nattam S, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer E, Kohn E, Ivy S, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian 2014, 32: lba5500-lba5500. versus paclitaxel in patients (pts) with BRCA1/2- proficient triple-negative breast cancer (TNBC)\u2014Evaluating the homologous recombination deficiency (HRD) biomarker.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps1145)Mayer E, Vaz-Luis I, Richardson A, Perou C, Tung N, Abramson V, Anders C, Forero-Torres A, Marcom P, Miller K, Puhalla S, Rimawi M, Stearns V, Traina T, Barry W, Jones J, Timms K, Hartman A, Wolff A, Winer E. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2- proficient triple-negative breast cancer (TNBC)\u2014Evaluating the homologous recombination deficiency 2014, 32: tps1145-tps1145. [DOI: 10.1200/jco.2014.32.15_suppl.tps1145](https://doi.org/10.1200/jco.2014.32.15_suppl.tps1145). [Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative cancer W, Untch M, McKee M, Giranda V, Rugo H. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps653)Yardley D, Awada A, Cortes J, Burris H, Peterson A, Tudor I, Stopatschinskaja S, Steinberg J, Gianni L, Miller K, Winer E. A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast [DOI: 10.1200/jco.2014.32.15_suppl.tps653](https://doi.org/10.1200/jco.2014.32.15_suppl.tps653). [Adjuvant palbociclib for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps654)Mayer E, Gropper A, Tung N, Higgins M, Traina T, Barry W, Winer E, Burstein H. Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study. Journal Of Oncology 2014, 32: tps654-tps654. [DOI: 10.1200/jco.2014.32.15_suppl.tps654](https://doi.org/10.1200/jco.2014.32.15_suppl.tps654). with trastuzumab in participants with brain metastases from HER2+ breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps660)Metzger-Filho O, Barry W, Krop I, Younger W, Lawler E, Winer E, Lin N. Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer. Of Clinical Oncology 2014, 10.1200/jco.2014.32.15_suppl.tps660](https://doi.org/10.1200/jco.2014.32.15_suppl.tps660). [A in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps668)Freedman R, Luis I, Barry W, Krop I, Wagle N, Lowe A, Galler S, Sohl J, Isakoff S, Tung N, Winer E, Lin N. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. Clinical Oncology 2014, 32: tps668-tps668. [DOI: 10.1200/jco.2014.32.15_suppl.tps668](https://doi.org/10.1200/jco.2014.32.15_suppl.tps668). [Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors](http://www.ncbi.nlm.nih.gov/pubmed/24827126)Balma\u00f1a J, Tung N, Isakoff S, Gra\u00f1a B, Ryan P, Saura C, Lowe E, Frewer P, Winer E, Baselga J, Garber J. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Annals Of Oncology 2014, 25: 1656-1663. [PMID: 24827126](https://pubmed.ncbi.nlm.nih.gov/24827126), Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline](http://www.ncbi.nlm.nih.gov/pubmed/24799465)Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Journal Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline](http://www.ncbi.nlm.nih.gov/pubmed/24799487)Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline Journal for older women receiving adjuvant trastuzumab-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/24756187)Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy Breast Cancer Research And Treatment 2014, 145: 491-501. [PMID: 24756187](https://pubmed.ncbi.nlm.nih.gov/24756187), [DOI: 10.1007/s10549-014-2968-9](https://doi.org/10.1007/s10549-014-2968-9). [Male breast cancer networking and telephone support group: a model for supporting a unique population](http://www.ncbi.nlm.nih.gov/pubmed/24700635)Farrell E, Borstelmann N, Meyer F, Partridge A, Winer E, Ruddy K. Male breast cancer networking and telephone support group: a model for supporting a unique 956-958. Y, Cantley LC, E, Arteaga CL. Buparlisib Defining success in neoadjuvant breast cancer outgrowth gene sets CALGB 40101 (Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/24513692)Chhibber A, Mefford J, Stahl EA, M, Winer EP, Hudis CA, of paclitaxel-induced sensory peripheral driven by axon outgrowth gene sets in CALGB Patients With Early-Stage Breast Cancer: A Population-Based Study](http://www.ncbi.nlm.nih.gov/pubmed/24516021)Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based preoperative capecitabine in women with operable hormone receptor positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/24464780)Tolaney SM, Jeong J, Guo H, Brock J, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer Cancer Medicine 2014, 3: 293-299. [PMID: 24464780](https://pubmed.ncbi.nlm.nih.gov/24464780), [PMCID: PMC3987079](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987079), [DOI: chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.](http://www.ncbi.nlm.nih.gov/pubmed/24453294)Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network 2014, 12: 10.1158/0008-5472.sabcs13-ms02-1](https://doi.org/10.1158/0008-5472.sabcs13-ms02-1). OT1-1-07: trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot1-1-07)Overmoyer B, Regan M, Brugge J, Perou C, Nakhlis F, Jennifer B, Heather J, Eren Y, Judith H, Winer E. Abstract OT1-1-07: Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory Research 2013, 73: ot1-1-07-ot1-1-07. [DOI: 10.1158/0008-5472.sabcs13-ot1-1-07](https://doi.org/10.1158/0008-5472.sabcs13-ot1-1-07). [Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC)](https://doi.org/10.1158/0008-5472.sabcs13-ot1-4-02)Matulonis U, Wulf G, Cantley L, Mills G, Lasonde B, Atkinson T, Whalen C, Isakoff S, Westin S, Bell-McGuinn K, Winer E. Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer ot1-4-02-ot1-4-02. trial evaluating survivorship care program for early stage breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot2-5-02)Ruddy K, Baker E, Guo H, Goldstein M, Winer E, Shulman L, Partridge A. Abstract OT2-5-02: Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer Cancer Research 2013, 73: ot2-5-02-ot2-5-02. trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot3-2-01)Yardley D, Awada A, Cortes J, Burris H, Peterson A, Bhattacharya S, Gianni L, Miller K, Winer E. Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified [Abstract OT3-2-05: fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot3-2-05)Lin N, Whitesell L, Gelman R, Mayer E, Krop I, Santagata S, Lowe A, Proia D, Farooq S, Brown M, Iannone M, Lindquist S, Winer E. Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast Cancer Research 2013, P2-18-02: Factors associated young women with breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-02)Rosenberg S, Sepucha K, Ruddy K, Tamimi R, Gelber S, Meyer M, Schapira L, Come S, Borges V, Winer E, Partridge A. Abstract P2-18-02: Factors associated with contralateral prophylactic mastectomy in young women with breast cancer 73: p2-18-02-p2-18-02. [DOI: 10.1158/0008-5472.sabcs13-p2-18-02](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-02). [Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-09)King T, Lyman J, Gonen M, Voci A, Boafo C, Hwang E, Rugo H, Alvarado M, Liu M, Boughey J, Jacobs L, Krontiras H, McGuire K, Storniolo A, Nanda R, Golshan M, C, Bijelic L, Meszoely I, Van Poznak C, Babiera G, Norton L, Morrow M, Winer E, Wolff A, Hudis C. Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer Cancer Research 2013, 73: p2-18-09-p2-18-09. [DOI: 10.1158/0008-5472.sabcs13-p2-18-09](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-09). - Ruddy K, Tolaney Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Hudis C, Krop I, P3-08-05: Chemotherapy-related amenorrhea p3-08-05-p3-08-05. [DOI: 10.1158/0008-5472.sabcs13-p3-08-05](https://doi.org/10.1158/0008-5472.sabcs13-p3-08-05). [Abstract P4-18-01: Sharing clinical trial results with patient participants: A project of the Dana Farber/Harvard Cancer Center (DF/HCC) breast cancer research advocacy group](https://doi.org/10.1158/0008-5472.sabcs13-p4-18-01)Frank E, Price K, Colten M, Fax R, Levine M, Matyka C, Dowton A, Barry W, Winer E, Partridge A. Abstract P4-18-01: Sharing clinical trial results with patient participants: A project of the Dana Farber/Harvard Cancer Center (DF/HCC) breast cancer research advocacy group Cancer Research 2013, 73: p4-18-01-p4-18-01. [DOI: 10.1158/0008-5472.sabcs13-p4-18-01](https://doi.org/10.1158/0008-5472.sabcs13-p4-18-01). - Seah D, Scott S, Guo Najita J, Lederman R, Frank E, Sohl J, Kronwitz C, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin N. Abstract P4-19-01: Attitudes of medical oncologists towards research biopsies Cancer Research 2013, 73: p4-19-01-p4-19-01. [DOI: 10.1158/0008-5472.sabcs13-p4-19-01](https://doi.org/10.1158/0008-5472.sabcs13-p4-19-01). [Abstract P6-11-09: Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-09)Meier C, Vaz-Luis I, Seah D, Macrae E, Burstein H, J, Arvold N, Winer E, Lin N. Abstract P6-11-09: Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease Cancer Research 2013, 73: p6-11-09-p6-11-09. [DOI: 10.1158/0008-5472.sabcs13-p6-11-09](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-09). [Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)](https://doi.org/10.1158/0008-5472.sabcs13-s1-04)Tolaney S, Barry W, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Partridge A, Guo H, Hudis C, Krop I, Burstein H, Winer E. Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer Research 2013, 73: s1-04-s1-04. 10.1158/0008-5472.sabcs13-s1-04](https://doi.org/10.1158/0008-5472.sabcs13-s1-04). [Abstract S5-01: Impact of (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response rates in triple-negative cancer (TNBC): CALGB 40603 (Alliance)](https://doi.org/10.1158/0008-5472.sabcs13-s5-01)Sikov Berry C, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E. Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment](https://doi.org/10.1158/0008-5472.sabcs13-s5-07)Smerage J, Barlow W, Hayes D, Winer E, Leyland-Jones B, Srkalovic G, Tejwani S, Schott A, O'Rourke M, Lew D, J, Livingston R, Hortobagyi G. Abstract S5-07: SWOG S0500 - A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment Cancer SE, Meyer ME, Winer EP, Partridge AH. Breast cancer presentation and diagnostic delays in young women Cancer 2013, 120: 20-25. [PMID: 24347383](https://pubmed.ncbi.nlm.nih.gov/24347383), [DOI: 10.1002/cncr.28287](https://doi.org/10.1002/cncr.28287). with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/24197661)Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, MacDonald SM, Mahadevan A, Eisenberg E, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases Breast Cancer Research And Treatment P.G. et al, O. Kaidar-Person et al, and A. Courdi et al Journal Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU. Prospective clinical experience with research biopsies in breast cancer patients Breast Cancer Research And Treatment 2013, Tolaney SM, Winer EP, cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice Breast 2013, 141: 421-427. [PMID: prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.](http://www.ncbi.nlm.nih.gov/pubmed/24042365)Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Annals Of Internal Golshan M. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction Breast Cancer Research And Treatment 2013, 141: 255-259. [PMID: 24026859](https://pubmed.ncbi.nlm.nih.gov/24026859), [DOI: 10.1007/s10549-013-2682-z](https://doi.org/10.1007/s10549-013-2682-z). [Longer-term cardiac of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).](https://doi.org/10.1200/jco.2013.31.26_suppl.167)Iyengar N, Morris P, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 167-167. [DOI: 10.1200/jco.2013.31.26_suppl.167](https://doi.org/10.1200/jco.2013.31.26_suppl.167). and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/24037735)Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Longterm cardiac safety and outcomes of dosedense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast Cancer 2013, 119: 3943-3951. [PMID: 24037735](https://pubmed.ncbi.nlm.nih.gov/24037735), [DOI: 10.1002/cncr.28284](https://doi.org/10.1002/cncr.28284). [Personalizing the treatment of with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](http://www.ncbi.nlm.nih.gov/pubmed/23917950)Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart members H, Bretel-Morales H, Cardoso F, Castiglione-Gertsch M, Coates A, Colleoni M, Costa A, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Goss P, Harris J, Hayes D, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Loibl S, Morrow M, Namer M, Osborne A, Penault-Llorca F, Perou M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Th\u00fcrlimann B, Toi M, Tutt A, Untch M, Viale G, Watanabe T, Wilcken N, Winer E, Wood W. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Annals Of Advanced Human Epidermal Growth Factor-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study](http://www.ncbi.nlm.nih.gov/pubmed/23829891)Vaz-Luis I, Seah Wagle N, Metzger-Filho IE, Winer EP, Lin NU. Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study 23928759](https://pubmed.ncbi.nlm.nih.gov/23928759), with weekly paclitaxel in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23868188)Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, AL, Agarwal S, inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer Breast Cancer Research 140: 331-339. [PMID: 23868188](https://pubmed.ncbi.nlm.nih.gov/23868188), [DOI: (AZD2281) in combination with the anti-angiogenic C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer European Journal Of of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 of Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From E, Winer EP, Gelber RD. Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From a Herceptin Adjuvant Trial With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up Winer EP, Wood WC. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.](https://doi.org/10.1200/jco.2013.31.15_suppl.1007)Shulman L, Berry D, Cirrincione C, Becker H, Perez E, O'Regan R, Martino S, Shapiro C, Atkins J, Schneider C, Kimmick G, Burstein H, Norton L, Muss H, Hudis C, Winer E. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: Ligibel Ingle J, Gradishar W, Martino S, Sikov W, Michaelson R, Hudis C, Winer E, Barry W. Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).](https://doi.org/10.1200/jco.2013.31.15_suppl.1065)Boucher Y, Martin J, Tolaney S, Ancukiewicz M, Seano G, Goel S, Yeh E, Meyer J, Isakoff S, Duda D, Winer E, Krop I, Jain R. Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts). Journal Of Clinical Oncology 2013, 31: 1065-1065. 10.1200/jco.2013.31.15_suppl.1065](https://doi.org/10.1200/jco.2013.31.15_suppl.1065). Tolaney Isakoff S, Krop I, Smith B, Jiang W, H, Brock J, Winer E, Golshan M. Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction. Journal Of Clinical Oncology 2013, 31: phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.500)Carey L, Berry D, Ollila D, Harris L, Krop I, Weckstein D, Henry N, Anders C, Cirrincione C, Winer E, Perou C, Hudis and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast 10.1200/jco.2013.31.15_suppl.500](https://doi.org/10.1200/jco.2013.31.15_suppl.500). rates: Surgical results from CALGB 40601 (Alliance).](https://doi.org/10.1200/jco.2013.31.15_suppl.501)Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).](https://doi.org/10.1200/jco.2013.31.15_suppl.513)Lin N, Gelman R, Younger W, Sohl J, Freedman R, Sorensen A, Bullitt E, Harris G, Morganstern D, Schneider B, Krop I, Winer E. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases 018: plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).](https://doi.org/10.1200/jco.2013.31.15_suppl.515)Anders C, Deal A, Abramson V, Liu M, Storniolo A, Carpenter J, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin N, Marcom P, Van Poznak C, Stearns V, Melisko M, Smith J, Karginova O, Winer E, Perou C, Wolff A, Carey L. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases 10.1200/jco.2013.31.15_suppl.515](https://doi.org/10.1200/jco.2013.31.15_suppl.515). [Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.](https://doi.org/10.1200/jco.2013.31.15_suppl.529)Metzger Filho R, Regan M, Colleoni M, Ejlertsen B, Bonnefoi H, Forbes J, Neven P, Wardley A, Lang I, Smith I, Price K, Coates A, Goldhirsch A. Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. Journal Of Clinical Oncology 2013, 31: 529-529. [DOI: 10.1200/jco.2013.31.15_suppl.529](https://doi.org/10.1200/jco.2013.31.15_suppl.529). - Freedman R, Luis I, Lin N, Lii J, Winer E, Keating N. Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 616-616. [DOI: 10.1200/jco.2013.31.15_suppl.616](https://doi.org/10.1200/jco.2013.31.15_suppl.616). [Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).](https://doi.org/10.1200/jco.2013.31.15_suppl.630)Morris P, Iyengar N, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 630-630. [DOI: 10.1200/jco.2013.31.15_suppl.630](https://doi.org/10.1200/jco.2013.31.15_suppl.630). [Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.6507)Rosenberg S, Sepucha K, Ruddy K, Tamimi R, Gelber S, Meyer M, Schapira L, Come S, Borges V, Winer E, Partridge A. Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer. Journal Of Clinical Oncology 2013, 31: 6507-6507. [DOI: 10.1200/jco.2013.31.15_suppl.6507](https://doi.org/10.1200/jco.2013.31.15_suppl.6507). [Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance).](https://doi.org/10.1200/jco.2013.31.15_suppl.9581)Polite B, Allred E, Hudis C, Winer E. Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance). Journal 31: 9581-9581. - Zeghibe C, Luis I, Frank E, Sohl J, Washington K, Silverman S, Fonte J, Mayer E, Overmoyer B, Richardson A, Krop I, Winer E, Lin N. Prospective clinical experience with research biopsies in breast cancer patients. Journal Of Clinical Oncology 2013, 31: e17574-e17574. [DOI: 10.1200/jco.2013.31.15_suppl.e17574](https://doi.org/10.1200/jco.2013.31.15_suppl.e17574). - Lin N, Gelman R, Brock J, Bardia A, Mayer E, Overmoyer B, Wang V, Iannone M, Krop I, Polyak K, Winer E. Phase II study of ruxolitinib in patients with pStat3+ breast cancer. Journal 2013, 31: 10.1200/jco.2013.31.15_suppl.tps1134](https://doi.org/10.1200/jco.2013.31.15_suppl.tps1134). [Human epidermal growth the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer David Muscato J, Rayson D, Houck W, Ellis C, DeSilvio M, Garofalo A, Levin J, Winer E. Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast Tamimi R, Schapira L, Come S, Meyer M, Larsen B, Winer E, Partridge A. Quality of life and psychosocial distress in young women with advanced breast cancer. Journal Of Clinical Oncology 2013, 31: e20508-e20508. [DOI: 10.1200/jco.2013.31.15_suppl.e20508](https://doi.org/10.1200/jco.2013.31.15_suppl.e20508). [Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907](http://www.ncbi.nlm.nih.gov/pubmed/23681403)Freedman RA, Pitcher B, Keating NL, Ballman HJ, HB, for the Alliance for Clinical Trials in Oncology. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907 Breast Cancer Research And Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care?](http://www.ncbi.nlm.nih.gov/pubmed/23663229)Freedman RA, He Y, Winer EP, Keating NL. Racial/Ethnic Differences in Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care? Health Services and trastuzumab in HER2-positive metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23645007)Lin NU, Seah Gelman Desantis S, Mayer EL, Isakoff S, DiPiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer Breast 403-410. [PMID: 23645007](https://pubmed.ncbi.nlm.nih.gov/23645007), [DOI: cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23601761)Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, Force E. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer phase II study bevacizumab (bev) followed with bev in HER2-negative operable breast cancer (BC)](https://doi.org/10.1158/1538-7445.am2013-lb-76)Boucher Y, Martin J, Tolaney S, Seano G, Goel M, R. Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study bevacizumab (bev) followed combination with bev in HER2-negative operable breast cancer (BC) Cancer Research 2013, 73: lb-76-lb-76. [DOI: 10.1158/1538-7445.am2013-lb-76](https://doi.org/10.1158/1538-7445.am2013-lb-76). [Abstract LB-81: A of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo](https://doi.org/10.1158/1538-7445.am2013-lb-81)Duda D, Tolaney S, Ancukiewicz M, Winer E, Krop I, Jain R. Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo Cancer Research 2013, 10.1158/1538-7445.am2013-lb-81](https://doi.org/10.1158/1538-7445.am2013-lb-81). - M, Winer EP, Bunnell C, study of ixabepilone and trastuzumab for metastatic HER2-positive Weeks JC, Winer EP, Partridge AH. LongTerm Risk Perceptions of Women With K, Frank E, Sohl ZK, Garrett M, Silverman SG, Peppercorn J, Winer EP, Come SE, Lin NU. Attitudes of patients with metastatic breast cancer toward research biopsies Annals Of CA, JM, Furi\u00f3 V, Garc\u00eda AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer Hudis C, Stijleman Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer Breast Cancer Research And factors, biology, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology BMJ Quality & Safety 2013, 22: 405. [PMID: 23349386](https://pubmed.ncbi.nlm.nih.gov/23349386), [DOI: 10.1136/bmjqs-2012-000948](https://doi.org/10.1136/bmjqs-2012-000948). [Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy](http://www.ncbi.nlm.nih.gov/pubmed/23204130)Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Shterev I, Kubo M, Zembutsu H, Y, Ratain MJ, Kroetz DL, B F, Cox NJ, Dolan ME. Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral EP, Partridge AH. Quality of life and symptoms in male breast cancer survivors The Breast 2013, (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)](https://doi.org/10.1158/0008-5472.sabcs12-ot1-1-07)Lin M, David A, Muscato J, Rayson D, Houck W, Ellis C, DeSilvio M, A, Nagarwala Y, Winer E. Abstract OT1-1-07: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases](https://doi.org/10.1158/0008-5472.sabcs12-ot1-1-11)Freedman R, Gelman R, Wefel J, Krop I, Melisko M, Ly A, Agar N, Connolly R, Blackwell K, Nabell L, Ingle J, Van Poznak C, Puhalla S, Niravath P, Ryabin N, Wolff A, Winer E, Lin N. Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Cancer Research 2012, agent BKM120 in patients with triple-negative metastatic breast cancer.](https://doi.org/10.1158/0008-5472.sabcs12-ot2-3-06)Saura Ciruelos A, J, Winer E, J. Abstract OT2-3-06: A phase II, non-randomized, multicenter, exploratory trial of single agent BKM120 in patients with triple-negative metastatic P2-10-01: PAM50 gene signature breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-01)Liu M, Pitcher B, Mardis E, Davies S, Snider J, Vickery T, Reed J, DeSchryver K, Singh B, Friedman P, Gradishar W, Perez E, Martino S, Citron M, Norton L, Winer E, Hudis C, Perou C, Ellis M, Barry W. Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Cancer Research 2012, 72: p2-10-01-p2-10-01. 10.1158/0008-5472.sabcs12-p2-10-01](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-01). Seah D, Scott T, Krag K, Frank E, Sohl J, Stadler Z, Garrett M, Winer E, Come S, Lin N. Abstract P2-16-04: Attitudes of metastatic breast cancer patients towards research biopsies Cancer Research 2012, 72: p2-16-04-p2-16-04. [DOI: 10.1158/0008-5472.sabcs12-p2-16-04](https://doi.org/10.1158/0008-5472.sabcs12-p2-16-04). - Desmedt C, Metzger Singhal S, Vincent D, Adnet P, Smeets D, Bertucci G, C. Abstract P3-05-03: Characterization of PIK3CA mutations in lobular P5-18-03: Clinicopathological features among breast cancer with prolonged response to trastuzumab based therapy](https://doi.org/10.1158/0008-5472.sabcs12-p5-18-03)Vaz-Luis I, Seah D, Olson E, Metzger J, Litsas G, Burstein I, Winer E, Lin N. Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy Cancer Research 2012, 72: p5-18-03-p5-18-03. [DOI: 10.1158/0008-5472.sabcs12-p5-18-03](https://doi.org/10.1158/0008-5472.sabcs12-p5-18-03). [Abstract P6-08-03: Informational needs and psychosocial assessment of patients in their first year after metastatic breast cancer diagnosis](https://doi.org/10.1158/0008-5472.sabcs12-p6-08-03)Seah D, Lin N, Curley C, Winer E, Partridge A. Abstract P6-08-03: Informational needs and psychosocial assessment of patients in their first year after metastatic breast cancer diagnosis Cancer Research 2012, 72: p6-08-03-p6-08-03. [DOI: 10.1158/0008-5472.sabcs12-p6-08-03](https://doi.org/10.1158/0008-5472.sabcs12-p6-08-03). [Abstract P6-08-05: Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907](https://doi.org/10.1158/0008-5472.sabcs12-p6-08-05)Freedman R, Pitcher B, Keating N, Barry W, Ballman K, Kornblith A, Mandelblatt J, Kimmick G, Hurria A, E, Hudis C, Cohen H, Muss H. Abstract P6-08-05: Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB V, Balko J, Isakoff S, Forero A, Kuba M, Sanders M, Li Y, Winer E, Arteaga C. Abstract P6-10-05: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer.](https://doi.org/10.1158/0008-5472.sabcs12-pd09-03)Isakoff S, Goss P, Mayer E, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Finkelstein D, Hartman A, Garber J, Ryan P, Winer E, Ellisen L. Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast pd09-03-pd09-03. [DOI: 10.1158/0008-5472.sabcs12-pd09-03](https://doi.org/10.1158/0008-5472.sabcs12-pd09-03). [Abstract PD10-04: Predictive adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study](https://doi.org/10.1158/0008-5472.sabcs12-pd10-04)Perez E, Eckel-Passow J, Ballman K, Anderson S, Thompson E, Asmann Y, Jen J, Dueck A, Lingle W, Sledge G, Winer E, Gralow J, Jenkins R, Reinholz M. Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 2012, pd10-04-pd10-04. [DOI: S1-1: Relative with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial.](https://doi.org/10.1158/0008-5472.sabcs12-s1-1)Metzger O, Giobbie-Hurder B, H, Coates A, Goldhirsch A, Gusterson B. Abstract S1-1: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 s1-1-s1-1. HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831](https://doi.org/10.1158/0008-5472.sabcs12-s5-5)Romond S, Davidson N, Mamounas E, Zujewski J, Wolmark N, Perez E. Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG Wolmark N, Albain K, Norton L, Winer E, Hudis C. Reply to S. Mahesh Journal Oncology 2012, 30: 4446-4446. Bunnell Kalfin M, Partridge A, Lane S, Burstein H, Fine B, Hilton N, Sullivan C, Colicchio L, Hagemeister E, Kelly A, Szabatura A, Winer E, Mann S, Weingart S. Implementation of team training in outpatient breast oncology. Journal Of Clinical Oncology 2012, 30: 83-83. [DOI: 10.1200/jco.2012.30.34_suppl.83](https://doi.org/10.1200/jco.2012.30.34_suppl.83). systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference](http://www.ncbi.nlm.nih.gov/pubmed/23143284)Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno A, Inamoto T. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference Breast Cancer Research And Treatment 2012, 136: 919-926. L, Winer EP, Partridge AH. Body image in recently diagnosed young women with early breast cancer Kereakoglow S, Borges S, Schapira L, Winer E, Partridge A. OR34 Sexual functioning in young women with breast cancer The Breast 2012, 21: s13. [DOI: 10.1016/s0960-9776(12)70046-2](https://doi.org/10.1016/s0960-9776(12)70046-2). - Warner ET, Tamimi RM, Partridge AH. Time to diagnosis and breast cancer stage by race/ethnicity Breast Cancer Research And survival and mediating effects of tumor characteristics, sociodemographic, and treatment factors.](https://doi.org/10.1158/1055-9965.disp12-pr06)Warner E, Tamimi R, Hughes M, Ottesen R, Wong Y, Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Partridge A. Abstract PR06: Racial/ethnic differences in breast cancer survival and mediating effects of tumor characteristics, sociodemographic, and treatment factors. Cancer Epidemiology Biomarkers & Prevention status define two distinct subtypes?](http://www.ncbi.nlm.nih.gov/pubmed/23022997)Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two 1 trial of vandetanib, a VEGFR R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative in K, Zembutsu H, C, Genome-Wide Association Study Identifies for Paclitaxel-Induced Sensory Peripheral Neuropathy in Fang G, Winer EP, Keating NL. Survival Implications Associated with Variation in Mastectomy Rates for Early-Staged Breast Cancer International Journal Of The natural history of 26: We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice?](http://www.ncbi.nlm.nih.gov/pubmed/22851555)Hudis CA, Citron ML, Muss H, Norton L, Winer EP. Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice? Journal Of health insurance reform on mammography use and breast cancer stage at diagnosis](http://www.ncbi.nlm.nih.gov/pubmed/22833148)Keating NL, Kouri EM, He Y, West DW, Winer EP. Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis Cancer 2012, 250-258. or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101](http://www.ncbi.nlm.nih.gov/pubmed/22826271)Shulman LN, Cirrincione Berry DA, Becker HP, Perez EA, Martino S, Atkins JN, Mayer E, G, Norton L, Muss H, Winer EP, Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101 Winer E, Partridge A. Psychosexual Functioning and Body Image Following a Diagnosis of Ductal Carcinoma In Situ The Journal Of Sexual Medicine 2012, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors Breast Cancer Research And oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)](http://www.ncbi.nlm.nih.gov/pubmed/22767584)Ruddy Pitcher CA, Muss HB, Partridge AH. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2012.30.18_suppl.cra1002)Rugo H, Barry W, Moreno-Aspitia A, Lyss A, Cirrincione C, Mayer E, Naughton M, Layman R, Carey L, Somer R, Perez E, Hudis C, Winer E. CALGB 40502/NCCTG N063H: Randomized phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22665533)Carey LA, Rugo HS, Rimawi MF, Ivanova A, Chiu WK, Ferraro M, 001: Study Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer Journal dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. American Society Of Clinical Oncology Educational Book 2012, 28-38. E, Piccart M. A Dickens Tale of the Treatment of Advanced Breast Cancer: The Past, the Present, and the Future American Society Of Clinical Oncology Educational Book 2012, 28-38. [DOI: 10.14694/edbook_am.2012.32.306](https://doi.org/10.14694/edbook_am.2012.32.306). [A Phase II Study of Trastuzumab Emtansine Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, Winer EP. Model Program to Improve Care for a Unique Cancer Population: Young Women With Breast Cancer Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines? Neville B, Partridge A, Cameron D, Winer E, Earle C. Reply to E. Warner Journal Of Clinical Oncology 2012, 30: 1893-1894. [DOI: 10.1200/jco.2012.42.1339](https://doi.org/10.1200/jco.2012.42.1339). - Balma\u00f1a J, Tung N, Isakoff S, Gra\u00f1a B, Ryan P, Rafi R, Tracy M, Winer E, Baselga J, Garber J. Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors. Journal Of Clinical Oncology 2012, 30: 1009-1009. combination with bev in HER2-negative operable breast cancer (BC).](https://doi.org/10.1200/jco.2012.30.15_suppl.1026)Tolaney S, Duda D, Boucher Y, Goel S, Martin J, Ancukiewicz M, Potler H, Incio D, Winer E, Krop I, phase study followed by in combination with bev in HER2-negative operable breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 1026-1026. [DOI: 10.1200/jco.2012.30.15_suppl.1026](https://doi.org/10.1200/jco.2012.30.15_suppl.1026). [Evaluation of gene expression RNA-seq single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer.](https://doi.org/10.1200/jco.2012.30.15_suppl.10558)Galanina N, Sprecher E, Bossuyt V, Sarkar S, Krop I, Winer E, Tuck D, Bruce C, Harris L. Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast Abramson V, Balko J, Isakoff S, Kuba M, Sanders M, Forero-Torres A, Yap J, Van Den Abbeele A, Li Y, Arteaga C, E. Results from a phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2012.30.15_suppl.535)Winer E, Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak C, Burris H, Ramies D, T, Shen X. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2012, 30: 535-535. [DOI: 10.1200/jco.2012.30.15_suppl.535](https://doi.org/10.1200/jco.2012.30.15_suppl.535). [Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC).](https://doi.org/10.1200/jco.2012.30.15_suppl.6015)Klepin H, Pitcher B, Ballman K, Kimmick G, Kornblith A, Cohen H, Hurria A, Winer E, Hudis C, Muss H. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 6015-6015. [DOI: 10.1200/jco.2012.30.15_suppl.6015](https://doi.org/10.1200/jco.2012.30.15_suppl.6015). [Use and duration of (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy (tx).](https://doi.org/10.1200/jco.2012.30.15_suppl.6089)Seah D, Luis I, Olson E, Sohl J, Litsas G, Winer E, Lin N, Burstein H. Use and duration of chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy Journal Tamimi Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Biomarkers of amenorrhea and ovarian function in breast cancer survivors. Journal Of Clinical Oncology 2012, 30: 9071-9071. [DOI: 10.1200/jco.2012.30.15_suppl.9071](https://doi.org/10.1200/jco.2012.30.15_suppl.9071). Partridge A, Tolaney S, Lin N, Winer E. Randomized trial of a physical activity intervention in patients with metastatic breast cancer. Journal Of Clinical Oncology 2012, 30: 9084-9084. 10.1200/jco.2012.30.15_suppl.9084](https://doi.org/10.1200/jco.2012.30.15_suppl.9084). Kereakoglow S, Borges V, Come S, Schapira L, Winer E, Partridge A. Sexual functioning in young women with breast cancer. Journal Of Clinical (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2012.30.15_suppl.cra1002)Rugo H, Barry W, Moreno-Aspitia A, Lyss A, Cirrincione C, Mayer E, Naughton M, Layman R, Carey L, Somer R, Perez E, Hudis C, Winer E. CALGB 40502/NCCTG N063H: Randomized phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Journal Of Clinical Oncology 2012, Bunnell Kalfin M, Partridge A, Lane S, Burstein H, Fine B, Hilton N, Sullivan C, Colicchio L, Hagemeister E, Kelly A, Szabatura A, Winer E, Mann S, Weingart S. Implementation of a team training program in the treatment of breast cancer patients. Journal Of Clinical Oncology carcinoma.](https://doi.org/10.1200/jco.2012.30.15_suppl.e21010)Metzger O, Michiels S, Singhal plasminogen gene (PLAU) to predict clinical outcome in invasive lobular carcinoma. Journal in HER2-positive metastatic breast cancer (LPT112515).](https://doi.org/10.1200/jco.2012.30.15_suppl.tps658)Lin M, David A, Muscato J, Rayson D, Houck W, Ellis C, DeSilvio A, Nagarwala Y, Winer E. HALT MBC: HER2 suppression the addition of lapatinib to trastuzumab in HER2-positive metastatic breast [DOI: 10.1200/jco.2012.30.15_suppl.tps658](https://doi.org/10.1200/jco.2012.30.15_suppl.tps658). - Partridge Tamimi RM. The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer The recurrence, and survival among women with triplenegative breast cancer in the National Comprehensive Cancer Network](http://www.ncbi.nlm.nih.gov/pubmed/22544643)Lin NU, Vanderplas A, Hughes ME, Theriault EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triplenegative breast cancer in the National Comprehensive Cancer Network line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci in paclitaxel-induced peripheral neuropathy](https://doi.org/10.1158/1538-7445.am2012-1881)Wheeler H, Gamazon E, Njiaju U, Wing C, Njoku C, Baldwin R, Owzar K, Winer E, Hudis C, Shulman L, Ratain M, Kroetz D, Cox N, Dolan M. Abstract 1881: Integration of cell line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci AH. Quality of Life in Long-Term Survivors of Metastatic Breast Cancer Clinical Breast Cancer 2012, 12: 119-126. [PMID: 22444718](https://pubmed.ncbi.nlm.nih.gov/22444718), [DOI: 10.1016/j.clbc.2012.01.010](https://doi.org/10.1016/j.clbc.2012.01.010). - Cardoso Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Leo Saghir Ganz Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1) The Breast 2012, 21: 242-252. [PMID: ErbB family blocker, in patients breast cancer progressing after trastuzumab](http://www.ncbi.nlm.nih.gov/pubmed/22418700)Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab Breast Cancer international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting](https://doi.org/10.1016/s0959-8049(12)70057-6)Cardoso F, Winer E, Norton L, Gomis R, Krop I, Harbeck N, Costa A. E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting European Journal Of Cancer 2012, 48: s13-s14. [DOI: 10.1016/s0959-8049(12)70057-6](https://doi.org/10.1016/s0959-8049(12)70057-6). [413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy-Results From CALGB/Intergroup 9741](https://doi.org/10.1016/s0959-8049(12)70479-3)Ligibel J, Cirrincione C, Citron Gradishar Martino S, Hudis C, Winer E, Berry D. 413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy-Results From CALGB/Intergroup 9741 Of Cancer 2012, [DOI: 10.1016/s0959-8049(12)70479-3](https://doi.org/10.1016/s0959-8049(12)70479-3). [The American Society of Clinical Oncology's for Transforming Clinical and Translational Cancer Research](http://www.ncbi.nlm.nih.gov/pubmed/22215747)Meropol NJ, Kris MG, Winer EP. The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research Journal Clinical Trastuzumab in HER2Positive Metastatic Breast Cancer (LPT112515).](https://doi.org/10.1158/0008-5472.sabcs11-ot1-02-02)Lin N, Danso M, David A, Muscato J, Ellis C, DeSilvio M, A, Nagarwala Y, Winer E. OT1-02-02: HALT HER2 Addition Lapatinib to Trastuzumab in HER2Positive Metastatic of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-ot3-02-04)Mayer E, Ligibel J, Burstein H, Peppercorn J, Miller K, Carey L, Dickler M, Mayer I, Forero A, Eng-Wong J, Pletcher P, Ryabin N, A, E. OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. Cancer Research 2011, 71: ot3-02-04-ot3-02-04. [DOI: 10.1158/0008-5472.sabcs11-ot3-02-04](https://doi.org/10.1158/0008-5472.sabcs11-ot3-02-04). [P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-p1-06-23)Sprecher E, Lezon-Geyda K, Sarkar Bossuyt V, Narayaan A, Krop I, Winer E, Tuck D, Kleinstein S, Harris L. P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer. Cancer Research 2011, 71: p1-06-23-p1-06-23. [DOI: 10.1158/0008-5472.sabcs11-p1-06-23](https://doi.org/10.1158/0008-5472.sabcs11-p1-06-23). [P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype.](https://doi.org/10.1158/0008-5472.sabcs11-p1-08-05)Partridge A, Hughes M, Ottesen R, Wong Y, Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Tamimi R. P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype. Cancer Research 2011, 71: p1-08-05-p1-08-05. [DOI: 10.1158/0008-5472.sabcs11-p1-08-05](https://doi.org/10.1158/0008-5472.sabcs11-p1-08-05). [P1-17-02: A 1/2 Study (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen.](https://doi.org/10.1158/0008-5472.sabcs11-p1-17-02)Tolaney S, Burris H, Gartner E, Mayer I, Saura Maurer M, DeCillis A, Ruiz-Soto R, Lager J, Winer E, I. P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous 71: from a Phase 2 Randomized Discontinuation Trial.](https://doi.org/10.1158/0008-5472.sabcs11-p1-17-10)Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak C, Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Cancer Research 2011, 71: p1-17-10-p1-17-10. [DOI: 10.1158/0008-5472.sabcs11-p1-17-10](https://doi.org/10.1158/0008-5472.sabcs11-p1-17-10). Metabolic Response Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Mayer I, Hobday Falkson C, Dees E, Gelman R, Rimawi M, Nanda R, Berkowitz J, Franchetti Y, Wolff A, Winer E, Lin N, Van den Abbeele A. P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative 2011, 71: p2-09-07-p2-09-07. [DOI: 10.1158/0008-5472.sabcs11-p2-09-07](https://doi.org/10.1158/0008-5472.sabcs11-p2-09-07). [P2-17-06: Patterns of Bone Density Evaluation in a Community Population Treated with Aromatase Inhibitors.](https://doi.org/10.1158/0008-5472.sabcs11-p2-17-06)Ligibel J, O'Malley A, Fisher M, Daniel G, Winer E, Keating N. P2-17-06: Patterns of Bone Density Evaluation in a Community Population Treated with Aromatase Inhibitors. Cancer Research 2011, 71: p2-17-06-p2-17-06. [DOI: 10.1158/0008-5472.sabcs11-p2-17-06](https://doi.org/10.1158/0008-5472.sabcs11-p2-17-06). [P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA).](https://doi.org/10.1158/0008-5472.sabcs11-p2-18-02)Dang C, Tolaney S, Najita J, Gelman R, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff A, Carey L, Vahdat L, Burdette-Radoux S, Budd T, Krop I, Burstein H, Hudis C, Winer E. P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA). Cancer Research 2011, 71: p2-18-02-p2-18-02. 10.1158/0008-5472.sabcs11-p2-18-02](https://doi.org/10.1158/0008-5472.sabcs11-p2-18-02). S, Winer E, Partridge A, Mayer E. P2-19-02: Multidisciplinary Treatment of Cancer Research 2011, 71: p2-19-02-p2-19-02. [DOI: 10.1158/0008-5472.sabcs11-p2-19-02](https://doi.org/10.1158/0008-5472.sabcs11-p2-19-02). [P3-16-05: A Phase Inhibitor Veliparib (ABT888) S, Overmoyer B, Tung N, Gelman R, Habin K, Qian J, Giranda V, Shepherd S, Garber J, Ellisen L, Winer E, Goss P. P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in 2011, 71: p3-16-05-p3-16-05. 10.1158/0008-5472.sabcs11-p3-16-05](https://doi.org/10.1158/0008-5472.sabcs11-p3-16-05). [P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-10)Tracy M, Meyer M, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come S, Winer E, Partridge A. P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer. Cancer Research 2011, 71: p4-11-10-p4-11-10. [DOI: 10.1158/0008-5472.sabcs11-p4-11-10](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-10). [P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy.](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-12)Collins L, Gelber S, Marotti J, Cole K, Kereakoglow S, Ruddy K, Brachtel E, Schapira L, Come S, Borges V, Schedin P, Warner E, Winer E, Partridge A. P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy. Cancer Research 2011, 71: p4-11-12-p4-11-12. [DOI: 10.1158/0008-5472.sabcs11-p4-11-12](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-12). E, Partridge A. P4-19-03: Physical and Psychological Sequelae of Breast Cancer in Men. Cancer Research 2011, 71: p4-19-03-p4-19-03. [DOI: 10.1158/0008-5472.sabcs11-p4-19-03](https://doi.org/10.1158/0008-5472.sabcs11-p4-19-03). [PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery.](https://doi.org/10.1158/0008-5472.sabcs11-pd04-05)Rosenberg S, Tamimi R, Gelber S, Kereakoglow S, Borges S, Schapira L, Winer E, Partridge A. PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery. Cancer Research 2011, 71: pd04-05-pd04-05. [DOI: 10.1158/0008-5472.sabcs11-pd04-05](https://doi.org/10.1158/0008-5472.sabcs11-pd04-05). [PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-pd05-07)Olson E, Flores L, Najita J, Curley C, Jeong J, Murray K, Savoie J, Winer E, Krop I. PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. Cancer Research A and Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-pd09-04)Schoffski P, De Benedictis E, Gendreau S, Gianni L, Krop I, Levy G, Ware J, H, Winer E. PD09-04: A Phase Ib, Open-Label, Dose-Escalation Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer. Cancer Research 2011, 71: Kuba M, Sanders M, Yap J, Y, Winer E, - Winer PL1-1: How To Use Endocrine Therapy for Breast Cancer: Beyond the Basics. Cancer Research 2011, 71: pl1-1-pl1-1. [DOI: 10.1158/0008-5472.sabcs11-pl1-1](https://doi.org/10.1158/0008-5472.sabcs11-pl1-1). - Olson EM, Lin NU, Krop IE, Winer EP. Use of discard pleural fluid in molecular research Cameron DB, Winer EP, Earle CC. Breast Cancer Survivors' Perceptions of [Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/22080245)Collins LC, Marotti JD, AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer Breast Cancer Research And Treatment 2011, 131: 1061-1066. [PMID: 22080245](https://pubmed.ncbi.nlm.nih.gov/22080245), [DOI: Omitted in a Subset of Patients with Low Local and Regional Failure Rates?](http://www.ncbi.nlm.nih.gov/pubmed/22017599)Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates? The Breast Journal 2011, 18: - Lim E, Winer EP. Adjuvant chemotherapy in luminal breast cancers The 20: s128-s131. [PMID: 22015279](https://pubmed.ncbi.nlm.nih.gov/22015279), [DOI: 10.1016/s0960-9776(11)70309-5](https://doi.org/10.1016/s0960-9776(11)70309-5). - Winer E, Lin N. State of the Art Treatment of Triple Negative Breast Cancer The Breast 2011, 20: s16-s17. [DOI: 10.1016/j.breast.2011.08.016](https://doi.org/10.1016/j.breast.2011.08.016). [Breast Medical Oncologists' Use Predict a 21Gene Recurrence Score](http://www.ncbi.nlm.nih.gov/pubmed/21934103)Kamal AH, Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21Gene in a cohort of community-based breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/21881937)Ligibel JA, James O'Malley A, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients Breast Cancer Research And Treatment 2011, 131: 589-597. [PMID: 21881937](https://pubmed.ncbi.nlm.nih.gov/21881937), [DOI: 10.1007/s10549-011-1754-1](https://doi.org/10.1007/s10549-011-1754-1). [5025 of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) - Results of an Exploratory Analysis by Prior Therapy](https://doi.org/10.1016/s0959-8049(11)71467-8)O'Shauqhnessv J, Telli M, Swain S, Gralow J, Rugo H, Litton J, Charpentier E, Smith J, Blackwood-Chirchir A, Winer E. 5025 POSTER DISCUSSION Phase 3 Study of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) - Results of an Exploratory Analysis by Prior Therapy European Journal Of Cancer 2011, 47: RS. Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer? International Journal Of Breast Krop IE, Winer EP. The ethical use of mandatory research biopsies Nature Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities](http://www.ncbi.nlm.nih.gov/pubmed/21810680)Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA. American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities Journal Of Clinical Oncology 2011, 29: 3816-3824. to trastuzumab exposure in cell lines and early stage HER2+ breast tumors](https://doi.org/10.1145/2147805.2147867)Sprecher E, Sarkar S, Kleinstein S, Narayan M, Winer E, Tuck D, Lezon-Geyda K, Krop I, Harris L. Association between response to brief trastuzumab exposure in cell lines and early stage HER2+ breast tumors 2011, 446-450. [DOI: 10.1145/2147805.2147867](https://doi.org/10.1145/2147805.2147867). [p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)](http://www.ncbi.nlm.nih.gov/pubmed/21693655)Lara IC, Norton L, Hudis CA, Ellis MJ, Berry DA, Hayes DF, B F. p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) Clinical (RAD001) in Patients With HER2-Overexpressing Breast Cancer Who on Trastuzumab-Based Therapy](http://www.ncbi.nlm.nih.gov/pubmed/21730275)Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer Esteva FJ. I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy Goldhirsch A. CMF revisited 305-311. or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/21706359)Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast ZK-EPO) in Patients With Breast Cancer and Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/21697017)Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU. A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and with metastatic breast cancer: combined analysis of CALGB 9342 and 9840](http://www.ncbi.nlm.nih.gov/pubmed/21693770)Lichtman Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H, B F. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB (G/C) (TNBC).](https://doi.org/10.1200/jco.2011.29.15_suppl.1007)O'Shaughnessy Danso M, Rugo H, Miller K, Yardley D, Carlson R, Finn R, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A, Winer E. A randomized phase III study of (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.](https://doi.org/10.1200/jco.2011.29.15_suppl.1025)Isakoff S, Goss P, Mayer E, Traina T, Carey L, Krag K, Rugo H, Liu M, Stearns V, Come S, Borger D, Quadrino C, Finkelstein D, Garber J, Ryan P, Winer E, Ellisen L. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal Of Clinical Oncology 2011, 29: 1025-1025. in combination with the in recurrent ovarian or triple-negative breast cancer.](https://doi.org/10.1200/jco.2011.29.15_suppl.5028)Liu J, Fleming G, Tolaney S, Birrer M, Penson R, Berlin S, Whalen C, Tyburski K, Matijevich K, Kasparian E, Roche M, Lee H, Winer E, Ivy S, Matulonis U. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast Oncology 2011, 29: 10.1200/jco.2011.29.15_suppl.5028](https://doi.org/10.1200/jco.2011.29.15_suppl.5028). of and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2011.29.15_suppl.527)Lin N, Mayer I, Najita T, Falkson C, Dees E, Rimawi M, Nanda R, Gelman R, Josephs K, Richardson A, Flores L, Van Den Abbeele A, Yap J, Arteaga C, Wolff A, Krop I, Winer E. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer Journal [DOI: 10.1200/jco.2011.29.15_suppl.527](https://doi.org/10.1200/jco.2011.29.15_suppl.527). Krop Mayer I, Hobday T, Falkson C, Arteaga C, Wolff A, Dees E, Rimawi M, Nanda R, Josephs K, Lin N, E. role of EGFR amplification in trastuzumab resistance: A correlative Tamimi Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Fertility concerns in young women with breast cancer: Results from a prospective cohort study. Journal Of Clinical Oncology 2011, 29: 6025-6025. [DOI: 10.1200/jco.2011.29.15_suppl.6025](https://doi.org/10.1200/jco.2011.29.15_suppl.6025). - Gropper A, Burstein H, Harris L, Anderson K, Gold J, Younger W, Bunnell C, Najita J, Winer E, Mayer E. Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. Oncology 2011, 29: e11074-e11074. 10.1200/jco.2011.29.15_suppl.e11074](https://doi.org/10.1200/jco.2011.29.15_suppl.e11074). [Predictors cancer (MBC) treated with trastuzumab.](https://doi.org/10.1200/jco.2011.29.15_suppl.e11100)Olson E, Najita Sohl J, Arnaout A, Winer E, Lin N. Predictors of survival in patients with HER2+ metastatic breast cancer (MBC) treated with 2011, 29: [DOI: in HER2-positive metastatic breast cancer (LPT112515).](https://doi.org/10.1200/jco.2011.29.15_suppl.tps113)Lin N, Danso M, David A, Muscato J, Ellis C, Lahiri S, Sessa T, Nagarwala Y, Winer E. HER2 suppression the addition of lapatinib to trastuzumab in HER2-positive metastatic breast 018: to treat triple-negative breast cancer (TNBC) brain metastases (BM).](https://doi.org/10.1200/jco.2011.29.15_suppl.tps127)Anders C, Nanda R, Liu M, Blackwell K, Van Poznak C, Abramson V, Storniolo A, Lin N, Stearns V, Melhem A, Puhalla S, Carpenter J, Melisko M, Deal A, Hudis C, Winer E, Perou C, Bradley C, Wolff A, Carey L. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain [Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib](http://www.ncbi.nlm.nih.gov/pubmed/21372222)Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur E, CA, Dang CT. Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib trastuzumab-DM1 in women with HER2-positive metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/21531783)Olson EP, Burstein to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast gene expression after one dose of trastuzumab (T) reveal novel biomarkers of response to combination therapy in HER2 positive early stage breast cancer](https://doi.org/10.1158/1538-7445.am2011-4719)Harris L, Sprecher E, Wei-Gu L, Lezon-Geyda K, Sakar S, Krop I, Winer E, Tuck D. Abstract 4719: Dynamic changes in gene expression after one dose of trastuzumab (T) reveal novel biomarkers of response to combination therapy in HER2 positive early stage breast cancer Cancer Research 2011, 71: 4719-4719. [DOI: 10.1158/1538-7445.am2011-4719](https://doi.org/10.1158/1538-7445.am2011-4719). [Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference](http://www.ncbi.nlm.nih.gov/pubmed/21431404)Toi M, Winer EP, Inamoto T, Benson JR, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference Annals Of 2011, 18: model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays](http://www.ncbi.nlm.nih.gov/pubmed/21398628)Li A, Liu Z, Lezon-Geyda D, Schulz V, Krop I, Winer E, Harris L, Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809](http://www.ncbi.nlm.nih.gov/pubmed/21324674)Shapiro C, Halabi S, Hars V, Archer C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809 European Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907](http://www.ncbi.nlm.nih.gov/pubmed/21300923)Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, Winer E, Casey R, Bennett S, Cohen HJ, Muss HB. Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907 Journal Of Will preoperative trials change future clinical practice? Clinical Investigation 2011, 1: 59-73. [DOI: 10.4155/cli.10.3](https://doi.org/10.4155/cli.10.3). [Abstract P2-15-01: Long-Term Risk Perceptions and Quality of Life of Women with Ductal Carcinoma In Situ](https://doi.org/10.1158/0008-5472.sabcs10-p2-15-01)Ruddy K, Meyer M, Giobbie-Hurder A, Emmons K, Weeks J, Winer E, Partridge A. Abstract P2-15-01: Long-Term Risk Perceptions and Quality of Life of Women with Ductal Carcinoma In Situ Cancer Research 2010, for Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-13)Mayer E, Shak S, Miller K, Rugo H, Carey L, Ryabin N, Pomeroy C, Yoshizawa C, E, Burstein P3-10-13: Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Cancer Research 2010, 70: p3-10-13-p3-10-13. [DOI: 10.1158/0008-5472.sabcs10-p3-10-13](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-13). [Abstract P3-10-15: Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-15)Anderson J, Yoshizawa C, Winer E, Watson D, Millward C, Tan V, Shak S, Baehner F. Abstract P3-10-15: Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer Cancer Research 2010, 70: p3-10-15-p3-10-15. [DOI: 10.1158/0008-5472.sabcs10-p3-10-15](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-15). [Abstract P3-14-08: Responses to Subsequent with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p3-14-08)Olson E, Lin DiPiro P, Krop I, Winer E, Burstein H. Abstract P3-14-08: Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast 70: p3-14-08-p3-14-08. [DOI: 10.1158/0008-5472.sabcs10-p3-14-08](https://doi.org/10.1158/0008-5472.sabcs10-p3-14-08). [Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial](https://doi.org/10.1158/0008-5472.sabcs10-p4-09-12)Partridge Winer E, Gelber R. Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA 2010, 70: p4-09-12-p4-09-12. [DOI: 10.1158/0008-5472.sabcs10-p4-09-12](https://doi.org/10.1158/0008-5472.sabcs10-p4-09-12). [Abstract P5-10-12: Adherence, Persistence and Toxicity with Oral CMF in Older Women with Early Stage Breast Cancer in CALGB 49907 (Adherence Companion Study 60104)](https://doi.org/10.1158/0008-5472.sabcs10-p5-10-12)Ruddy K, Archer L, Cohen H, Winer E, Hudis C, Muss H, Partridge A. Abstract P5-10-12: Adherence, Persistence and Toxicity with Oral CMF in Older Women with Early Stage Breast Cancer in CALGB 49907 (Adherence Companion Study Combination with Advanced HER2-Positive Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p6-15-02)Krop I, Wolff A, Winer E, Miller K, Park B, Ware J, Holden S, Levy G, Derynck M, Storniolo A. Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study](https://doi.org/10.1158/0008-5472.sabcs10-pd05-01)Burstein H, Barry W, Cirrincione C, Chew H, Tolaney S, Lake D, Pluard T, Blackwell K, Winer E, Hudis C. Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase 10.1158/0008-5472.sabcs10-pd05-01](https://doi.org/10.1158/0008-5472.sabcs10-pd05-01). [Abstract PD07-08: Integrated to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-pd07-08)Harris L, Liu Z, Li A, Sprecher E, Sarkar S, Lezon-Geyda K, Krop I, Winer E, Tuck D. Abstract PD07-08: Integrated Genomic Analysis before and after Brief Exposure to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast Cancer Cancer Research 2010, 70: pd07-08-pd07-08. [DOI: 10.1158/0008-5472.sabcs10-pd07-08](https://doi.org/10.1158/0008-5472.sabcs10-pd07-08). - Ligibel J, O'Malley A, Fisher M, Daniel G, Winer E, Keating N. Abstract S2-6: Aromatase Inhibitors and Risk of Myocardial Infarction, Stroke Research 2010, 70: s2-6-s2-6. 10.1158/0008-5472.sabcs10-s2-6](https://doi.org/10.1158/0008-5472.sabcs10-s2-6). [Abstract S6-3: Four Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 \u2014 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy](https://doi.org/10.1158/0008-5472.sabcs10-s6-3)Shulman L, Cirrincione C, Berry D, Becker H, Perez E, O'Regan R, Martino S, Atkins J, Hudis C, Winer E. Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 \u2014 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy Cancer Research 2010, 70: s6-3-s6-3. [DOI: 10.1158/0008-5472.sabcs10-s6-3](https://doi.org/10.1158/0008-5472.sabcs10-s6-3). [Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Time to Step Out of the Limelight](http://www.ncbi.nlm.nih.gov/pubmed/21149664)Lin NU, Winer EP. Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Time to Step Out of the Limelight Journal Of Clinical Oncology 2010, Carter WB, Edge SB, Erban JK, McCormick Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. Journal Of The National Comprehensive Network 2010, 8: 1182-207. [PMID: 20971842](https://pubmed.ncbi.nlm.nih.gov/20971842), [DOI: 10.6004/jnccn.2010.0087](https://doi.org/10.6004/jnccn.2010.0087). [The association of status, and socioeconomic factors with breast cancer care](http://www.ncbi.nlm.nih.gov/pubmed/20939011)Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care Cancer 2010, 117: 180-189. [PMID: 20939011](https://pubmed.ncbi.nlm.nih.gov/20939011), [DOI: 10.1002/cncr.25542](https://doi.org/10.1002/cncr.25542). - Golshan N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? Poly(ADP-Ribose) Polymerase Inhibition: \"Targeted\" Therapy Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes](http://www.ncbi.nlm.nih.gov/pubmed/20581724)Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes Menopause The Journal Of The North American Menopause Society 2010, 17: 908-916. [PMID: 20581724](https://pubmed.ncbi.nlm.nih.gov/20581724), EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review Progress In Cardiovascular Diseases 2010, 53: 94-104. [PMID: 20728696](https://pubmed.ncbi.nlm.nih.gov/20728696), [DOI: 10.1016/j.pcad.2010.05.006](https://doi.org/10.1016/j.pcad.2010.05.006). [Physical and Psychological Outcomes Among Women in a Telephone-Based Exercise Intervention During Adjuvant Therapy for Early Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20629579)Ligibel JA, Partridge A, Giobbie-Hurder A, Campbell N, Shockro L, Salinardi T, Winer EP. Physical and Psychological Outcomes Among Women in a Telephone-Based Exercise Intervention During Adjuvant Therapy for Early Stage Breast Cancer Journal Of Women's Health 2010, 19: 1553-1559. [PMID: 20629579](https://pubmed.ncbi.nlm.nih.gov/20629579), Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20625130)Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer Journal Women Receiving Adjuvant Tamoxifen for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20554945)Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett E, Kimmick Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N. Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer Journal Of The National Cancer Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians](http://www.ncbi.nlm.nih.gov/pubmed/20516438)Mandelblatt JS, Sheppard VB, Hurria A, Kimmick AM, Luta G, Tallarico M, Barry Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H. Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians Journal Of Clinical HER2-overexpressing breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.1014)Morrow P, Wulf G, Booser D, Moore J, Flores P, Krop I, Winer E, Hortobagyi G, Yu D, Esteva F. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing Oncology 2010, 28: temozolomide for metastatic Tung N, Gelman R, Giranda V, Bernhard K, Habin K, Ellisen L, Winer E, Goss P. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for 1019-1019. [DOI: 10.1200/jco.2010.28.15_suppl.1019](https://doi.org/10.1200/jco.2010.28.15_suppl.1019). [Phase I study (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.1154)Lin N, Ramakrishna N, Younger W, Storniolo A, Come S, Gelman R, Eisenberg E, Winer E. Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. Journal Of Clinical Oncology 2010, 28: 1154-1154. [DOI: 10.1200/jco.2010.28.15_suppl.1154](https://doi.org/10.1200/jco.2010.28.15_suppl.1154). - Partridge A, Hughes Wong Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Tamimi R. The effect of age on delay in diagnosis and stage of breast cancer. Journal Of Clinical Oncology 2010, 28: 1580-1580. [DOI: 10.1200/jco.2010.28.15_suppl.1580](https://doi.org/10.1200/jco.2010.28.15_suppl.1580). [Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.507)Hughes K, Schnaper L, Cirrincione C, Berry D, McCormick B, Muss H, Shank B, Hudis C, Winer E, Smith B. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. Journal Of Clinical Oncology 2010, 28: 507-507. [DOI: or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms.](https://doi.org/10.1200/jco.2010.28.15_suppl.549)Krop I, Flores L, Tuck D, Ryan P, Partridge A, Morganstern D, Najita J, lezon-Geyda K, Winer E, Harris L. Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. Journal Of Clinical Oncology 2010, 28: 549-549. [DOI: 10.1200/jco.2010.28.15_suppl.549](https://doi.org/10.1200/jco.2010.28.15_suppl.549). - Mayer E, Nohria A, Miller K, Rugo H, Carey L, Ryabin N, Gelman R, Winer E, Burstein H. Cardiovascular safety of adjuvant bevacizumab for breast cancer. Journal Of Clinical Oncology 2010, 28: 571-571. [DOI: 10.1200/jco.2010.28.15_suppl.571](https://doi.org/10.1200/jco.2010.28.15_suppl.571). [Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care?](https://doi.org/10.1200/jco.2010.28.15_suppl.574)Freedman R, Virgo K, He Y, Pavluck A, Winer E, Ward E, Keating N. Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care? Journal Of Clinical Oncology 2010, L, Come S, Meyer M, Winer E, Partridge A. Coping strategies in young women with breast cancer. Journal Of Clinical Oncology 2010, 28: of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.tps103)Mayer E, Ligibel J, Burstein H, Miller K, Carey L, Rugo H, Ryabin N, Gelman R, Winer E, Wolff A. TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. Journal Of Clinical Oncology 2010, 28: tps103-tps103. [DOI: 10.1200/jco.2010.28.15_suppl.tps103](https://doi.org/10.1200/jco.2010.28.15_suppl.tps103). [Randomized to neoadjuvant weekly paclitaxel and cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.tps110)Sikov W, Perou C, Golshan M, Collyar D, Berry D, Hahn O, Singh B, Hudis C, Winer E. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative 28: 10.1200/jco.2010.28.15_suppl.tps110](https://doi.org/10.1200/jco.2010.28.15_suppl.tps110). of and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2010.28.15_suppl.tps132)Lin N, Mayer I, Hobday C, Dees E, Nanda R, M, Wolff A, Winer E. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer Trastuzumab and Lapatinib in HER2/neu-Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea](http://www.ncbi.nlm.nih.gov/pubmed/20479410)Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Doxorubicin Cyclophosphamide Paclitaxel With Trastuzumab and Lapatinib in HER2/neu-Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea Journal Of Clinical EP, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations Breast Cancer Research Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104](http://www.ncbi.nlm.nih.gov/pubmed/20368559)Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study Can Metastatic Breast Cancer Be Cured?](http://www.ncbi.nlm.nih.gov/pubmed/20220104)Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? Journal Of The EP, Ligibel J, Emmons KM. The role of socioeconomic status in adjustment after ductal carcinoma in situ Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, EP, Garber JE. Efficacy of Cisplatin on the Point-Counterpoint on Leonard Zwelling MD; Letters: \"Advances in Bone Biology Research Setting Stage for New Cancer Therapies\" (11/25/09 issue), by W. Reid Pitts, Jr., MD](https://doi.org/10.1097/01.cot.0000368015.24121.d3)Seidman A, Hudis C, Winer E, Zwelling L. Letters: Andrew Seidman, Clifford Hudis, and Eric Winer on the Point-Counterpoint on Leonard Zwelling MD; Letters: \"Advances in Bone Biology Research Setting Stage for New Cancer Therapies\" (11/25/09 issue), by W. Reid Pitts, Jr., MD Oncology 32: 3-4. [DOI: Freedman EP. Adjuvant therapy for postmenopausal women with endocrine-sensitive Sequential A, Cufer T, Albain K. Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy Journal Of National Institute 2010, 102: 207-208. [DOI: 10.1093/jnci/djp484](https://doi.org/10.1093/jnci/djp484). [Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-1067)Ruddy K, Gelber S, Tamimi R, Mayer E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer. Cancer Research 2009, 69: 1067-1067. [DOI: 10.1158/0008-5472.sabcs-09-1067](https://doi.org/10.1158/0008-5472.sabcs-09-1067). [Prediction of 10-Year Chemotherapy Benefit and Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer - An Update of SWOG-8814 (INT0100).](https://doi.org/10.1158/0008-5472.sabcs-09-112)Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, Bugarini R, Baehner F, Davidson N, Sledge G, Winer E, Hudis C, Ingle J, Perez E, Pritchard K, Shepherd L, Gralow J, Yoshizawa C, Allred D, Osborne C, Hayes D. Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer - An Update Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity.](https://doi.org/10.1158/0008-5472.sabcs-09-3088)Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Patil S, Winer E, Norton L, Hudis C, Dang C. Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis.](https://doi.org/10.1158/0008-5472.sabcs-09-4032)Harris L, Parker J, Broadwater G, Schulz V, Halligan K, Geyda K, Seidman A, Berry D, Winer E, Hudis C, Krasnitz A, Hicks J, Tuck D, Perou C. Genome-Wide Profiling of Archived Material from CALGB 9840 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. Cancer Research 2009, 69: 4032-4032. [DOI: 10.1158/0008-5472.sabcs-09-4032](https://doi.org/10.1158/0008-5472.sabcs-09-4032). - Golshan M, Garber J, Gelman R, Tung N, Smith B, Troyan S, Greenberg C, Winer E, Ryan P. Surgical Complications and the Use of Neoadjuvant Bevacizumab. Cancer Research 2009, 69: 43-43. [DOI: 10.1158/0008-5472.sabcs-09-43](https://doi.org/10.1158/0008-5472.sabcs-09-43). [Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907).](https://doi.org/10.1158/0008-5472.sabcs-09-5035)Kornblith A, Archer L, Lan L, Kimmick G, Partridge A, Casey R, Bennett S, Hudis C, Winer E, Cohen H, Muss H. Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907). Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.](https://doi.org/10.1158/0008-5472.sabcs-09-5060)Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E. Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. Cancer Research 2009, 69: 5060-5060. [DOI: 10.1158/0008-5472.sabcs-09-5060](https://doi.org/10.1158/0008-5472.sabcs-09-5060). [Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study.](https://doi.org/10.1158/0008-5472.sabcs-09-6007)Collins L, Collins L, Gelber S, Gelber S, Ruddy K, Ruddy K, Tamimi R, Tamimi R, Come S, Come S, Marotti J, Marotti J, Schapira L, Schapira A, Partridge A. Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study. Cancer Research 2009, 69: 6007-6007. [DOI: 10.1158/0008-5472.sabcs-09-6007](https://doi.org/10.1158/0008-5472.sabcs-09-6007). [Benefits of Adding Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148).](https://doi.org/10.1158/0008-5472.sabcs-09-606)Berry Thor Jewell Broadwater G, Edgerton S, Hayes D, Hudis C, Winer E, Nielsen T, Ellis M. Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in and value of score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of trial](http://www.ncbi.nlm.nih.gov/pubmed/20005174)Albain KS, Barlow Shak Osborne CK, Hayes DF, America F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women Breast Cancer Research And Treatment 2009, 121: Mammography \u2014 More Agreement Than Disagreement New England Journal Of Medicine 2009, 361: With Frequent Short-Term Changes in Left Ventricular Ejection Fraction](http://www.ncbi.nlm.nih.gov/pubmed/19901120)Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction Journal Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology](http://www.ncbi.nlm.nih.gov/pubmed/19901123)Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith Obel J, Vogelzang N, R, D, Ganz PA, Kramer B. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology Journal Receptor 2-Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy](http://www.ncbi.nlm.nih.gov/pubmed/19884535)Burstein HJ, Winer EP. Refining Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy Journal Of Clinical Oncology PL, Hayes DF, C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Archives Of Pathology & Laboratory Medicine 2009, 133: 1515-38. [PMID: 19792042](https://pubmed.ncbi.nlm.nih.gov/19792042), [DOI: 10.5858/133.10.1515](https://doi.org/10.5858/133.10.1515). - Lester S, Chen Y, Connolly J, de Baca M, Fitzgibbons P, Hayes D, Kleer C, O'Malley F, Page D, Smith B, Tan L, Weaver D, Winer E. Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast Archives Of Pathology & Laboratory Medicine 2009, 133: 1515-1538. [DOI: 10.5858/133.10.1515](https://doi.org/10.5858/133.10.1515). [International Guidelines International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy Journal Of biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib](https://doi.org/10.1016/s1359-6349(09)70926-7)Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Winer E, Norton L, Hudis C, Dang C. 5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib European Journal Of Cancer Supplements 2009, 7: 271. [DOI: 10.1016/s1359-6349(09)70926-7](https://doi.org/10.1016/s1359-6349(09)70926-7). - Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial Differences in Definitive Breast Cancer Therapy in Older Women Medical Care 2009, 47: 765-773. [PMID: 19536008](https://pubmed.ncbi.nlm.nih.gov/19536008), [DOI: 10.1097/mlr.0b013e31819e1fe7](https://doi.org/10.1097/mlr.0b013e31819e1fe7). - Winer E. Adjuvant [DOI: Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in of CALGB 8541/150013](http://www.ncbi.nlm.nih.gov/pubmed/19470942)Harris DA, Winer P, Ellis M, Dressler L. Topoisomerase II Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB patients with metastatic breast cancer after failure of treatment with trastuzumab](https://doi.org/10.1200/jco.2009.27.15_suppl.1023)Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer patients with metastatic breast cancer after failure of treatment with trastuzumab Of Clinical Oncology 2009, 27: 1023-1023. [DOI: and postmenopausal women with estrogen receptor (ER)+ advanced breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.1050)Come S, Parker L, Wulf G, Kuter I, Ryan P, Tkaczuk K, Borges V, Kasper H, Gelman R, Winer E. Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast Clinical Oncology 2009, 27: 1050-1050. [DOI: 10.1200/jco.2009.27.15_suppl.1050](https://doi.org/10.1200/jco.2009.27.15_suppl.1050). [Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)](https://doi.org/10.1200/jco.2009.27.15_suppl.543)Lin N, Vanderplas A, Hughes M, Theriault R, Edge S, Wong Y, Blayney D, Niland J, Winer E, Weeks J. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN) Journal Of Clinical Oncology 2009, 27: 543-543. [DOI: 10.1200/jco.2009.27.15_suppl.543](https://doi.org/10.1200/jco.2009.27.15_suppl.543). - Ryan P, Tung N, Isakoff S, Golshan M, Richardson A, Corben A, Smith B, Gelman R, Winer E, Garber J. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy Journal Of Clinical Oncology 2009, [DOI: 10.1200/jco.2009.27.15_suppl.551](https://doi.org/10.1200/jco.2009.27.15_suppl.551). [Personalizing treatment in early-stage cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making](https://doi.org/10.1200/jco.2009.27.15_suppl.572)Gold J, Najita J, Lester S, Richardson A, Morganstern D, Chen W, Partridge A, Krop I, Winer E, Burstein H. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making Journal Of Clinical Oncology 2009, 27: 572-572. Come S, Kereakoglow S, Lin N, Winer E, Partridge A. Presentation of breast cancer in young women Journal Of Clinical Oncology 2009, 27: Partridge AH, LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer New England Journal Of strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors](http://www.ncbi.nlm.nih.gov/pubmed/19434504)Ligibel JA, Giobbie-Hurder D, Campbell N, Salinardi T, Winer EP, Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors Cancer Causes 2009, 20: 1523-1528. Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive 9: 101-107. [PMID: 19433391](https://pubmed.ncbi.nlm.nih.gov/19433391), [DOI: 10.3816/cbc.2009.n.019](https://doi.org/10.3816/cbc.2009.n.019). [Tolerability of therapy with gefitinib and capecitabine in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19294501)Mayer EL, Partridge AH, RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer Breast Cancer of postmenopausal women with hormone responsive breast cancer The Breast 2009, 18: s16-s17. [DOI: 10.1016/s0960-9776(09)70047-5](https://doi.org/10.1016/s0960-9776(09)70047-5). [Multicenter Phase II Study of with Brain Metastases from HER2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/19228746)Lin N, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler H, Roche H, Liu M, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum J, Rubin S, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, P, Winer E. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer Cancer Research HJ, Carter WB, EC, Smith Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2009, 7: [PMID: Breast Abreu DA. A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Study Results With Trial Participants: Time for Action Journal Of activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer.](https://doi.org/10.1158/0008-5472.sabcs-1117)Ligibel J, Campbell N, Anita G, Shockro L, Salinardi T, Winer E. Impact of a home-based physical activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer. Cancer Research 2009, 69: 1117. [DOI: 10.1158/0008-5472.sabcs-1117](https://doi.org/10.1158/0008-5472.sabcs-1117). [Dose-dense (DD) doxorubicin weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.](https://doi.org/10.1158/0008-5472.sabcs-2108)Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D'Andrea A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robson M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schnipper L, Chen C, Winer E, Norton L, Hudis C. Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. Cancer Research 2009, 69: 2108. [DOI: 10.1158/0008-5472.sabcs-2108](https://doi.org/10.1158/0008-5472.sabcs-2108). Tolaney Fornier M, Krop I, Winer E, Bunnell C. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer [DOI: 10.1158/0008-5472.sabcs-3137](https://doi.org/10.1158/0008-5472.sabcs-3137). - Anderson K, Hodi F, Sasada T, Canning C, Hassett M, Mayer E, Hannagan K, Wong J, Colson Y, Shoji B, Najita J, Sibani S, LaBaer J, Winer E, Dranoff G. A phase I study of an autologous GM-CSF-secreting breast cancer vaccine. Cancer [Uniformly positive (>80%) HER2 expression for prediction of response to trastuzumab in CALGB 9840.](https://doi.org/10.1158/0008-5472.sabcs-6046)Rimm D, Broadwater G, Friedman P, Berry D, Seidman A, Hudis C, Winer E, Harris L, Thor A. Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. Cancer Research 2009, 69: 6046. - Rugo H, Carey L, Mayer E, Marcom P, Liu M, Ma C, Storniolo A, Forero A, Esteva F, Wolff A, Hobday T, Ferraro M, Davidson N, Winer E, Moore D, Scott J, Park J. Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. Cancer Research 2009, 69: 6048. [DOI: 10.1158/0008-5472.sabcs-6048](https://doi.org/10.1158/0008-5472.sabcs-6048). [Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age.](https://doi.org/10.1158/0008-5472.sabcs-6112)Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H. Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age. Cancer Research 2009, 69: 6112. [DOI: 10.1158/0008-5472.sabcs-6112](https://doi.org/10.1158/0008-5472.sabcs-6112). - Mayer E, Isakoff S, Hannagan Savoie J, Beckman J, Klement G, Gelman R, Winer E, Burstein H. A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. Cancer Research 2009, 69: 906. [DOI: 10.1158/0008-5472.sabcs-906](https://doi.org/10.1158/0008-5472.sabcs-906). - Ligibel JA, Golshan M, Emmons K, Winer EP. Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ Annals of specimens from patients with ductal carcinoma in situ of the breast.](http://www.ncbi.nlm.nih.gov/pubmed/19123730)Lester SC, Bose S, Chen YY, PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Archives Of Pathology & Laboratory Medicine 2009, 133: 15-25. [PMID: 19123730](https://pubmed.ncbi.nlm.nih.gov/19123730), [DOI: 10.5858/133.1.15](https://doi.org/10.5858/133.1.15). - Gold J, Winer Chemotherapy for Metastatic Breast Cancer 2009, 1233-1261. [DOI: 10.1016/b978-1-4160-5221-0.00076-0](https://doi.org/10.1016/b978-1-4160-5221-0.00076-0). - Lester S, Bose S, Chen Y, Connolly J, de Baca M, Fitzgibbons P, Hayes D, Kleer C, O'Malley F, Page D, Smith B, Weaver D, Winer E. Protocol for the Examination of Specimens From Patients With Ductal Carcinoma In Situ of the Breast Archives Of Pathology & Laboratory Medicine 2009, 133: 15-25. [DOI: 10.5858/133.1.15](https://doi.org/10.5858/133.1.15). [Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology](http://www.ncbi.nlm.nih.gov/pubmed/19103723)Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology Journal Winer EP, Keating NL. Trends in Racial and Age Disparities in Definitive Local Therapy of Early-Stage Breast Cancer Journal Of Clinical Oncology 2008, GW, Carey LA. Triple-Negative Breast Cancer: Risk Factors to Potential Targets Clinical Cancer Research 2008, 14: 8010-8018. [PMID: 19088017](https://pubmed.ncbi.nlm.nih.gov/19088017), [DOI: 10.1158/1078-0432.ccr-08-1208](https://doi.org/10.1158/1078-0432.ccr-08-1208). - Reducing Disparities in Breast Cancer Care\u2014A Daunting but Essential Responsibility Journal Of The National Cancer Institute 2008, 100: 1661-1663. [PMID: 19033563](https://pubmed.ncbi.nlm.nih.gov/19033563), [DOI: 10.1093/jnci/djn412](https://doi.org/10.1093/jnci/djn412). [VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/19047116)Burstein HJ, Chen YH, LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos LN, Harris LN, Gelman R, Winer EP. VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy Joffe S. Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy [DOI: 10.1200/jco.2008.18.1420](https://doi.org/10.1200/jco.2008.18.1420). - Clinical Oncology 2008, 26: 5138-5139. [DOI: 10.1200/jco.2008.19.0660](https://doi.org/10.1200/jco.2008.19.0660). [Sites of distant recurrence clinical outcomes in patients with metastatic triplenegative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/18833576)Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triplenegative breast Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling H, Weeks J. Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis Journal Of The National Cancer Institute 2008, 100: - Winer duration of adjuvant hormonal therapy for early-stage breast cancer. Clinical Advances In Hematology And Oncology 2008, 6: 573-4. [PMID: 18820598](https://pubmed.ncbi.nlm.nih.gov/18820598). [Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival](http://www.ncbi.nlm.nih.gov/pubmed/18581232)Bafford AC, Burstein HJ, Barkley JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival Breast Cancer Research And Treatment 2008, 115: 7-12. [PMID: Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants Breast Cancer Research And Treatment 2008, 115: 123-129. [PMID: 18543100](https://pubmed.ncbi.nlm.nih.gov/18543100), [DOI: Cancer: A Pooled Analysis of CALGB 9342 and and Leukemia Group B](http://www.ncbi.nlm.nih.gov/pubmed/18509177)Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840\u2014Cancer and Leukemia Group B of Physicians Who Care for Women with Ductal Carcinoma In Situ](http://www.ncbi.nlm.nih.gov/pubmed/18650159)Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E. Perceptions and Management Approaches of Physicians Who Care for Women with Ductal Carcinoma In Situ Clinical Breast Cancer Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Research And Treatment 2008, L, Abusief M, Meyer M, Winer E, Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer Journal Of Clinical Oncology 2008, 26: 9571-9571. [DOI: 10.1200/jco.2008.26.15_suppl.9571](https://doi.org/10.1200/jco.2008.26.15_suppl.9571). - Freedman R, He Y, Winer E, Keating N. Racial disparity trends in definitive primary therapy of early stage breast cancer Journal Of Clinical Oncology 2008, 26: 535-535. [DOI: versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907](https://doi.org/10.1200/jco.2008.26.15_suppl.507)Muss H, Berry D, Cirrincione C, Theodoulou M, Mauer A, Cohen H, Partridge A, Norton L, Hudis C, Winer E. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907 mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980](https://doi.org/10.1200/jco.2008.26.15_suppl.512)Shapiro C, Halabi S, Gibson G, Weckstein R, Paskett E. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980 cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)](https://doi.org/10.1200/jco.2008.26.15_suppl.518)Dang C, Lin N, Lake D, Dickler M, Modi S, Seidman A, Steingart R, Norton L, Winer E, Hudis C. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast [DOI: 10.1200/jco.2008.26.15_suppl.518](https://doi.org/10.1200/jco.2008.26.15_suppl.518). pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.519)Mayer E, Miller K, Rugo H, Peppercorn J, Carey L, Ryabin N, Josephs K, Winer E, Burstein H. A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer Journal Of Clinical Oncology 2008, 26: 519-519. [DOI: 10.1200/jco.2008.26.15_suppl.519](https://doi.org/10.1200/jco.2008.26.15_suppl.519). [CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907](https://doi.org/10.1200/jco.2008.26.15_suppl.6542)Partridge A, Archer L, Kornblith A, Gralow J, Grenier D, Perez E, Wolff A, Hudis C, Winer E, Muss H. CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907 Journal of HER2-directed therapy: still questions after all these years Breast Cancer Research And Treatment 2008, 113: 207-209. [PMID: 18463974](https://pubmed.ncbi.nlm.nih.gov/18463974), [DOI: Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A RS, HJ, Winer EP, Weeks JC. Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis Journal Of The National Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18421051)Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, EP. Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Journal Prospective Keshaviah A, Silver B, Harris JR. Tangential Radiotherapy Without Axillary Surgery in Early-Stage Breast Cancer: Results of a Prospective Trial International Journal Of Radiation Oncology Biology Physics 2008, 72: 866-870. [PMID: 18394815](https://pubmed.ncbi.nlm.nih.gov/18394815), [DOI: With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840](http://www.ncbi.nlm.nih.gov/pubmed/18375893)Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake P, Norton L, Winer E, Hudis C. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840 Journal Of Clinical Force O. Metastatic Breast Cancer Session European Journal Of Cancer Supplements 2008, 6: 26. [DOI: 10.1016/s1359-6349(08)70304-5](https://doi.org/10.1016/s1359-6349(08)70304-5). [Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time](http://www.ncbi.nlm.nih.gov/pubmed/18332468)Lin NU, Winer EP. Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time Journal Of Clinical Oncology 2008, 26: 1919-1921. [PMID: quality of life in longterm breast cancer survivors: CALGB AB, Habin KR, Fleming GF, Bittoni MA. Applying a conceptual model for examining healthrelated quality of life in longterm breast MC, Winer EP, Earle CC. Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data Value mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)](http://www.ncbi.nlm.nih.gov/pubmed/18306034)Kimmick G, Cirrincione C, Duggan D, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson I, Hudis C, Winer E, On Behalf of the Cancer and Leukemia Group B. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) Breast Cancer Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors](http://www.ncbi.nlm.nih.gov/pubmed/18281663)Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors Journal Of Clinical Oncology 2008, women with ductal carcinoma in situ: longitudinal results from a cohort study.](http://www.ncbi.nlm.nih.gov/pubmed/18270338)Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. Journal Of The National Cancer Institute 2008, 100: 243-51. [PMID: 18270338](https://pubmed.ncbi.nlm.nih.gov/18270338), [DOI: 10.1093/jnci/djn010](https://doi.org/10.1093/jnci/djn010). [Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions](http://www.ncbi.nlm.nih.gov/pubmed/18258975)Gralow JR, Zujewski JA, Winer E. Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions Journal Of Clinical Oncology 2008, 26: in Adjuvant Endocrine Therapy for Postmenopausal Pathologic Assessment and Systemic Therapy Issues in Operable Disease](http://www.ncbi.nlm.nih.gov/pubmed/18258991)Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni Minckwitz WF, Singh EP. Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease Journal Of Clinical Oncology 2008, 26: Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial](http://www.ncbi.nlm.nih.gov/pubmed/18250349)Perez EA, Suman Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial Journal Of breast cancer: Summary statement for the Sixth Cambridge Conference](http://www.ncbi.nlm.nih.gov/pubmed/18072254)Come SE, Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference Cancer 2008, inhibitor clinical trials in postmenopausal women with early 2008, E, Sampson E, Rosenberg R, Przypyszny M, Winer EP. Fertility and Menopausal Outcomes in Young Breast Cancer Survivors Clinical Breast Cancer 2008, 8: 65-69. [PMID: and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients plus cyclophosphamide followed paclitaxel](http://www.ncbi.nlm.nih.gov/pubmed/18234424)Liu MC, Demetri DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA, B F. Dose-escalation of does improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer Journal Oncology Winer EP. NCCN Task Force Report: breast cancer in the older woman. Journal Of The National Comprehensive Cancer Network 2008, 6 Suppl 4: s1-25; Advances Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology](http://www.ncbi.nlm.nih.gov/pubmed/18086794)Gralow Mayer RJ, RL, Lichter AS. Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology Journal Clinical EP. Heterogeneity of breast cancer and implications of adjuvant Cancer 2007, 15: 31-34. [PMID: 18224391](https://pubmed.ncbi.nlm.nih.gov/18224391), [DOI: 10.1007/s12282-007-0007-y](https://doi.org/10.1007/s12282-007-0007-y). [Does MRI predict women with breast cancer undergoing preoperative chemotherapy?](http://www.ncbi.nlm.nih.gov/pubmed/17640031)Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? Journal Angiography during Treatment of Brain Metastases: A Feasibility Study1](http://www.ncbi.nlm.nih.gov/pubmed/17954616)Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG. Blood Vessel Morphologic Changes Depicted with MR Angiography during Treatment of Brain Rosenberg E, Cort A, Ebeling S, Peters C, Winer E, Harris J, Smith B, D'Alessandro H, Brachtel E. Case 32-2007 \u2014 A 62-Year-Old Woman with a Second Breast Cancer New England Journal Of Medicine 2007, 357: 1640-1648. [PMID: 17942877](https://pubmed.ncbi.nlm.nih.gov/17942877), [DOI: 10.1056/nejmcpc079026](https://doi.org/10.1056/nejmcpc079026). [Care in the Months before Death and Hospice Enrollment Among Older Women with Advanced Breast MB, Guadagnoli E, Winer EP, in the Months before Death and Hospice Enrollment Among Older Women with Advanced Breast Cancer Journal Of General Internal Medicine 2007, 23: Edgerton S, Broadwater G, Goldstein LJ, Martino JN, Hudis CA, Ellis MJ, Berry DA. HER2 and Response to Paclitaxel in Node-Positive Breast Cancer New England Journal Of 357: 1496-1506. [PMID: 17928597](https://pubmed.ncbi.nlm.nih.gov/17928597), [DOI: 10.1056/nejmoa071167](https://doi.org/10.1056/nejmoa071167). - Kornblith Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Longterm psychosocial adjustment of older vs younger survivors of breast cancer Winer EP. Sarcoidosis Extent Should Estrogen Receptor Status Influence the Decision to Recommend Adjuvant Chemotherapy?](https://doi.org/10.1016/s1043-321x(07)80290-6)Lin N, Winer E. Anatomy Versus Biology: To What Extent Should Estrogen Receptor Status Influence the Decision to Recommend Adjuvant Chemotherapy? Breast Diseases A Year Book Quarterly 2007, 18: 232-234. [DOI: 10.1016/s1043-321x(07)80290-6](https://doi.org/10.1016/s1043-321x(07)80290-6). [Erratum: Longterm psychosocial adjustment younger survivors of breast and endometrial cancer](https://doi.org/10.1002/pon.1220)Kornblith A, Powell M, Regan M, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Erratum: Longterm psychosocial adjustment of older vs younger survivors of endometrial cancer Psycho-Oncology or Baron R, Inhibitors and Arthralgias: New Frontier in Symptom Management for Breast Cancer Survivors](http://www.ncbi.nlm.nih.gov/pubmed/17761968)Burstein HJ, Winer EP. Aromatase Inhibitors and Arthralgias: A New Frontier in Symptom Management for Breast Cancer Survivors Journal Of Clinical Oncology 2007, 25: to after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17888101)Thompson D, Taylor Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer 367-376. Neoadjuvant antiHER2 therapy European Journal Of Cancer Supplements 2007, 5: 25. [DOI: 10.1016/s1359-6349(07)70201-x](https://doi.org/10.1016/s1359-6349(07)70201-x). [Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience](http://www.ncbi.nlm.nih.gov/pubmed/17704418)Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience Journal Of Clinical Oncology with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ HER2- metastatic breast cancer (MBC)](https://doi.org/10.1200/jco.2007.25.18_suppl.1009)Kaufman P, Broadwater G, Lezon-Geyda K, Dressler L, Berry D, Friedman P, Winer E, Hudis C, Ellis M, Seidman A, Harris L. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer [DOI: 10.1200/jco.2007.25.18_suppl.1009](https://doi.org/10.1200/jco.2007.25.18_suppl.1009). a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)](https://doi.org/10.1200/jco.2007.25.18_suppl.1012)Lin N, Dieras V, Paul H, Zembryki D, Oliva C, Winer E. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT) Journal Of Clinical Oncology 2007, 25: 1012-1012. [DOI: 10.1200/jco.2007.25.18_suppl.1012](https://doi.org/10.1200/jco.2007.25.18_suppl.1012). - Shin J, Gelber Garber J, Rosenberg R, Przypyszny M, Winer E, Partridge A. Genetic testing in young women with breast cancer: Results from a web-based survey Journal Of Clinical 25: 21093-21093. [Could inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis](https://doi.org/10.1200/jco.2007.25.18_suppl.502)Punglia R, Winer E, Weeks J, Burstein H. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis Journal Clinical Oncology 2007, 25: 502-502. [DOI: 10.1200/jco.2007.25.18_suppl.502](https://doi.org/10.1200/jco.2007.25.18_suppl.502). - Ligibel J, Campbell Chen Salinardi T, Chen W, Partridge A, Mantzoros C, Winer E. Impact of physical activity on insulin levels in breast cancer survivors Journal Of Clinical Oncology 2007, 25: 555-555. [DOI: 10.1200/jco.2007.25.18_suppl.555](https://doi.org/10.1200/jco.2007.25.18_suppl.555). - Mayer E, Miller Rugo Peppercorn J, Carey L, Ryabin N, Winer E, Burstein H. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer Journal Of Clinical Oncology 2007, 25: 561-561. [DOI: 10.1200/jco.2007.25.18_suppl.561](https://doi.org/10.1200/jco.2007.25.18_suppl.561). - Kamal A, Loprinzi C, Reynolds C, Dueck A, Geiger X, Ingle J, Carlson R, Hobday T, Winer E, Perez E, Goetz M. How well do standard prognostic criteria predict oncotype DX (ODX) cancer: A feasibility study](https://doi.org/10.1200/jco.2007.25.18_suppl.594)Burstein H, Mayer E, Peppercorn J, Parker L, Hannagan K, Moy B, Younger J, Schapira L, E. Dose-dense albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study Journal Of Clinical Oncology 2007, [DOI: Aromatase Inhibitors: To Lead Winer EP, Harris JR. Local Therapy and Survival in Breast Cancer New England Journal Of Medicine 2007, 356: 2399-2405. [PMID: 17554121](https://pubmed.ncbi.nlm.nih.gov/17554121), [DOI: 10.1056/nejmra065241](https://doi.org/10.1056/nejmra065241). [Age of menopause among who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI](http://www.ncbi.nlm.nih.gov/pubmed/17512721)Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI European Journal Of Cancer 2007, 43: 1646-1653. JZ. Surveillance Testing Among Survivors of Early-Stage Clinical Oncology 2007, second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions](http://www.ncbi.nlm.nih.gov/pubmed/17345004)Lin NU, Parker LM, Come SE, Burstein HJ, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions 369-375. 10.1007/s10637-007-9034-y](https://doi.org/10.1007/s10637-007-9034-y). - EC, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. Journal Of The National Comprehensive Cancer Network 2007, 5: 246-312. [PMID: 17439758](https://pubmed.ncbi.nlm.nih.gov/17439758), [DOI: 10.6004/jnccn.2007.0025](https://doi.org/10.6004/jnccn.2007.0025). [Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations](http://www.ncbi.nlm.nih.gov/pubmed/17570804)Wray RJ, Stryker JE, Winer E, Demetri G, Emmons KM. Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations Journal Of Cancer Education 2007, 22: 21. [PMID: 17570804](https://pubmed.ncbi.nlm.nih.gov/17570804), [DOI: 10.1007/bf03174370](https://doi.org/10.1007/bf03174370). - Winer S15 Role of baseline staging and follow-up: between reassurance and economic constraints The Breast 2007, 16: s4. [DOI: 10.1016/s0960-9776(07)70038-3](https://doi.org/10.1016/s0960-9776(07)70038-3). - Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials Cancer 2007, 109: 1239-1246. Witkiewicz Lu Ryan PD, SE, Burstein HJ, Lesnikoski Vinorelbine for HER2-Positive Early Breast 1198-1207. [PMID: 17317830](https://pubmed.ncbi.nlm.nih.gov/17317830), [DOI: 10.1158/1078-0432.ccr-06-1304](https://doi.org/10.1158/1078-0432.ccr-06-1304). - Winer E. Adjuvant women Breast Cancer Research 2007, 9: s17. [DOI: 10.1186/bcr1700](https://doi.org/10.1186/bcr1700). Ponte PR, Gross Connaughton MJ, Hassinger J. Implementing an interdisciplinary governance model in a comprehensive cancer center. Oncology Nursing 2007, 34: 611-6. [PMID: 17573318](https://pubmed.ncbi.nlm.nih.gov/17573318), Vredenburgh J, Winer E, Hortobagyi G, Muss H, Sartor C, Rubin E, Hall R, Holland R, Cocquyt V, Rosti G, Fiorentini G, Blondeel P, Avisar E, Doraiswamy P, Hurley J, Abernethy A, Crews J, Jorda M, Velasquez M, Yepes M, Angulo A, Bennett C, Takita C, Kharfan-Dabaja M, Morgensztern D, Heros D, Roman E, Negret L, Lopes G, Rosado M, Fein S, De Cesare T, Abdullah S, Ayala E, Sanchez O, Silva C, Gonzalez E, Brenner J, Silva J, Caldera H, Padmanabhan, Moreno S, Ceballos - Mayer E, Winer E. Aromatase Inhibitors for Breast Cancer Treatment and Prevention 2007, 159-174. [DOI: 10.3109/9781420019940.014](https://doi.org/10.3109/9781420019940.014). [Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342](http://www.ncbi.nlm.nih.gov/pubmed/17129383)Harris LN, Broadwater G, Lin Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing M, Winer E, Partridge A. Menopausal-type symptoms in young breast cancer 17: 1777-1782. [PMID: 16971671](https://pubmed.ncbi.nlm.nih.gov/16971671), [DOI: 10.1093/annonc/mdl299](https://doi.org/10.1093/annonc/mdl299). [Estrogen-Receptor Chemotherapy for Patients With Node-Positive Breast Cancer](https://doi.org/10.1097/01.ogx.0000234789.05150.7c)Berry D, Cirrincione C, Henderson I, Citron M, Budman D, Goldstein L, Martino S, Perez E, Muss H, Norton L, Hudis C, Winer E. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer Obstetrical effect of paclitaxel, dose density and trastuzumab](https://doi.org/10.1016/j.fertnstert.2006.07.514)Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. P-166 Chemotherapy-related amenorrhea in premenopausal women with breast cancer: The effect of paclitaxel, dose density and trastuzumab Fertility And Sterility [DOI: cancer: NCCN Task Force report and recommendations. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl The effect of paclitaxel or dose density](https://doi.org/10.1200/jco.2006.24.18_suppl.10506)Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density Journal Of Clinical Oncology 2006, breast cancer (MBC): A phase I trial](https://doi.org/10.1200/jco.2006.24.18_suppl.10564)Mayer E, Harris L, Partridge A, Gelman R, Schumer S, Comanaru R, Long M, Sampson E, Burstein H, Winer E. Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial Of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors](https://doi.org/10.1200/jco.2006.24.18_suppl.10574)Krop I, Kosh M, Fearen I, Savoie J, Dallob A, Matthews C, Stone J, Winer E, Freedman S, Lorusso P. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors Journal Of Clinical Oncology 2006, 24: 10574-10574. [DOI: 10.1200/jco.2006.24.18_suppl.10574](https://doi.org/10.1200/jco.2006.24.18_suppl.10574). [Superiority of measuring response of metastatic brain tumors](https://doi.org/10.1200/jco.2006.24.18_suppl.1542)Kilpatrick M, Linn N, Smith J, Winer E, Bullitt E, Carey L, Ewend M. Superiority of bi-dimensional measurements compared to RECIST in measuring response of metastatic brain tumors Journal Of Clinical Oncology 2006, 24: 1542-1542. [DOI: 10.1200/jco.2006.24.18_suppl.1542](https://doi.org/10.1200/jco.2006.24.18_suppl.1542). - Lin N, Carey L, Liu M, Younger J, Come S, Bullitt E, Van Den Abbeele A, Li X, Hochberg F, Winer E. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer Journal Of Clinical Oncology 2006, 24: 503-503. [DOI: 10.1200/jco.2006.24.18_suppl.503](https://doi.org/10.1200/jco.2006.24.18_suppl.503). - Partridge A, Wolff A, Marcom P, Kaufman P, Moore C, Lake D, Fleming G, Rugo H, Collyar D, Winer E. Study participants' perceptions of the process and impact of receiving results of N9831 Journal Of Clinical Oncology 2006, 24: 518-518. [DOI: 10.1200/jco.2006.24.18_suppl.518](https://doi.org/10.1200/jco.2006.24.18_suppl.518). [Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience](https://doi.org/10.1200/jco.2006.24.18_suppl.559)Muss H, Berry D, Cirrincione C, Budman D, Henderson I, Citron M, Norton L, Winer E, Hudis C. Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The 2006, 24: 559-559. [DOI: 10.1200/jco.2006.24.18_suppl.559](https://doi.org/10.1200/jco.2006.24.18_suppl.559). [The impact of an exercise intervention on body composition, fat distribution, and weight in breast cancer survivors](https://doi.org/10.1200/jco.2006.24.18_suppl.590)Ligibel J, Chen W, Keshaviah A, Adloff K, Partridge A, Salinardi T, Winer E. The impact of an exercise intervention on body composition, fat distribution, and weight in breast cancer survivors Journal Of Clinical Oncology 2006, 24: 590-590. Burstein H, Winer E. Use of experimental therapy outside of clinical trials among U.S. oncologists Journal Of Clinical Oncology The study](https://doi.org/10.1200/jco.2006.24.18_suppl.650)Burstein Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom P, Gelman R, Winer E. Trastuzumab chemotherapy for HER2+ breast 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer](https://doi.org/10.1200/jco.2006.24.18_suppl.674)Naughton M, Gu L, Wang X, Seidman A, Winer E, Kornblith A. Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast 674-674. [DOI: 10.1200/jco.2006.24.18_suppl.674](https://doi.org/10.1200/jco.2006.24.18_suppl.674). [The impact of tumor receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with earlystage RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806](http://www.ncbi.nlm.nih.gov/pubmed/16773437)Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H, for the Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 Breast Cancer Research And Treatment 2006, and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future Clinical Cancer Research 2006, 12: 3576s-3580s. [PMID: 16740788](https://pubmed.ncbi.nlm.nih.gov/16740788), [DOI: 10.1158/1078-0432.ccr-06-9016](https://doi.org/10.1158/1078-0432.ccr-06-9016). [Inadvertent Use of Aromatase in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons](http://www.ncbi.nlm.nih.gov/pubmed/16800976)Burstein H, Mayer E, Partridge A, O'Kane H, Litsas G, Come S, Hudis C, Goldstein D, Muss H, Winer E, Garber J. Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons Clinical Breast Cancer 2006, 7: 158-161. [PMID: 16800976](https://pubmed.ncbi.nlm.nih.gov/16800976), [DOI: 10.3816/cbc.2006.n.026](https://doi.org/10.3816/cbc.2006.n.026). [Estrogen-Receptor Status and Chemotherapy for Patients With Node-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16609087)Berry DA, Cirrincione C, Henderson IC, Citron ML, DR, Goldstein LJ, Martino S, Winer EP. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Task Force Report: Adjuvant Therapy for Breast Cancer. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 1: s1-26. [PMID: 16507275](https://pubmed.ncbi.nlm.nih.gov/16507275), [DOI: 10.6004/jnccn.2006.2001](https://doi.org/10.6004/jnccn.2006.2001). - Winer E. Should there be guidelines for the treatment of metastatic breast cancer: the U.S. perspective European Journal Of Cancer Supplements 2006, 4: 179. [DOI: 10.1016/s1359-6349(06)80458-1](https://doi.org/10.1016/s1359-6349(06)80458-1). [Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement](http://www.ncbi.nlm.nih.gov/pubmed/16467115)Come SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement Clinical Cancer Research 2006, to Underuse of Surveillance Mammography Among Breast Cancer Survivors Journal 85-94. MG, Zeng D, Winer EP, Carey LA, Smith JK. Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Treatment of Postmenopausal Women with Early Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/19803930)Ligibel JA, Winer EP. Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer Women's Health 2006, 2: 89-97. [PMID: 19803930](https://pubmed.ncbi.nlm.nih.gov/19803930), [DOI: 10.2217/17455057.2.1.89](https://doi.org/10.2217/17455057.2.1.89). [Early Breast Cancer (Stage I Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer](https://doi.org/10.1007/978-3-540-28266-2_17)Krop I, Winer E. Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer 2006, 327-348. [DOI: 10.1007/978-3-540-28266-2_17](https://doi.org/10.1007/978-3-540-28266-2_17). - Lin NU, Gelman R, Winer EP. Dose Density in Breast Cancer: A Simple Message? Journal Of The National Cancer EP. Standards for follow-up care of patients with breast The Breast 2005, 14: 500-508. [PMID: 16288876](https://pubmed.ncbi.nlm.nih.gov/16288876), [DOI: 10.1016/j.breast.2005.09.001](https://doi.org/10.1016/j.breast.2005.09.001). - Kornblith AB, Regan MM, Kim Y, Greer G, Parker B, Bennett S, Winer E. Cancerrelated communication between female patients and male partners scale: a study CA, Kulke MH, Fuchs CS. Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy Journal Of Every-2-Week Adjuvant Breast Cancer Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/16293865)Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy 8340-8347. [PMID: postmenopausal women: a therapeutic advance but many unresolved questions](http://www.ncbi.nlm.nih.gov/pubmed/16457700)Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions Breast Cancer Research 2005, 7: 255. [PMID: radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/16243442)Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer International Journal Of Radiation Oncology Biology Physics 2005, 64: 496-504. [PMID: 16243442](https://pubmed.ncbi.nlm.nih.gov/16243442), [DOI: 10.1016/j.ijrobp.2005.07.975](https://doi.org/10.1016/j.ijrobp.2005.07.975). [Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret](http://www.ncbi.nlm.nih.gov/pubmed/16242898)Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret Patient Education And Counseling 2005, 63: 104-109. [PMID: 16242898](https://pubmed.ncbi.nlm.nih.gov/16242898), [DOI: 10.1016/j.pec.2005.09.006](https://doi.org/10.1016/j.pec.2005.09.006). [Quality of life among patients with Stage II and III breast carcinoma randomized to receive highdose chemotherapy with autologous bone marrow support or intermediatedose chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/16118805)Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E, Group T. Quality of life among patients with Stage II and III breast carcinoma randomized to receive highdose chemotherapy with autologous bone marrow support Society for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16157938)Lyman GH, Giuliano AE, Somerfield AB, AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Journal HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/16150805)Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based Suppression for Breast Cancer: An Effective Treatment in Search of a Home Journal Of Clinical Oncology A Analysis](http://www.ncbi.nlm.nih.gov/pubmed/15998905)Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis [PMID: 15998905](https://pubmed.ncbi.nlm.nih.gov/15998905), [DOI: 10.1200/jco.2005.02.964](https://doi.org/10.1200/jco.2005.02.964). - Partridge Wong J, Knudsen K, Gelman R, Sampson E, Gadd M, Bishop K, Harris J, Winer E. Offering participants results of a clinical trial: sharing results of a negative study American Journal Of Ophthalmology 2005, 139: 1153. [DOI: 10.1016/j.ajo.2005.04.010](https://doi.org/10.1016/j.ajo.2005.04.010). - Peppercorn J, Blood E, Winer E, Partridge A. Pharmaceutical involvement in breast cancer clinical trials Journal Of Clinical Oncology 2005, 23: 6057-6057. [DOI: 10.1200/jco.2005.23.16_suppl.6057](https://doi.org/10.1200/jco.2005.23.16_suppl.6057). [Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG](https://doi.org/10.1200/jco.2005.23.16_suppl.620)Citron M, Berry D, Cirrincione C, Livingston R, Gradishar W, Perez E, Muss H, Norton L, Winer E, Hudis C. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, [DOI: 10.1200/jco.2005.23.16_suppl.620](https://doi.org/10.1200/jco.2005.23.16_suppl.620). [Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V](https://doi.org/10.1200/jco.2005.23.16_suppl.687)Partridge A, Gelber S, Gelber R, Goldhirsch A, Winer E. Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V Journal 10.1200/jco.2005.23.16_suppl.687](https://doi.org/10.1200/jco.2005.23.16_suppl.687). [Optimizing women with early stage breast cancer: A decision analysis for biological subsets of tumors](https://doi.org/10.1200/jco.2005.23.16_suppl.529)Burstein H, Winer E, Kuntz K, Weeks J, Punglia R. Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors Journal Of Clinical Oncology 2005, 23: 529-529. [DOI: 10.1200/jco.2005.23.16_suppl.529](https://doi.org/10.1200/jco.2005.23.16_suppl.529). [Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342](https://doi.org/10.1200/jco.2005.23.16_suppl.545)Harris L, Perou C, Szallasi Z, Eklund A, Carter You F, Broadwater G, Monovich L, Winer E, Erlander M, Ellis M. Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342 HER2 extracellular domain of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840](https://doi.org/10.1200/jco.2005.23.16_suppl.558)Seidman A, Broadwater G, Carney W, Dressler L, Berry D, Norton L, Hudis C, Winer E, Ellis M, Harris L. Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): Winer E, Stark N, Weeks JC, Paskett E. Economic outcomes of breast cancer survivorship: CALGB study 79804 Breast Cancer [DOI: Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. Journal Of The National Comprehensive Cancer Network 2005, 3: 238-89. [PMID: 16002000](https://pubmed.ncbi.nlm.nih.gov/16002000), [DOI: 10.6004/jnccn.2005.0015](https://doi.org/10.6004/jnccn.2005.0015). - Thompson D, O'Sullivan A, Stokes M, Montoya E, Earle C, Winer E, Kulig K, Weinstein M. PCN13 SURVIVAL AND COST FOLLOWING BREAST CANCER RECURRENCE: ESTIMATES FROM SEER-MEDICARE DATA Value In Health 2005, 8: 347. [DOI: 10.1016/s1098-3015(10)62919-1](https://doi.org/10.1016/s1098-3015(10)62919-1). - Partridge AH, Winer EP. Fertility After Breast Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L, B F. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node-Positive Breast Cancer K, Gelman R, Sampson E, Gadd M, Bishop KL, Harris JR, Winer EP. Offering participants results of a clinical trial: sharing results of a negative study The Lancet 2005, HER2: That Is Weeks JC. Patient Utilities for Advanced 2005, 43: 173-181. [PMID: 15655431](https://pubmed.ncbi.nlm.nih.gov/15655431), [DOI: 10.1097/00005650-200502000-00011](https://doi.org/10.1097/00005650-200502000-00011). [Prognosis after local conservative surgery and radiation for early-stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/15667952)Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer International Journal Of Radiation Oncology 61: 348-357. [PMID: 15667952](https://pubmed.ncbi.nlm.nih.gov/15667952), [DOI: 10.1016/j.ijrobp.2004.06.011](https://doi.org/10.1016/j.ijrobp.2004.06.011). [The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries](http://www.ncbi.nlm.nih.gov/pubmed/15693926)Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries Journal Of General Internal Medicine 2005, 20: 38-44. Jahanzeb M, Venook AP, KM, Rivera JA, Dibella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in Phase I/II clinical anthracyclines and other systemic therapies in the management of advanced breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/15717740)Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Shapiro CL, Park JW, Colbern GT, AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer Seminars In Oncology 2004, 31: Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004](http://www.ncbi.nlm.nih.gov/pubmed/15545664)Winer Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004 Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP. Web-Based Survey of Fertility Issues in Young Women With Breast Cancer Journal Of Clinical Oncology with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15342805)Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer New England Journal Of Medicine 2004, 351: 971-977. [PMID: for therapy in breast cancer: Small molecule tyrosine kinase inhibitors Breast weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC](https://doi.org/10.1200/jco.2004.22.14_suppl.512)Seidman A, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Norton L, Winer E, Hudis C. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 10.1200/jco.2004.22.14_suppl.512](https://doi.org/10.1200/jco.2004.22.14_suppl.512). Burstein H, Overmoyer Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Winer E. Rebeccamycin analog for refractory breast cancer: a randomized phase II Journal 22: 547-547. [DOI: 10.1200/jco.2004.22.14_suppl.547](https://doi.org/10.1200/jco.2004.22.14_suppl.547). Blood Dees C, Kaelin C, Weeks J, Emmons K, Winer E. Accuracy of risk perceptions of women with ductal carcinoma in situ Journal Of Clinical Oncology 2004, [DOI: 10.1200/jco.2004.22.14_suppl.6034](https://doi.org/10.1200/jco.2004.22.14_suppl.6034). Sampson E, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer E. Fertility outcomes in young women with breast cancer: A Web-based survey Journal Of Clinical Oncology cancer subjects with visceral disease](https://doi.org/10.1200/jco.2004.22.14_suppl.628)Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral Clinical Oncology 2004, 22: 628-628. [DOI: 10.1200/jco.2004.22.14_suppl.628](https://doi.org/10.1200/jco.2004.22.14_suppl.628). [The predictive value of and on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342](https://doi.org/10.1200/jco.2004.22.14_suppl.9562)Lin Broadwater G, Dressler L, Schnitt S, Lara J, Bleiweiss I, Ngo T, Miron A, Winer E, Harris L. The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from 9840: of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC](https://doi.org/10.1200/jco.2004.22.90140.512)Seidman A, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Norton L, Winer E, Hudis C. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 10.1200/jco.2004.22.90140.512](https://doi.org/10.1200/jco.2004.22.90140.512). Burstein H, Overmoyer Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Winer E. Rebeccamycin analog for refractory breast cancer: a randomized phase II Journal 22: 547-547. [DOI: 10.1200/jco.2004.22.90140.547](https://doi.org/10.1200/jco.2004.22.90140.547). Blood Dees C, Kaelin C, Weeks J, Emmons K, Winer E. Accuracy of risk perceptions of women with ductal carcinoma in situ Journal Of Clinical Oncology 2004, [DOI: 10.1200/jco.2004.22.90140.6034](https://doi.org/10.1200/jco.2004.22.90140.6034). Sampson E, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer E. Fertility outcomes in young women with breast cancer: A Web-based survey Journal Of Clinical Oncology cancer subjects with visceral disease](https://doi.org/10.1200/jco.2004.22.90140.628)Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral Clinical Oncology 2004, 22: 628-628. [DOI: 10.1200/jco.2004.22.90140.628](https://doi.org/10.1200/jco.2004.22.90140.628). [The predictive value of and on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342](https://doi.org/10.1200/jco.2004.22.90140.9562)Lin Broadwater G, Dressler L, Schnitt S, Lara J, Bleiweiss I, Ngo T, Miron A, Winer E, Harris L. The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from Piccart M, Winer E. Introducing Breast Cancer Research's updates on clinical trials Breast Cancer Research 2004, [PMCID: PMC468662](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC468662), [DOI: 10.1186/bcr810](https://doi.org/10.1186/bcr810). [Failure in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342](http://www.ncbi.nlm.nih.gov/pubmed/15169793)Winer EP, Berry DA, Woolf S, Duggan D, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342 10.1200/jco.2004.08.048](https://doi.org/10.1200/jco.2004.08.048). [Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants](http://www.ncbi.nlm.nih.gov/pubmed/15100341)Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, Bauer-Wu S, Knudsen K, Emmons K, Collyar D, Schilsky RL, Winer EP. Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants Journal Of The National Cancer Institute 2004, 96: 629-632. Therapy for Metastatic Breast Cancer: A C, Hudis C, Norton L, Winer E, Gradishar W, Davidson N, Martino S, Livingston R, Ingle J, Carpenter J, Hurd D, Holland J, Smith B, Sartor C, Leung E, Abrams J, Schilsky R, Muss H. In Reply: Journal Partridge AH, Winer EP. Long-Term Complications of Adjuvant Chemotherapy for Early Stage Breast Cancer Breast Disease 2004, 21: 55-64. [PMID: 15687723](https://pubmed.ncbi.nlm.nih.gov/15687723), [DOI: 10.3233/bd-2004-21108](https://doi.org/10.3233/bd-2004-21108). [Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. Journal Of Clinical 817-825. late effects of treatment and surviorship issues in early-stage breast carcinoma Seminars In Oncology 2003, cancer](https://doi.org/10.1016/s1359-6349(03)90429-0)Harris Kuter I, Borges V, Kaelin C, Bellon Preoperative trastuzumab and active regimen for Her2 3+/FISH+stage II/III breast cancer European Journal Of Cancer Supplements 1: s121. [DOI: 10.1016/s1359-6349(03)90429-0](https://doi.org/10.1016/s1359-6349(03)90429-0). [Trastuzumab breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.](http://www.ncbi.nlm.nih.gov/pubmed/12885806)Burstein HJ, Harris LN, breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Journal Of perceptions and decisionmaking among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses](http://www.ncbi.nlm.nih.gov/pubmed/12833555)Bluman LG, Rimer BK, Sterba Clark S, Borstelmann N, Iglehart JD, Winer EP. Attitudes, knowledge, risk perceptions and decisionmaking among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and as Treatment for Refractory Breast Cancer: A Phase II Study Breast Cancer Research Treatment 2003, 79: 391-397. [PMID: 12846423](https://pubmed.ncbi.nlm.nih.gov/12846423), [DOI: for metastatic breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/12784331)Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumabbased therapy for metastatic assessment working group update: use of aromatase inhibitors in the adjuvant setting.](http://www.ncbi.nlm.nih.gov/pubmed/12732612)Winer EP, C, AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. Journal Clinical Oncology Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. Journal Of Clinical Oncology 2003, inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. Journal Of The National Comprehensive Cancer Network 2003, 1: 215-21. [PMID: 19768880](https://pubmed.ncbi.nlm.nih.gov/19768880), [DOI: PK, Winer EP. Do Patients Participating in Clinical Trials Want to Know Study Results? Journal Of The National Cancer Institute 2003, of oral bexarotene for patients with metastatic breast cancer. Journal two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12637464)Buzdar A, O'Shaughnessy J, Booser DJ, Pippen PN, Peterson P, AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. Journal Of Clinical Avorn J. ABSTRACTS REPRINTED FROM JOURNAL OF CLINICAL scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.](http://www.ncbi.nlm.nih.gov/pubmed/12668651)Citron ML, Berry DA, Cirrincione C, Hudis Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study](http://www.ncbi.nlm.nih.gov/pubmed/12506169)Burstein HJ, Harris LN, Gelman R, RL, CA, J, Winer Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study Journal Of [PMID: 12506169](https://pubmed.ncbi.nlm.nih.gov/12506169), [DOI: 10.1200/jco.2003.03.124](https://doi.org/10.1200/jco.2003.03.124). [Second on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.](http://www.ncbi.nlm.nih.gov/pubmed/12538498)Come SE, Buzdar Davidson VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clinical Cancer Research 2003, 9: 443s-6s. [PMID: 12538498](https://pubmed.ncbi.nlm.nih.gov/12538498). - Ligibel JA, Winer EP. Clinical inhibitors. Cancer 2003, 9: 473s-9s. [PMID: 12538503](https://pubmed.ncbi.nlm.nih.gov/12538503). 10.1007/0-387-22621-4_34](https://doi.org/10.1007/0-387-22621-4_34). Avorn J, Wang P, E. RESPONSE: Re: Adherence to Therapy With Oral Antineoplastic Agents Journal Of The National Cancer Institute 2002, 94: [DOI: 10.1093/jnci/94.21.1652-a](https://doi.org/10.1093/jnci/94.21.1652-a). - DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. Journal Of Clinical Oncology 2002, 20: 34s-8s. the splitters take technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Journal technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.](http://www.ncbi.nlm.nih.gov/pubmed/12149307)Chlebowski Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase 363-365. [PMID: 12117402](https://pubmed.ncbi.nlm.nih.gov/12117402), [DOI: 10.1001/jama.288.3.363](https://doi.org/10.1001/jama.288.3.363). [2002 the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology*](http://www.ncbi.nlm.nih.gov/pubmed/12065567)Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology* Journal Of Clinical BRCA Testing: Does Tailoring Make a Difference? Genetic Winer EP. Adherence to Therapy With Oral Antineoplastic Agents Journal Of The National Cancer Institute 2002, as firstline therapy of metastatic breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/11815957)Harris Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, Group T. Liposomeencapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as firstline therapy [Side Effects Therapy in Women With Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/11773307)Partridge A, Burstein H, Winer E. Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage New cytotoxic agents and schedules for advanced breast In 2001, E. New cytotoxic agents and schedules for advanced breast cancer Seminars In Oncology 2001, 28: 28: 32-40. [DOI: 10.1053/sonc.2001.26436](https://doi.org/10.1053/sonc.2001.26436). [Knowledge, Satisfaction, and Perceived Cancer Risk among Women Diagnosed with Ductal Carcinoma In Situ](http://www.ncbi.nlm.nih.gov/pubmed/11559456)Bluman L, Borstelmann N, Rimer B, Iglehart J, Winer E. Knowledge, Satisfaction, and Perceived Cancer Risk among Women Diagnosed with Ductal Carcinoma In Situ Journal Of Women's Health 2001, metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/11352965)Burstein H, Kuter I, Campos S, Gelman R, Tribou L, Parker L, Manola J, Younger J, Matulonis U, Bunnell C, Partridge A, Richardson P, Clarke K, Shulman L, Winer E. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast 11352965](https://pubmed.ncbi.nlm.nih.gov/11352965), [DOI: 10.1200/jco.2001.19.10.2722](https://doi.org/10.1200/jco.2001.19.10.2722). [Changes in body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.](http://www.ncbi.nlm.nih.gov/pubmed/11331316)Demark-Wahnefried W, Peterson B, Winer E, Marks L, Aziz N, Marcom P, Blackwell K, Rimer B. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. Journal Of IIIII breast cancer](https://doi.org/10.1016/s0959-8049(01)81029-7)Burstein H, Harris L, Kaelin Parker L, Kuter I, Gadd M, Borges V, Bunnell C, Smith B, and paclitaxel (P) for HER2-overexpressing (HER2+) stage IIIII breast cancer Of Cancer 2001, 37: s146. 10.1016/s0959-8049(01)81029-7](https://doi.org/10.1016/s0959-8049(01)81029-7). trastuzumab in patients with advanced breast cancer](https://doi.org/10.1016/s0959-8049(01)81204-1)Theodoulou M, Campos S, Welles L, Batist G, Winer E, Hudis C. Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer European Journal Of Cancer 2001, 37: s195. [DOI: 10.1016/s0959-8049(01)81204-1](https://doi.org/10.1016/s0959-8049(01)81204-1). - Baidas S, Winer E, Fleming Harris L, Pluda J, Crawford J, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson, Hawkins M, Lippman M, Hayes D. Phase II Evaluation Of Thalidomide In Patients With Metastatic Breast Cancer Journal Of The Peripheral Nervous System 2001, 6: 65-66. [DOI: 10.1046/j.1529-8027.2001.01008-20.x](https://doi.org/10.1046/j.1529-8027.2001.01008-20.x). - Partridge A, Bunnell C, Winer E. Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer Breast Disease 2001, 14: 41-50. 15687635](https://pubmed.ncbi.nlm.nih.gov/15687635), [DOI: Farrar ML, Somlo R, Ward JH, Winer EP, Wolff A. 11195418](https://pubmed.ncbi.nlm.nih.gov/11195418). - Burstein HJ, Winer EP. Primary Care for Survivors of Breast Cancer New England Journal Of Medicine 2000, 343: 1086-1094. [PMID: 11027744](https://pubmed.ncbi.nlm.nih.gov/11027744), [DOI: 10.1056/nejm200010123431506](https://doi.org/10.1056/nejm200010123431506). Harris L, Pluda J, Crawford J, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson M, Hawkins M, Lippman M, Hayes D. Phase II evaluation of thalidomide in patients with metastatic breast cancer. Journal Winer E. Letter to the Editor Clinical Breast Cancer 2000, 1: 164-165. [PMID: 11899655](https://pubmed.ncbi.nlm.nih.gov/11899655), [DOI: 10.1016/s1526-8209(11)70117-3](https://doi.org/10.1016/s1526-8209(11)70117-3). - Clark N, Regan K, Winer E, Rimer B, Skinner C. Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2 Journal Of 10.1023/a:1009463905057](https://doi.org/10.1023/a:1009463905057). [Dexrazoxane and of chemotherapy and radiotherapy protectants: a critique.](http://www.ncbi.nlm.nih.gov/pubmed/10784645)Hellmann K, Hensley N, Pfister D. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. Journal E, Skinner C, Futreal P, Culler D, Calingaert B, Clark S, Marcom P, Iglehart J. Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States Annals Of Surgery 2000, Parker L, Bunnell C, Scheib R, Matulonis U, Garber J, Clarke K, Shulman L, Winer E. Docetaxel administered on a weekly basis for metastatic breast cancer. Journal Of group considerations of patients and oncological providers](http://www.ncbi.nlm.nih.gov/pubmed/10767748)Speice J, Harkness J, Laneri H, Frankel R, Trief P, Finkel J, Spira J, Greenberg D, Rowland J, Holland J. Involving family members in cancer care: focus group considerations of patients and versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/10679652)Dawson N, Conaway M, Halabi S, Winer E, Small E, Lake D, Vogelzang N. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma Cancer 2000, 88: 825-834. [PMID: 10679652](https://pubmed.ncbi.nlm.nih.gov/10679652), [DOI: 10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n](https://doi.org/10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n). [American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.](http://www.ncbi.nlm.nih.gov/pubmed/10506637)Hensley M, Schuchter L, Lindley C, Meropol N, Cohen G, Broder G, Gradishar W, Green D, Langdon R, Mitchell R, Negrin R, Szatrowski T, Thigpen J, VonHoff D, Wasserman T, Winer E, Pfister D. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal study of Doxil and vinorelbine men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.](http://www.ncbi.nlm.nih.gov/pubmed/10561316)Kantoff P, Halabi S, Conaway M, Picus J, Kirshner Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical C, Iglehart J, Prosnitz L. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. Journal [PMID: 10334532](https://pubmed.ncbi.nlm.nih.gov/10334532), a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.](http://www.ncbi.nlm.nih.gov/pubmed/10334524)Costanza M, Weiss R, Henderson I, Norton L, Berry D, Cirrincione C, Winer E, Wood W, Frei III E, McIntyre O, Schilsky R. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B Hochster H, Chang A, Adamkiewicz B, White R, McGuirt C. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older Annals Of Oncology 1999, 10: 397-402. (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182](https://doi.org/10.1097/00005392-199904010-00708)Kantoff P, Halabi S, Conaway M, Picus J, Kirshner Hars V, Trump D, Winer E, Vogelzang N. HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF 1999, 161: 176.. [DOI: 10.1097/00005392-199904010-00708](https://doi.org/10.1097/00005392-199904010-00708). [Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.](http://www.ncbi.nlm.nih.gov/pubmed/10071299)Bluman L, Rimer B, Berry D, Borstelmann N, Iglehart J, Regan K, Schildkraut J, Winer E. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. Journal 10.1200/jco.1999.17.3.1040](https://doi.org/10.1200/jco.1999.17.3.1040). [Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support](http://www.ncbi.nlm.nih.gov/pubmed/10335560)Winer E, Lindley C, Hardee M, Sawyer W, Brunatti C, Borstelmann N, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow intensity using a daily \u00d7 3 schedule with and without filgrastim in patients with metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/9923543)Havlin K, Ramirez M, Legler C, Harris L, Matulonis U, Hohneker J, Hayes D, Winer E. Inability to escalate vinorelbine dose intensity using a daily \u00d7 3 schedule with and without filgrastim in patients with metastatic breast cancer Cancer 9923543](https://pubmed.ncbi.nlm.nih.gov/9923543), [DOI: 10.1007/s002800050864](https://doi.org/10.1007/s002800050864). [Randomized and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal American Vorozole Study Group.](http://www.ncbi.nlm.nih.gov/pubmed/10458218)Goss PE, Winer EP, Tannock IF, Schwartz on of the North American Vorozole Study Grou L. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. Journal Of Clinical M\u00fcller P, Schildkraut J, Winer E. Modeling Risk of Breast Cancer and Decisions about Genetic Testing 1999, 140: 133-203. [DOI: 10.1007/978-1-4612-1502-8_3](https://doi.org/10.1007/978-1-4612-1502-8_3). - Warmuth M, Bowen G, Prosnitz Chu L, Broadwater G, Peterson B, Leight G, Winer E. Complications of axillary lymph node dissection for carcinoma of the breast Cancer 1998, 83: Berry DA. Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes 10372578](https://pubmed.ncbi.nlm.nih.gov/10372578), Winer E, Berry D, Shildkraut J. Overestimation of Hereditary Breast Cancer Risk Annals BRCA2: correlation of mutations with family history and ovarian cancer risk.](http://www.ncbi.nlm.nih.gov/pubmed/9667259)Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal Of Clinical Oncology 1998, E, Tremont S, Lindley C. Cancer Pain Survey Patient-Centered Issues in Control Journal Of Pain And Symptom Management 1998, 15: 275-284. R, Trief P, Finkel J, Spira J, Holland J, Greenberg D, Rowland J. Delivering bad news: the importance of involving family members Patient Education And Counseling 1998, 34: s5-s6. [DOI: 10.1016/s0738-3991(98)00058-5](https://doi.org/10.1016/s0738-3991(98)00058-5). [Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/9552041)Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. Journal Of Clinical E, Bluman L, Lerman C. Informed Consent for BRCA1 and BRCA2 Breast C, Iglehart J, Berry D. P53 Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis European Journal Of Cancer 1998, 34: s26. [DOI: 10.1016/s0959-8049(97)89271-4](https://doi.org/10.1016/s0959-8049(97)89271-4). [796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support](https://doi.org/10.1016/s0169-5002(97)80173-0)Crawford J, Blackwell S, Shoemaker D, Pupa M, Mulhausen T, Herndon J, Winer E, Flynn J, Dempsey H. 796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with Lung Cancer 1997, 18: 205. [DOI: 10.1016/s0169-5002(97)80173-0](https://doi.org/10.1016/s0169-5002(97)80173-0). [Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.](https://doi.org/10.1097/01893697-199715030-00018)DemarkWahnefried W, Hars V, Conaway, Havlin K, Rimer B, McElveen G, Winer E. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Rehabilitation Oncology 1997, 15: 21. [DOI: 10.1097/01893697-199715030-00018](https://doi.org/10.1097/01893697-199715030-00018). [Pharmacokinetics and all-trans acid metastatic breast cancer: a phase L, Warmuth M, Petros W, Winer E. Pharmacokinetics and impact of all-trans retinoic acid in metastatic breast cancer: a phase II K, Rimer B, Winer E. Genetic Testing for Susceptibility to Breast Cancer: Findings from Women's Focus Groups Journal Of Women's Health 1997, 6: 317-327. [PMID: 9201666](https://pubmed.ncbi.nlm.nih.gov/9201666), [DOI: 10.1089/jwh.1997.6.317](https://doi.org/10.1089/jwh.1997.6.317). [Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/9129482)Demark-Wahnefried W, Hars V, Conaway, Havlin K, Rimer B, McElveen G, Winer E. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy American Journal Of Clinical Nutrition 1997, 65: 1495-1501. WINER E. Weight Gain in Women Diagnosed with Breast Cancer Journal Of The Academy Of Nutrition And Dietetics 1997, 97: 519-529. Winer E. A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification The American Journal Of Medicine 1997, 102: 407-415. [PMID: 9217624](https://pubmed.ncbi.nlm.nih.gov/9217624), [DOI: 10.1016/s0002-9343(97)00093-4](https://doi.org/10.1016/s0002-9343(97)00093-4). Sanchez J, Schildkraut J, Winer E. Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History Journal Of The National Cancer Institute 1997, 89: 227-237. [PMID: 9017003](https://pubmed.ncbi.nlm.nih.gov/9017003), [DOI: 10.1093/jnci/89.3.227](https://doi.org/10.1093/jnci/89.3.227). 10.1007/978-1-4757-2705-0_20](https://doi.org/10.1007/978-1-4757-2705-0_20). C, Rimer B, Georgiade G. Factors Contributing to Patient Satisfaction with Breast Reconstruction Using Silicone Gel Implants Plastic & Reconstructive Surgery 1996, 97: 1420-1426. [PMID: EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. The Infusional 1996, S, Winer Vogel Laufman Hutchins B, D, J, J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast vinorelbine (Navelbine) in the treatment of advanced breast cancer. Seminars 1995, 22: 72-8; discussion 78-9. oral vinorelbine in patients with solid tumors.](http://www.ncbi.nlm.nih.gov/pubmed/8083697)Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas SE, Ettinger DS. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. Journal Of Clinical bone marrow Oncology 1994, C, Holmes V, Rimer BK. Silicone controversy: a survey of women with breast cancer and silicone implants. Journal Of The National Cancer Institute 1993, 85: BK. Why women gain weight with adjuvant chemotherapy for breast cancer. Journal Of Clinical Oncology 1993, marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/8501500)Peters W, Ross M, Vredenburgh J, Meisenberg B, Marks L, Winer E, Kurtzberg J, Bast R, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal Of Oncology phase I trial in combination with vinblastine.](http://www.ncbi.nlm.nih.gov/pubmed/1359155)Trump DL, Smith DC, Ellis PG, Rogers MP, Schold a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. Journal Of The National Cancer Institute DC, Schold SC, Rogers MP, Winer EP, Fine RL, of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a 1992, 52: 2456-9. [PMID: 1533174](https://pubmed.ncbi.nlm.nih.gov/1533174). - Brizel D, Winer E, Prosnitz L, Scott J, Crawford J, Moore J, Gockerman J. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy International Journal Of Radiation Oncology Biology Physics 1990, Cadman E. The use of adjuvant chemotherapy for breast cancer in a community practice. Connecticut Medicine 1985, 49: 281-5. [PMID: 3839177](https://pubmed.ncbi.nlm.nih.gov/3839177). - Breast CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 1st, suite ANew Haven, CT 06511 Biography Eric Winer, MD, is the Director of Yale Cancer Center, as well as President and Physician-in-Chief of the Smilow Cancer Hospital Yale New Haven Health System. An internationally renowned medical oncologist and expert in breast cancer, he has conducted clinical trials that have changed the face of the disease. His work has impacted almost all aspects of breast cancer. \"First and foremost, I'm a clinician,\" Dr. Winer says. \"I am fortunate to have been able to spend a great deal of time taking care of patients over the years. Patient care ultimately drives everything that I do professionally, and my patients have been my greatest teachers.\" Dr. Winer has long been an advocate of building teams of scientists and clinicians to accelerate progress in cancer care and research, and appreciates the wealth of experts and resources at Yale involved in this work. \"Our mission at Yale is to deliver the best cancer care today and investigate approaches to improve care in the years ahead,\" he says. Dr. Winer is the Alfred Gilman Professor of Medicine and Pharmacology and Deputy Dean of Cancer Research at Yale School of Medicine. His is also Chair of the Board for the American Society of Clinical Oncology (ASCO). For over a decade, he served as chief scientific advisor and chair of the scientific advisory board for Susan G. Komen for the Cure and is now on the scientific advisory board of the Breast Cancer Research Foundation. For the past six years he has co-led the National Cancer Institute breast cancer steering committee. Dr. Winer has published over 350 research articles, mentored many trainees, and received numerous awards for his breast cancer research. He has served as the principal investigator of a National Institutes of Health-funded SPORE in breast cancer for the last 10 years. \"I have seen the transformation of cancer care over the past three decades and look forward to even more remarkable advances over the next decade. I believe Yale will play a prominent role in cancer care and research in the coming years.\" Titles - Alfred Gilman Professor of Pharmacology and Professor of Medicine (Medical Oncology) - Director, Yale Cancer Center - President and Physician-in-Chief, Smilow Cancer Hospital - Deputy Dean for Cancer Research, Yale School of Medicine Education & Training - Chief ResidentYale School of Medicine (1987) - InternYale School of Medicine (1984) - MDYale School of Medicine - ResidentYale School of Medicine Additional Information - William Silen Lifetime Achievement in Mentoring Award: Harvard Medical School (2022) - Jill Rose Award for Scientific Excellence: Breast Cancer Research Foundation (2019) - Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research: San Antonio Breast Cancer Symposium (2018) - AB of Internal Medicine, Medical Oncology (1989) - AB of Internal Medicine, Internal Medicine (1987) [Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Treated Trastuzumab, O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, Tung N, Krop I, Parker J, Perou C, Prat A, Winer E, Tolaney S, Mittendorf E. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. tool](http://www.ncbi.nlm.nih.gov/pubmed/37356327)Leone J, Graham B, Freedman R, Hassett M, Vallejo C, Winer E, Lin N, Tayob N. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.](https://doi.org/10.1200/jco.2023.41.16_suppl.12001)Ligibel J, Ballman K, McCall L, Goodwin P, Weiss A, Delahanty L, Alfano C, Crane T, Neuhouser M, Spears P, Hershman D, Paskett E, Hopkins J, Bernstein V, Stearns V, White J, Wadden T, Winer E, Partridge A, Carey L. Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial. Journal Of Clinical Oncology 2023, 41: 12001-12001. [DOI: 10.1200/jco.2023.41.16_suppl.12001](https://doi.org/10.1200/jco.2023.41.16_suppl.12001). - Brastianos P, Kim A, Giobbie-Hurder A, Lee E, Lin N, Overmoyer B, Wen P, Nayak L, Cohen J, Dietrich J, Heist R, Krop I, Lawrence D, Mayer E, Winer E, Shih H, Oh K, Cahill D, Gerstner E, Sullivan R. Phase II trial of pembrolizumab in patients with brain metastases. Journal Of of Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.](http://www.ncbi.nlm.nih.gov/pubmed/37194964)Weiss A, Li T, Desai N, Tung N, Poorvu P, Partridge A, Nakhlis F, Dominici L, Sinclair N, Spring L, Faggen M, Constantine M, Krop I, DeMeo M, Wrabel E, Alberti J, Chikarmane T, Tolaney S, E, Mittendorf E, Waks A. Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. Journal Of The American College Of Surgeons 2023, Publish Ahead of Print [PMID: 37194964](https://pubmed.ncbi.nlm.nih.gov/37194964), [DOI: 10.1097/xcs.0000000000000761](https://doi.org/10.1097/xcs.0000000000000761). - Tarantino P, Villacampa G, Graham Waks A, Gonzalez P, Bras\u00f3-Maristany F, Torres E, Galv\u00e1n P, Brunet L, Demeo E, S. 6P Combined analysis of the HER2DX genomic tool in adjuvant APT and 8: of 18-Gene expression with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119](https://doi.org/10.1016/j.esmoop.2023.101379)Cort\u00e9s J, Lipatov O, Im S, Gon\u00e7alves A, Lee K, Schmid P, Tamura K, Testa L, Ohtani S, Harbeck N, Loi S, Salgado R, Lunceford J, Karantza V, Mejia J, Cristescu R, Nebozhyn M, Jelinic P, Huang L, Winer E. 190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) A correlative analysis from a phase II clinical trial](https://doi.org/10.1016/j.esmoop.2023.101236)Lynce F, Bras\u00f3-Maristany F, Waks A, Gonzalez P, Villacampa G, Torres E, Galv\u00e1n P, Brunet L, Anderson L, Perou C, Parker J, Vivancos A, Dilullo M, Simon S, Winer E, inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial ESMO Open 2023, 8: 101236. [DOI: 10.1016/j.esmoop.2023.101236](https://doi.org/10.1016/j.esmoop.2023.101236). - Sella Gelber S, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Carey L, Winer E, Partridge A. Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors Npj Breast Cancer D, E, D, H, De Laurentiis M, Nanda R, Iwata H, Awada A, Tan A, Sun Y, Karantza V, Wang A, Huang L, Saadatpour A, Cristescu R, Yearley J, Lunceford J, Jelinic P, Adams S. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Triple-Negative clinical T1-T2N0 human epidermal growth factor receptorpositive breast cancer: Results from two international cohorts](http://www.ncbi.nlm.nih.gov/pubmed/36951169)Weiss A, Mart\u00ednezS\u00e1ez O, Waks A, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia A, Partridge A, S, Cejalvo J, Mittendorf E, King T. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptorpositive breast cancer: Results from 1836-1845. [PMID: 36951169](https://pubmed.ncbi.nlm.nih.gov/36951169), [DOI: 10.1002/cncr.34750](https://doi.org/10.1002/cncr.34750). [Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040823)Pichardo M, Sanft A, Fayanju O, Winer E, Irwin M. Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review 10.3389/fonc.2023.1079293](https://doi.org/10.3389/fonc.2023.1079293). [Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review](http://www.ncbi.nlm.nih.gov/pubmed/36994212)Pichardo M, Sanft A, Fayanju O, Winer E, Irwin M. Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review open-label, single-arm, phase 2 APT trial](http://www.ncbi.nlm.nih.gov/pubmed/36858723)Tolaney S, Tarantino P, Graham N, Tayob N, Par\u00e8 L, Villacampa G, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo C, final 10-year analysis of the open-label, single-arm, phase 2 and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019](https://doi.org/10.1158/1538-7445.sabcs22-pd12-01)Puklin L, Li F, Cartmel B, Sanft T, Lisevick E, M, L. Abstract PD12-01: PD12-01 Impact of obesity and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019 Cancer Research 2023, 83: pd12-01-pd12-01. [DOI: 10.1158/1538-7445.sabcs22-pd12-01](https://doi.org/10.1158/1538-7445.sabcs22-pd12-01). - Tarantino P, Gupta H, Hughes M, Files J, Strauss S, Kirkner G, Feeney A, Li Y, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, MacConaill L, Lindeman N, Johnson B, Meyerson M, Kabraji S, Jeselsohn R, Qiu X, Li R, Long H, Winer E, Dillon D, Curigliano G, Cherniack A, Tolaney S, Lin N. Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast 2023, 83: her2-05-her2-05. [DOI: 10.1158/1538-7445.sabcs22-her2-05](https://doi.org/10.1158/1538-7445.sabcs22-her2-05). - Garrido-Castro A, Ngo L, Richardson Frangieh A, Mohammed-Abreu A, Hughes M, Zanudo J, Navarro J, Tarantino P, Mittendorf E, Tolaney S, King T, Winer E, Lin N, Wagle N. Abstract HER2-10: HER2-10 Dynamics of HER2-low expression in 2023, 83: her2-10-her2-10. [DOI: 10.1158/1538-7445.sabcs22-her2-10](https://doi.org/10.1158/1538-7445.sabcs22-her2-10). [Abstract OT1-12-02: Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer](https://doi.org/10.1158/1538-7445.sabcs22-ot1-12-02)Braunstein L, Wong J, Dillon D, Chen Y, Catalano P, Cahlon O, El-Tamer M, Jimenez R, Khan A, Perez C, Punglia R, Shiloh R, Warren L, Wazer D, Wright J, Buckley E, King T, Powell S, Winer E, Bellon J. Abstract OT1-12-02: Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast and pertuzumab (THP): a correlative II trial](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-05)Waks A, Ogayo E, Par\u00e9 L, Mar\u00edn-Aguilera M, Bras\u00f3-Maristany O, Mart\u00ednez-S\u00e1ez O, Vivancos A, Villagrasa P, Tarantino P, Desai N, Guerriero J, Metzger O, Tung N, Krop I, Parker J, Perou C, Prat A, Winer E, Tolaney S, validation of the HER2DX genomic in and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial Cancer Research 2023, 83: p1-04-05-p1-04-05. [DOI: 10.1158/1538-7445.sabcs22-p1-04-05](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-05). - Gupta H, Freedman R, Hughes M, Li Y, Kirkner G, Files J, Strauss S, Garrido-Castro A, Buckley L, Barroso-Sousa R, Bychkovsky B, Tolaney S, MacConaill L, Lindeman N, Johnson B, Meyerson M, Winer E, Dillon D, Cherniack A, Lin N. Abstract P5-14-06: Tumor Genomic Landscape in Older Women with Metastatic Breast [Abstract P6-05-05: Patient-reported outcomes, perceptions, and about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC)](https://doi.org/10.1158/1538-7445.sabcs22-p6-05-05)Rosenberg S, Zheng Y, Santos K, Riley E, Meadows H, Snow C, Hughes M, Frank E, Lin N, Partridge A, Winer E, Parsons H. Abstract P6-05-05: Patient-reported outcomes, perceptions, and knowledge about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC) 10.1158/1538-7445.sabcs22-p6-05-05](https://doi.org/10.1158/1538-7445.sabcs22-p6-05-05). [Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030](https://doi.org/10.1158/1538-7445.sabcs22-pd11-06)Parsons H, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson V, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina T, Carey L, Rimawi M, Elkhanany A, Stearns V, Specht J, Burstein H, Wolff A, Winer E, Tayob N, Krop I, Golub T, Mayer E, Adalsteinsson V. Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030 Cancer Research and correlative analyses from P, Tayob N, Dang C, Yardley D, Isakoff Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Garrett A, Marcom P, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz R, Rimawi M, Abramson V, Pohlmann P, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Barroso-Sousa R, Waks A, DeMeo A, Winer E, Viale G, Hui W, Mittendorf E, Schneider B, Prat A, Krop I, Tolaney PD18-01: Adjuvant 5-year results and (HER2+) Breast 10-year analysis](https://doi.org/10.1158/1538-7445.sabcs22-pd18-02)Tolaney S, Tarantino Tayob Dang Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Barroso-Sousa R, DeMeo M, DiLullo M, Partridge E. PD18-02: Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Growth Factor Receptor 2-Positive (HER2+) Breast [Abstract PD6-08: PD6-08 Mortality risks in men with stage I-III hormone receptor-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs22-pd6-08)Leone J, Hassett M, Freedman R, Tolaney S, Graham N, Tayob N, Vallejo C, Winer E, Lin N, Leone J. Abstract PD6-08: PD6-08 Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)](https://doi.org/10.1158/1538-7445.sabcs22-pd7-03)Freedman R, Ren S, Tayob N, Gelman R, Smith K, Davis R, Pereslete A, Attaya V, Cotter C, Chen W, Santa-Maria C, Van Poznak C, Moy B, Brufsky A, Melisko O'Sullivan N, Rauf Y, Nangia J, Trapani D, Savoie J, Burns R, Wolff A, Winer E, Rimawi M, Krop I, Lin N. Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast alterations in of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis](https://doi.org/10.1158/1538-7445.sabcs22-pd7-07)Kabraji S, Li Y, Hughes M, Gupta H, Buckley L, Files J, Mohammed-Abreu A, Feeney A, Kirkner G, Patel A, Garrido-Castro A, Barroso-Sousa R, Bychkovsky B, Meyerson M, Tolaney S, Dillon D, Johnson B, Winer E, Cherniack A, Lin N. Abstract PD7-07: Somatic alterations in primary tumors of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis Cancer Research 2023, 83: pd7-07-pd7-07. [DOI: 10.1158/1538-7445.sabcs22-pd7-07](https://doi.org/10.1158/1538-7445.sabcs22-pd7-07). [Tucatinib vs Placebo, Both in and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/36454580)Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Vallejo C, Leone B, Winer E, Lin N, Hassett M. Survival in male breast cancer over the past 3 decades. Journal Of The National Cancer capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases overall survival analysis\" G, Mueller Hamilton Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Corrigendum to \"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases overall survival analysis\" Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials](http://www.ncbi.nlm.nih.gov/pubmed/36521078)Pagani O, Walley B, Fleming G, Colleoni M, L\u00e1ng I, Gomez H, Tondini C, Burstein H, Goetz M, Ciruelos E, Stearns S, Ruhstaller T, Winer E, Ruepp B, Loi S, Coates A, Gelber R, Goldhirsch A, Regan M, Francis P, Group F. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials Oncology 2022, 41: 1376-1382. Bonnefoi H, Bellet M, Bernardo A, Climent M, Martino S, Bermejo B, Burstein H, Davidson N, Geyer C, Walley B, Ingle J, Coleman R, M\u00fcller B, Le Du F, Loibl S, Winer E, Ruepp B, Loi S, Colleoni M, Coates A, Gelber R, Goldhirsch A, Regan M, Group F. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results and Immune Checkpoint Inhibitor Benefit.](http://www.ncbi.nlm.nih.gov/pubmed/35797509)Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen (ATEMPT)](http://www.ncbi.nlm.nih.gov/pubmed/36450763)Sella T, Zheng Y, Tayob N, Ruddy K, Freedman R, Dang C, Yardley D, Isakoff S, Valero V, DeMeo M, Burstein H, Winer E, Wolff A, Krop I, A, Tolaney S. Treatment discontinuation, patient-reported ) advanced/metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/36401732)Bardia A, Mayer I, Winer E, Linden H, Ma C, Parker B, Bellet M, Arteaga C, Cheeti S, Gates M, Chang C, Fredrickson J, Spoerke J, Moore H, Giltnane J, Friedman L, Chow Maneval E, Chan I, Jhaveri K. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) + /HER2 ) advanced/metastatic breast Colleoni Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart M, Wolff AC, Viale G, Gelber RD. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for metastatic HER2-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/36252998)Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET, Attaya B, Tolaney Ib study pembrolizumab in combination with emtansine for metastatic HER2-positive in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/36215125)Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, EP, Getz G, Jeselsohn R. Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, RK, Winer EP, Anders CK, NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain NU. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers](http://www.ncbi.nlm.nih.gov/pubmed/36048535)Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, HP, Park PJ, Wulf GM. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers Clinical HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up](https://doi.org/10.1016/j.annonc.2022.06.009)Loibl Bergh J, Gelber R, Restuccia E, Im Y, Huang C, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Moreno H, Bliss J, Viale G, Bines J, Piccart M. VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in Correlation of early standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026)](https://doi.org/10.1016/j.annonc.2022.07.226)Hennessy M, Leal J, Huang C, Solnes L, Denbow R, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo A, Valero V, Vaklavas C, Winer E, Krop I, Wolff A, Cimino-Mathews A, Wahl R, Stearns V, Connolly R. 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026) Nagy Z, Feiglin A, Feit A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, Cornwell M, Liu W, Ors A, Mohammed H, Cejas P, Brock JB, Freedman ML, Metzger Filho O, Jeselsohn R. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast treated with a hypomethylating agent and venetoclax.](http://www.ncbi.nlm.nih.gov/pubmed/35289704)Chen EC, Liu Y, Harris CE, M, Lane AA, Vedula RS, Lindsley Copson KM, Charles A, Marty F, Neuberg D, DeAngelo DJ, Stone RM, Luskin MR, Issa NC, Garcia JS. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx](http://www.ncbi.nlm.nih.gov/pubmed/35902504)Kantor O, Burstein HJ, King TA, Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in Positive Breast Cancer Patients Enrolled in TAILORx](http://www.ncbi.nlm.nih.gov/pubmed/35900648)Kantor O, Burstein HJ, King TA, Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in AE, Ni W, Garg S, Sattler M, Azab AK, Sun J, Muz B, Sanchez D, Toure A, Stone RM, Galinsky I, Winer E, Gleim S, Gkountela S, Kedves A, Harrington E, Abrams T, Zoller T, Vaupel A, Manley P, Faller M, Chung B, Chen X, Busenhart P, Stephan C, Calkins K, Bonenfant D, W, Griffin JD. BRD9 degraders as chemosensitizers in acute leukemia and The 'ESTIMATE' tool](http://www.ncbi.nlm.nih.gov/pubmed/35841843)Leone JP, EP, Lin NU, N. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial](https://doi.org/10.1158/1538-7445.am2022-ct026)Ellis M, Anurag M, Hoog Fernandez-Martinez A, Fan C, Gibbs R, Sanati S, Vij K, Watson M, Dockter T, Hahn O, Guenther J, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Leitch A, Unzeitig G, Winer E, Weiss A, Hunt K, Partridge A, Perou C, Suman V, Ma C, Carey L. Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE Cancer Research 2022, 10.1158/1538-7445.am2022-ct026](https://doi.org/10.1158/1538-7445.am2022-ct026). Isakoff S, Winer E, Schrag D, Manz C. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/35658506)Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson Patel Howarth K, Winer EP, Lin NU, Parsons HA. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast in high-risk, hormone receptor-positive, HER2-negative breast cancer (CHiRP).](https://doi.org/10.1200/jco.2022.40.16_suppl.103)Lipsyc-Sharf M, De Bruin E, Santos K, McEwen R, Stetson D, Patel A, Kirkner G, Hughes M, Tolaney S, Krop I, Knape C, Feger U, Marsico G, Howarth K, Winer E, Lin N, Parsons H. Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast models of breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/35641483)Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ. STING agonism reprograms and overcomes resistance to PARP inhibition paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/35538105)Waks PD, Partridge AH, Sinclair N, Spring LM, Faggen M, M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, of in HER2-positive autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/35482127)Anderson KS, Erick TK, Chen M, H, Campbell M, Colson Y, Mihm M, Zakka LR, Hopper M, Barry W, Winer EP, Dranoff G, Overmoyer B. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers Breast Cancer for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust\" [Annals of Oncology 32 (2021) 1077-1082]](http://www.ncbi.nlm.nih.gov/pubmed/35487836)Piccart M, Kalinsky Barlow Poncet Cardoso F, Winer E, Sparano J. Erratum to \"Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust\" [Annals V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz M, Paplomata E, Pegram M, Slamon D, A, J, Feng W, Winer E. Aktualisierte Ergebnisse von Tucatinib versus Placebo of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial](https://doi.org/10.1200/jco.2022.40.36_suppl.360922)Chen W, Ballman K, Winer E, Openshaw T, Hahn O, Briccetti F, Irvin W, Pohlmann P, Carey L, Partridge A, Weiss A, McCall L, Matyka C, Carvan M, Holmes M. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial Journal Of Clinical Oncology 2022, 40: 360922-360922. [DOI: 10.1200/jco.2022.40.36_suppl.360922](https://doi.org/10.1200/jco.2022.40.36_suppl.360922). A, Winer in HER2+ breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/35304445)Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Leone JP, Long HW, Brown MA, Winer EP, Dillon DAR, Lin NU, Zhao JJ. p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in Dai Y, Verma A, Wang S, Mills CE, Chung M, Bergholz JS, Coy S, Lin JR, Jeselsohn R, Metzger EP, Dillon DA, Zhao JJ, Sorger PK, Santagata S. Temporal and spatial topography of cell proliferation in cancer Nature CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer New England 386: 942-950. [PMID: emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial](http://www.ncbi.nlm.nih.gov/pubmed/35173164)Barroso-Sousa SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman R, RC, M, Abramson V, Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa EP, Krop subjects adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial](https://doi.org/10.1158/1538-7445.sabcs21-gs1-07)Gnant M, Dueck A, Frantal S, Martin M, Burstein H, Greil R, Fox P, Wolff A, Chan A, Winer E, Singer C, Miller K, Colleoni M, Naughton M, Rubovszky G, Bliss J, Mayer I, Steger G, Nowecki Z, Hahn O, Wolmark N, Rugo G, Fohler H, Metzger K, Lu D, Tenner K, Fesl C, DeMichele A, Mayer E. Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS Overall survival by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal J, Stemmer S, Burris H, Yap L, Campone M, Petrakova K, Winer E, Janni W, Conte P, Cameron D, Andr\u00e9 F, Arteaga C, Zarate J, Chakravartty A, Taran T, Gac F, Serra P, Hortobagyi G. Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials](https://doi.org/10.1158/1538-7445.sabcs21-gs2-05)Regan M, Walley B, Fleming G, Francis P, Colleoni M, L\u00e1ng I, G\u00f3mez H, Tondini C, Burstein S, Ruhstaller T, Winer E, Ruepp B, Loi S, Coates A, Goldhirsch A, Gelber R, Pagani O. Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials 2022, 82: gs2-05-gs2-05. [DOI: for patients with hypermutated her2-negative metastatic breast (MBC)](https://doi.org/10.1158/1538-7445.sabcs21-gs2-10)Barroso-Sousa Li L, Overmoyer B, Lange P, Dilullo J, E, Tayob N, Tolaney S. Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated of expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with Hether J, Tolaney S, Krop I, Divakar P, Metzger O, O'Donnell M, Church S, Winer E, Guerriero J, Mittendorf E. Abstract P2-07-03: Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients and non-BCSM in patients with triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p2-10-01)Leone J, Graham N, Leone J, Tolaney S, Leone B, Freedman R, Hassett M, Vallejo C, Winer E, Lin N, Tayob N. Abstract P2-10-01: Estimating risk of breast cancer-specific mortality (BCSM) and non-BCSM in patients with patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis](https://doi.org/10.1158/1538-7445.sabcs21-p2-13-02)Weiss A, Waks A, Laws A, Tolaney S, Winer E, E, Partridge A, King T. Abstract P2-13-02: Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution p2-13-02-p2-13-02. [DOI: or without nivolumab in metastatic triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p2-14-18)Garrido-Castro A, Graham N, Bi K, Park J, Fu J, Keenan T, Richardson E, Pastorello R, Lange P, Attaya V, Wesolowski R, Sinclair N, Lucas Z, Lo S, Tung N, Faggen M, Kaufman P, Block C, Briccetti F, Toke M, Chen W, Wucherpfennig K, Marx S, Tian Y, Agudo J, Guerriero J, Schnitt S, Lin N, Winer E, Mittendorf E, Tayob N, Van Allen E, Tolaney S. Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic in metastatic triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p3-08-01)Santos K, Jin Q, Miller P, Patel A, Kirkner G, Files J, Hughes M, Stokes S, Tayob N, Stover D, Gibson C, Winer E, Lin N, Garber J, Parsons H. Abstract P3-08-01: Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple Cancer Research breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial](https://doi.org/10.1158/1538-7445.sabcs21-p3-18-05)Weiss A, Li T, Desai N, Tung N, Tayob N, King T, Winer E, Mittendorf E, Waks A. Abstract P3-18-05: Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (CDK4/6i)](https://doi.org/10.1158/1538-7445.sabcs21-p4-01-06)Zanudo J, Barroso-Sousa Jain Tayob N, Rees R, Pereslete A, Ferreira A, Abravanel A, S. Abstract P4-01-06: Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib + everolimus + exemestane) in a phase study in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) dimensional flow cytometric analysis or the peripheral immune profile and response to HER2-targeted antibody therapy](https://doi.org/10.1158/1538-7445.sabcs21-p5-13-15)Ogayo E, Waks A, Rogers W, Ionita M, Adigwe K, Alberti J, Kadel S, Moore J, King T, Krop I, Tolaney S, Winer E, Guerriero J, Mittendorf E. Abstract P5-13-15: High dimensional flow cytometric analysis or the peripheral immune profile and response to HER2-targeted antibody therapy Cancer Research PD13-10: Extended adjuvant endocrine in a longitudinal cohort of young breast cancer survivors](https://doi.org/10.1158/1538-7445.sabcs21-pd13-10)Sella T, Zheng Y, Rosenberg S, Ruddy K, Gelber S, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Carey L, Winer E, Partridge A. Abstract PD13-10: Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors Cancer Research 2022, 82: pd13-10-pd13-10. [DOI: 10.1158/1538-7445.sabcs21-pd13-10](https://doi.org/10.1158/1538-7445.sabcs21-pd13-10). [Abstract placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)](https://doi.org/10.1158/1538-7445.sabcs21-pd4-04)Lin N, Murthy Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer deruxtecan in breast cancer brain metastases (BCBM)](https://doi.org/10.1158/1538-7445.sabcs21-pd4-05)Kabraji S, Ni J, Sammons S, Van Swearingen A, Wang Y, Pereslete A, Hsu L, Lascola C, Moore H, Hughes M, Raghavendra A, Gule-Monroe M, Murthy R, Winer E, Anders C, Zhao J, Lin N. Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast patients enrolled the TAILORx trial](https://doi.org/10.1158/1538-7445.sabcs21-pd9-01)Kantor O, Burstein H, King T, Shak S, Russell Giuliano A, Hortobagyi G, Winer E, L, Sparano hormone-receptor positive patients of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)](https://doi.org/10.1158/1538-7445.sabcs21-pd9-03)Ma C, Anurag M, Dockter T, Hoog J, Fernandez-Martinez A, Fan C, Gibbs R, Sanati S, Vij K, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Leitch A, Unzeitig G, Weiss A, Winer E, Hunt K, Partridge A, Carey L, Perou C, Ellis M, Suman V. Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial Research 2022, with Advanced Triple-Negative Breast CancerAlpelisib plus Olaparib for Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/35149538)Batalini UA, GM, Mayer EL. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerAlpelisib plus Olaparib for Triple-Negative oncologists toward biospecimen donation in the setting of abnormal breast imaging findings](http://www.ncbi.nlm.nih.gov/pubmed/35066788)Seah DS, Tayob N, Leone JP, Hu J, Yin J, Hughes M, Scott SM, Winer EP, Silverman SG, Come SE, Lin NU. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings Breast Cancer Research And Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Combination with Fulvestrant HER2-Mutated, Breast CancerNeratinib and Fulvestrant C, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant HER2-Mutated, Non-amplified Metastatic Breast CancerNeratinib and CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).](http://www.ncbi.nlm.nih.gov/pubmed/34995105)Mayer Fesl C, Hlauschek D, N, Wette V, KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz Lu DR, Dueck A, Gnant M, DeMichele A. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34990776)Bellon JR, Tayob N, Yang SM. and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer International Journal Of Radiation for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis](http://www.ncbi.nlm.nih.gov/pubmed/34954044)Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention](http://www.ncbi.nlm.nih.gov/pubmed/34932888)Delahanty LM, Wadden TA, Goodwin PJ, Alfano CM, Thomson CA, Irwin ML, Neuhouser ML, Crane TE, Frank E, Spears PA, Gillis BP, Hershman DL, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hudis C, Winer EP, Carey L, Partridge AH, Ligibel JA. The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle Winer E, Schnitt S, Hamilton E, Hurvitz S, Rugo H, Curigliano G, Tolaney S. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study](http://www.ncbi.nlm.nih.gov/pubmed/34890214)Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Pertuzumab Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, JM, Mayer Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, HS, KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Chemotherapy Response in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34849445)Collier KA, Asad S, Tallman D, ER, Parsons Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer](https://doi.org/10.1016/j.ijrobp.2021.07.103)Bellon J, Tayob N, Burstein H, Partridge A, Demeo M, Tralins J, Yang D, Dang C, Isakoff S, Yardley D, Valero V, Winer E, Krop I, Tolaney S. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer International Journal Of Radiation Oncology Biology Physics 2021, 111: s34. of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery](http://www.ncbi.nlm.nih.gov/pubmed/34648061)Knoerl R, Giobbie-Hurder A, Sannes TS, Chagpar AB, Dillon D, Dominici LS, the impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery Supportive Care In Cancer 2021, 30: 2027-2036. Regimen in Patients with Early Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34472667)BarrosoSousa R, VazLuis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early metastatic N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn A, EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM)](https://doi.org/10.1093/noajnl/vdab112.034)Leone J, Tayob N, Pereslete A, Ligibel J, Parsons H, Bi W, Zhao J, Winer E, Lin N. SYST-06. PHASE II TRIAL OF PAXALISIB (GDC-0084) IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE IE. Reply to the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2) advanced breast cancer (ABC) treated with endocrine therapy (ET) \u00b1 ribociclib (RIB)](https://doi.org/10.1016/j.annonc.2021.08.2090)Hortobagyi G, Stemmer L, Campone M, Petrakova K, Winer E, Janni W, Conte P, Cameron D, Andr\u00e9 F, Arteaga C, Zarate J, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2) advanced breast cancer (ABC) treated with endocrine therapy (ET) cancer: a phase II and biomarker study](http://www.ncbi.nlm.nih.gov/pubmed/34433812)Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson III cancer: a phase II metastatic breast cancer patients with and without BRCA1/2 mutations](http://www.ncbi.nlm.nih.gov/pubmed/34417675)Xu J, Keenan TE, Overmoyer B, Tung NM, trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations Breast Cancer Research A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to Neven A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago Fraser Hilbers Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, C, IT, Ruddy KJ, van Asperen C, Van Weyngaert van C, van Leeuwen-Stok E, Vermeij J, Winer E, Giordano SH, Cardoso F, Bartlett JMS. Evaluation of multiple transcriptomic gene risk signatures in male breast cancer Npj risks of breast cancerspecific mortality in the SEER registry](http://www.ncbi.nlm.nih.gov/pubmed/34231078)Leone JP, Vallejo CT, Hassett Leone BA, Winer EP, Lin NU. Correction to: Factors associated with late risks of breast cancerspecific mortality in the SEER registry Breast Cancer Research for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021](http://www.ncbi.nlm.nih.gov/pubmed/34242744)Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant Bergh J, Bonnefoi H, Morales D, Brucker S, Burstein H, Cameron D, Cardoso F, Carey L, Chua B, Ciruelos E, Colleoni M, Curigliano G, Delaloge S, Denkert P, Ejlertsen B, Fitzal F, Francis P, Galimberti V, Mahmoud H, Garber J, Gnant M, Gradishar W, Gulluoglu B, Harbeck N, Huang C, Huober J, Ilbawi A, Jiang Z, Johnston S, Lee E, Loibl S, Morrow M, Partridge A, Piccart M, Poortmans P, Prat A, Regan M, Rubio I, Rugo H, Rutgers E, Sedlmayer F, Semiglazov V, Senn H, Shao Z, Spanic T, Tesarova P, Th\u00fcrlimann B, Tjulandin S, Toi M, Trudeau M, Turner N, Luis I, Viale G, Watanabe T, Weber W, Winer E, Xu B. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer breast cancer: Barrios Di\u00e9ras V, A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. First-line metastatic triple-negative breast cancer: a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119](https://doi.org/10.1016/j.pathol.2021.06.099)Emancipator Winer E, Lipatov O, Im S, Goncalves A, Mu\u00f1oz-Couselo E, Lee K, Nowecki Z, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Hund S, Kulangara K, Karantza V, Mejia J, Ma J, Jelinic P, Huang L, Cortes J. Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative in triple-negative breast cancer and high-grade serous cancer](https://doi.org/10.1158/1538-7445.am2021-156)Batalini F, Gulhan D, Mao V, Polak M, Winer E, Mayer E, Matulonis U, Konstantinopoulos P, Park P, Wulf G. Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and inhibition in HER2+ breast cancer brain metastases](https://doi.org/10.1158/1538-7445.am2021-337)Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Long H, Brown M, Winer E, Dillon D, Lin N, Zhao J. Abstract 337: p16INK4A-deficiency predicts for response to combined HER2 and CDK4/6 inhibition in HER2+ Dai Y, Bergholz J, Coy S, Lin J, Winer E, Dillon D, Zhao J, Sorger P, Santagata S. Abstract 4: Temporal and spatial topography of cell proliferation in cancer Cancer Research 2021, 81: 4-4. [DOI: 10.1158/1538-7445.am2021-4](https://doi.org/10.1158/1538-7445.am2021-4). [Abstract CT026: A (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER](https://doi.org/10.1158/1538-7445.am2021-ct026)Ma C, Luo J, Freedman R, Pluard T, Nangia J, Lu J, Valdez-Albini F, Cobleigh M, Jones J, Lin N, Winer E, Marcom P, Thomas S, Anderson J, Haas B, Hamann K, Bryce R, Lalani A, Carey L, Goetz M, Gao F, Kimmick G, Pegram M, Ellis M, Bose R. Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic ATEMPT Trial)](http://www.ncbi.nlm.nih.gov/pubmed/34120223)Ruddy Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34097070)Rugo HS, Loi G, L, Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer Journal Of Breast Cancer (ATEMPT): A Randomized Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman R, RC, M, Abramson V, PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, in With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust](http://www.ncbi.nlm.nih.gov/pubmed/34082017)Piccart M, Kalinsky K, Gray R, Barlow W, Poncet C, Cardoso F, Winer E, Sparano J. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).](https://doi.org/10.1200/jco.2021.39.15_suppl.1043)Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Zhang C, Winer E. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without D, Dai Y, Wang S, Bergholz J, Coy S, Lin J, Jeselsohn R, Metzger O, Winer E, Dillon D, Zhao J, Sorger P, Santagata S. Temporal and spatial topography of cell proliferation in cancer. Journal Of Clinical Oncology 2021, 39: 3122-3122. Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Survival in male breast cancer (MaBC) over the past three decades. Journal (MBC).](https://doi.org/10.1200/jco.2021.39.15_suppl.tps1102)Garrido-Castro Keenan Li T, Lange P, Callahan C, Guerriero J, Tayob N, Anderson L, Stover D, Gogineni K, Carey L, E, PD-L1- metastatic Li T, Lange P, Callahan C, Guerriero J, Tayob N, Anderson L, Yam C, Daniel B, Carey L, Nanda R, Winer E, Mittendorf E, Tolaney [DOI: 10.1200/jco.2021.39.15_suppl.tps1106](https://doi.org/10.1200/jco.2021.39.15_suppl.tps1106). [ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.](https://doi.org/10.1200/jco.2021.39.15_suppl.tps597)Saji S, McArthur Ignatiadis M, Bailey El-Abed S, Brandao M, Metzger O, Lai C, Guillaume E, Gelber R, Piccart-Gebhart M. ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast 10.1200/jco.2021.39.15_suppl.tps597](https://doi.org/10.1200/jco.2021.39.15_suppl.tps597). Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. Journal Of The National S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai ST, Verschraegen DG. Genomic features of rapid versus late relapse in for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0](http://www.ncbi.nlm.nih.gov/pubmed/34003702)Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0 Journal Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33999652)Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Rosovsky R, PiperVallillo A, Gao R, Freeman H, Kirkner Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab](http://www.ncbi.nlm.nih.gov/pubmed/33941592)Filho OM, Viale G, Stein S, Trippa L, Yardley F, Winer EP, Krop IE. of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)](https://doi.org/10.1016/j.annonc.2021.03.056)Metzger O, Lambertini C, Krop I, Phillips G, Perou C, Symmans F, Melero I, Harbeck N, Winer E, Im S, Barrios C, Bonnefoi H, Gralow J, Ellis P, Gianni L, Toi M, Swain S, Boulet T, Song C, de Haas S. 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast SM, Leone BA, Winer EP, Lin NU. Factors associated with late risks of breast cancer-specific mortality in the SEER registry Breast Cancer Research heterogeneity on treatment responses in HER2-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/33886505)Janiszewska M, Stein S, Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alekovi M, Trinh A, Murphy Marangoni EP, Krop I, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/33981951)Ligibel JA, Huebner L, Rugo HS, LA, Partridge AH, Hudis CA, Winer EP. Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance) Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33507222)Freedman RA, Minami CA, Winer EP, Morrow Ruddy Jagsi Lin NU, Canin Schonberg MA, Keating NL. Individualizing Surveillance Mammography for Older Patients Adjuvant endocrine therapy for pre- and postmenopausal women The Breast 2021, 56: s4-s5. [DOI: subtypes and survival in male breast cancer Breast Cancer Research Treatment 2021, of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33713742)Bellon JR, Chen YH, Rees R, Taghian JS, Punglia RS, Shiloh Warren LEG, Krishnan MS, Phillips J, Pretz J, Jimenez SM. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer International Journal Of Radiation Mu\u00f1oz-Couselo Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J, investigators K. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry](http://www.ncbi.nlm.nih.gov/pubmed/33590387)Leone JP, Leone BA, Tayob NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry Breast Cancer Research And Treatment 2021, AD, P, MR, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Jain E, Files J, Mohammed-Abreu A, Krevalin M, MacKichan C, Barry WT, Guo H, Xia D, Cerami E, Rollins BJ, MacConaill LE, Lindeman NI, Krop IE, Johnson BE, Wagle N, Winer EP, Dillon DA, Lin NU. Genomic Characterization of de novo Metastatic Breast Cancer the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Vallius B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, EM, Shapiro GI, Tolaney SM. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)](https://doi.org/10.1158/1538-7445.sabcs20-gs4-05)Ma C, Suman V, Leitch A, Sanati S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Maluf H, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Dockter T, Zujewski J, Weiss A, Hunt K, Hudis C, Winer E, Ellis M, Carey L, Partridge A. Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance 2021, 81: patients with localized (NeoSTAR)](https://doi.org/10.1158/1538-7445.sabcs20-ot-03-06)Spring L, Tolaney S, Desai N, Comander Mulvey I, E, Mittendorf E, Ellisen L, of neoadjuvant sacituzumab govitecan (IMMU-132) in patients of cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119](https://doi.org/10.1158/1538-7445.sabcs20-pd14-04)Winer E, Lipatov O, Im S, Goncalves A, Mu\u00f1oz-Couselo E, Lee K, Nowecki Z, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Hund S, Kulangara K, Karantza V, Mejia J, Ma J, Jelinic P, Huang L, Emancipator K, Cortes J. Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer and nab -paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial](https://doi.org/10.1158/1538-7445.sabcs20-pd14-05)Emens L, Molinero L, Adams S, Rugo Di\u00e9ras V, Iwata H, Barrios C, Winer E, Chang C, Chui S, Schmid P, Loi S. Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab and nab -paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 Research in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086](https://doi.org/10.1158/1538-7445.sabcs20-pd14-07)Loi S, Schmid P, Cortes J, Cescon D, Winer E, D, H, De Laurentiis Nanda Iwata Awada A, Tan A, Salgado R, Karantza V, Jelinic P, Wang A, Huang L, Cristescu R, Annamalai L, Yearley J, Yearley J, Adams S. Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)](https://doi.org/10.1158/1538-7445.sabcs20-pd2-10)Ellis M, Suman V, Leitch A, Sanati S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Maluf H, Dowsett M, Tiersten A, Mita M, Razaq W, Hieken T, Wang Y, Dockter T, Zujewski J, Weiss A, Hudis C, Winer E, Hunt K, Partridge A, Ma C, Carey L. Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-pd3-05)Waks A, Desai N, Li T, Poorvu P, Partridge A, Sinclair N, Spring L, Faggen M, Constantine M, Alberti J, Deane J, Rosenberg S, Tolaney S, Krop I, Tung N, Tayob N, King T, Mittendorf E, Winer E. Abstract PD3-05: The DAPHNE trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) samples and in cellular models](https://doi.org/10.1158/1538-7445.sabcs20-pd7-08)Wander S, Mao P, Lloyd M, Johnson G, Kowalski K, Nayar U, Guenther L, Stegmaier K, mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor 2021, 81: pd7-08-pd7-08. [DOI: metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases](https://doi.org/10.1158/1538-7445.sabcs20-ps12-01)Winer E, Lipatov O, Im S, Goncalves A, Lee K, Schmid P, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Lin J, Karantza V, Mejia J, Cortes J. Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs20-ps4-25)Barroso-Sousa R, Forman J, Weber Z, Collier K, Kao K, Richardson E, Keenan T, Cohen O, Manos M, Brennick R, Ott P, Hodi F, Dillon D, Lin N, Van Allen E, Rodig S, Winer E, Mittendorf E, Wu C, Stover D, N, Shukla S, Tolaney S. Abstract PS4-25: Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast tool risks of breast cancer specific mortality (BCSM) and non-BCSM](https://doi.org/10.1158/1538-7445.sabcs20-ps6-13)Leone J, Tolaney S, Leone B, Freedman R, Hassett M, Leone J, Vallejo C, Winer E, Lin N, Tayob N. Abstract PS6-13: Population-based tool to estimate residual risks of breast cancer specific mortality (BCSM) and non-BCSM Cancer Research for the treatment of metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/33585999)Lynce F, Williams JT, Regan MM, Bunnell Freedman RA, Mayer EL, Partridge AH, study of JAK1/2 inhibitor with weekly paclitaxel for the treatment of P, Winer E, Mittendorf E, King T. Utility of the 21-Gene Recurrence Score the Study](http://www.ncbi.nlm.nih.gov/pubmed/33523233)Emens V, H, Barrios EP, Adams S, Schmid nab-Paclitaxel Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study Journal Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. The global landscape of treatment standards for breast cancer Journal Of The National Cancer Institute 2021, cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study](http://www.ncbi.nlm.nih.gov/pubmed/33460574)Mayer EL, Dueck AC, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff A, Gnant M. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, EP, Come SE, Lin NU. Perceptions of patients with early stage breast cancer toward research biopsies Cancer in Breast and Colorectal Cancer: A Randomized Trial](http://www.ncbi.nlm.nih.gov/pubmed/32859615)Brown JC, Zhang S, PS, Hu FB, Fuchs CS, Meyerhardt JA. Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32988969)Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, O'Brien T, Kelly C, Winer E, Yardley D. A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer Clinical Cancer 2020, 26: 6149-6157. [PMID: 32988969](https://pubmed.ncbi.nlm.nih.gov/32988969), [DOI: 10.1158/1078-0432.ccr-20-1693](https://doi.org/10.1158/1078-0432.ccr-20-1693). - Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop Sohl J, Hu J, Kasparian E, Winer EP, Lin NU. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases Breast Cancer Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32723837)Mao Cohen MS, Exman P, Wander SA, Waks AG, Nayar U, Chung J, Freeman S, Rozenblatt-Rosen O, Miller VA, Piccioni F, Root DE, Regev A, EP, Lin NU, Wagle N. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, Meyer O, KD, Giambartolomei C, Pasaniuc C, Ellis MJ, Krop I, Winer E, Letai A, Brown M, Dawson Long HW, Zhao JJ, Goel S. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/33150547)Sella T, Gelber SI, Poorvu Borges VF, Come SE, Warner E, Snow C, Jakubowski DM, Russell CA, Winer EP, Rosenberg SM, Partridge AH. Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer Breast Cancer Research 186: 157-165. AC, Saura C, Barroso-Sousa R, Guo Ciruelos E, Bermejo B, Gavil\u00e1 J, Serra V, Prat A, Par\u00e9 L, C\u00e9liz P, buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation](https://doi.org/10.1016/j.annonc.2020.10.064)Im O, Goncalves Lee K, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Zambelli S, Harbeck N, Andre F, Dent R, Lin J, Karantza V, Mejia J, Winer E. 44O Pembrolizumab (pembro) vs chemotherapy (chemo) IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer](https://doi.org/10.1016/j.annonc.2020.10.069)Iwata H, Emens L, Adams S, Barrios Di\u00e9ras V, Loi S, Rugo H, Schneeweiss A, Winer E, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Chui S, Schmid P. 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast of Cancer and Mutations in Homologous Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/33095682)Fernandez-Martinez JS, L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. of Systemic Adjuvant Therapy for Solid Tumors.](http://www.ncbi.nlm.nih.gov/pubmed/33052755)Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, Na\u00eft Kaoudjt R, Schumacher E, Spears PA, Regan MM, Gelber RD, Davidson NE, Norton L, Winer EP. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal Of Clinical Oncology Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32880602)Tolaney SM, Barroso-Sousa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer Krop Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone resistance to cyclin-dependent kinase 4/6 inhibitors](https://doi.org/10.1158/1557-3125.pi3k-mtor18-b23)Wander S, Cohen O, Johnson G, Buendia J, Luo F, Geradts J, Winer E, Lin N, driving resistance to cyclin-dependent kinase B24: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation](https://doi.org/10.1158/1557-3125.pi3k-mtor18-b24)Xing Y, Lin N, Mauer M, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abraham V, Litton J, Chavez-McGregor M, Valero V, Piha-Paul S, Hong D, Do K, Tarco E, Riall D, Eterovic K, Cantley L, Mills G, Doyle L, Winer E, Hortobagyi G, Gonzalez-Angulo A, Meric-Bernstam F. Abstract B24: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Molecular Cancer 2020, Saghir N, Elzayat M, Eniu A, Fallowfield PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim S, Lin NU, Mertz C, Vorobiof DA, T, B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Annals Of the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506448)Emens L, Adams S, Barrios C, Dieras Iwata H, Loi S, Rugo H, Schneeweiss A, Winer E, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Chui S, Schmid P. IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center](http://www.ncbi.nlm.nih.gov/pubmed/32939592)Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center Breast Cancer Research And Treatment 2020, 185: 215-227. [PMID: 32939592](https://pubmed.ncbi.nlm.nih.gov/32939592), [DOI: 10.1007/s10549-020-05931-9](https://doi.org/10.1007/s10549-020-05931-9). Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole MJM, Savenkov A, Carey LA, Winer EP, Rugo HS. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab Clinical outcomes among hospitalized COVID-19 patients: A case-control analysis](https://doi.org/10.1158/1557-3265.covid-19-po-063)Klein I, Rosenberg S, Kotton C, Reynolds K, Zubiri L, Gaither R, Freeman H, Kirkner G, Rhee C, Klompas M, Baker M, Wadleigh M, Winer E, Partridge A. Abstract PO-063: Impact of cancer history on outcomes among hospitalized COVID-19 patients: A case-control analysis Clinical Cancer Research 2020, 26: po-063-po-063. and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial](https://doi.org/10.1016/j.annonc.2020.08.398)Emens L, Molinero L, Adams S, Rugo V, Iwata H, Barrios C, Nechaeva M, Winer E, Chang C, Chui S, Schmid P, Loi S. Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 Annals Oncology 2020, 31: s360-s361. [DOI: adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1016/j.annonc.2020.08.2240)Mayer E, Gnant M, DeMichele A, Martin M, Burstein H, Prat A, Rubovszky G, Miller K, Pfeiler G, Winer E, Zdenkowski N, Anderson D, Nowecki C, Dueck A. PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast Annals 2020, 31: s1145. [DOI: 10.1016/j.annonc.2020.08.2240](https://doi.org/10.1016/j.annonc.2020.08.2240). [Impact of free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases](https://doi.org/10.1016/j.annonc.2020.08.395)Bachelot T, Lin N, Murthy R, Hurvitz S, Borges V, Oliveira M, Oakman C, Khan S, Lynch C, Westbrook K, Doyle C, Reinisch M, Colleoni M, Slamon D, Hortobagyi G, Winer E, McGoldrick S, An X, Loibl S. Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain Of Oncology 2020, 31: s359-s360. [DOI: 10.1016/j.annonc.2020.08.395](https://doi.org/10.1016/j.annonc.2020.08.395). [A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials](http://www.ncbi.nlm.nih.gov/pubmed/32866625)Amiri-Kordestani L, Xie D, Tolaney SM, Bloomquist E, Tang S, Ibrahim A, Goldberg KB, Theoret MR, Pazdur R, Sridhara R, Winer EP, Beaver JA. A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials Annals Of for radiotherapy omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer](https://doi.org/10.1158/1538-7445.am2020-ct271)Patel M, Dillon D, Digiovanni G, Chen Y, Catalano P, Perez C, Wazer D, Wright J, Jimenez R, Winer E, Wong J, Bellon J, Braunstein L. Abstract CT271: PRECISION (Profiling early breast cancer for radiotherapy omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast 2020, 80: ct271-ct271. versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker](http://www.ncbi.nlm.nih.gov/pubmed/32798689)Mayer Abramson V, Jankowitz R, Falkson Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski AC, versus paclitaxel in triple-negative breast cancer: evaluating the Cancer Receiving First-Line Dirix L, C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy Journal Of The National CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC CANCER WITH R, Anders Borges Loi S, Abramson V, Bedard P, Oliveira M, Zelnack A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, Mueller V, Carey L, McGoldrick S, An X, Winer E. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ CANCER (MBC) WITH Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32404308)Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu SG, Wagle N. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Reply. New Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32019858)Barroso-Sousa R, Keenan TE, Pernas S, Exman Jain E, Garrido-Castro AC, Hughes JL, Lindeman NI, EP, EA, Tolaney SM. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins Trippa DeFelice Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson VA. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer Clinical Cancer Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the Borges Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial NU, Wulf GM. Response of Brain Metastases From PIK3CA-Mutant Breast Cancer Block CC, Lin NU, King TA, Muss HB, Winer EP. Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond Journal Of The National Cancer Institute combination with trastuzumab in patients with HER2-positive breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/32461105)Filho O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, Younger J, Lawler E, L, Freedman RA, Tolaney SM, Krop I, Winer EP, Lin NU. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).](https://doi.org/10.1200/jco.2020.38.15_suppl.1002)Tung N, Robson M, Ventz C, Marcom Nanda R, Shah P, Ballinger T, Yang E, Melisko M, Brufsky A, Vinayak S, Demeo M, Jenkins C, Domchek S, Wulf G, Krop I, Wolff A, Winer E, Garber J. TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). Journal Of Clinical Oncology 2020, 1002-1002. [Tucatinib versus placebo added capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).](https://doi.org/10.1200/jco.2020.38.15_suppl.1005)Lin N, Murthy R, Anders C, Borges V, Hurvitz Loi S, Abramson V, Bedard P, Oliveira M, Zelnak A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, M\u00fcller V, Carey L, McGoldrick S, An G, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.](https://doi.org/10.1200/jco.2020.38.15_suppl.1013)Winer E, Lipatov O, Im S, Goncalves A, Mu\u00f1oz-Couselo E, Lee K, Schmid P, Testa L, Witzel I, Ohtani S, Lunceford J, Karantza V, Mejia J, Cristescu R, Aurora-Garg D, Jelinic P, Huang L, Cortes J. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from A, Keenan T, Li T, Tayob N, Wulf G, Richardson E, Mittendorf E, Overmoyer B, Krop I, Winer E, Van Allen E, Agudo J, Tolaney S. A Ib [DOI: 10.1200/jco.2020.38.15_suppl.1046](https://doi.org/10.1200/jco.2020.38.15_suppl.1046). Kabraji Li Y, Leone J, Garrido-Castro A, Barroso-Sousa R, Files J, Kirkner G, Johnson B, Winer E, Cherniack A, Lin N. Genomic profiling of breast cancer brain metastases reveals targetable alterations. Of Clinical [DOI: 10.1200/jco.2020.38.15_suppl.2525](https://doi.org/10.1200/jco.2020.38.15_suppl.2525). [Primary (T-DM1) versus trastuzumab + pertuzumab after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).](https://doi.org/10.1200/jco.2020.38.15_suppl.500)Harbeck N, Im S, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis P, Gianni L, Swain S, Im Y, De Laurentiis M, Nowecki Z, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer E, Krop I. Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) versus trastuzumab + pertuzumab after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). Journal Neoadjuvant endocrine or III estrogen receptor-positive HER2-negative breast cancer (ER+ S, Vij K, Unzeitig G, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Dockter T, Korde L, Weiss A, Hunt K, Hudis C, Winer E, Partridge A, Carey L, Ellis M. ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) to neoadjuvant chemotherapy and the breast recurrence score in young women with estrogen receptor-positive early breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.514)Sella T, Gelber S, Poorvu P, Kim H, Guzman Arocho Y, Collins L, Ruddy K, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Warner E, Snow C, Jakubowski D, Russell C, Winer E, Rosenberg S, Partridge A. Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer. Journal Of Clinical Oncology 2020, 514-514. [DOI: 10.1200/jco.2020.38.15_suppl.514](https://doi.org/10.1200/jco.2020.38.15_suppl.514). - Kantor Giuliano A, Hortobagyi G, Burstein H, Winer E, Sparano J, Mittendorf E. Expanding criteria for prognostic stage IA disease in HR+ breast cancer. Journal Of Oncology 2020, 38: 550-550. [DOI: 10.1200/jco.2020.38.15_suppl.550](https://doi.org/10.1200/jco.2020.38.15_suppl.550). [Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.](https://doi.org/10.1200/jco.2020.38.15_suppl.587)Leone J, Freedman R, Hassett M, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. Journal Of placebo-controlled trial of aspirin as adjuvant therapy breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.tps600)Chen W, Winer E, Ballman K, Partridge A, Carey M, Matyka C, Openshaw T, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo-controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2020, 38: tps600-tps600. Savoie Agarwal A, Guo H, Hu J, Fell G, Lederman R, Hughes ME, Winer EP, Lin NU, Tolaney SM. Barriers to Clinical Trial Accrual: Perspectives of Community-Based on health-related quality of life in patients with metastatic triple negative breast cancer](https://doi.org/10.1016/j.annonc.2020.03.242)Schmid P, Haiderali A, Mejia J, Guo Z, Zhou X, Martin-Nguyen A, Cort\u00e9s J, Winer E. 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer Annals Of Oncology 2020, 31: [DOI: capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)](https://doi.org/10.1016/j.annonc.2020.03.238)Curigliano G, Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Cameron D, Borges V, Bedard P, Oliveira M, Jakobsen E, Bachelot T, Shachar S, Mueller V, Carey L, Loibl S, Feng W, Walker L, Winer E. 137O Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain Regimen: A Prospective Study](http://www.ncbi.nlm.nih.gov/pubmed/32330102)Vaz-Luis I, Meglio Hu J, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, O'Neil K, Partridge of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A P, Leo Viale G, Senn H, M, Curigliano G. The legacy of Professor G, Hylton N. in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).](http://www.ncbi.nlm.nih.gov/pubmed/32097092)Tung N, Arun B, Hacker Hofstatter AC, Marcom PK, Mayer EL, Lange PB, AJ, Jenkins SJ, in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/32245699)Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso NU, Shapiro GI, Wagle N. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic plus nab-paclitaxel Chui SY, Rugo HS, Emens LA, Schmid P. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)](https://doi.org/10.1158/1538-7445.sabcs19-gs1-01)Murthy R, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz S, Lin N, Borges V, Abramson V, Anders C, Bedard P, Oliveira V, Braga S, Duhoux F, Greil R, Cameron D, Carey L, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels M, Walker L, Feng W, Winer E. Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)](https://doi.org/10.1158/1538-7445.sabcs19-gs1-05)Tolaney S, Trippa L, Barry W, Hu J, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett M, Marcom K, Albain K, DeFusco P, Tung N, Ardman M, GS1-05: of adjuvant emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) Research 2020, 80: in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state](https://doi.org/10.1158/1538-7445.sabcs19-gs2-02)Cohen O, Mao P, Nayar U, Buendia-Bue J, Kim D, Jain E, Helvie K, Abravanel D, Kowalski K, Kapstad C, Freeman S, Adalsteinsson V, Wander S, Waks A, Getz G, Regev A, Winer E, Lin N, Wagle N. Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell ( BRCA carriers) with HER2-negative breast Results from the INFORM trial (TBCRC 031)](https://doi.org/10.1158/1538-7445.sabcs19-gs6-03)Tung N, Arun B, Hofstatter E, Hacker Isakoff S, Borges V, Legare R, Isaacs C, Wolff A, Marcom P, Mayer E, Lange P, Goss A, Krop I, Winer E, Schnitt S, Garber J. Abstract versus treatment ( BRCA carriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC Research 2020, 80: gs6-03-gs6-03. [DOI: 10.1158/1538-7445.sabcs19-gs6-03](https://doi.org/10.1158/1538-7445.sabcs19-gs6-03). RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment](https://doi.org/10.1158/1538-7445.sabcs19-gs6-05)Cohen O, Abravanel D, Slyper M, Klughammer L, Frangieh A, Vigneau S, Wu J, Mayorga A, Waldman J, Nguyen L, Dionne D, Ashenberg O, Hofree M, Cuoco M, Rodman C, Winer E, Lin N, Johnson B, Rotem A, Rozenblatt-Rosen O, Regev A, Wagle N. Abstract GS6-05: A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the Research 2020, 80: gs6-05-gs6-05. [DOI: 10.1158/1538-7445.sabcs19-gs6-05](https://doi.org/10.1158/1538-7445.sabcs19-gs6-05). [Abstract II trial in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases (BCBM)](https://doi.org/10.1158/1538-7445.sabcs19-ot1-08-05)Leone J, Trippa L, Milisits L, Andrews C, Ligibel J, Parsons H, Bi W, Zhao J, Winer E, Lin N. Abstract OT1-08-05: Phase II trial of GDC-0084 in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases [DOI: 10.1158/1538-7445.sabcs19-ot1-08-05](https://doi.org/10.1158/1538-7445.sabcs19-ot1-08-05). A, Spoerke J, Zhou Guan J, Ingalla E, Young A, Hafner M, Aimi J, Chang C, Giltnane J, Gates M, Mayer I, Azaro A, Winer E, Loi S, Jhaveri K, Lauchle J, Gendreau S, Humke E, Metcalfe C. Abstract P2-11-05: ER pathway activity signature as a biomarker for (TBCRC033: ATEMPT trial)](https://doi.org/10.1158/1538-7445.sabcs19-p2-13-02)Ruddy K, Trippa L, Hu J, Barry W, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett A, Marcom P, Albain K, DeFusco P, Tung N, Ardman in combination with Clonal heterogeneity and treatment resistance in a patient with HER2+ breast cancer](https://doi.org/10.1158/1538-7445.sabcs19-p3-01-09)Buendia-Buendia J, Pernas S, Cohen O, Mao P, Kowalski K, Lin N, Winer E, Wagle N. Abstract P3-01-09: Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer Cancer Research 2020, 80: p3-01-09-p3-01-09. [DOI: 10.1158/1538-7445.sabcs19-p3-01-09](https://doi.org/10.1158/1538-7445.sabcs19-p3-01-09). [Abstract P3-09-10: A phase combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-10)Barroso-Sousa R, Trippa L, Li T, Keenan T, Winship G, Andrews C, Osmani W, Overmoyer B, Winer E, Mittendorf E, Duda D, Tolaney S. Abstract P3-09-10: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative [Abstract P3-09-16: Fecal microbiome and among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-16)de Sousa R, Ajami N, Keenan T, Andrews C, Pittenger J, Wulf G, Spring L, Krop I, Winer E, Mittendorf E, Tolaney S. Abstract P3-09-16: Fecal microbiome and association with outcomes among patients (pts) receiving eribulin (E) +/- pembrolizumab (P) for hormone receptor positive (HR+) [Abstract adavosertib Guerriero J, Tahara R, Winship G, Osmani W, Andrews C, Conway J, He M, Pastorello R, Tracy A, Godin R, Overmoyer B, Winer E, Mittendorf E, Shapiro G, Van Allen E, Tolaney S. Abstract P3-10-08: A phase II study of cisplatin and the Wee1 inhibitor adavosertib in in combination with PD-1 inhibitor hormone receptor-positive MBC) and metastatic ovarian cancer (MOC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-14-03)Herold C, Trippa L, Li T, Do K, Bardia A, Anderson L, Montazeri K, Pittenger J, Andrews C, Mittendorf E, Goel S, Winer E, Shapiro G, Tolaney S. Abstract P3-14-03: A phase 1b study of the inhibitor ribociclib in combination with PD-1 inhibitor hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic Cancer Research 2020, 80: p3-14-03-p3-14-03. [DOI: 10.1158/1538-7445.sabcs19-p3-14-03](https://doi.org/10.1158/1538-7445.sabcs19-p3-14-03). - Zhang Y, Nock W, Wyse M, Weber Z, Adams E, Sarah A, Stockard S, Tallman D, Singh J, Bae J, Winer E, Lin N, Jiang Y, Ma D, Wang P, Shi L, Huang W, Shao Z, Verschraegen C, Cherian M, Lustberg M, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Robert W, Stover D. Abstract P4-05-02: Machine learning predicts rapid relapse in triple negative breast cancer Cancer Research 2020, 80: p4-05-02-p4-05-02. [DOI: 10.1158/1538-7445.sabcs19-p4-05-02](https://doi.org/10.1158/1538-7445.sabcs19-p4-05-02). [Abstract P4-06-01: Using multi-omic complexity of triple-negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p4-06-01)Goel S, Brauer H, Ren Y, Gorman K, Osmani W, Pittenger J, Andrews C, Richardson E, Mittendorf E, PhD M, Winer E, Schnitt S, Tolaney S. Abstract P4-06-01: Using multi-omic profiling to unravel the complexity of triple-negative breast cancer Cancer [Abstract P4-10-03: genomic cancers using the oncomine comprehensive assay for actionable mutations](https://doi.org/10.1158/1538-7445.sabcs19-p4-10-03)Bayani J, Poncet C, Crozier C, Trinh Q, Hopkins M, Uwimana A, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, C, Rubio I, Ruddy K, van Asperen C, Weyngaert van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Stein L, Giordano S, Cardoso F, Bartlett J. Abstract P4-10-03: The genomic landscape of male breast cancers using the oncomine comprehensive assay for actionable mutations Cancer Research 2020, [DOI: 10.1158/1538-7445.sabcs19-p4-10-03](https://doi.org/10.1158/1538-7445.sabcs19-p4-10-03). [Abstract P5-06-13: Factors breast cancer-specific mortality (BCSM) for locally-advanced breast cancer (LABC) in the surveillance, epidemiology, and end results (SEER) registry](https://doi.org/10.1158/1538-7445.sabcs19-p5-06-13)Leone J, Leone B, Hassett M, Leone J, Freedman R, Tolaney S, Winer E, Vallejo C, Lin N. Abstract P5-06-13: Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) for locally-advanced breast cancer (LABC) in the surveillance, epidemiology, and end results (SEER) registry Cancer Research 2020, 80: p5-06-13-p5-06-13. [DOI: and in hormone-receptor positive (HR+)/HER2- metastatic cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study](https://doi.org/10.1158/1538-7445.sabcs19-p5-11-04)Barroso-Sousa R, Li T, Trippa L, Rees R, Andrews C, Ferreira A, Helvie K, Partridge A, Overmoyer B, Winer E, Wagle N, phase study of palbociclib (PALBO) plus and in hormone-receptor positive (HR+)/HER2- metastatic cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II 80: p5-11-04-p5-11-04. breast cancer: A retrospective substudy of IMpassion130](https://doi.org/10.1158/1538-7445.sabcs19-pd1-07)Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios C, Iwata H, Di\u00e9ras V, Winer E, Kockx M, Peeters D, Chui S, Lin J, Duc A, Viale G, Molinero L, Emens L. Abstract PD1-07: breast [DOI: paclitaxel + trastuzumab (TH) A, Zheng Y, Rosenberg S, Gelber R, Gelber S, Barry W, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett M, Marcom P, Albain K, Defusco P, Tung N, Ardman M, E, Krop I, Tolaney S. Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab [Abstract PD2-09: The resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs19-pd2-09)Wander S, Cohen O, Gong X, Johnson G, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, Ye X, Yu C, Jansen V, Garraway L, Winer E, Tolaney S, Lin N, Buchanan S, Wagle N. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone 10.1158/1538-7445.sabcs19-pd2-09](https://doi.org/10.1158/1538-7445.sabcs19-pd2-09). [Abstract PD4-08: An FDA analysis of survival outcomes comparing adjuvant paclitaxel and trastuzumab trial (APT) to an external control from historical clinical trials](https://doi.org/10.1158/1538-7445.sabcs19-pd4-08)Amiri-Kordestani L, Xie D, Bloomquist E, Tang S, Pazdur R, Sridhara R, Tolaney S, Winer E, Beaver J. Abstract PD4-08: An FDA analysis of survival outcomes comparing adjuvant paclitaxel and trastuzumab trial (APT) to an external control from historical clinical trials Cancer Research 2020, 80: in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs19-pd5-03)Loi S, Winer E, Lipatov O, Im S, Goncalves A, Cortes J, Lee K, Schmid P, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Huang L, Mejia J, Karantza V, Salgado R. Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast [Abstract PD7-05: A first-in-human phase oral selective estrogen receptor degrader Fidalgo J, Bellet M, Mayer I, Boni V, Patel J, Bardia A, Garcia J, Kabos P, Gates M, Chen Y, Fredrickson J, Wang X, Friedman L, Spoerke J, Gendreau S, Metcalfe C, Liu L, Chang C, Monemi S, Gonzalez M, McCurry U, Milan S, Humke E, Loi S. Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader Morrow M, Radiotherapy for Hormone Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32113750)Barroso-Sousa Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic [DOI: 10.1016/j.clbc.2020.01.012](https://doi.org/10.1016/j.clbc.2020.01.012). Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney S, Wagle N. Prevalence and mutational determinants of high tumor mutation burden in breast cancer Of Oncology E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira Hortobagyi G, Capecitabine for HER2-Positive Metastatic [PMID: 31825569](https://pubmed.ncbi.nlm.nih.gov/31825569), With Node-Negative Borges VF, Come SE, Warner Jakubowski DM, Russell C, Winer EP, Partridge AH. Prognostic Impact of the 21-Gene Recurrence Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Reported Outcome: CALGB 40502 (Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/31802506)Sharma MR, Mehrotra S, C, Winer EP, Lyss AP, Toppmeyer B, HS, MJ, Gobburu JV. Personalized Management on a Patient Reported Outcome: CALGB 40502 (Alliance) advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial](http://www.ncbi.nlm.nih.gov/pubmed/31786121)Schmid V, Husain A, Winer EP, Loi S, Emens LA, Investigators I. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase or both on metabolic biomarkers in colorectal and breast cancer survivors](http://www.ncbi.nlm.nih.gov/pubmed/32090192)Meyerhardt JA, Irwin ML, Jones LW, Zhang S, Campbell N, Brown JC, Pollak M, Sorrentino Cartmel B, Harrigan K, Abrams T, Fuchs CS, Sanft T, Douglas PS, Hu F, Ligibel JA. Randomized phase II trial of exercise, metformin, or both on metabolic biomarkers in colorectal and breast cancer survivors Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.](http://www.ncbi.nlm.nih.gov/pubmed/32923853)Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, SM, Krop CX, DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries](https://doi.org/10.1093/annonc/mdz418)Iwata H, Im S, Sohn J, Jung K, Im Y, Lee K, Inoue K, Tamura K, Wong A, Emens L, Barrios C, Adams S, Schneeweiss A, Di\u00e9ras V, Winer E, Chui S, Henschel V, Rugo H, Loi S, Schmid P. 37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries Annals Of Oncology 30: ix13-ix14. [DOI: 10.1093/annonc/mdz418](https://doi.org/10.1093/annonc/mdz418). - Freedman RA, Winer EP. Adjuvant chemotherapy for older patients with breast cancer: When is the pain worth the gain? Journal Of The National Cancer early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019](http://www.ncbi.nlm.nih.gov/pubmed/31373601)Burstein H, Curigliano G, Loibl S, Dubsky M, Regan M, Senn H, Winer E, Thurlimann B, 2019 M. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 Annals Of phase study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer](https://doi.org/10.1093/annonc/mdz240.112)Ignatiadis M, McArthur H, Bailey A, Martinez J, de Azambuja E, Metzger O, Lai C, Franzoi M, Goulioti T, Daly F, Bouhlel A, Balta V, Maetens M, Viale G, Andr\u00e9 R, Piccart M, Winer E. 289TiP ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer Annals Of Oncology 2019, 30: v97. versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)](https://doi.org/10.1093/annonc/mdz394.010)Cort\u00e9s J, Lipatov O, Im S, Gon\u00e7alves A, Lee K, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Zambelli S, Harbeck N, Andr\u00e9 F, Dent R, Zhou X, Karantza V, Mejia J, Winer E. LBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative Of cancer (mTNBC): Post-hoc analysis of IMpassion130](https://doi.org/10.1093/annonc/mdz394.009)Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios C, Iwata H, Dieras V, Winer E, Kockx M, Peeters D, Chui S, Lin J, Duc A, Viale G, Molinero L, Emens 10.1093/annonc/mdz394.009](https://doi.org/10.1093/annonc/mdz394.009). [PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor Forero-Torres A, imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic 10.1038/s41523-019-0126-6](https://doi.org/10.1038/s41523-019-0126-6). [A phase cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/31541381)Leone JP, Duda DG, Hu J, Barry EP, NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases Breast Cancer Research And Treatment Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study](http://www.ncbi.nlm.nih.gov/pubmed/31018921)Ligibel JA, Dillon D, Giobbie-Hurder A, McTiernan A, Frank E, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney S, Chagpar AB, Yung RA, Dominici LS, Golshan M, Rhei E, Taneja K, Huang Y, Brown M, Winer EP, Jeselsohn R, Irwin ML. Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study 5398-5406. [PMID: 10.1158/1078-0432.ccr-18-3143](https://doi.org/10.1158/1078-0432.ccr-18-3143). [A phase of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/31250880)Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Bartlett C, Koehler M, Winer EP, Burstein HJ. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma 31250880](https://pubmed.ncbi.nlm.nih.gov/31250880), I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC)](https://doi.org/10.1016/j.ijrobp.2019.06.466)Bellon J, Chen Y, Rees R, Taghian A, Wong J, Punglia R, Shiloh R, Krishnan M, Andrews C, Isakoff S, Winer E, Tolaney S. A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC) International Journal Of Radiation Oncology Metastases: Translational Breast Research Consortium 022](http://www.ncbi.nlm.nih.gov/pubmed/31558424)Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Lopez B, Connolly RM, IF, Van Poznak CH, SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, Consortium T. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium of first-line ribociclib plus letrozole versus placebo plus P, Arteaga Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213424)Leone J, Trippa L, Milisits L, Andrews C, Ligibel J, Parsons H, Bi W, Zhao J, Winer E, Lin N. TRLS-03. PHASE II TRIAL OF GDC-0084 IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN Preoperative Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy Clinical PMC6677598](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677598), Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, EP, NU, DG. Aggressive Subsets of Metastatic Triple Negative 20: e20-e26. [PMID: 31631016](https://pubmed.ncbi.nlm.nih.gov/31631016), [DOI: Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast the CALGB Kornblith AB, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation](http://www.ncbi.nlm.nih.gov/pubmed/31277699)Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation Breast first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA and CALGB 40503 (Alliance) trials](http://www.ncbi.nlm.nih.gov/pubmed/31276981)Mart\u00edn M, Loibl J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Ja\u00f1ez N, Hahn O, Winer MN, G, Oncology A. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials European to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-314)Mao P, Cohen O, Kowalski K, Kusiel Buendia J, Exman P, Wander S, Waks A, Winer E, Lin N, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer 2019, 314-314. [DOI: 10.1158/1538-7445.sabcs18-314](https://doi.org/10.1158/1538-7445.sabcs18-314). [Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations](https://doi.org/10.1158/1538-7445.sabcs18-ct050)Keenan T, Liu D, Elmarakeby H, Stover D, Kochupurakkal B, Tracy A, Danielczyk E, Anderson L, Andrews C, Reardon B, Overmoyer B, Winer E, Zheleva D, Chiao J, Blake D, Allen E, Shapiro G, Tolaney S. Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast BRCA1/2 mutations 2019, ct050-ct050. [DOI: 10.1158/1538-7445.sabcs18-ct050](https://doi.org/10.1158/1538-7445.sabcs18-ct050). [Abstract LB-225: RNA as predictive response to monotherapy pembrolizumab in patients M, Nanda R, Iwata H, Awada A, Tan A, Zhang C, Loboda A, Albright A, Cristescu R, Lane M, Wang A, Lunceford J, Aktan G, Karantza V, Adams S. Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in alterations to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer](https://doi.org/10.1158/1538-7445.am2019-314)Mao P, Cohen O, Kowalski K, Kusiel Buendia J, Exman P, Wander S, Waks A, Winer E, Lin N, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast Research 2019, 79: 314-314. [DOI: 10.1158/1538-7445.am2019-314](https://doi.org/10.1158/1538-7445.am2019-314). [Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations](https://doi.org/10.1158/1538-7445.am2019-ct050)Keenan T, Liu D, Elmarakeby H, Stover D, Kochupurakkal B, Tracy A, Danielczyk E, Anderson L, Andrews C, Reardon B, Overmoyer B, Winer E, Zheleva D, Chiao J, Blake D, Allen E, Shapiro G, Tolaney S. Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 Research 2019, 79: ct050-ct050. [DOI: 10.1158/1538-7445.am2019-ct050](https://doi.org/10.1158/1538-7445.am2019-ct050). [Abstract LB-225: RNA response to monotherapy pembrolizumab in patients M, Nanda R, Iwata H, Awada A, Tan A, Zhang C, Loboda A, Albright A, Cristescu R, Lane M, Wang A, Lunceford J, Aktan G, Karantza V, Adams S. Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with Breast Cancer: Results of a Phase 1b/2 Trial 19: 399-404. [PMID: 31235441](https://pubmed.ncbi.nlm.nih.gov/31235441), [DOI: 10.1016/j.clbc.2019.05.010](https://doi.org/10.1016/j.clbc.2019.05.010). randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab- paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1003)Schmid P, Adams S, Rugo Barrios C, Iwata H, Dieras V, Henschel V, Molinero L, Chui S, Husain A, Winer E, Loi S, Emens L. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab- paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). phase eribulin or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1004)Tolaney S, Barroso-Sousa R, Keenan T, Trippa L, Hu J, Luis I, Wulf G, Spring L, Sinclair N, Andrews C, Pittenger J, Richardson E, Dillon D, Lin N, Overmoyer B, Partridge A, VanAllen E, Mittendorf E, Winer I. Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast 1004-1004. [DOI: 10.1200/jco.2019.37.15_suppl.1004](https://doi.org/10.1200/jco.2019.37.15_suppl.1004). Buendia-Buendia J, Cohen Kim D, Jain E, Winer E, Lin N, Wagle N. Characterization of mutational processes in ER+ metastatic breast Journal [DOI: 10.1200/jco.2019.37.15_suppl.1019](https://doi.org/10.1200/jco.2019.37.15_suppl.1019). - Garrido-Castro Y, Cherniack A, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Files Kumari P, Cerami E, Krop I, MacConaill L, Lindeman N, Rollins B, Johnson B, Wagle N, Winer E, Dillon D, Lin N. Genomic landscape of de novo stage IV breast cancer. Journal Of Clinical Oncology 2019, 37: 1022-1022. [DOI: 10.1200/jco.2019.37.15_suppl.1022](https://doi.org/10.1200/jco.2019.37.15_suppl.1022). [A palliative radiotherapy (RT) for hormone Krop I, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson E, Winer E, Mittendorf E, Schoenfeld J, Tolaney S. A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR+) metastatic [DOI: 10.1200/jco.2019.37.15_suppl.1047](https://doi.org/10.1200/jco.2019.37.15_suppl.1047). hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients Scott J, Park J, Dickler M, Partridge A, Carey L, Winer E, Rugo H. Clinical significance of circulating tumor cells (CTCs) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients or Let plus bevacizumab (Bev): CALGB 10.1200/jco.2019.37.15_suppl.1049](https://doi.org/10.1200/jco.2019.37.15_suppl.1049). [Patient-reported outcomes of atezolizumab (atezo) plus nabpaclitaxel (nP) Barrios C, Winer E, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui S, Rugo H, Emens L, Schmid P. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic [DOI: 10.1200/jco.2019.37.15_suppl.1067](https://doi.org/10.1200/jco.2019.37.15_suppl.1067). Expanded safety a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-na\u00efve, locally advanced or metastatic triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1068)Schneeweiss H, Winer C, Iwata H, Dieras V, Loi S, Maiya V, Bond J, Lei G, Chui S, Adams S, Emens L, Schmid P. IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-na\u00efve, locally advanced or metastatic triple-negative breast cancer receptor-positive (HR+), HER2- breast cancer (ABC): MONALEESA-2 long-term J, Campone M, Andre F, Nusch A, Grischke E, Villanueva C, Marschner N, Winer E, Paluch-Shimon S, Rodriguez-Lorenc K, Hilliard Hortobagyi First-line (1L) ribociclib (RIB) receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term 1078-1078. [DOI: 10.1200/jco.2019.37.15_suppl.1078](https://doi.org/10.1200/jco.2019.37.15_suppl.1078). PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2 -mutant metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.1085)Waks A, Cohen O, Kochupurakkal B, Kim D, Wander S, Buendia-Buendia J, Helvie K, Matulonis U, Krop I, Tolaney S, Winer E, D'Andrea A, Shapiro G, Lin N, Wagle N. Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2 -mutant metastatic breast [DOI: to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.](https://doi.org/10.1200/jco.2019.37.15_suppl.502)Metzger Filho O, Viale G, Trippa L, Li T, Yardley D, Mayer I, Abramson V, Arteaga C, Spring L, Waks A, Janiszewska M, Wrabel E, Demeo M, Bardia K, Winer E, Krop I. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. Clinical 2019, 37: 502-502. [DOI: paclitaxel in TNBC\u2014Evaluating the homologous recombination deficiency biomarker.](https://doi.org/10.1200/jco.2019.37.15_suppl.507)Mayer E, Abramson V, Jankowitz R, Falkson C, Marcom P, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Perou C, Richardson A, Tung N, Barry W, Tan-Wasielewski Z, Timms K, Hartman A, Wolff A, Winer E. 030: randomized II study of preoperative cisplatin paclitaxel in TNBC\u2014Evaluating the homologous recombination (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study.](https://doi.org/10.1200/jco.2019.37.15_suppl.517)Barroso-Sousa R, Luis I, Di Meglio A, Hu J, Rees R, Sinclair N, Milisits L, Leone J, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein A, Trippa L, Tolaney N. Avoiding peg-filgrastim (Peg-F) prophylaxis during the (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective 517-517. [DOI: 10.1200/jco.2019.37.15_suppl.517](https://doi.org/10.1200/jco.2019.37.15_suppl.517). [Factors risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.](https://doi.org/10.1200/jco.2019.37.15_suppl.540)Leone J, Vallejo C, Hassett M, Leone J, Freedman R, Tolaney S, Leone B, Lin N, Winer E. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal Of Clinical Oncology 2019, 37: 540-540. W, Polley M, Twohy E, Perou C, Singh B, Berry D, Tolaney S, Somlo G, Port E, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Hudis C, Winer E, Partridge A, Carey L. CALGB 37: [DOI: hypermutated HER2-negative L, Winer E, Mittendorf E, Tolaney S. Nimbus: A of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.](https://doi.org/10.1200/jco.2019.37.15_suppl.tps599)Chen W, Winer E, Ballman K, Partridge A, Carey L, Carvan M, Matyka C, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer. Journal Of Clinical Oncology 2019, 37: tps599-tps599. for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Breast Cancer EP, Singer CF, Hurvitz S, Est\u00e9vez LG, van Dam PA, K\u00fcmmel S, Mundhenke C, Holmes Babbar Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)](http://www.ncbi.nlm.nih.gov/pubmed/31004299)Bellon JR, Guo H, Barry Overmoyer BA, Partridge AH, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) Breast Cancer Research And 176: 303-310. Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30939096)Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay Overmoyer B, for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Tan YB, Fuhrman K, Osmani W, Getz A, of small HER2-positive breast cancers: a secondary analysis from the APT trial dose-expansion phase Birrer Westin SN, Cadoo Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills cancer: dose-escalation and dose-expansion phase Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/30860945)Freedman RA, Gelman RS, Anders CK, Melisko ME, SL, Jankowitz Smith N, Moynihan TJ, O'Sullivan C, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, . TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases cohort B of the phase KEYNOTE-086 study](http://www.ncbi.nlm.nih.gov/pubmed/30475947)Adams S, Loi S, Toppmeyer H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase A of the phase G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cort\u00e9s J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II therapy in patients with early breast cancer: Principles and practical considerations](https://doi.org/10.1016/s0960-9776(19)30093-1)Winer E. SL 2.1 Adjuvant and neoadjuvant therapy in patients with early breast cancer: Principles and practical considerations The Breast 2019, 44: s11. [DOI: 10.1016/s0960-9776(19)30093-1](https://doi.org/10.1016/s0960-9776(19)30093-1). [P246 nodenegative (N0) and node-positive (N+) breast cancer (BC) real-world G. (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials](http://www.ncbi.nlm.nih.gov/pubmed/30770494)Wang Y, Ayres KL, Goldman DA, Dickler PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials Clinical Cancer global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-na\u00efve, locally advanced or metastatic triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-gs1-04)Emens L, Loi Rugo V, Iwata H, Barrios C, Nechaeva M, Molinero L, Nguyen Duc A, Funke R, Chui S, Husain A, Winer E, Adams S, Schmid P. Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-na\u00efve, locally advanced or metastatic triple-negative OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs18-ot3-02-07)Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, Loi S, Krop I, Gianni I, A. Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast [Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-ot3-05-02)Ignatiadis M, McArthur H, Bailey A, Martinez J, De Azambuja E, Metzger O, Lai C, Ponde N, Goulioti T, Daly F, Bouhlel A, Balta V, Van Dooren V, Viale G, Maetens M, Dufrane C, Nguyen Duc Winer E, Gelber R, Piccart M. Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer Cancer Research 2019, 79: ot3-05-02-ot3-05-02. [DOI: 10.1158/1538-7445.sabcs18-ot3-05-02](https://doi.org/10.1158/1538-7445.sabcs18-ot3-05-02). young women with node-negative and node-positive ER+/HER2- breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p2-08-07)Poorvu P, Gelber S, Rosenberg Ruddy Tamimi R, Collins L, Peppercorn J, Schapira L, Borges V, Come S, Warner E, Jakubowski D, Russell C, Winer E, Partridge A. Abstract P2-08-07: Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER+/HER2- [DOI: [Abstract P3-08-04: Transient state change, subtype change, after HER2-targeted therapy for HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p3-08-04)Tanioka M, Parker J, Henry L, Tolaney S, Dang C, Krop I, Harris L, Polley M, Berry D, Winer E, Carey L, Perou C. Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast node-negative (N0) and node-positive (N+) breast cancer N. Abstract P3-11-02: cancer-specific patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: breast cancer: Inflammatory breast cancer and young patients in the Dana-Farber cell-free DNA cohort](https://doi.org/10.1158/1538-7445.sabcs18-p4-01-17)Singh J, Asad S, Nock W, Zhang Y, Adams E, Damicis A, Parsons H, Adalsteinsson V, Winer E, Lin N, Partridge A, Overmoyer B, Stover D. Abstract P4-01-17: Aggressive subgroups of metastatic triple-negative breast cancer: Inflammatory breast cancer and young patients in the Dana-Farber cell-free DNA cohort Cancer in HER2 negative tumors for clinical trials - Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice](https://doi.org/10.1158/1538-7445.sabcs18-p4-04-02)Exman P, Garrido-Castro A, Hughes M, Freedman R, Ma C, Bose R, Cerami E, Wagle N, Barroso-Sousa R, Fitz C, Kumari P, Tolaney S, Krop I, Winer E, Dillon D, Lin N. Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials - Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice Cancer Research 2019, 79: p4-04-02-p4-04-02. [DOI: 10.1158/1538-7445.sabcs18-p4-04-02](https://doi.org/10.1158/1538-7445.sabcs18-p4-04-02). [Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor antagonist/ degrader (SERD)](https://doi.org/10.1158/1538-7445.sabcs18-p5-11-01)Spoerke C, Dickler M, Bardia A, Perez Fidalgo J, Mayer I, Boni V, Winer E, Hamilton E, Bellet M, Urruticoechea A, Gonzalez Martin A, Cortes J, Martin M, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman L, Liu L, Li R, Chan I, Mueller L, Milan S, Lauchle J, Humke E, Lackner M. Abstract P5-11-01: Phamacodynamic and circulating tumor DNA evaluation in a phase I study of GDC-0927, a selective estrogen receptor (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs18-p5-12-02)Barroso-Sousa R, Tyekucheva S, Pernas-Simon P, Jain E, A, Hughes M, Bychkovsky B, Di Lascio S, Umeton R, Files J, Lindeman N, MacConaill L, Hodi F, Krop I, Dillon D, Winer E, Wagle N, Lin N, Mittendorf E, Tolaney S. Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer for the treatment of advanced, treatment-refractory HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10)Goel S, Spring L, Rees R, Andrews C, Tahara R, Mayer E, Bardia A, Winer E, Tolaney S. Abstract P6-18-10: A phase 1b/2 study of ribociclib plus trastuzumab for the treatment of advanced, treatment-refractory HER2-positive breast cancer Cancer Research 2019, 79: p6-18-10-p6-18-10. [DOI: 10.1158/1538-7445.sabcs18-p6-18-10](https://doi.org/10.1158/1538-7445.sabcs18-p6-18-10). - Bayani J, Poncet C, Yao C, Crozier C, Anouk N, Piper T, Cunningham C, Sobol M, Aebi S, Benstead K, Bogler O, Dal Lago Fraser Hilbers Hedenfalk I, Korde L, Linderholm B, Martens J, Middleton L, Murray M, Kelly C, Nilsson C, Nowaczyk M, Peeters S, Peric A, Porter P, Schr\u00f6der C, Rubio I, Ruddy K, van Asperen C, Van Den Weyngaert D, van Deurzen C, van Leeuwen-Stok E, Vermeij J, Winer E, Boutros P, Giordano S, Cardoso F, Bartlett J. Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer Cancer Research 2019, 79: p6-19-01-p6-19-01. [DOI: 10.1158/1538-7445.sabcs18-p6-19-01](https://doi.org/10.1158/1538-7445.sabcs18-p6-19-01). - Leone J, Freedman Tolaney S, Vallejo C, Leone B, Winer E, Leone J. Abstract P6-19-02: Tumor subtypes and survival in male breast cancer: 2019, 79: clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-pd1-05)Jeselsohn R, Guo H, Rees R, Barry W, Barlett C, Tung N, Krop I, Brown M, Winer E. Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast 79: pd1-05-pd1-05. [DOI: 10.1158/1538-7445.sabcs18-pd1-05](https://doi.org/10.1158/1538-7445.sabcs18-pd1-05). [Abstract PD9-01: Genomic alterations of HR expression in metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-pd9-01)Garrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Di Lascio S, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, MacConaill L, Dillon D, Winer E, Lin N. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research 2019, 79: pd9-01-pd9-01. [DOI: 10.1158/1538-7445.sabcs18-pd9-01](https://doi.org/10.1158/1538-7445.sabcs18-pd9-01). [Abstract PD9-02: Evolutionary analysis of from 208 patients with estrogen receptor-positive Buendia-Buendia J, Wander S, Nayar U, Mao P, Waks A, Kim D, Freeman S, Adalsteinsson V, Helvie K, Livitz D, Rosebrock L, Krop I, Garraway L, Getz G, Winer E, Lin N, Wagle N. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) [DOI: 10.1158/1538-7445.sabcs18-pd9-02](https://doi.org/10.1158/1538-7445.sabcs18-pd9-02). Phase II Trial Correlating Standardized Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30721110)Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer 10.1001/jama.2018.19323](https://doi.org/10.1001/jama.2018.19323). checkpoint triple negative breast cancer: Comment on the IMpassion130 study](http://www.ncbi.nlm.nih.gov/pubmed/30351400)Kok M, Winer EP, Loi S. Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)](https://doi.org/10.29289/259453942019v29s1g04)Sousa R, Tyekucheva S, Exman R, Hodi F, E, Lin N, Tolaney S. TUMOR MUTATIONAL BURDEN (TMB) IS A POTENTIAL PREDICTOR OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICI) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER estrogen receptor-directed therapies](http://www.ncbi.nlm.nih.gov/pubmed/30531871)Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, A, Winer EP, N. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to Breast: Prognosis and the Importance of Histologic Grade](http://www.ncbi.nlm.nih.gov/pubmed/30518616)MetzgerFilho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, VazLuis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Cancer: ASCO Clinical Practice Guideline Focused Update](http://www.ncbi.nlm.nih.gov/pubmed/30452337)Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update Glass B, Beck AH, Hazra A, Rosner Eliassen Hankinson SE, Winer EP, Brown M, Tamimi RM. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. Journal Of The National Cancer from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy HER2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30037817)Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang ER, Winer EP, Hudis CA, Carey LA, Perou CM. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast CH, Iwata H, Di\u00e9ras V, R, Im SA, Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain EP, S, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer New England breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](http://www.ncbi.nlm.nih.gov/pubmed/29733336)Curigliano G, Burstein HJ, Winer EP, Gnant L, E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Annals clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance)](https://doi.org/10.1093/annonc/mdy373)Tanioka M, Parker J, Henry L, Tolaney S, Dang C, Krop I, Harris L, Hillman D, Polley M, Berry D, Winer E, Carey L, Perou C. SPS-3 A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)](https://doi.org/10.1093/annonc/mdy272.357)Loibl S, Metzger O, Mandrekar S, Mundhenke C, Seiler S, Valagussa P, DeMichele A, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, Loi S, Krop I, Gianni L, Ciruelos E. 369TiP PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P locally advanced or metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1093/annonc/mdy424.008)Schmid P, Adams S, Rugo A, Barrios C, Iwata H, Dieras V, Hegg R, Im S, Wright G, Henschel V, Molinero L, Chui S, Funke R, Husain A, Winer E, Loi S, Emens L. LBA1_PR IMpassion130: Results from a global, randomised, III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P locally advanced or metastatic triple-negative capecitabine and with T, C, Loibl E. A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/30185228)Sch\u00f6ffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, VW, of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer Breast Cancer 2018, BrinJones H, Sceneay J, Li B, Khan N, Ubellacker J, Xie S, Metzger-Filho O, Hoog J, Ellis M, Ma C, Ramm S, Krop I, Winer E, Roberts T, Kim H, Zhao J, McAllister S. Abstract B04: CDK4/6 inhibition triggers an b04-b04. [DOI: [Unraveling the ESR1 mutations in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/30083595)Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, EP, Brown M, Jeselsohn R. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer Npj Breast 10.1038/s41523-018-0075-5](https://doi.org/10.1038/s41523-018-0075-5). [4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO).](http://www.ncbi.nlm.nih.gov/pubmed/30032243)Cardoso F, Senkus E, Costa A, Papadopoulos E, N, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop GW, Spence D, C, DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) These guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical of first-line ribociclib plus letrozole versus placebo plus P, Arteaga Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab](https://doi.org/10.1158/1538-7445.am2018-4564)Waks A, Stover D, Barry W, Dillon D, Gjini E, Rodig S, Brock J, Baltay M, I, S. Abstract 4564: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus Cancer confer resistance to ER-directed therapies](https://doi.org/10.1158/1538-7445.am2018-4952)Nayar U, Cohen O, Kapstad C, Waks A, Wander S, Painter C, Freeman S, Ram P, Persky N, Marini L, Helvie K, Oliver N, Ma C, Winer E, Lin N, Wagle N. Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to therapies Cancer Research 2018, 78: 4952-4952. [DOI: 10.1158/1538-7445.am2018-4952](https://doi.org/10.1158/1538-7445.am2018-4952). [Systemic Therapy for Patients With Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update](http://www.ncbi.nlm.nih.gov/pubmed/29939838)Giordano SH, Temin Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, Krop IE, Levinson J, Lin NU, S, Patt DA, Perlmutter J, Ramakrishna N, Winer EP, Davidson NE. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update jco.2018.79.269. [PMID: 29939838](https://pubmed.ncbi.nlm.nih.gov/29939838), [DOI: 10.1200/jco.2018.79.2697](https://doi.org/10.1200/jco.2018.79.2697). Management Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update](http://www.ncbi.nlm.nih.gov/pubmed/29939840)Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, S, Patt DA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update Journal jco.2018.79.271. [PMID: S, Climent MA, Pavesi L, Ruhstaller T, Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer New England Journal for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study](http://www.ncbi.nlm.nih.gov/pubmed/29789969)Li W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study 29789969](https://pubmed.ncbi.nlm.nih.gov/29789969), Sepucha K, Miller K, Dang C, Northfelt D, Winer E, Sledge G, Schneider B, Partridge A. Symptom burden and employment status in breast cancer (BC) survivors. Journal Of Clinical Oncology 2018, 36: 10073-10073. [DOI: 10.1200/jco.2018.36.15_suppl.10073](https://doi.org/10.1200/jco.2018.36.15_suppl.10073). [A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).](https://doi.org/10.1200/jco.2018.36.15_suppl.1026)Leone J, Hu J, Barry W, Duda D, Gerstner E, Jain R, Tan S, Lawler E, Winer E, Lin N, Tolaney S. A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM). Journal (met) tumors and prior treatment (tx) received.](https://doi.org/10.1200/jco.2018.36.15_suppl.1054)Waks A, Tolaney S, Schnitt S, Dillon Abdelrahman S, Marino-Enriquez A, Helvie K, Marini L, Cohen O, Kim D, Wander S, Stover D, Rodig S, Krop I, Winer E, HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received. Journal Of Clinical Oncology 2018, 36: and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic cancer safety, tolerability and pharmacokinetic (PK) analysis.](https://doi.org/10.1200/jco.2018.36.15_suppl.1068)Barroso-Sousa Barry W, Ferreira A, Rees R, Winer E, Wagle N, Tolaney S. A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic cancer (CDK4/6i): safety, tolerability resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).](https://doi.org/10.1200/jco.2018.36.15_suppl.12016)Wander S, Cohen O, Johnson G, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway L, Winer E, Lin N, Wagle exome (WES) in hormone-receptor positive (HR+) metastatic breast resistance cyclin-dependent kinase with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2018.36.15_suppl.tps1100)Barroso-Sousa R, Barry W, Kumthekar Guo H, Silvestri K, Krop I, Winer E, Tolaney S, Lin N. A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic pre-treated Regan DeMichele A, Forero-Torres A, Rimawi M, Ma C, Cristofanilli M, Anders C, Bartlett C, Winer E, Burstein after CDK and endocrine for pre-treated 10.1200/jco.2018.36.15_suppl.tps1104](https://doi.org/10.1200/jco.2018.36.15_suppl.tps1104). [A nivolumab in first- or second-line metastatic TNBC.](https://doi.org/10.1200/jco.2018.36.15_suppl.tps1118)Garrido-Castro A, Barry W, Traina T, Wesolowski R, Tung N, Keenan T, Van Allen E, Lin N, Winer E, Krop I, Tolaney S. A randomized phase II trial of carboplatin with or without nivolumab in first- or trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer.](https://doi.org/10.1200/jco.2018.36.15_suppl.tps597)Chen W, Winer E, Barry W, Partridge A, Carey L, Carvan M, Matyka C, Visvanathan K, Symington B, Holmes M. ABC trial (A011502): Randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for breast cancer. Journal Of Clinical Oncology 2018, 36: tps597-tps597. (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).](https://doi.org/10.1200/jco.2018.36.15_suppl.tps598)Ligibel J, Barry W, Alfano C, Hershman D, Irwin M, Neuhouser M, Thomson C, Delahanty L, Frank E, Spears P, Paskett E, Hopkins J, Bernstein V, Stearns V, White J, Wadden T, Goodwin P, Carey L, Partridge A, Winer E. The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401). Journal Garrido-Castro AC, Winer L, Sledge GW, Winer EP. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer Breast Cancer Research 2018, 171: [PMID: 29736741](https://pubmed.ncbi.nlm.nih.gov/29736741), with cancer](http://www.ncbi.nlm.nih.gov/pubmed/29761158)Stover Alcazar CR, Brock Guo H, B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer [PMCID: PMC5935675](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935675), [DOI: 10.1038/s41523-018-0060-z](https://doi.org/10.1038/s41523-018-0060-z). - Lin NU, Xie S, Winer EP, Zhao JJ. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clinical EP, VazLuis I, Lii J, Exman P, Barry WT. Breast cancerspecific survival by age: Worse outcomes for the in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab](https://doi.org/10.1158/1538-7445.sabcs17-gs3-02)Krop I, Hillman D, Polley M, Tanioka M, Parker J, Huebner L, Henry N, Tolaney S, Dang C, Harris L, Berry D, Perou C, Partridge A, Winer E, Carey L. Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs17-gs3-06)Rugo H, Barry W, Moreno-Aspitia A, Lyss A, Huebner L, Mayer E, Naughton M, Layman R, Carey L, Somer R, Toppmeyer D, Velasco M, Perez E, Hudis C, A randomized phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic cancer from cell-free DNA](https://doi.org/10.1158/1538-7445.sabcs17-gs3-07)Stover D, Parsons H, Ha G, Freeman S, Barry B, Guo H, Choudhury A, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Dillon D, Partridge A, Wagle N, Krop I, Getz G, Golub T, Love J, Winer E, Tolaney S, Lin N, Adalsteinsson V. copy analysis of chemotherapy-resistant metastatic triple-negative evaluating exemestane \u00b1 enzalutamide in patients with hormone receptor-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-gs4-07)Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Gucalp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Tudor I, Markova D, Barry E, Tarazi J, Stewart R, Winer E, Yardley D. Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane \u00b1 enzalutamide in patients with hormone receptor-positive 78: GS5-05: ductal carcinoma in ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-01)Overmoyer B, Regan M, Polyak K, Brock J, Van Poznak C, King T, Haddad T, Stearns V, Hwang S, Winer E. Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast Research 78: ot3-05-01-ot3-05-01. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-01](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-01). [Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-07)Metzger-Filho O, Mandrekar S, Loibl S, Ciruelos E, Gianni L, Lim E, Miller K, Huang C, Koehler M, Francis P, Valagussa P, Goel S, Prat A, Goetz M, Loi S, Krop I, Carey L, Lanzillotti J, Winer E, Tripathy D, DeMichele A. Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-08)Mayer E, DeMichele A, Gnant M, Barry W, Pfeiler G, Metzger O, Burstein H, Miller K, Rastogi T, Zardavas D, Fesl M, Huang-Bartlett C, Huang X, OT3-05-08: PALLAS: PALbociclib Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer II study of fulvestrant versus palbociclib DeMichele A, Forero A, Rimawi M, Ma C, Cristofanilli M, Anders C, Huang Bartlett C, Koehler M, II study of fulvestrant versus palbociclib 10.1158/1538-7445.sabcs17-ot3-05-11](https://doi.org/10.1158/1538-7445.sabcs17-ot3-05-11). [Abstract P1-07-04: Physical activity, weight and in patients receiving first-line chemotherapy for metastatic breast cancer: Results Anders C, Ma C, Hudis C, Winer E, Barry W. Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from in chemotherapy-treated metastatic breast cancer (Alliance)/NCCTG E, Hudis C, Toppmeyer D, Burnstein H, Qadir M, Ma C, Scott J, Park J, Rugo H. Abstract P2-01-01: Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p4-10-04)Hughes M, Frank E, Merrill M, Santiago R, Kuhnly N, Crowley L, Gupta G, Winer E, Lin N. Abstract P4-10-04: EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer Cancer Research 2018, 78: p4-10-04-p4-10-04. [DOI: 10.1158/1538-7445.sabcs17-p4-10-04](https://doi.org/10.1158/1538-7445.sabcs17-p4-10-04). P5-21-10: Phase a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative cancer](https://doi.org/10.1158/1538-7445.sabcs17-p5-21-10)Stover D, Gil Del Alcazar C, Tolaney S, Bardia A, Guo H, Balko J, Overmoyer B, Gelman R, Lloyd M, Wang V, Brock J, Winer E, Polyak K, Lin N. Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, HER2 positive inflammatory breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p6-15-11)Overmoyer B, Regan M, Hu J, Nakhlis F, Dominici L, Lin N, Freedman R, Morganstern D, Partridge A, Schlosnagle E, Hirshfield-Bartek J, Bellon J, and trastuzumab (TPH) neoadjuvant therapy for Research 2018, 78: p6-15-11-p6-15-11. [DOI: 10.1158/1538-7445.sabcs17-p6-15-11](https://doi.org/10.1158/1538-7445.sabcs17-p6-15-11). - Tolaney S, Barry W, Guo H, Dillon D, Tan Y, Fuhrman K, Osmani W, Getz A, Baltay M, Dang D, B, Marcom K, Krop I, Winer E. Abstract PD3-01: Immune profile of small HER2+ tumors in the APT trial Cancer Research 2018, [DOI: 10.1158/1538-7445.sabcs17-pd3-01](https://doi.org/10.1158/1538-7445.sabcs17-pd3-01). [Abstract hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study](https://doi.org/10.1158/1538-7445.sabcs17-pd5-06)Mayer E, DeMichele A, Guo H, Miller K, Rugo H, Schneider B, Waks A, Come S, Mulvey T, Huang Bartlett C, Koehler M, Barry W, Winer E, Burstein H. Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study Cancer 2018, 78: pd5-06-pd5-06. [DOI: 10.1158/1538-7445.sabcs17-pd5-06](https://doi.org/10.1158/1538-7445.sabcs17-pd5-06). [Abstract PD5-10: A first-in-human phase oral selective estrogen receptor degrader (SERD), GDC-0927, metastatic breast cancer (BC)](https://doi.org/10.1158/1538-7445.sabcs17-pd5-10)Dickler M, Villanueva R, Perez Fidalgo J, Mayer I, Boni V, Winer E, Hamilton E, Bellet M, Urruticoechea A, Gonzalez-Martin A, Cortes J, Martin M, Giltnane J, Gates M, Cheeti S, Fredrickson J, Wang X, Friedman L, Spoerke J, Metcalfe C, Liu L, Li R, Morley R, McCurry U, Chan I, Mueller L, Milan S, Lauchle J, Humke E, Bardia A. Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, positive [Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab](https://doi.org/10.1158/1538-7445.sabcs17-pd6-09)Waks A, Stover D, Barry W, Dillon D, Gjini E, Rodig S, Brock J, Baltay M, I, S. Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab S, Loi S, Toppmeyer D, D, De Laurentiis M, Nanda R, Winer E, Mukai H, Tamura K, Armstrong A, Liu M, Iwata H, Ryvo L, Wimberger P, Rugo H, Tan A, D'Aquanno C, Ding Y, [Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC Weerd V, Slaets L, Piper T, van Deurzen C, Schroder C, Stangle C, Kloosterman W, van Leeuwen-Stok Nilsson Goulioti M, Aebi S, Rubio I, Kelly C, Bayani J, Porter P, Murray M, Hudis C, Middleton L, Korde L, Ruddy K, Winer E, Bogler O, van den Weyngaert D, dal Lago L, Fraser J, Benstead K, van Asperen C, Linderholm B, Hedenfalk I, Tryfonidis K, Giordano S, Bartlett J, Cardoso F. Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, Kwiatkowski N, Zhang T, Gray N, Melchers D, Houtman R, Liu XS, Cohen O, Wagle N, Winer EP, Zhao J, Brown M. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program](http://www.ncbi.nlm.nih.gov/pubmed/29092024)Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schr\u00f6der C, Martens J, Bayani J, Asperen Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio I, Aebi S, Kelly C, Ruddy K, E, C, Lago K, Poncet C, Tryfonidis K, Giordano S. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer LS, O'Shaughnessy J, Gradishar C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast metastatic breast cancer in the United States](http://www.ncbi.nlm.nih.gov/pubmed/29332137)Poorvu PD, Vaz-Luis I, RA, Lin EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States Breast Cancer Research And Treatment 2018, 168: 727-737. [PMID: 29332137](https://pubmed.ncbi.nlm.nih.gov/29332137), Alterations With Survival in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/29298117)Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, SM, Lin NU, Adalsteinsson VA. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.](http://www.ncbi.nlm.nih.gov/pubmed/29045519)Dubsky L, E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. breast cancer: current practice and future directions Therapeutic Advances In Therapy for ER+ Breast Cancer: A Sea Change is Underway. Journal Of The National Institute 2017, chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](http://www.ncbi.nlm.nih.gov/pubmed/29242041)Group E, Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordstr\u00f6m E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G, Bradley R, Brain E, Braybrooke J, Broet P, Bryant J, Burrett J, Cameron D, Clarke M, Coates A, Coleman R, Coombes R, Correa C, Costantino J, Cuzick J, Danforth D, Davidson N, Davies C, Davies L, Di Leo A, Dodwell D, Dowsett M, Duane F, Evans V, Ewertz M, Fisher B, Forbes J, Ford L, Gazet J, Gelber R, Gettins L, Gianni L, Gnant M, Godwin J, Goldhirsch A, Goodwin P, Gray R, Hayes D, Hill C, Ingle J, Jagsi R, Jakesz R, James S, Janni W, Liu H, Liu Z, Lohrisch C, Loibl S, MacKinnon L, Makris L, McGale P, McHugh T, Morris P, Mukai H, Norton L, Ohashi Y, Olivotto I, Paik S, Pan H, Peto R, Piccart M, Pierce L, Poortmans P, Powles T, Pritchard K, Ragaz J, Raina V, Ravdin P, Read S, Regan M, Robertson J, Rutgers E, Scholl S, Slamon D, S\u00f6lkner L, Sparano J, Steinberg S, Sutcliffe R, Swain S, Taylor C, Tutt A, Valagussa P, van de Velde C, van der Hage J, Viale G, von Minckwitz G, Wang Y, Wang Z, Wang X, Whelan T, Wilcken N, Winer E, Wolmark N, Wood W, Zambetti M, Zujewski J. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten Stover DG, Parsons HA, Gydush Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor E, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang L, Golub JS, JC, Meyerson M. Scalable sequencing of cell-free DNA reveals Mutations in HER2 Nonamplified Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/28679771)X. C, Bose Gao Telli ML, Kimmick G, Winer E, Naughton M, Goetz M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, K, Bedard PL, Al-Kateb H, Ellis MJC. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial)](https://doi.org/10.1016/j.ijrobp.2017.06.141)Bellon J, Tolaney S, Guo H, Barry W, Burstein H, Winer E, Harris J. Local-Regional Recurrence in Women with N0/N1mi, HER2-Positive Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial) International Journal Of Radiation Oncology Biology Physics 2017, 99: s56. [DOI: 10.1016/j.ijrobp.2017.06.141](https://doi.org/10.1016/j.ijrobp.2017.06.141). [Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design](http://www.ncbi.nlm.nih.gov/pubmed/28948213)Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design Npj Breast and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results Adams Schmid P, Cort\u00e9s J, Cescon D, E, Laurentiis M, Nanda R, Iwata H, Awada A, Tan A, Wang A, Aktan G, Karantza V, Salgado R. LBA13 Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer](https://doi.org/10.1093/annonc/mdx365.087)Metzger Mandrekar S, Ciruelos P, Demichele A, Lim E, Tripathy D, Winer E, Huang C, Khoeler M, Carey L, Francis P, Miller K, Goel S, Goetz M, Prat A, Loi S, Krop I, Gianni L. 324TiP PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1093/annonc/mdx362.064)Mayer E, Demichele A, Pfeiler G, Barry W, Metzger O, Rastogi P, Symmans F, Burstein H, Miller S, Goulioti T, Zardavas D, Fesl C, Koehler M, Bartlett C, 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast 10.1093/annonc/mdx362.064](https://doi.org/10.1093/annonc/mdx362.064). [Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)](http://www.ncbi.nlm.nih.gov/pubmed/28825227)Hopkins JO, Allred J, Hurria A, Jatoi Carey L, Muss HB. Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302) Breast Cancer Research N, Ubellacker JM, Ramm IE, Winer EP, McAllister SS, an important agent in the history of breast cancer management Nature breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](http://www.ncbi.nlm.nih.gov/pubmed/28838210)Curigliano G, Burstein HJ, Winer EP, Gnant F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D, Huang C, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne K, Pagani O, Partridge A, Pritchard K, Ro J, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan T, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 aromatase inhibitor and fulvestrant therapy](https://doi.org/10.1158/1538-7445.am2017-4950)Kuang Y, Siddiqui B, Hu J, Barry W, Lin N, Wagle N, Kirschmeier P, J\u00e4nne P, Paweletz C, Krop I, Winer E, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort](https://doi.org/10.1158/1538-7445.am2017-ct008)Konstantinopoulos P, Barry W, Birrer M, Westin S, Farooq S, Cadoo K, Whalen C, Luo W, Liu H, Aghajanian C, Solit D, Mills G, Taylor B, Won H, Berger M, Palakurthi S, Liu J, Cantley L, Kaufmann S, Swisher E, A, Winer E, Wulf G, Matulonis U. Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort Cancer Research 2017, 77: ( HER2 mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.am2017-ct011)Ma C, Bose R, Gao F, Freedman R, Telli M, Kimmick G, Winer E, Naughton M, Goetz D, Cobleigh M, Forero A, Pluard T, Anders C, Thomas S, Anderson J, Bumb C, Banks K, Lanman R, Bryce R, Lalani A, Pfeifer J, Hays D, Pegram M, Blackwell K, Bedard P, Al-Kateb H, Ellis M. Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for HER2 mutation ( HER2 mut) screening and response monitoring to neratinib in placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated metastatic breast carcinoma (MBC) (HER2CLIMB)](https://doi.org/10.1158/1538-7445.am2017-ct055)Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, M\u00fcller V, Curigliano G, Gelmon K, Hortobagyi G, Krop S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. CT055: A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated locally or Ixabepilone: CALGB 40502 (Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/28620884)Mehrotra C, Winer EP, Lyss Cancer Treated Paclitaxel, Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials](http://www.ncbi.nlm.nih.gov/pubmed/28011460)Wang Y, Ayres KL, Goldman DA, Dickler PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials Clinical TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER](https://doi.org/10.1158/1557-3265.ovcasymp16-ntoc-112)Wang Z, Birkbak N, Barry W, Roberts T, Winer E, Iglehart J, Matulonis U, Ivy S, Liu J. Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER 23: ntoc-112-ntoc-112. [DOI: 10.1158/1557-3265.ovcasymp16-ntoc-112](https://doi.org/10.1158/1557-3265.ovcasymp16-ntoc-112). [Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors.](https://doi.org/10.1200/jco.2017.35.15_suppl.10059)Meyerhardt J, Irwin M, Jones L, Zhang S, Campbell N, Brown J, Pollak M, Sorrentino A, Cartmel B, Harrigan M, West M, Tolaney S, Yung R, Winer E, Ng K, Abrams T, Fuchs C, Sanft T, Douglas P, Ligibel J. Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast 35: + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).](https://doi.org/10.1200/jco.2017.35.15_suppl.1005)Freedman R, Gelman R, Melisko M, Anders C, Moy B, Blackwell K, Connolly R, Niravath P, Van Poznak C, Puhalla S, Farooq S, Cropp A, Cotter C, Liu M, Krop I, Nangia J, Tung N, Wolff A, Winer E, Lin N. TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Card D, Zhao J, Karantza V, Cortes J. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): from CALGB 40503 Loibl Haba-Rodriguez J, Aktas B, Cirrincione C, Carrasco E, Mehta K, Barry W, Morales S, Carey L, Garcia Saenz J, Partridge A, Martinez N, Hahn O, Winer E, Guerrero A, Hudis C, Casas M, Dickler M. Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB with TDM1 in advanced HER2-positive breast cancer (MBC).](https://doi.org/10.1200/jco.2017.35.15_suppl.1030)Metzger Filho O, Goel S, Barry W, Hamilton E, Tolaney S, Yardley D, Rees R, Demeo M, Mills C, Hafner M, Winer E, Zhao J, Krop I. A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2017.35.15_suppl.1034)Luis I, Guo H, Barry W, Krop I, Wagle N, Lowe A, Gore D, Andrews C, Osmani W, Isakoff S, Tung N, Winer E, Lin N, Freedman R. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic + letrozole hormone Y, Sonke K, Blackwell K, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, Xuan F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.](https://doi.org/10.1200/jco.2017.35.15_suppl.1088)Adams S, Loi S, Toppmeyer D, Cescon D, Laurentiis M, Nanda R, Winer E, Mukai H, Tamura K, Armstrong A, Liu M, Iwata H, Ryvo L, Wimberger P, Card D, Ding Y, Karantza V, Schmid P. Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from with chemotherapy-resistant metastatic triple-negative breast cancer.](https://doi.org/10.1200/jco.2017.35.15_suppl.1092)Stover D, Parsons H, Ha G, Freeman S, Barry W, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Krop I, Tolaney S, Wagle N, Getz G, Meyerson M, Love J, Winer E, Lin N, Adalsteinsson V. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).](https://doi.org/10.1200/jco.2017.35.15_suppl.511)Tolaney S, Barry W, Guo H, Dillon D, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Partridge A, Hudis C, Krop I, (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).](https://doi.org/10.1200/jco.2017.35.15_suppl.e12134)Waks A, Barry W, Gjini E, Dillon D, Rodig Brock J, Baltay J, I, Tolaney S. biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated metastatic breast carcinoma (mBC) (HER2CLIMB).](https://doi.org/10.1200/jco.2017.35.15_suppl.tps1107)Anders C, Murthy R, Hamilton E, Borges V, Cameron D, Carey L, M\u00fcller V, Curigliano G, Gelmon K, Hortobagyi G, Krop S, Pivot X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated locally advanced phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer.](https://doi.org/10.1200/jco.2017.35.15_suppl.tps586)Chen W, Winer E, Barry W, Hudis C, Openshaw T, Visvanathan K, Symington B, Matyka C, Holmes M. ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer. Journal Of Clinical Oncology 2017, Kimmick G, Clapp J, Isaacs C, Pitcher B, Barry W, Winer E, Sugarman S, Hudis C, Muss H, Cohen HJ, Hurria A. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance) Breast Survival benefit needed to undergo chemotherapy: Patient and Can Tumor Biology Guide Locoregional Therapy? Journal Of The in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)](http://www.ncbi.nlm.nih.gov/pubmed/28283904)Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin JM, Hopkins J, Winer H, H, Jatoi A, A, Mandelblatt J. Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503) Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/28275032)Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: A, Older Cancer\u2014Can pathway inhibitor BKM120 and the oral poly (ADP olaparib for the serous ovarian and breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/27993796)Matulonis U, Wulf G, Barry W, Birrer M, Westin S, Farooq S, Bell-McGuinn K, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok R, Aghajanian C, Solit D, Mills G, Taylor B, Won H, Berger M, Palakurthi S, Liu J, Cantley L, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP olaparib for the treatment of with De Novo Metastatic Breast Cancer: A PopulationBased Study](http://www.ncbi.nlm.nih.gov/pubmed/28242790)VazLuis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Correction to: 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-ot1-01-07)Overmoyer B, Goel S, Regan M, Hirshfield-Bartek J, Schlosnagel E, Yeh E, Qin L, Bellon J, Nakhlis F, Jacene H, Winer E. Abstract OT1-01-07: A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for ot1-01-07-ot1-01-07. colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen](https://doi.org/10.1158/1538-7445.sabcs16-ot1-01-09)Barroso-Sousa R, Vaz-Luis I, Guo H, Barry W, Brackett A, Brock V, Roche K, Kasparian E, Winer E, Lin N. Abstract OT1-01-09: Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced metastatic E, Borges V, Murthy R, Anders C, Cameron Carey L, M\u00fcller V, Curigliano G, Gelmon K, Hortobagy M, D, Hurvitz S, Tsai M, Winer E. Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced direct patient engagement](https://doi.org/10.1158/1538-7445.sabcs16-p1-05-13)Painter C, Anastasio E, Krevalin M, Kim D, Larken K, Lennon N, Frank E, Winer E, Lander E, Golub T. Abstract P1-05-13: The metastatic breast cancer project: Translational 10.1158/1538-7445.sabcs16-p1-05-13](https://doi.org/10.1158/1538-7445.sabcs16-p1-05-13). paradox': High proliferation, chemosensitivity, and poor prognosis](https://doi.org/10.1158/1538-7445.sabcs16-p1-07-05)Stover D, Selfors L, Winer E, Partridge A, Barry W. Abstract P1-07-05: Integrated transcriptional analysis of the triple negative 'proliferation paradox': High proliferation, chemosensitivity, and in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases](https://doi.org/10.1158/1538-7445.sabcs16-p1-12-04)Metzger O, Barry W, Krop I, Guo H, Younger J, Lawler E, Walker L, Freedman R, Tolaney S, Winer E, Lin N. Abstract P1-12-04: Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer evaluating exemestane \u00b1 enzalutamide in patients with hormone receptor-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-p2-08-01)Krop I, Abramson V, Colleoni M, Holmes F, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly C, Uppal H, Tudor I, Peterson A, Winer E, Yardley D. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane \u00b1 enzalutamide in patients with hormone cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial](https://doi.org/10.1158/1538-7445.sabcs16-p4-22-16)Burris H, Chan A, Campone M, Blackwell K, Winer E, Janni W, Verma S, Burdaeva O, Alba E, Favret A, Mondal S, Miller M, C, Y. letrozole in patients with HR+, HER2- cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-p5-11-02)Ligibel J, Giobbie-Hurder A, Dillion D, Shockro L, Campbell N, Rhei E, Troyan S, Dominici L, Golshan M, Chagpar A, Yung R, Freedman R, Tolaney S, Winer E, Frank E, McTiernan A, Irwin M. Abstract P5-11-02: Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer Cancer Research 2017, 77: p5-11-02-p5-11-02. [DOI: 10.1158/1538-7445.sabcs16-p5-11-02](https://doi.org/10.1158/1538-7445.sabcs16-p5-11-02). [Abstract JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs16-p6-12-12)Overmoyer B, Regan M, Schlosnagle E, Bunnell C, Freedman R, Tolaney S, Chen W, Mayer E, Partridge A, Silver D, Winer E. Abstract P6-12-12: Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 Cancer Research 2017, 77: p6-12-12-p6-12-12. [DOI: 10.1158/1538-7445.sabcs16-p6-12-12](https://doi.org/10.1158/1538-7445.sabcs16-p6-12-12). - Cohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, Tamayo P, Johannessen C, Krop I, L, E, N. exome and transcriptome sequencing 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-s3-05)Tanioka M, Fan C, Carey L, Hyslop T, Pitcher B, Parker J, Hoadley K, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Mardis E, Perou C, Winer E, Hudis C. Abstract analysis data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast Cancer [DOI: 10.1158/1538-7445.sabcs16-s3-05](https://doi.org/10.1158/1538-7445.sabcs16-s3-05). Ligibel J, Irwin Barry W, Giobbie-Hurder A, Frank E, Winer E, McTiernan A, Cornwell M, Pun M, Brown M, Jeselsohn R. Abstract S5-05: Impact of pre-operative exercise on breast cancer gene expression s5-05-s5-05. [DOI: 10.1158/1538-7445.sabcs16-s5-05](https://doi.org/10.1158/1538-7445.sabcs16-s5-05). [Corrigendum to \"3rd breast cancer (ABC 3)\" [Breast 31 (February 2017) 244-259]](http://www.ncbi.nlm.nih.gov/pubmed/28109648)Cardoso F, Costa C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, B, Norton L, Winer E. Corrigendum to \"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)\" [Breast 31 Cancer in Patients Treated with Neoadjuvant Systemic Golshan M. Axillary Management Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic of CALGB 40601 (HER2-Positive) and CALGB for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, X. C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) MV, ME, Juric HH, Li LC, with Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527](http://www.ncbi.nlm.nih.gov/pubmed/27992272)Freedman RA, Foster JC, Seisler A, Kimmick G, Jatoi A, Hurria A. Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527 Journal Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: of in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) The Breast 2016, 31: 244-259. [PMID: 27927580](https://pubmed.ncbi.nlm.nih.gov/27927580), C, Bergh V, Saghir N, Eniu P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Annals Of versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC](https://doi.org/10.1093/annonc/mdw577.019)Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V, de la Haba-Rodriguez J, L, Kusuma N, Chui S, Schmid P. IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive Of Oncology 2016, III versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC](https://doi.org/10.1016/s0923-7534(21)00294-5)Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V, de la Haba-Rodriguez J, L, Kusuma N, Chui S, Schmid P. IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in ix40. [DOI: 10.1016/s0923-7534(21)00294-5](https://doi.org/10.1016/s0923-7534(21)00294-5). [TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/27185372)Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, J, C, Bonechi M, Laing N, Winer EP, Brown M, Di Leo A, Malorni L. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer Clinical myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)](http://www.ncbi.nlm.nih.gov/pubmed/27866278)Freedman RA, Seisler DK, Foster JC, Sloan JA, AH, Carey LA, Jatoi A, Klepin HD, Citron M, DA, Shulman LN, AU, Suman VJ, Muss HB. Risk of acute leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511) Breast Cancer Research And HJ. Perils of the Pathologic Complete Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer New England Journal Medicine randomized study](http://www.ncbi.nlm.nih.gov/pubmed/27714541)Tolaney Nechushtan H, Ron Awada A, Laird AD, O'Keeffe GI, Winer EP. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study Breast Cancer Research granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study](http://www.ncbi.nlm.nih.gov/pubmed/27721193)Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study The Breast [PMID: 27721193](https://pubmed.ncbi.nlm.nih.gov/27721193), [DOI: 10.1016/j.breast.2016.09.013](https://doi.org/10.1016/j.breast.2016.09.013). [Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW, for the Alliance for Clinical Trials in Oncology. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) Yap Y, Sonke K, Andr\u00e9 F, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, Xuan F, Souami F, Miller M, Germa C, O'Shaughnessy J. LBA1_PR breast cancer, locally advanced and metastatic First-line HER2-negative (HER2-), 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab](http://www.ncbi.nlm.nih.gov/pubmed/27484879)Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab Breast Cancer Research And [PMID: 27484879](https://pubmed.ncbi.nlm.nih.gov/27484879), [DOI: 10.1007/s10549-016-3927-4](https://doi.org/10.1007/s10549-016-3927-4). - Partridge AH, RM. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival Journal Of Clinical Oncology 2016, Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26957554)Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Z, V, JT, JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer matched biopsies enables genomic discovery in metastatic cancer](https://doi.org/10.1158/1538-7445.am2016-lb-136)Adalsteinsson V, Ha G, Freeman S, Choudhury A, Stover D, Parsons H, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Cohen O, Oh C, Kim J, Stewart C, Rosenberg M, Ding H, Lloyd M, Mahmud S, Helvie K, Merrill M, Santiago R, O'Connor E, Jeong S, Kramkowski J, Lohr J, Polacek L, Oliver N, Marini L, Francis J, Harshman L, Van Allen E, Winer E, Lin N, Nakabayashi M, Taplin M, Garraway L, Golub T, Boehm J, Wagle N, Getz G, Meyerson M, Love C. Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer Cancer Research 2016, 10.1158/1538-7445.am2016-lb-136](https://doi.org/10.1158/1538-7445.am2016-lb-136). - Carey LA, Winer EP. I-SPY 2 \u2014 Toward More Rapid Progress in Breast Cancer Treatment New England Journal Of Medicine 2016, 375: 83-84. [PMID: 27406352](https://pubmed.ncbi.nlm.nih.gov/27406352), Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26842237)Varadan V, Gilmore H, Miskimen KL, G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris L. Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer Clinical adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.](https://doi.org/10.1200/jco.2016.34.18_suppl.lba1)Goss P, Ingle Pritchard Robert H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff A, Winer E, Hudis C, Stopeck A, Beck J, Kaur J, Whelan K, Tu D, Parulekar W. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. to accelerate genomics research.](https://doi.org/10.1200/jco.2016.34.18_suppl.lba1519)Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer E, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. orthotopic xenografts of HER2-positive breast cancer brain Xie S, Goel S, Stover DG, Guo H, Luu V, Marco LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Zhao JJ. Combination inhibition of PI3K and remissions in mice orthotopic patient-derived xenografts of HER2-positive incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis](http://www.ncbi.nlm.nih.gov/pubmed/27271765)Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis Breast Cancer Research And Treatment K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, C, Stopeck D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years New England Journal Of in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab A CALGB 40503 (Alliance) correlative study.](https://doi.org/10.1200/jco.2016.34.15_suppl.10047)Li D, Dickler M, McCall L, Hahn O, Hudis C, Cohen H, Muss H, Ballman K, Winer E, Tripathy D, Schneider B, Cirrincione C, Barry W, Hurria A. Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) 2016, 10047-10047. [DOI: 10.1200/jco.2016.34.15_suppl.10047](https://doi.org/10.1200/jco.2016.34.15_suppl.10047). - King T, Lyman J, Gonen M, Reyes S, Hwang E, Rugo H, Liu M, Boughey J, Jacobs L, McGuire K, Storniolo A, Isaacs C, Meszoely I, Van Poznak C, Babiera G, Norton L, Morrow M, Wolff A, Winer E, Hudis C. A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). Journal Of Clinical Oncology 2016, 34: 1006-1006. [DOI: 10.1200/jco.2016.34.15_suppl.1006](https://doi.org/10.1200/jco.2016.34.15_suppl.1006). [Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.](https://doi.org/10.1200/jco.2016.34.15_suppl.1024)Freedman R, Seisler D, Foster J, Lafky J, Kimmick Jatoi A, Muss H, Cohen E, Hudis C, Cirrincione C, Moreno-Aspitia A, Hurria A. Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527. Journal Of [Effect of cabozantinib treatment circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.1093)Duda D, Ziehr D, Guo H, Ng M, Barry W, Higgins M, Isakoff S, Brock J, Ivanova E, Paweletz R, Winer E, Tolaney S. Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). 1093-1093. [DOI: 10.1200/jco.2016.34.15_suppl.1093](https://doi.org/10.1200/jco.2016.34.15_suppl.1093). cancer from metastatic biopsies (bx) in Helvie K, Lloyd M, Marini L, Waks A, Cohen O, Oh C, Sougnez C, Oliver N, Quartey Q, Rotem A, Shah P, Lindeman N, Krop I, Garraway L, Winer E, Lin N. A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.](https://doi.org/10.1200/jco.2016.34.15_suppl.538)Innocenti F, Owzar K, Jiang C, Sibley A, Mulkey F, Carey L, Tripathy D, Schneider B, Barry W, Winer E, Hudis C, McLeod H, Dickler M. A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 538-538. [DOI: [Mechanisms of resistance DNA therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.542)Waks A, Cohen O, Helvie K, Lloyd M, Marini L, Oh C, Oliver N, Lindeman N, Matulonis U, Krop I, Garraway L, Winer E, Lin N, Wagle N. Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer 34: 542-542. [DOI: 10.1200/jco.2016.34.15_suppl.542](https://doi.org/10.1200/jco.2016.34.15_suppl.542). - Vaz Luis I, Lin N, Keating N, Barry W, Lii J, Burstein H, Winer E, Freedman R. Factors associated with non use of adjuvant trastuzumab in older patients with HER2+ breast cancer. Journal Of Clinical Oncology 2016, 34: 601-601. [DOI: 10.1200/jco.2016.34.15_suppl.601](https://doi.org/10.1200/jco.2016.34.15_suppl.601). - Vaz Luis I, Lin N, Freedman R, Barry W, Winer E, Hassett M. Quality of care for metastatic breast cancer (MBC). Of Clinical Oncology 2016, 34: e18031-e18031. [DOI: 10.1200/jco.2016.34.15_suppl.e18031](https://doi.org/10.1200/jco.2016.34.15_suppl.e18031). [Patterns of utilization of imaging and tumor markers (TM) among metastatic breast cancer (MBC) patients (pts).](https://doi.org/10.1200/jco.2016.34.15_suppl.e18224)Di Meglio A, Lin N, Freedman R, Barry W, Winer E, Vaz Luis I. Patterns of utilization of imaging and tumor markers (TM) among metastatic breast cancer (MBC) patients (pts). Journal extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.](https://doi.org/10.1200/jco.2016.34.15_suppl.lba1)Goss K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff A, Winer E, Hudis C, Stopeck A, Beck J, Kaur J, Whelan K, Tu D, Parulekar W. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. to accelerate genomics research.](https://doi.org/10.1200/jco.2016.34.15_suppl.lba1519)Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer E, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. 34: lba1519-lba1519. single-agent per physician's choice triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.tps1102)Winer E, Dang T, Karantza V, Su S. KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab single-agent per physician's choice nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).](https://doi.org/10.1200/jco.2016.34.15_suppl.tps1104)Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V, de la Haba-Rodriguez J, Gianni L, Chui S, Schmid P. IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.](https://doi.org/10.1200/jco.2016.34.15_suppl.tps629)Freedman R, Polley M, Dueck A, Hurria A, Muss H, Ruddy K, Hubbard J, Liu H, Rogak L, Basch E, Dakhil S, Huff J, Bajaj M, Wilkinson M, Al Baghadadi T, Benjamin S, Mowat R, Hudis C, Rugo H, Winer E. Academic and Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Journal Of phase 2 trial](http://www.ncbi.nlm.nih.gov/pubmed/27155741)Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, J, Schmid P. Pictilisib for oestrogen receptor-positive, Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women Hurria Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26976419)Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer Journal Of AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors in Breast Cancer Treatment\u2014The Sooner, Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression](http://www.ncbi.nlm.nih.gov/pubmed/26884586)Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Journal Of of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs15-ot1-01-06)Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, Chui S, Winer E. Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-21)Mayer E, DeMichele A, Dubsky P, Barry W, Metzger O, Symmans W, Burstein H, Miller K, Wolff A, Rastogi P, Loibl S, von Minckwitz G, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang Bartlett C, Chen L, Piccart Winer Gnant phase of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast Cancer 76: direct-to-patient research initiative to accelerate genomics research](https://doi.org/10.1158/1538-7445.sabcs15-ot2-05-03)Wagle N, Painter C, Ilzarbe M, Van Allen E, Frank E, Oh C, Krevalin M, Lloyd M, Anderka K, Kryukov G, Boehm J, Winer E, Lander E, Golub T. Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics Research 2016, 76: ot2-05-03-ot2-05-03. [DOI: 10.1158/1538-7445.sabcs15-ot2-05-03](https://doi.org/10.1158/1538-7445.sabcs15-ot2-05-03). [Abstract P1-07-08: Time trends in incidence rates and survival for women with de novo metastatic lobular vs. ductal carcinoma, a population-based study](https://doi.org/10.1158/1538-7445.sabcs15-p1-07-08)Di Meglio A, Freedman R, Lin N, Barry W, Metzger-Filho O, Keating N, Winer E, Vaz-Luis I. Abstract P1-07-08: Time trends in incidence rates and survival for women with de novo metastatic lobular vs. ductal carcinoma, a population-based study Cancer Research 2016, 76: p1-07-08-p1-07-08. [DOI: 10.1158/1538-7445.sabcs15-p1-07-08](https://doi.org/10.1158/1538-7445.sabcs15-p1-07-08). - Garber J, Tung N, Elkin E, Allen B, Singh N, Wenstrup R, Hartman A, Winer E, Lin N. Abstract P1-08-07: Predisposing germline mutations in a clinic based breast cancer (BC) population Cancer Research 2016, 76: p1-08-07-p1-08-07. [DOI: 10.1158/1538-7445.sabcs15-p1-08-07](https://doi.org/10.1158/1538-7445.sabcs15-p1-08-07). [Abstract P3-07-31: Immune activation signatures subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy](https://doi.org/10.1158/1538-7445.sabcs15-p3-07-31)Stover D, Waks A, Erica M, Brugge J, Winer E, Selfors L. Abstract P3-07-31: Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant Cancer Research 2016, 76: p3-07-31-p3-07-31. [DOI: 10.1158/1538-7445.sabcs15-p3-07-31](https://doi.org/10.1158/1538-7445.sabcs15-p3-07-31). [Abstract P5-11-02: Survival benefit needed to undergo chemotherapy: Patients and physicians preferences](https://doi.org/10.1158/1538-7445.sabcs15-p5-11-02)Vaz Luis I, O'Neill A, Sepucha K, Miller K, Baker E, Dang C, Northfelt D, Winer E, Sledge G, Schneider B, Partridge A. Abstract P5-11-02: Survival benefit needed to undergo chemotherapy: Patients and physicians preferences Cancer Research 2016, 76: p5-11-02-p5-11-02. [DOI: 10.1158/1538-7445.sabcs15-p5-11-02](https://doi.org/10.1158/1538-7445.sabcs15-p5-11-02). [Abstract P6-09-10: All-cause survival estimates compared to observed survival in older women with breast cancer in CALGB 49907 and 369901 (Alliance A151503)](https://doi.org/10.1158/1538-7445.sabcs15-p6-09-10)Kimmick G, Pitcher B, Mandelblatt J, Clapp J, Ballman K, Barginear M, Freedman R, Artz A, Klepin H, Lafky J, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A. Abstract P6-09-10: All-cause survival estimates compared to observed survival in older women with breast cancer in CALGB 49907 and 369901 +/- (Alliance)](https://doi.org/10.1158/1538-7445.sabcs15-s2-05)Sikov Berry Perou C, Singh B, Cirrincione C, Tolaney S, Somlo G, Port E, Qamar K, Mamounas E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E. Abstract S2-05: Event-free and overall +/- SM, Lin NU, Winer EP. Randomized trial of a physical activity intervention in women with metastatic breast cancer Cancer 2016, 122: 1169-1177. [PMID: 26872302](https://pubmed.ncbi.nlm.nih.gov/26872302), [DOI: 10.1002/cncr.29899](https://doi.org/10.1002/cncr.29899). [Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers](http://www.ncbi.nlm.nih.gov/pubmed/26868124)Vaz-Luis I, Hughes ME, Cronin A, EP, Lin NU. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers Breast Cancer Research And Treatment 2016, 155: 569-578. [PMID: 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/26834058)Freedman RA, Gelman RS, Wefel JS, Melisko ME, RM, Van Puhalla SL, N, Blackwell Herold C, Liu MC, Lowe A, Agar Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases RM, Tabassum DP, Roberts JM, Janiszewska M, Jin Huh S, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop I, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao P, Duarte M, Wu S, Chiang C, Anders L, Young R, Winer E, Letai A, Barry W, Carroll J, Long H, Brown M, Shirley Liu X, Meyer C, Bradner J, Polyak K. Response and resistance to BET bromodomain inhibitors in triple-negative breast and taxane-based Gradishar WJ, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26539793)Dang Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, EP, SM. Outcomes Adjuvant and Trastuzumab for Node-Negative, compensatory activation of MEK-ERK signaling](http://www.ncbi.nlm.nih.gov/pubmed/26640141)Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, NU, Krop and Her2-initiated escape PI3K dependency by compensatory CA, Barry WT. Response Journal Of The National Cancer Institute 2015, 108 [PMID: 26719886](https://pubmed.ncbi.nlm.nih.gov/26719886), [DOI: 10.1093/jnci/djv334](https://doi.org/10.1093/jnci/djv334). [Molecular Heterogeneity and Response to Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib](http://www.ncbi.nlm.nih.gov/pubmed/26527775)Carey LA, Berry Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/26578779)Tolaney RK. density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients Proceedings Of The National Academy Of Sciences Of The United States Of America Evolution and Potential Therapeutic Targets](http://www.ncbi.nlm.nih.gov/pubmed/26410082)Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG, Gill CM, Van Hummelen Thorner Hoang MP, Choueiri TK, EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Cancer Discovery 2015, 5: 1164-1177. 29: 797-8, 802. [PMID: 26573058](https://pubmed.ncbi.nlm.nih.gov/26573058). - Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ. PI3K-p110 mediates resistance to and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors](http://www.ncbi.nlm.nih.gov/pubmed/26420402)Waks AG, Tolaney SM, A, SP, LR. Pneumocystis pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors Breast Cancer Research And Treatment 154: 359-367. [PMID: II-III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates](http://www.ncbi.nlm.nih.gov/pubmed/26222764)Golshan M, of Neoadjuvant Chemotherapy in Stage II-III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates Annals Of that targets leukemia.](https://doi.org/10.1158/1557-3265.hemmal14-a14)Reagan J, Fast L, Nevola M, Schumacher A, Rosati K, Safran H, Quesenberry M, E, generate an allogeneic leukemia. Clinical [DOI: chemotherapy regimens for patients with triple negative breast cancer The Breast 2015, 24: s132-s135. [PMID: 26255198](https://pubmed.ncbi.nlm.nih.gov/26255198), [DOI: 10.1016/j.breast.2015.07.032](https://doi.org/10.1016/j.breast.2015.07.032). [Variation in the Attitudes Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26240134)Seah DS, Scott S, Guo H, Najita J, Lederman R, Frank E, Sohl J, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin NU. Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K inhibitor taselisib (GDC-0032) in solid malignancies](https://doi.org/10.1158/1538-7445.am2015-2399)Wilson T, Savage H, Aimi J, Jin J, Parmar H, Hsu J, Krop I, Saura C, Cervantes A, Sachdev J, Patel M, Cejalvo J, Oliveira M, Winer E, Von Hoff D, Baselga J, Juric D. Abstract 2399: Circulating tumor DNA (ctDNA) analysis of PIK3CA and AKT1 mutations in patients enrolled onto the Phase 1b study of the PI3K discovery and validation set of breast cancer preoperative clinical trials show an increase in immune score upon brief-exposure to trastuzumab (T) and the HER2-enriched subtype predict response to combination chemotherapy and T](https://doi.org/10.1158/1538-7445.am2015-2836)Varadan V, Miskimen K, Parsai S, Krop I, Winer E, V, Abu-Khalaf M, Sikov W, Harris L. Abstract 2836: A discovery and validation set of breast cancer preoperative clinical trials show an increase in immune score upon brief-exposure to trastuzumab (T) and the HER2-enriched subtype predict response to combination chemotherapy and T 2015, 2836-2836. [DOI: 10.1158/1538-7445.am2015-2836](https://doi.org/10.1158/1538-7445.am2015-2836). [Abstract CT231: A first-in-human phase I oral selective estrogen receptor degrader M, Bardia A, Mayer I, Winer E, Rix P, Hager J, Chen M, Chan I, Chow-Maneval E, Arteaga C, Baselga J. Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader ER+/HER2-metastatic V, Balko J, Sanders M, Juric D, Solit D, Li Y, Cantley L, Winer E, Arteaga C. for high-grade serous ovarian cancer or triple-negative cancer: results of the BKM120 plus olaparib cohort](https://doi.org/10.1158/1538-7445.am2015-ct324)Matulonis U, Wulf G, Barry W, Birrer Westin Spagnoletti T, Bell-McGuinn K, Obermayer E, Whalen C, Aghajanian C, D, Mills G, Cantley L, Winer E. Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results BKM120 plus 2015, [DOI: 10.1158/1538-7445.am2015-ct324](https://doi.org/10.1158/1538-7445.am2015-ct324). [Relative Letrozole Compared With Tamoxifen With Lobular Carcinoma in the BIG 1-98 Filho M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial Journal J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, G, M, C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno Etten Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs Mayo Clinic Proceedings Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)](http://www.ncbi.nlm.nih.gov/pubmed/26169615)Lin Mayer Falkson Hobday TJ, Dees Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, B, Wright JJ, Shapiro GI, Winer EP, Krop IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer treatment of triple-negative breast cancer](https://doi.org/10.1158/1538-8514.pi3k14-ia21)Wulf G, Juvekar A, Lyssiotis C, Hu H, Baek K, Yadegarynia S, Scully R, Winer E, Asara J, Cantley L, Matulonis U. Abstract IA21: Combination treatments that include PI3K-inhibitors for the treatment of triple-negative breast cancer Molecular Cancer Sikov Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance) Journal Of The [PMID: 26113580](https://pubmed.ncbi.nlm.nih.gov/26113580), [PMCID: PMC4651106](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651106), [DOI: 10.1093/jnci/djv179](https://doi.org/10.1093/jnci/djv179). [Randomized Phase Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype Breast Cancer Research [DOI: 10.1007/s10549-015-3432-1](https://doi.org/10.1007/s10549-015-3432-1). [Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women](http://www.ncbi.nlm.nih.gov/pubmed/26025931)Collins LC, Gelber Borges T, Tamimi RM, Winer EP, Partridge AH. Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women The rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40601 (Alliance).](https://doi.org/10.1200/jco.2015.33.15_suppl.1007)Golshan M, Cirrincione C, Carey L, Sikov W, Berry D, Burstein H, Overmoyer B, Henry N, Somlo G, Port E, Winer E, Hudis C, Ollila D. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 [DOI: 10.1200/jco.2015.33.15_suppl.1007](https://doi.org/10.1200/jco.2015.33.15_suppl.1007). [Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907.](https://doi.org/10.1200/jco.2015.33.15_suppl.1022)Muss H, Berry D, Cirrincione C, Theodoulou M, Hurria A, Cohen H, Partridge A, Norton L, Hudis C, Winer E. Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. neurotoxic chemotherapy for metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2015.33.15_suppl.1041)Sharma M, Gray E, Mehrotra S, Wu K, Barry W, Hudis C, Winer E, Lyss A, Toppmeyer D, H, Ratain M, Gobburu J. A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). Journal [DOI: 10.1200/jco.2015.33.15_suppl.1041](https://doi.org/10.1200/jco.2015.33.15_suppl.1041). - Tolaney S, Ziehr Guo Barry W, Higgins M, Isakoff S, Brock J, Ivanova E, Paweletz B, Jain R, Duda D, Winer E. A Phase II study of cabozantinib for metastatic triple-negative breast cancer 2015, 33: 1080-1080. [DOI: 10.1200/jco.2015.33.15_suppl.1080](https://doi.org/10.1200/jco.2015.33.15_suppl.1080). - Garber J, Tung N, Elkin E, Allen B, Hartman A, Singh N, Wenstrup R, Winer E, Lin N. Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed (Dx). Journal Of Clinical Oncology 2015, 33: 1503-1503. [DOI: 10.1200/jco.2015.33.15_suppl.1503](https://doi.org/10.1200/jco.2015.33.15_suppl.1503). [Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort.](https://doi.org/10.1200/jco.2015.33.15_suppl.1577)Luis I, Lin N, Keating N, Lii J, Barry W, Winer E, Freedman R. Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort. Journal Of Clinical Oncology 2015, 33: 1577-1577. [DOI: 10.1200/jco.2015.33.15_suppl.1577](https://doi.org/10.1200/jco.2015.33.15_suppl.1577). [Variation in the granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study.](https://doi.org/10.1200/jco.2015.33.15_suppl.561)Paes F, Luis I, Costa R, Metzger Filho O, Hughes M, Losk K, Camuso K, Bunnell C, Golshan M, Winer E, Lin N. Variation in the use of granulocyte-colony stimulating factor (G-CSF) for dose dense paclitaxel: A single institution retrospective study. Journal Of Clinical Oncology 2015, 33: 561-561. with HER2+ metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2015.33.15_suppl.608)Jhaveri K, Hamilton E, Miller K, Roche M, Berger M, Winer E, Lin N. A phase 1b HER2+ metastatic breast cancer patients (pts) with extraordinary responses to trastuzumab (T).](https://doi.org/10.1200/jco.2015.33.15_suppl.611)Luis I, Oh C, Wang Z, Dipiro P, Macrae E, Painter C, Kryukov G, Krop I, Winer E, Lin N, Wagle N. exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). Journal Of Clinical Oncology 2015, 33: 611-611. [DOI: 10.1200/jco.2015.33.15_suppl.611](https://doi.org/10.1200/jco.2015.33.15_suppl.611). - Calip G, Law E, Winer E, Ko N. Racial and ethnic differences in risk of second primary cancers among breast cancer survivors. Journal Of Clinical Oncology 2015, 33: e12592-e12592. [DOI: 10.1200/jco.2015.33.15_suppl.e12592](https://doi.org/10.1200/jco.2015.33.15_suppl.e12592). [A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or cancer.](https://doi.org/10.1200/jco.2015.33.15_suppl.tps640)Trudeau Winer E, Steinberg J, Liosatos M, Poondru S, Dydo M, Peterson A, Gradishar W. A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or locally Oncology 2015, 33: tps640-tps640. [DOI: 10.1200/jco.2015.33.15_suppl.tps640](https://doi.org/10.1200/jco.2015.33.15_suppl.tps640). [Phase III bevacizumab to letrozole as first-line endocrine therapy for positive breast cancer: CALGB 40503 (Alliance).](https://doi.org/10.1200/jco.2015.33.15_suppl.501)Dickler M, Barry Cirrincione Moynahan M, Innocenti F, Hurria A, Rugo H, Lake D, Hahn O, Schneider B, Tripathy D, Winer E, Hudis C. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 [DOI: 10.1200/jco.2015.33.15_suppl.501](https://doi.org/10.1200/jco.2015.33.15_suppl.501). [Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance.](https://doi.org/10.1200/jco.2015.33.15_suppl.509)Stover D, Selfors L, Coloff J, Brugge J, Winer E. Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance. Journal Of Clinical Oncology 2015, 33: 509-509. [DOI: 10.1200/jco.2015.33.15_suppl.509](https://doi.org/10.1200/jco.2015.33.15_suppl.509). [Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study.](https://doi.org/10.1200/jco.2015.33.15_suppl.515)Rosenberg S, Ruddy K, Tamimi R, Gelber S, Schapira L, Borges V, Come S, Meyer M, Winer E, Partridge A. Ovarian function suppression, symptom burden, and quality of life in young women with breast cancer: A prospective study. Journal Of Clinical Oncology 2015, 33: 515-515. [DOI: 10.1200/jco.2015.33.15_suppl.515](https://doi.org/10.1200/jco.2015.33.15_suppl.515). adjuvant Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors](http://www.ncbi.nlm.nih.gov/pubmed/25964252)Warner ET, Tamimi RM, Hughes ME, Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors Journal Of breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015](http://www.ncbi.nlm.nih.gov/pubmed/25939896)Coates AS, Winer EP, Goldhirsch J, Bonnefoi H, Burstein F, Castiglione-Gertsch M, Coates A, Colleoni M, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Galimberti V, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Harbeck N, Hayes D, Huober J, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne C, Partridge A, de la Pe\u00f1a L, Piccart-Gebhart M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Th\u00fcrlimann B, Toi M, Tutt A, Viale G, von Minckwitz G, Watanabe T, Whelan T, Winer E, Xu B. Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Annals Of T, Forbes JF, von Minckwitz Robertson J, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow L, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov DY, Klimberg VS. Personalization of loco-regional care for primary breast cancer patients (part Future Oncology 2015, 11: T, Forbes JF, von Minckwitz Robertson J, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow L, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov DY, Klimberg VS. Personalization of loco-regional care for primary breast cancer patients (part Borges VF, Golshan M, AH. Local Therapy and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer es9-3-es9-3. [DOI: 10.1158/1538-7445.sabcs14-es9-3](https://doi.org/10.1158/1538-7445.sabcs14-es9-3). [Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study](https://doi.org/10.1158/1538-7445.sabcs14-ot2-1-04)Ma Suman Sanati S, DeSchryver K, Unzeitig G, Haluska P, Watson M, Hahn O, Zujewski J, Hunt K, Winer E, Hudis C, Ellis M. Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study ot2-1-04-ot2-1-04. [DOI: 10.1158/1538-7445.sabcs14-ot2-1-04](https://doi.org/10.1158/1538-7445.sabcs14-ot2-1-04). [Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-ot3-1-06)Trudeau M, Winer E, Steinberg J, Liosatos M, Poondru S, Dydo M, Zhou Y, Westphal M, Peterson A, Gradishar W. Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer 2015, ot3-1-06-ot3-1-06. [DOI: 10.1158/1538-7445.sabcs14-ot3-1-06](https://doi.org/10.1158/1538-7445.sabcs14-ot3-1-06). [Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with Mayer I, Winer E, Mahmood U, Ulaner G, Manning H, Rix P, Hager J, Roychowdhury D, Chow Maneval E, Arteaga C, Baselga J. Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival](https://doi.org/10.1158/1538-7445.sabcs14-p1-13-04)Overmoyer B, Sanz-Altimira P, Partridge A, Extermann M, Liu J, Winer E, Lin N, Hassett M, Parker L, Taylor R, Hancock M, Small S, Johnston M. Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival 2015, p1-13-04-p1-13-04. [DOI: 10.1158/1538-7445.sabcs14-p1-13-04](https://doi.org/10.1158/1538-7445.sabcs14-p1-13-04). [Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy](https://doi.org/10.1158/1538-7445.sabcs14-p1-16-01)Sagara Y, Barry W, Vaz-Luis Aydogan F, Winer E, Golshan M, Metzger-Filho O. Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy 2015, p1-16-01-p1-16-01. [DOI: 10.1158/1538-7445.sabcs14-p1-16-01](https://doi.org/10.1158/1538-7445.sabcs14-p1-16-01). [Abstract P2-13-03: Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions](https://doi.org/10.1158/1538-7445.sabcs14-p2-13-03)Vaz Luis I, Hughes M, Cronin A, Rugo H, Edge S, Moy B, Theriault R, Hassett M, Winer E, Lin N. Abstract P2-13-03: Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions 2015, p2-13-03-p2-13-03. [DOI: 10.1158/1538-7445.sabcs14-p2-13-03](https://doi.org/10.1158/1538-7445.sabcs14-p2-13-03). - Anderson K, Overmoyer B, Canning C, J, Wallstrom G, Winer E, Dranoff G. Abstract P2-15-03: A Phase Ib Study of an adjuvant GM-CSF-Secreting Breast Cancer Vaccine 2015, [DOI: 10.1158/1538-7445.sabcs14-p2-15-03](https://doi.org/10.1158/1538-7445.sabcs14-p2-15-03). [Abstract response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-11)Richardson A, Silver D, Szallasi Z, Birkbak N, Wang Z, Iglehart J, Mayer E, Winer E, Tung N, Ryan P, Isakoff S, Barry W, Greene-Collozi A, Gutin A, Reid J, Neff C, Jones J, Timms K, Hartman A, Garber J. Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer 2015, p3-06-11-p3-06-11. [DOI: 10.1158/1538-7445.sabcs14-p3-06-11](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-11). [Abstract P3-06-24: Brief exposure to trastuzumab chemotherapy confirms predictors of response to treatment](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-24)Vadodkar A, Varadan Miskimen K, Bossuyt V, Abu-khalaf M, Krop I, Winer E, Harris L. Abstract P3-06-24: Brief exposure to trastuzumab prior to preoperative chemotherapy confirms predictors of response to treatment 2015, p3-06-24-p3-06-24. [DOI: 10.1158/1538-7445.sabcs14-p3-06-24](https://doi.org/10.1158/1538-7445.sabcs14-p3-06-24). [Abstract P4-01-02: Prospective characterization of HER2-positive in patients with HER2-negative metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p4-01-02)Krop I, Macrae E, Galler S, Bischoff Fauni R, Sales E, Huynh L, Mitchell C, Clarin-Tamayo T, Anderson M, Abad L, Winer E. Abstract P4-01-02: Prospective characterization of HER2-positive circulating tumor cells in patients with HER2-negative metastatic breast cancer 2015, p4-01-02-p4-01-02. [DOI: 10.1158/1538-7445.sabcs14-p4-01-02](https://doi.org/10.1158/1538-7445.sabcs14-p4-01-02). [Abstract P4-17-01: Attitudes of medical oncologists towards research breast biopsies in patients with newly diagnosed stage I-III breast cancer not enrolled in a clinical trial](https://doi.org/10.1158/1538-7445.sabcs14-p4-17-01)Seah D, Scott S, Guo H, Najita J, Lederman R, Frank E, Sohl J, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin N. Abstract P4-17-01: Attitudes of medical oncologists towards research breast biopsies in patients with newly diagnosed stage I-III breast cancer not enrolled in a clinical trial 2015, p4-17-01-p4-17-01. [DOI: 10.1158/1538-7445.sabcs14-p4-17-01](https://doi.org/10.1158/1538-7445.sabcs14-p4-17-01). [Abstract P5-19-09: Preliminary results from a phase single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in AR+ cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs14-p5-19-09)Traina T, O'Shaughnessy J, Nanda R, Schwartzberg L, Abramson V, Cortes J, Peterson A, Tudor I, Blaney M, Steinberg J, Kelly C, Trudeau M, Awada A, Winer E, Hudis C, Schmid P, Yardley D. Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p5-19-10)Sch\u00f6ffski P, Cresta S, Mayer I, Wildiers H, Rooney I, Apt D, Gendreau S, Morrissey K, Lackner M, Spoerke J, Winer E. Abstract P5-19-10: activity the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603](https://doi.org/10.1158/1538-7445.sabcs14-pd1-2)Iglesia M, Vincent B, Serody J, Carey L, Barry W, Sikov W, Hudis C, Winer E, Perou C. Abstract PD1-2: of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003](https://doi.org/10.1158/1538-7445.sabcs14-pd3-5)Wagle N, Lin N, Richardson A, Leshchiner I, Mayer I, Forero-Torres A, Hobday T, Dees E, Nanda R, Rimawi M, Guo H, Barry W, Bose R, Shen W, Wolff A, Gabriel S, Garraway L, Winer E, Krop I. Abstract PD3-5: (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): combination with letrozole in patients with hormone receptor-positive advanced breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-pd5-2)Saura C, Sachdev J, Patel M, Cervantes A, Juric D, Infante J, Richards D, Sanabria S, Lu X, Ware J, Wilson T, Parmar H, Hsu J, Oliveira M, Winer E, Von Hoff D, Baselga J, inhibitor taselisib (GDC-0032) in combination with letrozole in patients advanced breast cancer 2015, pd5-2-pd5-2. [DOI: 10.1158/1538-7445.sabcs14-pd5-2](https://doi.org/10.1158/1538-7445.sabcs14-pd5-2). plus fulvestrant in patients with PIK3CA -altered wild type ER+/HER2- locally advanced or metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-pd5-5)Janku F, Juric D, Cortes J, Rugo H, Burris H, Schuler M, Deschler-Baier B, Middleton M, Gil-Martin M, Berlin J, Winer L, D, Coughlin C, Quadt C, Baselga J. PD5-5: I study of the PI3K inhibitor BYL719 plus fulvestrant in patients with PIK3CA -altered and wild type ER+/HER2- locally advanced [Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant](https://doi.org/10.1158/1538-7445.sabcs14-s1-01)Jeselsohn R, Barry W, Zhao J, Buchwalter G, Guarducci Migliaccio I, Biagioni C, Bonechi M, Laing N, Rukazenkov Y, Winer E, Brown M, Di Leo A, Malorni L. Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant 2015, s1-01-s1-01. [DOI: 10.1158/1538-7445.sabcs14-s1-01](https://doi.org/10.1158/1538-7445.sabcs14-s1-01). pictilisib (GDC-0941) plus fulvestrant ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer - Part I results](https://doi.org/10.1158/1538-7445.sabcs14-s2-02)Krop I, Johnston S, Mayer I, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S, de Boer R, Gendreau S, Derynck M, Lackner M, Spoerke J, Yeh R, Levy G, Ng V, O'Brien C, Savage H, Xiao Y, Wilson T, Lee S, Petrakova K, Vallentin S, Yardley D, Ellis M, Piccart M, Perez E, Winer E, Schmid P. Abstract S2-02: The FERGI phase PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-s3-06)Hoadley K, Barry W, Pitcher B, Parker J, Wilkerson M, Irvin W, Henry N, Tolaney S, Dang C, Krop I, Berry D, Mardis E, Perou C, Winer E, Hudis C, Carey L. S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) HER2-positive breast cancer 2015, s3-06-s3-06. S4-05: Impact of intrinsic subtype by and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer Hoadley Singh B, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Berry D, Hahn O, Carey L, Perou C, Hudis C, Winer E. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program](https://doi.org/10.1158/1538-7445.sabcs14-s6-05)Cardoso F, Bartlett J, Slaets L, van Deurzen C, van Leewen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schroder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Peeters S, Fraser J, Nowaczyk M, Rubio I, Aebi S, Kelly C, Ruddy K, E, Nilsson C, Dal Lago L, Korde Benstead Van Den Weyngaert D, Bogler O, Goulioti T, Dif N, Messina C, Tryfonidis K, Bogaerts J, Giordano S. Abstract S6-05: Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program 2015, s6-05-s6-05. [DOI: 10.1158/1538-7445.sabcs14-s6-05](https://doi.org/10.1158/1538-7445.sabcs14-s6-05). [Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast](http://www.ncbi.nlm.nih.gov/pubmed/25893416)Sagara Y, Barry WT, Mallory JE, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast Annals Of With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25847936)Isakoff SJ, L, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, PE, Ellisen LW. Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast of adjuvant chemotherapy received among patients with stage I breast cancer: A multiinstitutional study](http://www.ncbi.nlm.nih.gov/pubmed/25757412)Vaz-Luis I, Hughes ME, EP, Lin NU. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multiinstitutional 12.01 Tailoring the chemotherapy regimen in patients with triple negative subtypes The Breast 2015, 24: s22. [DOI: 10.1016/s0960-9776(15)70045-7](https://doi.org/10.1016/s0960-9776(15)70045-7). - Gonzalez-Angulo AM, Krop I, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer Journal Of The National Cancer Institute 2015, 107 [PMID: 25688104](https://pubmed.ncbi.nlm.nih.gov/25688104), [PMCID: PMC4342675](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342675), [DOI: 10.1093/jnci/dju493](https://doi.org/10.1093/jnci/dju493). [Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial](http://www.ncbi.nlm.nih.gov/pubmed/25605861)Perez Gralow JR, Reinholz MM. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial Journal I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Trastuzumab for Node-Negative, HER2-Positive Breast Response to Platinum in the breast: Case report and review of the literature](https://doi.org/10.1016/j.ctrc.2015.04.001)Tahara R, Keraliya A, Ramaiya N, Ritterhouse L, Winer E, Tolaney S. Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature Cancer Treatment And Research Communications 2015, 4: 41-45. [DOI: 10.1016/j.ctrc.2015.04.001](https://doi.org/10.1016/j.ctrc.2015.04.001). [Phase I/II HER2-positive metastatic E, Mayer IA, Saura C, Maurer M, Ciruelos E, Garcia AA, Campana F, Wu B, Xu Y, Jiang J, Winer E, Krop I. Phase I/II study of pilaralisib (SAR245408) plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast 151-161. [PMID: Winer EP. Reply to V. 2014, 33: 291-291. [PMID: 25512457](https://pubmed.ncbi.nlm.nih.gov/25512457), I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada Burstein HJ, Martino S, Davidson NE, Geyer CE, M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer New England Journal Of E. Heterogeneity, Genome Complexity of TNBC MD Conference Express 2014, 14: 23-24. [DOI: 10.1177/1559897715571080](https://doi.org/10.1177/1559897715571080). - Emblem Gerstner E, Stufflebeam S, Sorenson G, Harris G, Freedman R, Sohl J, Younger J, Krop I, Winer E, Lin N. NI-23BRAIN BREAST METASTASES RESPOND TO ANTI-ANGIOGENIC THERAPY BY of PST on Pathologic Response and Survival in Breast Cancer MD Conference Express 2014, 14: 21-22. [DOI: 10.1177/155989771431020](https://doi.org/10.1177/155989771431020). [Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Blackwell KL, Winer EP, CA. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer\u2014CALGB and Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, RW, Finn RS, Charpentier Winer EP. Phase Study Plus Gemcitabine and Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival Wolmark N. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations](https://doi.org/10.1158/1538-7445.am2014-ng03)Brastianos P, Carter S, Santagata S, Taylor-Weiner A, Jones R, Horowitz P, Ligon K, Seaone J, Martinez-Saez E, Tabernero J, Cahill D, Paek S, Dunn I, Johnson B, Choueiri T, Rabin M, Winer E, Lin N, Hummelen P, Stemmer-Rachamimov A, Beroukhim R, Louis D, Batchelor T, Baselga J, Getz G, Hahn W. Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations 2014, ng03-ng03. [DOI: 10.1158/1538-7445.am2014-ng03](https://doi.org/10.1158/1538-7445.am2014-ng03). - Cardoso F, Costa A, Norton Aapro M, Andr\u00e9 F, Barrios C, Bergh M, Cufer T, Saghir N, Fallowfield L, Fenech J, Goldhirsch A, Harbeck N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin U, Mayer M, Merjaver S, Nordstr\u00f6m E, Pagani O, Partridge G, Thomssen C, Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) The Breast 2014, 23: 489-502. [PMID: 25244983](https://pubmed.ncbi.nlm.nih.gov/25244983), Aapro M, Andr\u00e9 F, Barrios C, Bergh M, Cufer T, Saghir N, Fallowfield L, Fenech J, Goldhirsch A, Harbeck N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin U, Mayer M, Merjaver S, Nordstr\u00f6m E, Pagani O, Partridge G, Thomssen C, Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) platinum-sensitive ovarian a randomised phase Obermayer L, Lee H, Winer EP, EC, SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 in Breast [DOI: [Long-Term Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25205424)Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast ML, Liu R, Carrasco E, Mart\u00edn M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer British Journal and Cyclophosphamide on Pathologic Complete Response Rates in to III Triple-Negative Breast Cancer: CALGB 40603 Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the Addition of and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 GG. Comorbidity, Chemotherapy Toxicity, and Outcomes Among Older Women Receiving Adjuvant Chemotherapy for Breast Cancer on a Clinical Trial: CALGB 49907 iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/25001612)Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases Breast Cancer Research And of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib recurrent platinum-sensitive ovarian cancer.](https://doi.org/10.1200/jco.2014.32.18_suppl.lba5500)Liu J, Barry W, Birrer M, Lee J, Buckanovich R, Fleming G, Rimel B, Buss M, Nattam S, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer E, Kohn E, Ivy S, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian Clinical Oncology 2014, 32: lba5500-lba5500. [DOI: 10.1200/jco.2014.32.18_suppl.lba5500](https://doi.org/10.1200/jco.2014.32.18_suppl.lba5500). [Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901](http://www.ncbi.nlm.nih.gov/pubmed/24934786)Sheppard VB, Faul JS. Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901 Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 Schneider of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901](http://www.ncbi.nlm.nih.gov/pubmed/24917307)Faul LA, Luta G, Sheppard V, R, Clapp JD, Winer E, Wang J, Barry WT, Mandelblatt JS. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study](http://www.ncbi.nlm.nih.gov/pubmed/24888816)Vaz-Luis I, Ottesen RL, Winer EP, Lin NU. Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG Premenopausal Patients With Breast Cancer After Tamoxifen](http://www.ncbi.nlm.nih.gov/pubmed/24970714)Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, V, Winer EP, Partridge AH. Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen Clinical Breast 14: 413-416. M, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer New England Journal Of Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update](http://www.ncbi.nlm.nih.gov/pubmed/24868023)Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update Journal Of chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009.](https://doi.org/10.1200/jco.2014.32.15_suppl.1020)Isakoff S, He L, Mayer E, Goss P, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Ryan P, Finkelstein D, Hartman A, Garber J, Timms K, Winer E, Ellisen L. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative 1020-1020. [DOI: 10.1200/jco.2014.32.15_suppl.1020](https://doi.org/10.1200/jco.2014.32.15_suppl.1020). Tolaney Barry W, Larrabee K, Brock J, Wagle N, Van Allen E, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright J, Shapiro G, Winer E, Krop I. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast [DOI: 10.1200/jco.2014.32.15_suppl.1106](https://doi.org/10.1200/jco.2014.32.15_suppl.1106). [Phase for high-grade serous ovarian cancer triple-negative breast (TNBC).](https://doi.org/10.1200/jco.2014.32.15_suppl.2510)Matulonis Wulf G, Birrer Westin Quy K, Lasonde B, Whalen C, Aghajanian C, Solit D, Mills G, Cantley L, Winer E. Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative 32: specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).](https://doi.org/10.1200/jco.2014.32.15_suppl.506)Carey L, Barry W, Pitcher B, Hoadley K, Cheang M, Anders C, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Perou C, Winer E, Hudis C. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast [DOI: 10.1200/jco.2014.32.15_suppl.506](https://doi.org/10.1200/jco.2014.32.15_suppl.506). [Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.](https://doi.org/10.1200/jco.2014.32.15_suppl.509)Perez E, Thompson E, Anderson Asmann Y, Kalari K, Eckel-Passow J, Dueck A, Tenner K, Jen J, Fan J, Geiger X, McCullough A, Chen B, Zschunke M, Jenkins R, Sledge G, Winer E, Gralow J, Reinholz M, Ballman K. Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. metastatic breast I, Abramson V, Balko J, Sanders M, Juric D, Li Y, Cantley L, Winer E, Arteaga [DOI: 10.1200/jco.2014.32.15_suppl.516](https://doi.org/10.1200/jco.2014.32.15_suppl.516). [Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC).](https://doi.org/10.1200/jco.2014.32.15_suppl.522)Luis I, Hughes M, Cronin A, Rugo H, Edge S, Moy B, Theriault R, Winer E, Lin N. Emerging trends in type of chemotherapy (CT) received among patients (pts) with stage I breast cancer (BC). Journal Of Clinical Oncology 2014, 32: 522-522. [DOI: 10.1200/jco.2014.32.15_suppl.522](https://doi.org/10.1200/jco.2014.32.15_suppl.522). [TBCRC 022: Phase of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).](https://doi.org/10.1200/jco.2014.32.15_suppl.528)Freedman R, Gelman R, Wefel J, Krop I, Melisko M, Lowe A, Agar N, Blackwell K, Connolly R, Niravath P, Van Poznak C, Puhalla S, Ryabin N, Lawler E, Ibrahim N, Liu M, Wolff A, Winer E, Lin N. TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.](https://doi.org/10.1200/jco.2014.32.15_suppl.536)Wagle N, Lin N, Richardson A, Leshchiner I, Mayer I, Forero-Torres A, Hobday T, Dees E, Nanda R, Rimawi M, Guo H, Barry W, Wolff A, Gabriel S, Garraway L, Winer E, Krop I. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of 32: 536-536. [DOI: 10.1200/jco.2014.32.15_suppl.536](https://doi.org/10.1200/jco.2014.32.15_suppl.536). [Disparities among older women with de novo stage IV breast cancer treated with trastuzumab from 1999 to 2009.](https://doi.org/10.1200/jco.2014.32.15_suppl.646)Luis I, Keating N, Lin N, Lii J, Winer E, Freedman R. Disparities among older women with de novo stage IV breast cancer treated with trastuzumab from 1999 to 2009. Journal Of Clinical Oncology 2014, 32: 646-646. [DOI: 10.1200/jco.2014.32.15_suppl.646](https://doi.org/10.1200/jco.2014.32.15_suppl.646). [A randomized phase 2 of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib recurrent platinum-sensitive ovarian cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.lba5500)Liu J, Barry W, Birrer M, Lee J, Buckanovich R, Fleming G, Rimel B, Buss M, Nattam S, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer E, Kohn E, Ivy S, Matulonis U. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian 2014, 32: lba5500-lba5500. versus paclitaxel in patients (pts) with BRCA1/2- proficient triple-negative breast cancer (TNBC)\u2014Evaluating the homologous recombination deficiency (HRD) biomarker.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps1145)Mayer E, Vaz-Luis I, Richardson A, Perou C, Tung N, Abramson V, Anders C, Forero-Torres A, Marcom P, Miller K, Puhalla S, Rimawi M, Stearns V, Traina T, Barry W, Jones J, Timms K, Hartman A, Wolff A, Winer E. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2- proficient triple-negative breast cancer (TNBC)\u2014Evaluating the homologous recombination deficiency 2014, 32: tps1145-tps1145. [DOI: 10.1200/jco.2014.32.15_suppl.tps1145](https://doi.org/10.1200/jco.2014.32.15_suppl.tps1145). [Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative cancer W, Untch M, McKee M, Giranda V, Rugo H. Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps653)Yardley D, Awada A, Cortes J, Burris H, Peterson A, Tudor I, Stopatschinskaja S, Steinberg J, Gianni L, Miller K, Winer E. A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast [DOI: 10.1200/jco.2014.32.15_suppl.tps653](https://doi.org/10.1200/jco.2014.32.15_suppl.tps653). [Adjuvant palbociclib for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps654)Mayer E, Gropper A, Tung N, Higgins M, Traina T, Barry W, Winer E, Burstein H. Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study. Journal Of Oncology 2014, 32: tps654-tps654. [DOI: 10.1200/jco.2014.32.15_suppl.tps654](https://doi.org/10.1200/jco.2014.32.15_suppl.tps654). with trastuzumab in participants with brain metastases from HER2+ breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps660)Metzger-Filho O, Barry W, Krop I, Younger W, Lawler E, Winer E, Lin N. Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer. Of Clinical Oncology 2014, 10.1200/jco.2014.32.15_suppl.tps660](https://doi.org/10.1200/jco.2014.32.15_suppl.tps660). [A in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.tps668)Freedman R, Luis I, Barry W, Krop I, Wagle N, Lowe A, Galler S, Sohl J, Isakoff S, Tung N, Winer E, Lin N. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. Clinical Oncology 2014, 32: tps668-tps668. [DOI: 10.1200/jco.2014.32.15_suppl.tps668](https://doi.org/10.1200/jco.2014.32.15_suppl.tps668). [Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors](http://www.ncbi.nlm.nih.gov/pubmed/24827126)Balma\u00f1a J, Tung N, Isakoff S, Gra\u00f1a B, Ryan P, Saura C, Lowe E, Frewer P, Winer E, Baselga J, Garber J. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Annals Of Oncology 2014, 25: 1656-1663. [PMID: 24827126](https://pubmed.ncbi.nlm.nih.gov/24827126), Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline](http://www.ncbi.nlm.nih.gov/pubmed/24799465)Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Journal Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline](http://www.ncbi.nlm.nih.gov/pubmed/24799487)Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline Journal for older women receiving adjuvant trastuzumab-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/24756187)Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy Breast Cancer Research And Treatment 2014, 145: 491-501. [PMID: 24756187](https://pubmed.ncbi.nlm.nih.gov/24756187), [DOI: 10.1007/s10549-014-2968-9](https://doi.org/10.1007/s10549-014-2968-9). [Male breast cancer networking and telephone support group: a model for supporting a unique population](http://www.ncbi.nlm.nih.gov/pubmed/24700635)Farrell E, Borstelmann N, Meyer F, Partridge A, Winer E, Ruddy K. Male breast cancer networking and telephone support group: a model for supporting a unique 956-958. Y, Cantley LC, E, Arteaga CL. Buparlisib Defining success in neoadjuvant breast cancer outgrowth gene sets CALGB 40101 (Alliance)](http://www.ncbi.nlm.nih.gov/pubmed/24513692)Chhibber A, Mefford J, Stahl EA, M, Winer EP, Hudis CA, of paclitaxel-induced sensory peripheral driven by axon outgrowth gene sets in CALGB Patients With Early-Stage Breast Cancer: A Population-Based Study](http://www.ncbi.nlm.nih.gov/pubmed/24516021)Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based preoperative capecitabine in women with operable hormone receptor positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/24464780)Tolaney SM, Jeong J, Guo H, Brock J, Golshan M, Bellon J, Winer EP, Krop IE. A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer Cancer Medicine 2014, 3: 293-299. [PMID: 24464780](https://pubmed.ncbi.nlm.nih.gov/24464780), [PMCID: PMC3987079](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987079), [DOI: chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.](http://www.ncbi.nlm.nih.gov/pubmed/24453294)Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network 2014, 12: 10.1158/0008-5472.sabcs13-ms02-1](https://doi.org/10.1158/0008-5472.sabcs13-ms02-1). OT1-1-07: trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot1-1-07)Overmoyer B, Regan M, Brugge J, Perou C, Nakhlis F, Jennifer B, Heather J, Eren Y, Judith H, Winer E. Abstract OT1-1-07: Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory Research 2013, 73: ot1-1-07-ot1-1-07. [DOI: 10.1158/0008-5472.sabcs13-ot1-1-07](https://doi.org/10.1158/0008-5472.sabcs13-ot1-1-07). [Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC)](https://doi.org/10.1158/0008-5472.sabcs13-ot1-4-02)Matulonis U, Wulf G, Cantley L, Mills G, Lasonde B, Atkinson T, Whalen C, Isakoff S, Westin S, Bell-McGuinn K, Winer E. Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer ot1-4-02-ot1-4-02. trial evaluating survivorship care program for early stage breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot2-5-02)Ruddy K, Baker E, Guo H, Goldstein M, Winer E, Shulman L, Partridge A. Abstract OT2-5-02: Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer Cancer Research 2013, 73: ot2-5-02-ot2-5-02. trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot3-2-01)Yardley D, Awada A, Cortes J, Burris H, Peterson A, Bhattacharya S, Gianni L, Miller K, Winer E. Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified [Abstract OT3-2-05: fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-ot3-2-05)Lin N, Whitesell L, Gelman R, Mayer E, Krop I, Santagata S, Lowe A, Proia D, Farooq S, Brown M, Iannone M, Lindquist S, Winer E. Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast Cancer Research 2013, P2-18-02: Factors associated young women with breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-02)Rosenberg S, Sepucha K, Ruddy K, Tamimi R, Gelber S, Meyer M, Schapira L, Come S, Borges V, Winer E, Partridge A. Abstract P2-18-02: Factors associated with contralateral prophylactic mastectomy in young women with breast cancer 73: p2-18-02-p2-18-02. [DOI: 10.1158/0008-5472.sabcs13-p2-18-02](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-02). [Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-09)King T, Lyman J, Gonen M, Voci A, Boafo C, Hwang E, Rugo H, Alvarado M, Liu M, Boughey J, Jacobs L, Krontiras H, McGuire K, Storniolo A, Nanda R, Golshan M, C, Bijelic L, Meszoely I, Van Poznak C, Babiera G, Norton L, Morrow M, Winer E, Wolff A, Hudis C. Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer Cancer Research 2013, 73: p2-18-09-p2-18-09. [DOI: 10.1158/0008-5472.sabcs13-p2-18-09](https://doi.org/10.1158/0008-5472.sabcs13-p2-18-09). - Ruddy K, Tolaney Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Hudis C, Krop I, P3-08-05: Chemotherapy-related amenorrhea p3-08-05-p3-08-05. [DOI: 10.1158/0008-5472.sabcs13-p3-08-05](https://doi.org/10.1158/0008-5472.sabcs13-p3-08-05). [Abstract P4-18-01: Sharing clinical trial results with patient participants: A project of the Dana Farber/Harvard Cancer Center (DF/HCC) breast cancer research advocacy group](https://doi.org/10.1158/0008-5472.sabcs13-p4-18-01)Frank E, Price K, Colten M, Fax R, Levine M, Matyka C, Dowton A, Barry W, Winer E, Partridge A. Abstract P4-18-01: Sharing clinical trial results with patient participants: A project of the Dana Farber/Harvard Cancer Center (DF/HCC) breast cancer research advocacy group Cancer Research 2013, 73: p4-18-01-p4-18-01. [DOI: 10.1158/0008-5472.sabcs13-p4-18-01](https://doi.org/10.1158/0008-5472.sabcs13-p4-18-01). - Seah D, Scott S, Guo Najita J, Lederman R, Frank E, Sohl J, Kronwitz C, Stadler Z, Silverman S, Peppercorn J, Winer E, Come S, Lin N. Abstract P4-19-01: Attitudes of medical oncologists towards research biopsies Cancer Research 2013, 73: p4-19-01-p4-19-01. [DOI: 10.1158/0008-5472.sabcs13-p4-19-01](https://doi.org/10.1158/0008-5472.sabcs13-p4-19-01). [Abstract P6-11-09: Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-09)Meier C, Vaz-Luis I, Seah D, Macrae E, Burstein H, J, Arvold N, Winer E, Lin N. Abstract P6-11-09: Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease Cancer Research 2013, 73: p6-11-09-p6-11-09. [DOI: 10.1158/0008-5472.sabcs13-p6-11-09](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-09). [Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)](https://doi.org/10.1158/0008-5472.sabcs13-s1-04)Tolaney S, Barry W, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Partridge A, Guo H, Hudis C, Krop I, Burstein H, Winer E. Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer Research 2013, 73: s1-04-s1-04. 10.1158/0008-5472.sabcs13-s1-04](https://doi.org/10.1158/0008-5472.sabcs13-s1-04). [Abstract S5-01: Impact of (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response rates in triple-negative cancer (TNBC): CALGB 40603 (Alliance)](https://doi.org/10.1158/0008-5472.sabcs13-s5-01)Sikov Berry C, Tolaney S, Kuzma C, Pluard T, Somlo G, Port E, Golshan M, Bellon J, Collyar D, Hahn O, Carey L, Hudis C, Winer E. Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment](https://doi.org/10.1158/0008-5472.sabcs13-s5-07)Smerage J, Barlow W, Hayes D, Winer E, Leyland-Jones B, Srkalovic G, Tejwani S, Schott A, O'Rourke M, Lew D, J, Livingston R, Hortobagyi G. Abstract S5-07: SWOG S0500 - A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment Cancer SE, Meyer ME, Winer EP, Partridge AH. Breast cancer presentation and diagnostic delays in young women Cancer 2013, 120: 20-25. [PMID: 24347383](https://pubmed.ncbi.nlm.nih.gov/24347383), [DOI: 10.1002/cncr.28287](https://doi.org/10.1002/cncr.28287). with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/24197661)Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, MacDonald SM, Mahadevan A, Eisenberg E, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases Breast Cancer Research And Treatment P.G. et al, O. Kaidar-Person et al, and A. Courdi et al Journal Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU. Prospective clinical experience with research biopsies in breast cancer patients Breast Cancer Research And Treatment 2013, Tolaney SM, Winer EP, cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice Breast 2013, 141: 421-427. [PMID: prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.](http://www.ncbi.nlm.nih.gov/pubmed/24042365)Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Annals Of Internal Golshan M. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction Breast Cancer Research And Treatment 2013, 141: 255-259. [PMID: 24026859](https://pubmed.ncbi.nlm.nih.gov/24026859), [DOI: 10.1007/s10549-013-2682-z](https://doi.org/10.1007/s10549-013-2682-z). [Longer-term cardiac of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).](https://doi.org/10.1200/jco.2013.31.26_suppl.167)Iyengar N, Morris P, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 167-167. [DOI: 10.1200/jco.2013.31.26_suppl.167](https://doi.org/10.1200/jco.2013.31.26_suppl.167). and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/24037735)Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT. Longterm cardiac safety and outcomes of dosedense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast Cancer 2013, 119: 3943-3951. [PMID: 24037735](https://pubmed.ncbi.nlm.nih.gov/24037735), [DOI: 10.1002/cncr.28284](https://doi.org/10.1002/cncr.28284). [Personalizing the treatment of with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](http://www.ncbi.nlm.nih.gov/pubmed/23917950)Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart members H, Bretel-Morales H, Cardoso F, Castiglione-Gertsch M, Coates A, Colleoni M, Costa A, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Goss P, Harris J, Hayes D, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Loibl S, Morrow M, Namer M, Osborne A, Penault-Llorca F, Perou M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Th\u00fcrlimann B, Toi M, Tutt A, Untch M, Viale G, Watanabe T, Wilcken N, Winer E, Wood W. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Annals Of Advanced Human Epidermal Growth Factor-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study](http://www.ncbi.nlm.nih.gov/pubmed/23829891)Vaz-Luis I, Seah Wagle N, Metzger-Filho IE, Winer EP, Lin NU. Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor-2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study 23928759](https://pubmed.ncbi.nlm.nih.gov/23928759), with weekly paclitaxel in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23868188)Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, AL, Agarwal S, inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer Breast Cancer Research 140: 331-339. [PMID: 23868188](https://pubmed.ncbi.nlm.nih.gov/23868188), [DOI: (AZD2281) in combination with the anti-angiogenic C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer European Journal Of of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 of Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From E, Winer EP, Gelber RD. Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From a Herceptin Adjuvant Trial With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up Winer EP, Wood WC. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.](https://doi.org/10.1200/jco.2013.31.15_suppl.1007)Shulman L, Berry D, Cirrincione C, Becker H, Perez E, O'Regan R, Martino S, Shapiro C, Atkins J, Schneider C, Kimmick G, Burstein H, Norton L, Muss H, Hudis C, Winer E. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: Ligibel Ingle J, Gradishar W, Martino S, Sikov W, Michaelson R, Hudis C, Winer E, Barry W. Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts).](https://doi.org/10.1200/jco.2013.31.15_suppl.1065)Boucher Y, Martin J, Tolaney S, Ancukiewicz M, Seano G, Goel S, Yeh E, Meyer J, Isakoff S, Duda D, Winer E, Krop I, Jain R. Differential changes in tissue biomarkers after bevacizumab (BEV) alone in a neoadjuvant study of BEV and chemotherapy in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients (pts). Journal Of Clinical Oncology 2013, 31: 1065-1065. 10.1200/jco.2013.31.15_suppl.1065](https://doi.org/10.1200/jco.2013.31.15_suppl.1065). Tolaney Isakoff S, Krop I, Smith B, Jiang W, H, Brock J, Winer E, Golshan M. Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction. Journal Of Clinical Oncology 2013, 31: phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.500)Carey L, Berry D, Ollila D, Harris L, Krop I, Weckstein D, Henry N, Anders C, Cirrincione C, Winer E, Perou C, Hudis and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast 10.1200/jco.2013.31.15_suppl.500](https://doi.org/10.1200/jco.2013.31.15_suppl.500). rates: Surgical results from CALGB 40601 (Alliance).](https://doi.org/10.1200/jco.2013.31.15_suppl.501)Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).](https://doi.org/10.1200/jco.2013.31.15_suppl.513)Lin N, Gelman R, Younger W, Sohl J, Freedman R, Sorensen A, Bullitt E, Harris G, Morganstern D, Schneider B, Krop I, Winer E. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases 018: plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets).](https://doi.org/10.1200/jco.2013.31.15_suppl.515)Anders C, Deal A, Abramson V, Liu M, Storniolo A, Carpenter J, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin N, Marcom P, Van Poznak C, Stearns V, Melisko M, Smith J, Karginova O, Winer E, Perou C, Wolff A, Carey L. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases 10.1200/jco.2013.31.15_suppl.515](https://doi.org/10.1200/jco.2013.31.15_suppl.515). [Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.](https://doi.org/10.1200/jco.2013.31.15_suppl.529)Metzger Filho R, Regan M, Colleoni M, Ejlertsen B, Bonnefoi H, Forbes J, Neven P, Wardley A, Lang I, Smith I, Price K, Coates A, Goldhirsch A. Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. Journal Of Clinical Oncology 2013, 31: 529-529. [DOI: 10.1200/jco.2013.31.15_suppl.529](https://doi.org/10.1200/jco.2013.31.15_suppl.529). - Freedman R, Luis I, Lin N, Lii J, Winer E, Keating N. Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 616-616. [DOI: 10.1200/jco.2013.31.15_suppl.616](https://doi.org/10.1200/jco.2013.31.15_suppl.616). [Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).](https://doi.org/10.1200/jco.2013.31.15_suppl.630)Morris P, Iyengar N, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger K, Lin N, Moy B, Come S, Winer E, Norton L, Hudis C, Dang C. Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 630-630. [DOI: 10.1200/jco.2013.31.15_suppl.630](https://doi.org/10.1200/jco.2013.31.15_suppl.630). [Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.6507)Rosenberg S, Sepucha K, Ruddy K, Tamimi R, Gelber S, Meyer M, Schapira L, Come S, Borges V, Winer E, Partridge A. Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer. Journal Of Clinical Oncology 2013, 31: 6507-6507. [DOI: 10.1200/jco.2013.31.15_suppl.6507](https://doi.org/10.1200/jco.2013.31.15_suppl.6507). [Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance).](https://doi.org/10.1200/jco.2013.31.15_suppl.9581)Polite B, Allred E, Hudis C, Winer E. Differences in psychosocial factors among diverse women enrolled in a phase III cooperative group metastatic breast cancer trial (CALGB 40502/Alliance). Journal 31: 9581-9581. - Zeghibe C, Luis I, Frank E, Sohl J, Washington K, Silverman S, Fonte J, Mayer E, Overmoyer B, Richardson A, Krop I, Winer E, Lin N. Prospective clinical experience with research biopsies in breast cancer patients. Journal Of Clinical Oncology 2013, 31: e17574-e17574. [DOI: 10.1200/jco.2013.31.15_suppl.e17574](https://doi.org/10.1200/jco.2013.31.15_suppl.e17574). - Lin N, Gelman R, Brock J, Bardia A, Mayer E, Overmoyer B, Wang V, Iannone M, Krop I, Polyak K, Winer E. Phase II study of ruxolitinib in patients with pStat3+ breast cancer. Journal 2013, 31: 10.1200/jco.2013.31.15_suppl.tps1134](https://doi.org/10.1200/jco.2013.31.15_suppl.tps1134). [Human epidermal growth the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer David Muscato J, Rayson D, Houck W, Ellis C, DeSilvio M, Garofalo A, Levin J, Winer E. Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast Tamimi R, Schapira L, Come S, Meyer M, Larsen B, Winer E, Partridge A. Quality of life and psychosocial distress in young women with advanced breast cancer. Journal Of Clinical Oncology 2013, 31: e20508-e20508. [DOI: 10.1200/jco.2013.31.15_suppl.e20508](https://doi.org/10.1200/jco.2013.31.15_suppl.e20508). [Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907](http://www.ncbi.nlm.nih.gov/pubmed/23681403)Freedman RA, Pitcher B, Keating NL, Ballman HJ, HB, for the Alliance for Clinical Trials in Oncology. Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907 Breast Cancer Research And Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care?](http://www.ncbi.nlm.nih.gov/pubmed/23663229)Freedman RA, He Y, Winer EP, Keating NL. Racial/Ethnic Differences in Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care? Health Services and trastuzumab in HER2-positive metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23645007)Lin NU, Seah Gelman Desantis S, Mayer EL, Isakoff S, DiPiro P, Krop IE, Come SE, Weckstein D, Winer EP, Burstein HJ. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer Breast 403-410. [PMID: 23645007](https://pubmed.ncbi.nlm.nih.gov/23645007), [DOI: cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23601761)Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, Force E. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer phase II study bevacizumab (bev) followed with bev in HER2-negative operable breast cancer (BC)](https://doi.org/10.1158/1538-7445.am2013-lb-76)Boucher Y, Martin J, Tolaney S, Seano G, Goel M, R. Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study bevacizumab (bev) followed combination with bev in HER2-negative operable breast cancer (BC) Cancer Research 2013, 73: lb-76-lb-76. [DOI: 10.1158/1538-7445.am2013-lb-76](https://doi.org/10.1158/1538-7445.am2013-lb-76). [Abstract LB-81: A of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo](https://doi.org/10.1158/1538-7445.am2013-lb-81)Duda D, Tolaney S, Ancukiewicz M, Winer E, Krop I, Jain R. Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo Cancer Research 2013, 10.1158/1538-7445.am2013-lb-81](https://doi.org/10.1158/1538-7445.am2013-lb-81). - M, Winer EP, Bunnell C, study of ixabepilone and trastuzumab for metastatic HER2-positive Weeks JC, Winer EP, Partridge AH. LongTerm Risk Perceptions of Women With K, Frank E, Sohl ZK, Garrett M, Silverman SG, Peppercorn J, Winer EP, Come SE, Lin NU. Attitudes of patients with metastatic breast cancer toward research biopsies Annals Of CA, JM, Furi\u00f3 V, Garc\u00eda AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer Hudis C, Stijleman Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer Breast Cancer Research And factors, biology, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology BMJ Quality & Safety 2013, 22: 405. [PMID: 23349386](https://pubmed.ncbi.nlm.nih.gov/23349386), [DOI: 10.1136/bmjqs-2012-000948](https://doi.org/10.1136/bmjqs-2012-000948). [Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the Winer EP, Lin NU. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy](http://www.ncbi.nlm.nih.gov/pubmed/23204130)Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Shterev I, Kubo M, Zembutsu H, Y, Ratain MJ, Kroetz DL, B F, Cox NJ, Dolan ME. Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral EP, Partridge AH. Quality of life and symptoms in male breast cancer survivors The Breast 2013, (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)](https://doi.org/10.1158/0008-5472.sabcs12-ot1-1-07)Lin M, David A, Muscato J, Rayson D, Houck W, Ellis C, DeSilvio M, A, Nagarwala Y, Winer E. Abstract OT1-1-07: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases](https://doi.org/10.1158/0008-5472.sabcs12-ot1-1-11)Freedman R, Gelman R, Wefel J, Krop I, Melisko M, Ly A, Agar N, Connolly R, Blackwell K, Nabell L, Ingle J, Van Poznak C, Puhalla S, Niravath P, Ryabin N, Wolff A, Winer E, Lin N. Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Cancer Research 2012, agent BKM120 in patients with triple-negative metastatic breast cancer.](https://doi.org/10.1158/0008-5472.sabcs12-ot2-3-06)Saura Ciruelos A, J, Winer E, J. Abstract OT2-3-06: A phase II, non-randomized, multicenter, exploratory trial of single agent BKM120 in patients with triple-negative metastatic P2-10-01: PAM50 gene signature breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-01)Liu M, Pitcher B, Mardis E, Davies S, Snider J, Vickery T, Reed J, DeSchryver K, Singh B, Friedman P, Gradishar W, Perez E, Martino S, Citron M, Norton L, Winer E, Hudis C, Perou C, Ellis M, Barry W. Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Cancer Research 2012, 72: p2-10-01-p2-10-01. 10.1158/0008-5472.sabcs12-p2-10-01](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-01). Seah D, Scott T, Krag K, Frank E, Sohl J, Stadler Z, Garrett M, Winer E, Come S, Lin N. Abstract P2-16-04: Attitudes of metastatic breast cancer patients towards research biopsies Cancer Research 2012, 72: p2-16-04-p2-16-04. [DOI: 10.1158/0008-5472.sabcs12-p2-16-04](https://doi.org/10.1158/0008-5472.sabcs12-p2-16-04). - Desmedt C, Metzger Singhal S, Vincent D, Adnet P, Smeets D, Bertucci G, C. Abstract P3-05-03: Characterization of PIK3CA mutations in lobular P5-18-03: Clinicopathological features among breast cancer with prolonged response to trastuzumab based therapy](https://doi.org/10.1158/0008-5472.sabcs12-p5-18-03)Vaz-Luis I, Seah D, Olson E, Metzger J, Litsas G, Burstein I, Winer E, Lin N. Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy Cancer Research 2012, 72: p5-18-03-p5-18-03. [DOI: 10.1158/0008-5472.sabcs12-p5-18-03](https://doi.org/10.1158/0008-5472.sabcs12-p5-18-03). [Abstract P6-08-03: Informational needs and psychosocial assessment of patients in their first year after metastatic breast cancer diagnosis](https://doi.org/10.1158/0008-5472.sabcs12-p6-08-03)Seah D, Lin N, Curley C, Winer E, Partridge A. Abstract P6-08-03: Informational needs and psychosocial assessment of patients in their first year after metastatic breast cancer diagnosis Cancer Research 2012, 72: p6-08-03-p6-08-03. [DOI: 10.1158/0008-5472.sabcs12-p6-08-03](https://doi.org/10.1158/0008-5472.sabcs12-p6-08-03). [Abstract P6-08-05: Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907](https://doi.org/10.1158/0008-5472.sabcs12-p6-08-05)Freedman R, Pitcher B, Keating N, Barry W, Ballman K, Kornblith A, Mandelblatt J, Kimmick G, Hurria A, E, Hudis C, Cohen H, Muss H. Abstract P6-08-05: Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB V, Balko J, Isakoff S, Forero A, Kuba M, Sanders M, Li Y, Winer E, Arteaga C. Abstract P6-10-05: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer.](https://doi.org/10.1158/0008-5472.sabcs12-pd09-03)Isakoff S, Goss P, Mayer E, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Finkelstein D, Hartman A, Garber J, Ryan P, Winer E, Ellisen L. Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast pd09-03-pd09-03. [DOI: 10.1158/0008-5472.sabcs12-pd09-03](https://doi.org/10.1158/0008-5472.sabcs12-pd09-03). [Abstract PD10-04: Predictive adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study](https://doi.org/10.1158/0008-5472.sabcs12-pd10-04)Perez E, Eckel-Passow J, Ballman K, Anderson S, Thompson E, Asmann Y, Jen J, Dueck A, Lingle W, Sledge G, Winer E, Gralow J, Jenkins R, Reinholz M. Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 2012, pd10-04-pd10-04. [DOI: S1-1: Relative with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial.](https://doi.org/10.1158/0008-5472.sabcs12-s1-1)Metzger O, Giobbie-Hurder B, H, Coates A, Goldhirsch A, Gusterson B. Abstract S1-1: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 s1-1-s1-1. HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831](https://doi.org/10.1158/0008-5472.sabcs12-s5-5)Romond S, Davidson N, Mamounas E, Zujewski J, Wolmark N, Perez E. Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG Wolmark N, Albain K, Norton L, Winer E, Hudis C. Reply to S. Mahesh Journal Oncology 2012, 30: 4446-4446. Bunnell Kalfin M, Partridge A, Lane S, Burstein H, Fine B, Hilton N, Sullivan C, Colicchio L, Hagemeister E, Kelly A, Szabatura A, Winer E, Mann S, Weingart S. Implementation of team training in outpatient breast oncology. Journal Of Clinical Oncology 2012, 30: 83-83. [DOI: 10.1200/jco.2012.30.34_suppl.83](https://doi.org/10.1200/jco.2012.30.34_suppl.83). systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference](http://www.ncbi.nlm.nih.gov/pubmed/23143284)Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno A, Inamoto T. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference Breast Cancer Research And Treatment 2012, 136: 919-926. L, Winer EP, Partridge AH. Body image in recently diagnosed young women with early breast cancer Kereakoglow S, Borges S, Schapira L, Winer E, Partridge A. OR34 Sexual functioning in young women with breast cancer The Breast 2012, 21: s13. [DOI: 10.1016/s0960-9776(12)70046-2](https://doi.org/10.1016/s0960-9776(12)70046-2). - Warner ET, Tamimi RM, Partridge AH. Time to diagnosis and breast cancer stage by race/ethnicity Breast Cancer Research And survival and mediating effects of tumor characteristics, sociodemographic, and treatment factors.](https://doi.org/10.1158/1055-9965.disp12-pr06)Warner E, Tamimi R, Hughes M, Ottesen R, Wong Y, Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Partridge A. Abstract PR06: Racial/ethnic differences in breast cancer survival and mediating effects of tumor characteristics, sociodemographic, and treatment factors. Cancer Epidemiology Biomarkers & Prevention status define two distinct subtypes?](http://www.ncbi.nlm.nih.gov/pubmed/23022997)Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two 1 trial of vandetanib, a VEGFR R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative in K, Zembutsu H, C, Genome-Wide Association Study Identifies for Paclitaxel-Induced Sensory Peripheral Neuropathy in Fang G, Winer EP, Keating NL. Survival Implications Associated with Variation in Mastectomy Rates for Early-Staged Breast Cancer International Journal Of The natural history of 26: We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice?](http://www.ncbi.nlm.nih.gov/pubmed/22851555)Hudis CA, Citron ML, Muss H, Norton L, Winer EP. Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice? Journal Of health insurance reform on mammography use and breast cancer stage at diagnosis](http://www.ncbi.nlm.nih.gov/pubmed/22833148)Keating NL, Kouri EM, He Y, West DW, Winer EP. Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis Cancer 2012, 250-258. or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101](http://www.ncbi.nlm.nih.gov/pubmed/22826271)Shulman LN, Cirrincione Berry DA, Becker HP, Perez EA, Martino S, Atkins JN, Mayer E, G, Norton L, Muss H, Winer EP, Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101 Winer E, Partridge A. Psychosexual Functioning and Body Image Following a Diagnosis of Ductal Carcinoma In Situ The Journal Of Sexual Medicine 2012, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors Breast Cancer Research And oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)](http://www.ncbi.nlm.nih.gov/pubmed/22767584)Ruddy Pitcher CA, Muss HB, Partridge AH. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2012.30.18_suppl.cra1002)Rugo H, Barry W, Moreno-Aspitia A, Lyss A, Cirrincione C, Mayer E, Naughton M, Layman R, Carey L, Somer R, Perez E, Hudis C, Winer E. CALGB 40502/NCCTG N063H: Randomized phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22665533)Carey LA, Rugo HS, Rimawi MF, Ivanova A, Chiu WK, Ferraro M, 001: Study Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer Journal dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. American Society Of Clinical Oncology Educational Book 2012, 28-38. E, Piccart M. A Dickens Tale of the Treatment of Advanced Breast Cancer: The Past, the Present, and the Future American Society Of Clinical Oncology Educational Book 2012, 28-38. [DOI: 10.14694/edbook_am.2012.32.306](https://doi.org/10.14694/edbook_am.2012.32.306). [A Phase II Study of Trastuzumab Emtansine Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu Zheng M, Girish S, Amler L, Winer EP, Rugo HS. A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, Winer EP. Model Program to Improve Care for a Unique Cancer Population: Young Women With Breast Cancer Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines? Neville B, Partridge A, Cameron D, Winer E, Earle C. Reply to E. Warner Journal Of Clinical Oncology 2012, 30: 1893-1894. [DOI: 10.1200/jco.2012.42.1339](https://doi.org/10.1200/jco.2012.42.1339). - Balma\u00f1a J, Tung N, Isakoff S, Gra\u00f1a B, Ryan P, Rafi R, Tracy M, Winer E, Baselga J, Garber J. Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors. Journal Of Clinical Oncology 2012, 30: 1009-1009. combination with bev in HER2-negative operable breast cancer (BC).](https://doi.org/10.1200/jco.2012.30.15_suppl.1026)Tolaney S, Duda D, Boucher Y, Goel S, Martin J, Ancukiewicz M, Potler H, Incio D, Winer E, Krop I, phase study followed by in combination with bev in HER2-negative operable breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 1026-1026. [DOI: 10.1200/jco.2012.30.15_suppl.1026](https://doi.org/10.1200/jco.2012.30.15_suppl.1026). [Evaluation of gene expression RNA-seq single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast cancer.](https://doi.org/10.1200/jco.2012.30.15_suppl.10558)Galanina N, Sprecher E, Bossuyt V, Sarkar S, Krop I, Winer E, Tuck D, Bruce C, Harris L. Evaluation of gene expression by RNA-seq after single dose of trastuzumab (T) reveals predictors of pathologic complete response (pCR) in HER2-positive early breast Abramson V, Balko J, Isakoff S, Kuba M, Sanders M, Forero-Torres A, Yap J, Van Den Abbeele A, Li Y, Arteaga C, E. Results from a phase II randomized discontinuation trial (RDT).](https://doi.org/10.1200/jco.2012.30.15_suppl.535)Winer E, Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak C, Burris H, Ramies D, T, Shen X. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT). Journal Of Clinical Oncology 2012, 30: 535-535. [DOI: 10.1200/jco.2012.30.15_suppl.535](https://doi.org/10.1200/jco.2012.30.15_suppl.535). [Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC).](https://doi.org/10.1200/jco.2012.30.15_suppl.6015)Klepin H, Pitcher B, Ballman K, Kimmick G, Kornblith A, Cohen H, Hurria A, Winer E, Hudis C, Muss H. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 6015-6015. [DOI: 10.1200/jco.2012.30.15_suppl.6015](https://doi.org/10.1200/jco.2012.30.15_suppl.6015). [Use and duration of (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy (tx).](https://doi.org/10.1200/jco.2012.30.15_suppl.6089)Seah D, Luis I, Olson E, Sohl J, Litsas G, Winer E, Lin N, Burstein H. Use and duration of chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy Journal Tamimi Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Biomarkers of amenorrhea and ovarian function in breast cancer survivors. Journal Of Clinical Oncology 2012, 30: 9071-9071. [DOI: 10.1200/jco.2012.30.15_suppl.9071](https://doi.org/10.1200/jco.2012.30.15_suppl.9071). Partridge A, Tolaney S, Lin N, Winer E. Randomized trial of a physical activity intervention in patients with metastatic breast cancer. Journal Of Clinical Oncology 2012, 30: 9084-9084. 10.1200/jco.2012.30.15_suppl.9084](https://doi.org/10.1200/jco.2012.30.15_suppl.9084). Kereakoglow S, Borges V, Come S, Schapira L, Winer E, Partridge A. Sexual functioning in young women with breast cancer. Journal Of Clinical (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2012.30.15_suppl.cra1002)Rugo H, Barry W, Moreno-Aspitia A, Lyss A, Cirrincione C, Mayer E, Naughton M, Layman R, Carey L, Somer R, Perez E, Hudis C, Winer E. CALGB 40502/NCCTG N063H: Randomized phase III of paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Journal Of Clinical Oncology 2012, Bunnell Kalfin M, Partridge A, Lane S, Burstein H, Fine B, Hilton N, Sullivan C, Colicchio L, Hagemeister E, Kelly A, Szabatura A, Winer E, Mann S, Weingart S. Implementation of a team training program in the treatment of breast cancer patients. Journal Of Clinical Oncology carcinoma.](https://doi.org/10.1200/jco.2012.30.15_suppl.e21010)Metzger O, Michiels S, Singhal plasminogen gene (PLAU) to predict clinical outcome in invasive lobular carcinoma. Journal in HER2-positive metastatic breast cancer (LPT112515).](https://doi.org/10.1200/jco.2012.30.15_suppl.tps658)Lin M, David A, Muscato J, Rayson D, Houck W, Ellis C, DeSilvio A, Nagarwala Y, Winer E. HALT MBC: HER2 suppression the addition of lapatinib to trastuzumab in HER2-positive metastatic breast [DOI: 10.1200/jco.2012.30.15_suppl.tps658](https://doi.org/10.1200/jco.2012.30.15_suppl.tps658). - Partridge Tamimi RM. The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer The recurrence, and survival among women with triplenegative breast cancer in the National Comprehensive Cancer Network](http://www.ncbi.nlm.nih.gov/pubmed/22544643)Lin NU, Vanderplas A, Hughes ME, Theriault EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triplenegative breast cancer in the National Comprehensive Cancer Network line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci in paclitaxel-induced peripheral neuropathy](https://doi.org/10.1158/1538-7445.am2012-1881)Wheeler H, Gamazon E, Njiaju U, Wing C, Njoku C, Baldwin R, Owzar K, Winer E, Hudis C, Shulman L, Ratain M, Kroetz D, Cox N, Dolan M. Abstract 1881: Integration of cell line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci AH. Quality of Life in Long-Term Survivors of Metastatic Breast Cancer Clinical Breast Cancer 2012, 12: 119-126. [PMID: 22444718](https://pubmed.ncbi.nlm.nih.gov/22444718), [DOI: 10.1016/j.clbc.2012.01.010](https://doi.org/10.1016/j.clbc.2012.01.010). - Cardoso Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Leo Saghir Ganz Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1) The Breast 2012, 21: 242-252. [PMID: ErbB family blocker, in patients breast cancer progressing after trastuzumab](http://www.ncbi.nlm.nih.gov/pubmed/22418700)Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab Breast Cancer international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting](https://doi.org/10.1016/s0959-8049(12)70057-6)Cardoso F, Winer E, Norton L, Gomis R, Krop I, Harbeck N, Costa A. E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting European Journal Of Cancer 2012, 48: s13-s14. [DOI: 10.1016/s0959-8049(12)70057-6](https://doi.org/10.1016/s0959-8049(12)70057-6). [413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy-Results From CALGB/Intergroup 9741](https://doi.org/10.1016/s0959-8049(12)70479-3)Ligibel J, Cirrincione C, Citron Gradishar Martino S, Hudis C, Winer E, Berry D. 413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy-Results From CALGB/Intergroup 9741 Of Cancer 2012, [DOI: 10.1016/s0959-8049(12)70479-3](https://doi.org/10.1016/s0959-8049(12)70479-3). [The American Society of Clinical Oncology's for Transforming Clinical and Translational Cancer Research](http://www.ncbi.nlm.nih.gov/pubmed/22215747)Meropol NJ, Kris MG, Winer EP. The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research Journal Clinical Trastuzumab in HER2Positive Metastatic Breast Cancer (LPT112515).](https://doi.org/10.1158/0008-5472.sabcs11-ot1-02-02)Lin N, Danso M, David A, Muscato J, Ellis C, DeSilvio M, A, Nagarwala Y, Winer E. OT1-02-02: HALT HER2 Addition Lapatinib to Trastuzumab in HER2Positive Metastatic of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-ot3-02-04)Mayer E, Ligibel J, Burstein H, Peppercorn J, Miller K, Carey L, Dickler M, Mayer I, Forero A, Eng-Wong J, Pletcher P, Ryabin N, A, E. OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. Cancer Research 2011, 71: ot3-02-04-ot3-02-04. [DOI: 10.1158/0008-5472.sabcs11-ot3-02-04](https://doi.org/10.1158/0008-5472.sabcs11-ot3-02-04). [P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-p1-06-23)Sprecher E, Lezon-Geyda K, Sarkar Bossuyt V, Narayaan A, Krop I, Winer E, Tuck D, Kleinstein S, Harris L. P1-06-23: Changes in Gene Expression after One Dose of Trastuzumab (T) in HER2+ Breast Cancer Cell Lines Predict Novel Pathways of Response in HER2 Positive Early Stage Breast Cancer. Cancer Research 2011, 71: p1-06-23-p1-06-23. [DOI: 10.1158/0008-5472.sabcs11-p1-06-23](https://doi.org/10.1158/0008-5472.sabcs11-p1-06-23). [P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype.](https://doi.org/10.1158/0008-5472.sabcs11-p1-08-05)Partridge A, Hughes M, Ottesen R, Wong Y, Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Tamimi R. P1-08-05: Age and Survival in Women with Early Stage Breast Cancer: An Analysis Controlling for Tumor Subtype. Cancer Research 2011, 71: p1-08-05-p1-08-05. [DOI: 10.1158/0008-5472.sabcs11-p1-08-05](https://doi.org/10.1158/0008-5472.sabcs11-p1-08-05). [P1-17-02: A 1/2 Study (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen.](https://doi.org/10.1158/0008-5472.sabcs11-p1-17-02)Tolaney S, Burris H, Gartner E, Mayer I, Saura Maurer M, DeCillis A, Ruiz-Soto R, Lager J, Winer E, I. P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous 71: from a Phase 2 Randomized Discontinuation Trial.](https://doi.org/10.1158/0008-5472.sabcs11-p1-17-10)Tolaney S, Nechushtan H, Berger R, Kurzrock R, Ron I, Schoffski P, Awada A, Yasenchak C, Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Cancer Research 2011, 71: p1-17-10-p1-17-10. [DOI: 10.1158/0008-5472.sabcs11-p1-17-10](https://doi.org/10.1158/0008-5472.sabcs11-p1-17-10). Metabolic Response Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Mayer I, Hobday Falkson C, Dees E, Gelman R, Rimawi M, Nanda R, Berkowitz J, Franchetti Y, Wolff A, Winer E, Lin N, Van den Abbeele A. P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative 2011, 71: p2-09-07-p2-09-07. [DOI: 10.1158/0008-5472.sabcs11-p2-09-07](https://doi.org/10.1158/0008-5472.sabcs11-p2-09-07). [P2-17-06: Patterns of Bone Density Evaluation in a Community Population Treated with Aromatase Inhibitors.](https://doi.org/10.1158/0008-5472.sabcs11-p2-17-06)Ligibel J, O'Malley A, Fisher M, Daniel G, Winer E, Keating N. P2-17-06: Patterns of Bone Density Evaluation in a Community Population Treated with Aromatase Inhibitors. Cancer Research 2011, 71: p2-17-06-p2-17-06. [DOI: 10.1158/0008-5472.sabcs11-p2-17-06](https://doi.org/10.1158/0008-5472.sabcs11-p2-17-06). [P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA).](https://doi.org/10.1158/0008-5472.sabcs11-p2-18-02)Dang C, Tolaney S, Najita J, Gelman R, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff A, Carey L, Vahdat L, Burdette-Radoux S, Budd T, Krop I, Burstein H, Hudis C, Winer E. P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA). Cancer Research 2011, 71: p2-18-02-p2-18-02. 10.1158/0008-5472.sabcs11-p2-18-02](https://doi.org/10.1158/0008-5472.sabcs11-p2-18-02). S, Winer E, Partridge A, Mayer E. P2-19-02: Multidisciplinary Treatment of Cancer Research 2011, 71: p2-19-02-p2-19-02. [DOI: 10.1158/0008-5472.sabcs11-p2-19-02](https://doi.org/10.1158/0008-5472.sabcs11-p2-19-02). [P3-16-05: A Phase Inhibitor Veliparib (ABT888) S, Overmoyer B, Tung N, Gelman R, Habin K, Qian J, Giranda V, Shepherd S, Garber J, Ellisen L, Winer E, Goss P. P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in 2011, 71: p3-16-05-p3-16-05. 10.1158/0008-5472.sabcs11-p3-16-05](https://doi.org/10.1158/0008-5472.sabcs11-p3-16-05). [P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-10)Tracy M, Meyer M, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come S, Winer E, Partridge A. P4-11-10: Perceptions, Knowledge and Satisfaction with Contralateral Prophylactic Mastectomy among Young Women with Breast Cancer. Cancer Research 2011, 71: p4-11-10-p4-11-10. [DOI: 10.1158/0008-5472.sabcs11-p4-11-10](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-10). [P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy.](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-12)Collins L, Gelber S, Marotti J, Cole K, Kereakoglow S, Ruddy K, Brachtel E, Schapira L, Come S, Borges V, Schedin P, Warner E, Winer E, Partridge A. P4-11-12: Molecular Phenotype of Breast Cancers in a Large Cohort of Young Women According to Time Interval Since Pregnancy. Cancer Research 2011, 71: p4-11-12-p4-11-12. [DOI: 10.1158/0008-5472.sabcs11-p4-11-12](https://doi.org/10.1158/0008-5472.sabcs11-p4-11-12). E, Partridge A. P4-19-03: Physical and Psychological Sequelae of Breast Cancer in Men. Cancer Research 2011, 71: p4-19-03-p4-19-03. [DOI: 10.1158/0008-5472.sabcs11-p4-19-03](https://doi.org/10.1158/0008-5472.sabcs11-p4-19-03). [PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery.](https://doi.org/10.1158/0008-5472.sabcs11-pd04-05)Rosenberg S, Tamimi R, Gelber S, Kereakoglow S, Borges S, Schapira L, Winer E, Partridge A. PD04-05: Body Image Issues in Young Breast Cancer Patients: The Impact of Chemotherapy, Hormone Treatment, and Surgery. Cancer Research 2011, 71: pd04-05-pd04-05. [DOI: 10.1158/0008-5472.sabcs11-pd04-05](https://doi.org/10.1158/0008-5472.sabcs11-pd04-05). [PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-pd05-07)Olson E, Flores L, Najita J, Curley C, Jeong J, Murray K, Savoie J, Winer E, Krop I. PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. Cancer Research A and Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs11-pd09-04)Schoffski P, De Benedictis E, Gendreau S, Gianni L, Krop I, Levy G, Ware J, H, Winer E. PD09-04: A Phase Ib, Open-Label, Dose-Escalation Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer. Cancer Research 2011, 71: Kuba M, Sanders M, Yap J, Y, Winer E, - Winer PL1-1: How To Use Endocrine Therapy for Breast Cancer: Beyond the Basics. Cancer Research 2011, 71: pl1-1-pl1-1. [DOI: 10.1158/0008-5472.sabcs11-pl1-1](https://doi.org/10.1158/0008-5472.sabcs11-pl1-1). - Olson EM, Lin NU, Krop IE, Winer EP. Use of discard pleural fluid in molecular research Cameron DB, Winer EP, Earle CC. Breast Cancer Survivors' Perceptions of [Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/22080245)Collins LC, Marotti JD, AH. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer Breast Cancer Research And Treatment 2011, 131: 1061-1066. [PMID: 22080245](https://pubmed.ncbi.nlm.nih.gov/22080245), [DOI: Omitted in a Subset of Patients with Low Local and Regional Failure Rates?](http://www.ncbi.nlm.nih.gov/pubmed/22017599)Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates? The Breast Journal 2011, 18: - Lim E, Winer EP. Adjuvant chemotherapy in luminal breast cancers The 20: s128-s131. [PMID: 22015279](https://pubmed.ncbi.nlm.nih.gov/22015279), [DOI: 10.1016/s0960-9776(11)70309-5](https://doi.org/10.1016/s0960-9776(11)70309-5). - Winer E, Lin N. State of the Art Treatment of Triple Negative Breast Cancer The Breast 2011, 20: s16-s17. [DOI: 10.1016/j.breast.2011.08.016](https://doi.org/10.1016/j.breast.2011.08.016). [Breast Medical Oncologists' Use Predict a 21Gene Recurrence Score](http://www.ncbi.nlm.nih.gov/pubmed/21934103)Kamal AH, Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21Gene in a cohort of community-based breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/21881937)Ligibel JA, James O'Malley A, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients Breast Cancer Research And Treatment 2011, 131: 589-597. [PMID: 21881937](https://pubmed.ncbi.nlm.nih.gov/21881937), [DOI: 10.1007/s10549-011-1754-1](https://doi.org/10.1007/s10549-011-1754-1). [5025 of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) - Results of an Exploratory Analysis by Prior Therapy](https://doi.org/10.1016/s0959-8049(11)71467-8)O'Shauqhnessv J, Telli M, Swain S, Gralow J, Rugo H, Litton J, Charpentier E, Smith J, Blackwood-Chirchir A, Winer E. 5025 POSTER DISCUSSION Phase 3 Study of Iniparib (I) Plus Gemcitabine (G) and Carboplatin (C) in Metastatic Triple-negative Breast Cancer (mTNBC) - Results of an Exploratory Analysis by Prior Therapy European Journal Of Cancer 2011, 47: RS. Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer? International Journal Of Breast Krop IE, Winer EP. The ethical use of mandatory research biopsies Nature Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities](http://www.ncbi.nlm.nih.gov/pubmed/21810680)Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, Newman LA. American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities Journal Of Clinical Oncology 2011, 29: 3816-3824. to trastuzumab exposure in cell lines and early stage HER2+ breast tumors](https://doi.org/10.1145/2147805.2147867)Sprecher E, Sarkar S, Kleinstein S, Narayan M, Winer E, Tuck D, Lezon-Geyda K, Krop I, Harris L. Association between response to brief trastuzumab exposure in cell lines and early stage HER2+ breast tumors 2011, 446-450. [DOI: 10.1145/2147805.2147867](https://doi.org/10.1145/2147805.2147867). [p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)](http://www.ncbi.nlm.nih.gov/pubmed/21693655)Lara IC, Norton L, Hudis CA, Ellis MJ, Berry DA, Hayes DF, B F. p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) Clinical (RAD001) in Patients With HER2-Overexpressing Breast Cancer Who on Trastuzumab-Based Therapy](http://www.ncbi.nlm.nih.gov/pubmed/21730275)Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer Esteva FJ. I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy Goldhirsch A. CMF revisited 305-311. or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases](http://www.ncbi.nlm.nih.gov/pubmed/21706359)Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast ZK-EPO) in Patients With Breast Cancer and Brain Metastases](http://www.ncbi.nlm.nih.gov/pubmed/21697017)Freedman RA, Bullitt E, Sun L, Gelman R, Harris G, Ligibel JA, Krop IE, Partridge AH, Eisenberg E, Winer EP, Lin NU. A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and with metastatic breast cancer: combined analysis of CALGB 9342 and 9840](http://www.ncbi.nlm.nih.gov/pubmed/21693770)Lichtman Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H, B F. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB (G/C) (TNBC).](https://doi.org/10.1200/jco.2011.29.15_suppl.1007)O'Shaughnessy Danso M, Rugo H, Miller K, Yardley D, Carlson R, Finn R, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A, Winer E. A randomized phase III study of (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.](https://doi.org/10.1200/jco.2011.29.15_suppl.1025)Isakoff S, Goss P, Mayer E, Traina T, Carey L, Krag K, Rugo H, Liu M, Stearns V, Come S, Borger D, Quadrino C, Finkelstein D, Garber J, Ryan P, Winer E, Ellisen L. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal Of Clinical Oncology 2011, 29: 1025-1025. in combination with the in recurrent ovarian or triple-negative breast cancer.](https://doi.org/10.1200/jco.2011.29.15_suppl.5028)Liu J, Fleming G, Tolaney S, Birrer M, Penson R, Berlin S, Whalen C, Tyburski K, Matijevich K, Kasparian E, Roche M, Lee H, Winer E, Ivy S, Matulonis U. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast Oncology 2011, 29: 10.1200/jco.2011.29.15_suppl.5028](https://doi.org/10.1200/jco.2011.29.15_suppl.5028). of and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2011.29.15_suppl.527)Lin N, Mayer I, Najita T, Falkson C, Dees E, Rimawi M, Nanda R, Gelman R, Josephs K, Richardson A, Flores L, Van Den Abbeele A, Yap J, Arteaga C, Wolff A, Krop I, Winer E. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer Journal [DOI: 10.1200/jco.2011.29.15_suppl.527](https://doi.org/10.1200/jco.2011.29.15_suppl.527). Krop Mayer I, Hobday T, Falkson C, Arteaga C, Wolff A, Dees E, Rimawi M, Nanda R, Josephs K, Lin N, E. role of EGFR amplification in trastuzumab resistance: A correlative Tamimi Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Fertility concerns in young women with breast cancer: Results from a prospective cohort study. Journal Of Clinical Oncology 2011, 29: 6025-6025. [DOI: 10.1200/jco.2011.29.15_suppl.6025](https://doi.org/10.1200/jco.2011.29.15_suppl.6025). - Gropper A, Burstein H, Harris L, Anderson K, Gold J, Younger W, Bunnell C, Najita J, Winer E, Mayer E. Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. Oncology 2011, 29: e11074-e11074. 10.1200/jco.2011.29.15_suppl.e11074](https://doi.org/10.1200/jco.2011.29.15_suppl.e11074). [Predictors cancer (MBC) treated with trastuzumab.](https://doi.org/10.1200/jco.2011.29.15_suppl.e11100)Olson E, Najita Sohl J, Arnaout A, Winer E, Lin N. Predictors of survival in patients with HER2+ metastatic breast cancer (MBC) treated with 2011, 29: [DOI: in HER2-positive metastatic breast cancer (LPT112515).](https://doi.org/10.1200/jco.2011.29.15_suppl.tps113)Lin N, Danso M, David A, Muscato J, Ellis C, Lahiri S, Sessa T, Nagarwala Y, Winer E. HER2 suppression the addition of lapatinib to trastuzumab in HER2-positive metastatic breast 018: to treat triple-negative breast cancer (TNBC) brain metastases (BM).](https://doi.org/10.1200/jco.2011.29.15_suppl.tps127)Anders C, Nanda R, Liu M, Blackwell K, Van Poznak C, Abramson V, Storniolo A, Lin N, Stearns V, Melhem A, Puhalla S, Carpenter J, Melisko M, Deal A, Hudis C, Winer E, Perou C, Bradley C, Wolff A, Carey L. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain [Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib](http://www.ncbi.nlm.nih.gov/pubmed/21372222)Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler M, McArthur E, CA, Dang CT. Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib trastuzumab-DM1 in women with HER2-positive metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/21531783)Olson EP, Burstein to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast gene expression after one dose of trastuzumab (T) reveal novel biomarkers of response to combination therapy in HER2 positive early stage breast cancer](https://doi.org/10.1158/1538-7445.am2011-4719)Harris L, Sprecher E, Wei-Gu L, Lezon-Geyda K, Sakar S, Krop I, Winer E, Tuck D. Abstract 4719: Dynamic changes in gene expression after one dose of trastuzumab (T) reveal novel biomarkers of response to combination therapy in HER2 positive early stage breast cancer Cancer Research 2011, 71: 4719-4719. [DOI: 10.1158/1538-7445.am2011-4719](https://doi.org/10.1158/1538-7445.am2011-4719). [Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference](http://www.ncbi.nlm.nih.gov/pubmed/21431404)Toi M, Winer EP, Inamoto T, Benson JR, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference Annals Of 2011, 18: model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays](http://www.ncbi.nlm.nih.gov/pubmed/21398628)Li A, Liu Z, Lezon-Geyda D, Schulz V, Krop I, Winer E, Harris L, Tuck D. GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809](http://www.ncbi.nlm.nih.gov/pubmed/21324674)Shapiro C, Halabi S, Hars V, Archer C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809 European Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907](http://www.ncbi.nlm.nih.gov/pubmed/21300923)Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, Winer E, Casey R, Bennett S, Cohen HJ, Muss HB. Quality of Life of Older Patients With Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy: A Companion Study to Cancer and Leukemia Group B 49907 Journal Of Will preoperative trials change future clinical practice? Clinical Investigation 2011, 1: 59-73. [DOI: 10.4155/cli.10.3](https://doi.org/10.4155/cli.10.3). [Abstract P2-15-01: Long-Term Risk Perceptions and Quality of Life of Women with Ductal Carcinoma In Situ](https://doi.org/10.1158/0008-5472.sabcs10-p2-15-01)Ruddy K, Meyer M, Giobbie-Hurder A, Emmons K, Weeks J, Winer E, Partridge A. Abstract P2-15-01: Long-Term Risk Perceptions and Quality of Life of Women with Ductal Carcinoma In Situ Cancer Research 2010, for Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-13)Mayer E, Shak S, Miller K, Rugo H, Carey L, Ryabin N, Pomeroy C, Yoshizawa C, E, Burstein P3-10-13: Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Cancer Research 2010, 70: p3-10-13-p3-10-13. [DOI: 10.1158/0008-5472.sabcs10-p3-10-13](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-13). [Abstract P3-10-15: Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-15)Anderson J, Yoshizawa C, Winer E, Watson D, Millward C, Tan V, Shak S, Baehner F. Abstract P3-10-15: Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer Cancer Research 2010, 70: p3-10-15-p3-10-15. [DOI: 10.1158/0008-5472.sabcs10-p3-10-15](https://doi.org/10.1158/0008-5472.sabcs10-p3-10-15). [Abstract P3-14-08: Responses to Subsequent with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p3-14-08)Olson E, Lin DiPiro P, Krop I, Winer E, Burstein H. Abstract P3-14-08: Responses to Subsequent Anti-HER2 Therapy after Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast 70: p3-14-08-p3-14-08. [DOI: 10.1158/0008-5472.sabcs10-p3-14-08](https://doi.org/10.1158/0008-5472.sabcs10-p3-14-08). [Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial](https://doi.org/10.1158/0008-5472.sabcs10-p4-09-12)Partridge Winer E, Gelber R. Abstract P4-09-12: The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA 2010, 70: p4-09-12-p4-09-12. [DOI: 10.1158/0008-5472.sabcs10-p4-09-12](https://doi.org/10.1158/0008-5472.sabcs10-p4-09-12). [Abstract P5-10-12: Adherence, Persistence and Toxicity with Oral CMF in Older Women with Early Stage Breast Cancer in CALGB 49907 (Adherence Companion Study 60104)](https://doi.org/10.1158/0008-5472.sabcs10-p5-10-12)Ruddy K, Archer L, Cohen H, Winer E, Hudis C, Muss H, Partridge A. Abstract P5-10-12: Adherence, Persistence and Toxicity with Oral CMF in Older Women with Early Stage Breast Cancer in CALGB 49907 (Adherence Companion Study Combination with Advanced HER2-Positive Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p6-15-02)Krop I, Wolff A, Winer E, Miller K, Park B, Ware J, Holden S, Levy G, Derynck M, Storniolo A. Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study](https://doi.org/10.1158/0008-5472.sabcs10-pd05-01)Burstein H, Barry W, Cirrincione C, Chew H, Tolaney S, Lake D, Pluard T, Blackwell K, Winer E, Hudis C. Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase 10.1158/0008-5472.sabcs10-pd05-01](https://doi.org/10.1158/0008-5472.sabcs10-pd05-01). [Abstract PD07-08: Integrated to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-pd07-08)Harris L, Liu Z, Li A, Sprecher E, Sarkar S, Lezon-Geyda K, Krop I, Winer E, Tuck D. Abstract PD07-08: Integrated Genomic Analysis before and after Brief Exposure to Trastuzumab (T): The11q13 and 17q12 Amplicons Are Associated with Response to T+Chemotherapy in Early Stage HER2 Positive Breast Cancer Cancer Research 2010, 70: pd07-08-pd07-08. [DOI: 10.1158/0008-5472.sabcs10-pd07-08](https://doi.org/10.1158/0008-5472.sabcs10-pd07-08). - Ligibel J, O'Malley A, Fisher M, Daniel G, Winer E, Keating N. Abstract S2-6: Aromatase Inhibitors and Risk of Myocardial Infarction, Stroke Research 2010, 70: s2-6-s2-6. 10.1158/0008-5472.sabcs10-s2-6](https://doi.org/10.1158/0008-5472.sabcs10-s2-6). [Abstract S6-3: Four Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 \u2014 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy](https://doi.org/10.1158/0008-5472.sabcs10-s6-3)Shulman L, Cirrincione C, Berry D, Becker H, Perez E, O'Regan R, Martino S, Atkins J, Hudis C, Winer E. Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 \u2014 A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy Cancer Research 2010, 70: s6-3-s6-3. [DOI: 10.1158/0008-5472.sabcs10-s6-3](https://doi.org/10.1158/0008-5472.sabcs10-s6-3). [Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Time to Step Out of the Limelight](http://www.ncbi.nlm.nih.gov/pubmed/21149664)Lin NU, Winer EP. Chemotherapy Agents in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Time to Step Out of the Limelight Journal Of Clinical Oncology 2010, Carter WB, Edge SB, Erban JK, McCormick Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. Journal Of The National Comprehensive Network 2010, 8: 1182-207. [PMID: 20971842](https://pubmed.ncbi.nlm.nih.gov/20971842), [DOI: 10.6004/jnccn.2010.0087](https://doi.org/10.6004/jnccn.2010.0087). [The association of status, and socioeconomic factors with breast cancer care](http://www.ncbi.nlm.nih.gov/pubmed/20939011)Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care Cancer 2010, 117: 180-189. [PMID: 20939011](https://pubmed.ncbi.nlm.nih.gov/20939011), [DOI: 10.1002/cncr.25542](https://doi.org/10.1002/cncr.25542). - Golshan N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P. Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? Poly(ADP-Ribose) Polymerase Inhibition: \"Targeted\" Therapy Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes](http://www.ncbi.nlm.nih.gov/pubmed/20581724)Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes Menopause The Journal Of The North American Menopause Society 2010, 17: 908-916. [PMID: 20581724](https://pubmed.ncbi.nlm.nih.gov/20581724), EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review Progress In Cardiovascular Diseases 2010, 53: 94-104. [PMID: 20728696](https://pubmed.ncbi.nlm.nih.gov/20728696), [DOI: 10.1016/j.pcad.2010.05.006](https://doi.org/10.1016/j.pcad.2010.05.006). [Physical and Psychological Outcomes Among Women in a Telephone-Based Exercise Intervention During Adjuvant Therapy for Early Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20629579)Ligibel JA, Partridge A, Giobbie-Hurder A, Campbell N, Shockro L, Salinardi T, Winer EP. Physical and Psychological Outcomes Among Women in a Telephone-Based Exercise Intervention During Adjuvant Therapy for Early Stage Breast Cancer Journal Of Women's Health 2010, 19: 1553-1559. [PMID: 20629579](https://pubmed.ncbi.nlm.nih.gov/20629579), Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20625130)Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer Journal Women Receiving Adjuvant Tamoxifen for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20554945)Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett E, Kimmick Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N. Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer Journal Of The National Cancer Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians](http://www.ncbi.nlm.nih.gov/pubmed/20516438)Mandelblatt JS, Sheppard VB, Hurria A, Kimmick AM, Luta G, Tallarico M, Barry Hunegs L, Zon R, Naughton M, Winer E, Hudis C, Edge SB, Cohen HJ, Muss H. Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians Journal Of Clinical HER2-overexpressing breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.1014)Morrow P, Wulf G, Booser D, Moore J, Flores P, Krop I, Winer E, Hortobagyi G, Yu D, Esteva F. Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing Oncology 2010, 28: temozolomide for metastatic Tung N, Gelman R, Giranda V, Bernhard K, Habin K, Ellisen L, Winer E, Goss P. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for 1019-1019. [DOI: 10.1200/jco.2010.28.15_suppl.1019](https://doi.org/10.1200/jco.2010.28.15_suppl.1019). [Phase I study (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.1154)Lin N, Ramakrishna N, Younger W, Storniolo A, Come S, Gelman R, Eisenberg E, Winer E. Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. Journal Of Clinical Oncology 2010, 28: 1154-1154. [DOI: 10.1200/jco.2010.28.15_suppl.1154](https://doi.org/10.1200/jco.2010.28.15_suppl.1154). - Partridge A, Hughes Wong Edge S, Theriault R, Blayney D, Niland J, Winer E, Weeks J, Tamimi R. The effect of age on delay in diagnosis and stage of breast cancer. Journal Of Clinical Oncology 2010, 28: 1580-1580. [DOI: 10.1200/jco.2010.28.15_suppl.1580](https://doi.org/10.1200/jco.2010.28.15_suppl.1580). [Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.507)Hughes K, Schnaper L, Cirrincione C, Berry D, McCormick B, Muss H, Shank B, Hudis C, Winer E, Smith B. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. Journal Of Clinical Oncology 2010, 28: 507-507. [DOI: or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms.](https://doi.org/10.1200/jco.2010.28.15_suppl.549)Krop I, Flores L, Tuck D, Ryan P, Partridge A, Morganstern D, Najita J, lezon-Geyda K, Winer E, Harris L. Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. Journal Of Clinical Oncology 2010, 28: 549-549. [DOI: 10.1200/jco.2010.28.15_suppl.549](https://doi.org/10.1200/jco.2010.28.15_suppl.549). - Mayer E, Nohria A, Miller K, Rugo H, Carey L, Ryabin N, Gelman R, Winer E, Burstein H. Cardiovascular safety of adjuvant bevacizumab for breast cancer. Journal Of Clinical Oncology 2010, 28: 571-571. [DOI: 10.1200/jco.2010.28.15_suppl.571](https://doi.org/10.1200/jco.2010.28.15_suppl.571). [Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care?](https://doi.org/10.1200/jco.2010.28.15_suppl.574)Freedman R, Virgo K, He Y, Pavluck A, Winer E, Ward E, Keating N. Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care? Journal Of Clinical Oncology 2010, L, Come S, Meyer M, Winer E, Partridge A. Coping strategies in young women with breast cancer. Journal Of Clinical Oncology 2010, 28: of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.tps103)Mayer E, Ligibel J, Burstein H, Miller K, Carey L, Rugo H, Ryabin N, Gelman R, Winer E, Wolff A. TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. Journal Of Clinical Oncology 2010, 28: tps103-tps103. [DOI: 10.1200/jco.2010.28.15_suppl.tps103](https://doi.org/10.1200/jco.2010.28.15_suppl.tps103). [Randomized to neoadjuvant weekly paclitaxel and cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.tps110)Sikov W, Perou C, Golshan M, Collyar D, Berry D, Hahn O, Singh B, Hudis C, Winer E. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative 28: 10.1200/jco.2010.28.15_suppl.tps110](https://doi.org/10.1200/jco.2010.28.15_suppl.tps110). of and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2010.28.15_suppl.tps132)Lin N, Mayer I, Hobday C, Dees E, Nanda R, M, Wolff A, Winer E. TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer Trastuzumab and Lapatinib in HER2/neu-Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea](http://www.ncbi.nlm.nih.gov/pubmed/20479410)Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Doxorubicin Cyclophosphamide Paclitaxel With Trastuzumab and Lapatinib in HER2/neu-Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea Journal Of Clinical EP, Volya R. Outcomes following local therapy for early-stage breast cancer in non-trial populations Breast Cancer Research Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104](http://www.ncbi.nlm.nih.gov/pubmed/20368559)Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H. Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study Can Metastatic Breast Cancer Be Cured?](http://www.ncbi.nlm.nih.gov/pubmed/20220104)Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? Journal Of The EP, Ligibel J, Emmons KM. The role of socioeconomic status in adjustment after ductal carcinoma in situ Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, EP, Garber JE. Efficacy of Cisplatin on the Point-Counterpoint on Leonard Zwelling MD; Letters: \"Advances in Bone Biology Research Setting Stage for New Cancer Therapies\" (11/25/09 issue), by W. Reid Pitts, Jr., MD](https://doi.org/10.1097/01.cot.0000368015.24121.d3)Seidman A, Hudis C, Winer E, Zwelling L. Letters: Andrew Seidman, Clifford Hudis, and Eric Winer on the Point-Counterpoint on Leonard Zwelling MD; Letters: \"Advances in Bone Biology Research Setting Stage for New Cancer Therapies\" (11/25/09 issue), by W. Reid Pitts, Jr., MD Oncology 32: 3-4. [DOI: Freedman EP. Adjuvant therapy for postmenopausal women with endocrine-sensitive Sequential A, Cufer T, Albain K. Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy Journal Of National Institute 2010, 102: 207-208. [DOI: 10.1093/jnci/djp484](https://doi.org/10.1093/jnci/djp484). [Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-1067)Ruddy K, Gelber S, Tamimi R, Mayer E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer. Cancer Research 2009, 69: 1067-1067. [DOI: 10.1158/0008-5472.sabcs-09-1067](https://doi.org/10.1158/0008-5472.sabcs-09-1067). [Prediction of 10-Year Chemotherapy Benefit and Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer - An Update of SWOG-8814 (INT0100).](https://doi.org/10.1158/0008-5472.sabcs-09-112)Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, Bugarini R, Baehner F, Davidson N, Sledge G, Winer E, Hudis C, Ingle J, Perez E, Pritchard K, Shepherd L, Gralow J, Yoshizawa C, Allred D, Osborne C, Hayes D. Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer - An Update Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity.](https://doi.org/10.1158/0008-5472.sabcs-09-3088)Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Patil S, Winer E, Norton L, Hudis C, Dang C. Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis.](https://doi.org/10.1158/0008-5472.sabcs-09-4032)Harris L, Parker J, Broadwater G, Schulz V, Halligan K, Geyda K, Seidman A, Berry D, Winer E, Hudis C, Krasnitz A, Hicks J, Tuck D, Perou C. Genome-Wide Profiling of Archived Material from CALGB 9840 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. Cancer Research 2009, 69: 4032-4032. [DOI: 10.1158/0008-5472.sabcs-09-4032](https://doi.org/10.1158/0008-5472.sabcs-09-4032). - Golshan M, Garber J, Gelman R, Tung N, Smith B, Troyan S, Greenberg C, Winer E, Ryan P. Surgical Complications and the Use of Neoadjuvant Bevacizumab. Cancer Research 2009, 69: 43-43. [DOI: 10.1158/0008-5472.sabcs-09-43](https://doi.org/10.1158/0008-5472.sabcs-09-43). [Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907).](https://doi.org/10.1158/0008-5472.sabcs-09-5035)Kornblith A, Archer L, Lan L, Kimmick G, Partridge A, Casey R, Bennett S, Hudis C, Winer E, Cohen H, Muss H. Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907). Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.](https://doi.org/10.1158/0008-5472.sabcs-09-5060)Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E. Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. Cancer Research 2009, 69: 5060-5060. [DOI: 10.1158/0008-5472.sabcs-09-5060](https://doi.org/10.1158/0008-5472.sabcs-09-5060). [Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study.](https://doi.org/10.1158/0008-5472.sabcs-09-6007)Collins L, Collins L, Gelber S, Gelber S, Ruddy K, Ruddy K, Tamimi R, Tamimi R, Come S, Come S, Marotti J, Marotti J, Schapira L, Schapira A, Partridge A. Pathologic Features and Biomarker Expression among Young Women with Breast Cancer: Results from the Young Women's Breast Cancer Study. Cancer Research 2009, 69: 6007-6007. [DOI: 10.1158/0008-5472.sabcs-09-6007](https://doi.org/10.1158/0008-5472.sabcs-09-6007). [Benefits of Adding Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148).](https://doi.org/10.1158/0008-5472.sabcs-09-606)Berry Thor Jewell Broadwater G, Edgerton S, Hayes D, Hudis C, Winer E, Nielsen T, Ellis M. Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in and value of score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of trial](http://www.ncbi.nlm.nih.gov/pubmed/20005174)Albain KS, Barlow Shak Osborne CK, Hayes DF, America F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women Breast Cancer Research And Treatment 2009, 121: Mammography \u2014 More Agreement Than Disagreement New England Journal Of Medicine 2009, 361: With Frequent Short-Term Changes in Left Ventricular Ejection Fraction](http://www.ncbi.nlm.nih.gov/pubmed/19901120)Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction Journal Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology](http://www.ncbi.nlm.nih.gov/pubmed/19901123)Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith Obel J, Vogelzang N, R, D, Ganz PA, Kramer B. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology Journal Receptor 2-Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy](http://www.ncbi.nlm.nih.gov/pubmed/19884535)Burstein HJ, Winer EP. Refining Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: T Stands for Trastuzumab, Tumor Size, and Treatment Strategy Journal Of Clinical Oncology PL, Hayes DF, C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Archives Of Pathology & Laboratory Medicine 2009, 133: 1515-38. [PMID: 19792042](https://pubmed.ncbi.nlm.nih.gov/19792042), [DOI: 10.5858/133.10.1515](https://doi.org/10.5858/133.10.1515). - Lester S, Chen Y, Connolly J, de Baca M, Fitzgibbons P, Hayes D, Kleer C, O'Malley F, Page D, Smith B, Tan L, Weaver D, Winer E. Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast Archives Of Pathology & Laboratory Medicine 2009, 133: 1515-1538. [DOI: 10.5858/133.10.1515](https://doi.org/10.5858/133.10.1515). [International Guidelines International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy Journal Of biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib](https://doi.org/10.1016/s1359-6349(09)70926-7)Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Winer E, Norton L, Hudis C, Dang C. 5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib European Journal Of Cancer Supplements 2009, 7: 271. [DOI: 10.1016/s1359-6349(09)70926-7](https://doi.org/10.1016/s1359-6349(09)70926-7). - Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial Differences in Definitive Breast Cancer Therapy in Older Women Medical Care 2009, 47: 765-773. [PMID: 19536008](https://pubmed.ncbi.nlm.nih.gov/19536008), [DOI: 10.1097/mlr.0b013e31819e1fe7](https://doi.org/10.1097/mlr.0b013e31819e1fe7). - Winer E. Adjuvant [DOI: Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in of CALGB 8541/150013](http://www.ncbi.nlm.nih.gov/pubmed/19470942)Harris DA, Winer P, Ellis M, Dressler L. Topoisomerase II Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB patients with metastatic breast cancer after failure of treatment with trastuzumab](https://doi.org/10.1200/jco.2009.27.15_suppl.1023)Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer patients with metastatic breast cancer after failure of treatment with trastuzumab Of Clinical Oncology 2009, 27: 1023-1023. [DOI: and postmenopausal women with estrogen receptor (ER)+ advanced breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.1050)Come S, Parker L, Wulf G, Kuter I, Ryan P, Tkaczuk K, Borges V, Kasper H, Gelman R, Winer E. Tolerability and efficacy of 500 mg fulvestrant in postmenopausal women with estrogen receptor (ER)+ advanced breast Clinical Oncology 2009, 27: 1050-1050. [DOI: 10.1200/jco.2009.27.15_suppl.1050](https://doi.org/10.1200/jco.2009.27.15_suppl.1050). [Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)](https://doi.org/10.1200/jco.2009.27.15_suppl.543)Lin N, Vanderplas A, Hughes M, Theriault R, Edge S, Wong Y, Blayney D, Niland J, Winer E, Weeks J. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN) Journal Of Clinical Oncology 2009, 27: 543-543. [DOI: 10.1200/jco.2009.27.15_suppl.543](https://doi.org/10.1200/jco.2009.27.15_suppl.543). - Ryan P, Tung N, Isakoff S, Golshan M, Richardson A, Corben A, Smith B, Gelman R, Winer E, Garber J. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy Journal Of Clinical Oncology 2009, [DOI: 10.1200/jco.2009.27.15_suppl.551](https://doi.org/10.1200/jco.2009.27.15_suppl.551). [Personalizing treatment in early-stage cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making](https://doi.org/10.1200/jco.2009.27.15_suppl.572)Gold J, Najita J, Lester S, Richardson A, Morganstern D, Chen W, Partridge A, Krop I, Winer E, Burstein H. Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making Journal Of Clinical Oncology 2009, 27: 572-572. Come S, Kereakoglow S, Lin N, Winer E, Partridge A. Presentation of breast cancer in young women Journal Of Clinical Oncology 2009, 27: Partridge AH, LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer New England Journal Of strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors](http://www.ncbi.nlm.nih.gov/pubmed/19434504)Ligibel JA, Giobbie-Hurder D, Campbell N, Salinardi T, Winer EP, Mantzoros CS. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors Cancer Causes 2009, 20: 1523-1528. Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive 9: 101-107. [PMID: 19433391](https://pubmed.ncbi.nlm.nih.gov/19433391), [DOI: 10.3816/cbc.2009.n.019](https://doi.org/10.3816/cbc.2009.n.019). [Tolerability of therapy with gefitinib and capecitabine in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19294501)Mayer EL, Partridge AH, RS, Schumer ST, Burstein HJ, Winer EP. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer Breast Cancer of postmenopausal women with hormone responsive breast cancer The Breast 2009, 18: s16-s17. [DOI: 10.1016/s0960-9776(09)70047-5](https://doi.org/10.1016/s0960-9776(09)70047-5). [Multicenter Phase II Study of with Brain Metastases from HER2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/19228746)Lin N, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler H, Roche H, Liu M, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum J, Rubin S, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, P, Winer E. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer Cancer Research HJ, Carter WB, EC, Smith Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2009, 7: [PMID: Breast Abreu DA. A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Study Results With Trial Participants: Time for Action Journal Of activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer.](https://doi.org/10.1158/0008-5472.sabcs-1117)Ligibel J, Campbell N, Anita G, Shockro L, Salinardi T, Winer E. Impact of a home-based physical activity intervention upon exercise behaviors and anthropometric measures in women undergoing treatment for early stage breast cancer. Cancer Research 2009, 69: 1117. [DOI: 10.1158/0008-5472.sabcs-1117](https://doi.org/10.1158/0008-5472.sabcs-1117). [Dose-dense (DD) doxorubicin weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results.](https://doi.org/10.1158/0008-5472.sabcs-2108)Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D'Andrea A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robson M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schnipper L, Chen C, Winer E, Norton L, Hudis C. Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. Cancer Research 2009, 69: 2108. [DOI: 10.1158/0008-5472.sabcs-2108](https://doi.org/10.1158/0008-5472.sabcs-2108). Tolaney Fornier M, Krop I, Winer E, Bunnell C. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer [DOI: 10.1158/0008-5472.sabcs-3137](https://doi.org/10.1158/0008-5472.sabcs-3137). - Anderson K, Hodi F, Sasada T, Canning C, Hassett M, Mayer E, Hannagan K, Wong J, Colson Y, Shoji B, Najita J, Sibani S, LaBaer J, Winer E, Dranoff G. A phase I study of an autologous GM-CSF-secreting breast cancer vaccine. Cancer [Uniformly positive (>80%) HER2 expression for prediction of response to trastuzumab in CALGB 9840.](https://doi.org/10.1158/0008-5472.sabcs-6046)Rimm D, Broadwater G, Friedman P, Berry D, Seidman A, Hudis C, Winer E, Harris L, Thor A. Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. Cancer Research 2009, 69: 6046. - Rugo H, Carey L, Mayer E, Marcom P, Liu M, Ma C, Storniolo A, Forero A, Esteva F, Wolff A, Hobday T, Ferraro M, Davidson N, Winer E, Moore D, Scott J, Park J. Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. Cancer Research 2009, 69: 6048. [DOI: 10.1158/0008-5472.sabcs-6048](https://doi.org/10.1158/0008-5472.sabcs-6048). [Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age.](https://doi.org/10.1158/0008-5472.sabcs-6112)Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H. Paclitaxel in older women with breast cancer. Combined analysis of CALGB 9342 and 9840 with a focus on age. Cancer Research 2009, 69: 6112. [DOI: 10.1158/0008-5472.sabcs-6112](https://doi.org/10.1158/0008-5472.sabcs-6112). - Mayer E, Isakoff S, Hannagan Savoie J, Beckman J, Klement G, Gelman R, Winer E, Burstein H. A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. Cancer Research 2009, 69: 906. [DOI: 10.1158/0008-5472.sabcs-906](https://doi.org/10.1158/0008-5472.sabcs-906). - Ligibel JA, Golshan M, Emmons K, Winer EP. Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ Annals of specimens from patients with ductal carcinoma in situ of the breast.](http://www.ncbi.nlm.nih.gov/pubmed/19123730)Lester SC, Bose S, Chen YY, PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Archives Of Pathology & Laboratory Medicine 2009, 133: 15-25. [PMID: 19123730](https://pubmed.ncbi.nlm.nih.gov/19123730), [DOI: 10.5858/133.1.15](https://doi.org/10.5858/133.1.15). - Gold J, Winer Chemotherapy for Metastatic Breast Cancer 2009, 1233-1261. [DOI: 10.1016/b978-1-4160-5221-0.00076-0](https://doi.org/10.1016/b978-1-4160-5221-0.00076-0). - Lester S, Bose S, Chen Y, Connolly J, de Baca M, Fitzgibbons P, Hayes D, Kleer C, O'Malley F, Page D, Smith B, Weaver D, Winer E. Protocol for the Examination of Specimens From Patients With Ductal Carcinoma In Situ of the Breast Archives Of Pathology & Laboratory Medicine 2009, 133: 15-25. [DOI: 10.5858/133.1.15](https://doi.org/10.5858/133.1.15). [Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology](http://www.ncbi.nlm.nih.gov/pubmed/19103723)Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology Journal Winer EP, Keating NL. Trends in Racial and Age Disparities in Definitive Local Therapy of Early-Stage Breast Cancer Journal Of Clinical Oncology 2008, GW, Carey LA. Triple-Negative Breast Cancer: Risk Factors to Potential Targets Clinical Cancer Research 2008, 14: 8010-8018. [PMID: 19088017](https://pubmed.ncbi.nlm.nih.gov/19088017), [DOI: 10.1158/1078-0432.ccr-08-1208](https://doi.org/10.1158/1078-0432.ccr-08-1208). - Reducing Disparities in Breast Cancer Care\u2014A Daunting but Essential Responsibility Journal Of The National Cancer Institute 2008, 100: 1661-1663. [PMID: 19033563](https://pubmed.ncbi.nlm.nih.gov/19033563), [DOI: 10.1093/jnci/djn412](https://doi.org/10.1093/jnci/djn412). [VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/19047116)Burstein HJ, Chen YH, LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos LN, Harris LN, Gelman R, Winer EP. VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy Joffe S. Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy [DOI: 10.1200/jco.2008.18.1420](https://doi.org/10.1200/jco.2008.18.1420). - Clinical Oncology 2008, 26: 5138-5139. [DOI: 10.1200/jco.2008.19.0660](https://doi.org/10.1200/jco.2008.19.0660). [Sites of distant recurrence clinical outcomes in patients with metastatic triplenegative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/18833576)Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triplenegative breast Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling H, Weeks J. Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis Journal Of The National Cancer Institute 2008, 100: - Winer duration of adjuvant hormonal therapy for early-stage breast cancer. Clinical Advances In Hematology And Oncology 2008, 6: 573-4. [PMID: 18820598](https://pubmed.ncbi.nlm.nih.gov/18820598). [Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival](http://www.ncbi.nlm.nih.gov/pubmed/18581232)Bafford AC, Burstein HJ, Barkley JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival Breast Cancer Research And Treatment 2008, 115: 7-12. [PMID: Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants Breast Cancer Research And Treatment 2008, 115: 123-129. [PMID: 18543100](https://pubmed.ncbi.nlm.nih.gov/18543100), [DOI: Cancer: A Pooled Analysis of CALGB 9342 and and Leukemia Group B](http://www.ncbi.nlm.nih.gov/pubmed/18509177)Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840\u2014Cancer and Leukemia Group B of Physicians Who Care for Women with Ductal Carcinoma In Situ](http://www.ncbi.nlm.nih.gov/pubmed/18650159)Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E. Perceptions and Management Approaches of Physicians Who Care for Women with Ductal Carcinoma In Situ Clinical Breast Cancer Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Research And Treatment 2008, L, Abusief M, Meyer M, Winer E, Ginsburg E. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer Journal Of Clinical Oncology 2008, 26: 9571-9571. [DOI: 10.1200/jco.2008.26.15_suppl.9571](https://doi.org/10.1200/jco.2008.26.15_suppl.9571). - Freedman R, He Y, Winer E, Keating N. Racial disparity trends in definitive primary therapy of early stage breast cancer Journal Of Clinical Oncology 2008, 26: 535-535. [DOI: versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907](https://doi.org/10.1200/jco.2008.26.15_suppl.507)Muss H, Berry D, Cirrincione C, Theodoulou M, Mauer A, Cohen H, Partridge A, Norton L, Hudis C, Winer E. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907 mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980](https://doi.org/10.1200/jco.2008.26.15_suppl.512)Shapiro C, Halabi S, Gibson G, Weckstein R, Paskett E. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980 cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)](https://doi.org/10.1200/jco.2008.26.15_suppl.518)Dang C, Lin N, Lake D, Dickler M, Modi S, Seidman A, Steingart R, Norton L, Winer E, Hudis C. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast [DOI: 10.1200/jco.2008.26.15_suppl.518](https://doi.org/10.1200/jco.2008.26.15_suppl.518). pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.519)Mayer E, Miller K, Rugo H, Peppercorn J, Carey L, Ryabin N, Josephs K, Winer E, Burstein H. A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer Journal Of Clinical Oncology 2008, 26: 519-519. [DOI: 10.1200/jco.2008.26.15_suppl.519](https://doi.org/10.1200/jco.2008.26.15_suppl.519). [CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907](https://doi.org/10.1200/jco.2008.26.15_suppl.6542)Partridge A, Archer L, Kornblith A, Gralow J, Grenier D, Perez E, Wolff A, Hudis C, Winer E, Muss H. CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907 Journal of HER2-directed therapy: still questions after all these years Breast Cancer Research And Treatment 2008, 113: 207-209. [PMID: 18463974](https://pubmed.ncbi.nlm.nih.gov/18463974), [DOI: Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A RS, HJ, Winer EP, Weeks JC. Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis Journal Of The National Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18421051)Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, EP. Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Journal Prospective Keshaviah A, Silver B, Harris JR. Tangential Radiotherapy Without Axillary Surgery in Early-Stage Breast Cancer: Results of a Prospective Trial International Journal Of Radiation Oncology Biology Physics 2008, 72: 866-870. [PMID: 18394815](https://pubmed.ncbi.nlm.nih.gov/18394815), [DOI: With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840](http://www.ncbi.nlm.nih.gov/pubmed/18375893)Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake P, Norton L, Winer E, Hudis C. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840 Journal Of Clinical Force O. Metastatic Breast Cancer Session European Journal Of Cancer Supplements 2008, 6: 26. [DOI: 10.1016/s1359-6349(08)70304-5](https://doi.org/10.1016/s1359-6349(08)70304-5). [Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time](http://www.ncbi.nlm.nih.gov/pubmed/18332468)Lin NU, Winer EP. Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time Journal Of Clinical Oncology 2008, 26: 1919-1921. [PMID: quality of life in longterm breast cancer survivors: CALGB AB, Habin KR, Fleming GF, Bittoni MA. Applying a conceptual model for examining healthrelated quality of life in longterm breast MC, Winer EP, Earle CC. Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data Value mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)](http://www.ncbi.nlm.nih.gov/pubmed/18306034)Kimmick G, Cirrincione C, Duggan D, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson I, Hudis C, Winer E, On Behalf of the Cancer and Leukemia Group B. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) Breast Cancer Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors](http://www.ncbi.nlm.nih.gov/pubmed/18281663)Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP. Impact of a Mixed Strength and Endurance Exercise Intervention on Insulin Levels in Breast Cancer Survivors Journal Of Clinical Oncology 2008, women with ductal carcinoma in situ: longitudinal results from a cohort study.](http://www.ncbi.nlm.nih.gov/pubmed/18270338)Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. Journal Of The National Cancer Institute 2008, 100: 243-51. [PMID: 18270338](https://pubmed.ncbi.nlm.nih.gov/18270338), [DOI: 10.1093/jnci/djn010](https://doi.org/10.1093/jnci/djn010). [Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions](http://www.ncbi.nlm.nih.gov/pubmed/18258975)Gralow JR, Zujewski JA, Winer E. Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions Journal Of Clinical Oncology 2008, 26: in Adjuvant Endocrine Therapy for Postmenopausal Pathologic Assessment and Systemic Therapy Issues in Operable Disease](http://www.ncbi.nlm.nih.gov/pubmed/18258991)Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni Minckwitz WF, Singh EP. Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease Journal Of Clinical Oncology 2008, 26: Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial](http://www.ncbi.nlm.nih.gov/pubmed/18250349)Perez EA, Suman Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial Journal Of breast cancer: Summary statement for the Sixth Cambridge Conference](http://www.ncbi.nlm.nih.gov/pubmed/18072254)Come SE, Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference Cancer 2008, inhibitor clinical trials in postmenopausal women with early 2008, E, Sampson E, Rosenberg R, Przypyszny M, Winer EP. Fertility and Menopausal Outcomes in Young Breast Cancer Survivors Clinical Breast Cancer 2008, 8: 65-69. [PMID: and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients plus cyclophosphamide followed paclitaxel](http://www.ncbi.nlm.nih.gov/pubmed/18234424)Liu MC, Demetri DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA, B F. Dose-escalation of does improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer Journal Oncology Winer EP. NCCN Task Force Report: breast cancer in the older woman. Journal Of The National Comprehensive Cancer Network 2008, 6 Suppl 4: s1-25; Advances Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology](http://www.ncbi.nlm.nih.gov/pubmed/18086794)Gralow Mayer RJ, RL, Lichter AS. Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening\u2014A Report From the American Society of Clinical Oncology Journal Clinical EP. Heterogeneity of breast cancer and implications of adjuvant Cancer 2007, 15: 31-34. [PMID: 18224391](https://pubmed.ncbi.nlm.nih.gov/18224391), [DOI: 10.1007/s12282-007-0007-y](https://doi.org/10.1007/s12282-007-0007-y). [Does MRI predict women with breast cancer undergoing preoperative chemotherapy?](http://www.ncbi.nlm.nih.gov/pubmed/17640031)Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? Journal Angiography during Treatment of Brain Metastases: A Feasibility Study1](http://www.ncbi.nlm.nih.gov/pubmed/17954616)Bullitt E, Lin NU, Smith JK, Zeng D, Winer EP, Carey LA, Lin W, Ewend MG. Blood Vessel Morphologic Changes Depicted with MR Angiography during Treatment of Brain Rosenberg E, Cort A, Ebeling S, Peters C, Winer E, Harris J, Smith B, D'Alessandro H, Brachtel E. Case 32-2007 \u2014 A 62-Year-Old Woman with a Second Breast Cancer New England Journal Of Medicine 2007, 357: 1640-1648. [PMID: 17942877](https://pubmed.ncbi.nlm.nih.gov/17942877), [DOI: 10.1056/nejmcpc079026](https://doi.org/10.1056/nejmcpc079026). [Care in the Months before Death and Hospice Enrollment Among Older Women with Advanced Breast MB, Guadagnoli E, Winer EP, in the Months before Death and Hospice Enrollment Among Older Women with Advanced Breast Cancer Journal Of General Internal Medicine 2007, 23: Edgerton S, Broadwater G, Goldstein LJ, Martino JN, Hudis CA, Ellis MJ, Berry DA. HER2 and Response to Paclitaxel in Node-Positive Breast Cancer New England Journal Of 357: 1496-1506. [PMID: 17928597](https://pubmed.ncbi.nlm.nih.gov/17928597), [DOI: 10.1056/nejmoa071167](https://doi.org/10.1056/nejmoa071167). - Kornblith Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Longterm psychosocial adjustment of older vs younger survivors of breast cancer Winer EP. Sarcoidosis Extent Should Estrogen Receptor Status Influence the Decision to Recommend Adjuvant Chemotherapy?](https://doi.org/10.1016/s1043-321x(07)80290-6)Lin N, Winer E. Anatomy Versus Biology: To What Extent Should Estrogen Receptor Status Influence the Decision to Recommend Adjuvant Chemotherapy? Breast Diseases A Year Book Quarterly 2007, 18: 232-234. [DOI: 10.1016/s1043-321x(07)80290-6](https://doi.org/10.1016/s1043-321x(07)80290-6). [Erratum: Longterm psychosocial adjustment younger survivors of breast and endometrial cancer](https://doi.org/10.1002/pon.1220)Kornblith A, Powell M, Regan M, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E. Erratum: Longterm psychosocial adjustment of older vs younger survivors of endometrial cancer Psycho-Oncology or Baron R, Inhibitors and Arthralgias: New Frontier in Symptom Management for Breast Cancer Survivors](http://www.ncbi.nlm.nih.gov/pubmed/17761968)Burstein HJ, Winer EP. Aromatase Inhibitors and Arthralgias: A New Frontier in Symptom Management for Breast Cancer Survivors Journal Of Clinical Oncology 2007, 25: to after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17888101)Thompson D, Taylor Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer 367-376. Neoadjuvant antiHER2 therapy European Journal Of Cancer Supplements 2007, 5: 25. [DOI: 10.1016/s1359-6349(07)70201-x](https://doi.org/10.1016/s1359-6349(07)70201-x). [Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience](http://www.ncbi.nlm.nih.gov/pubmed/17704418)Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience Journal Of Clinical Oncology with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ HER2- metastatic breast cancer (MBC)](https://doi.org/10.1200/jco.2007.25.18_suppl.1009)Kaufman P, Broadwater G, Lezon-Geyda K, Dressler L, Berry D, Friedman P, Winer E, Hudis C, Ellis M, Seidman A, Harris L. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer [DOI: 10.1200/jco.2007.25.18_suppl.1009](https://doi.org/10.1200/jco.2007.25.18_suppl.1009). a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT)](https://doi.org/10.1200/jco.2007.25.18_suppl.1012)Lin N, Dieras V, Paul H, Zembryki D, Oliva C, Winer E. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT) Journal Of Clinical Oncology 2007, 25: 1012-1012. [DOI: 10.1200/jco.2007.25.18_suppl.1012](https://doi.org/10.1200/jco.2007.25.18_suppl.1012). - Shin J, Gelber Garber J, Rosenberg R, Przypyszny M, Winer E, Partridge A. Genetic testing in young women with breast cancer: Results from a web-based survey Journal Of Clinical 25: 21093-21093. [Could inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis](https://doi.org/10.1200/jco.2007.25.18_suppl.502)Punglia R, Winer E, Weeks J, Burstein H. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis Journal Clinical Oncology 2007, 25: 502-502. [DOI: 10.1200/jco.2007.25.18_suppl.502](https://doi.org/10.1200/jco.2007.25.18_suppl.502). - Ligibel J, Campbell Chen Salinardi T, Chen W, Partridge A, Mantzoros C, Winer E. Impact of physical activity on insulin levels in breast cancer survivors Journal Of Clinical Oncology 2007, 25: 555-555. [DOI: 10.1200/jco.2007.25.18_suppl.555](https://doi.org/10.1200/jco.2007.25.18_suppl.555). - Mayer E, Miller Rugo Peppercorn J, Carey L, Ryabin N, Winer E, Burstein H. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer Journal Of Clinical Oncology 2007, 25: 561-561. [DOI: 10.1200/jco.2007.25.18_suppl.561](https://doi.org/10.1200/jco.2007.25.18_suppl.561). - Kamal A, Loprinzi C, Reynolds C, Dueck A, Geiger X, Ingle J, Carlson R, Hobday T, Winer E, Perez E, Goetz M. How well do standard prognostic criteria predict oncotype DX (ODX) cancer: A feasibility study](https://doi.org/10.1200/jco.2007.25.18_suppl.594)Burstein H, Mayer E, Peppercorn J, Parker L, Hannagan K, Moy B, Younger J, Schapira L, E. Dose-dense albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study Journal Of Clinical Oncology 2007, [DOI: Aromatase Inhibitors: To Lead Winer EP, Harris JR. Local Therapy and Survival in Breast Cancer New England Journal Of Medicine 2007, 356: 2399-2405. [PMID: 17554121](https://pubmed.ncbi.nlm.nih.gov/17554121), [DOI: 10.1056/nejmra065241](https://doi.org/10.1056/nejmra065241). [Age of menopause among who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI](http://www.ncbi.nlm.nih.gov/pubmed/17512721)Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI European Journal Of Cancer 2007, 43: 1646-1653. JZ. Surveillance Testing Among Survivors of Early-Stage Clinical Oncology 2007, second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions](http://www.ncbi.nlm.nih.gov/pubmed/17345004)Lin NU, Parker LM, Come SE, Burstein HJ, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions 369-375. 10.1007/s10637-007-9034-y](https://doi.org/10.1007/s10637-007-9034-y). - EC, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. Journal Of The National Comprehensive Cancer Network 2007, 5: 246-312. [PMID: 17439758](https://pubmed.ncbi.nlm.nih.gov/17439758), [DOI: 10.6004/jnccn.2007.0025](https://doi.org/10.6004/jnccn.2007.0025). [Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations](http://www.ncbi.nlm.nih.gov/pubmed/17570804)Wray RJ, Stryker JE, Winer E, Demetri G, Emmons KM. Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations Journal Of Cancer Education 2007, 22: 21. [PMID: 17570804](https://pubmed.ncbi.nlm.nih.gov/17570804), [DOI: 10.1007/bf03174370](https://doi.org/10.1007/bf03174370). - Winer S15 Role of baseline staging and follow-up: between reassurance and economic constraints The Breast 2007, 16: s4. [DOI: 10.1016/s0960-9776(07)70038-3](https://doi.org/10.1016/s0960-9776(07)70038-3). - Peppercorn J, Blood E, Winer E, Partridge A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials Cancer 2007, 109: 1239-1246. Witkiewicz Lu Ryan PD, SE, Burstein HJ, Lesnikoski Vinorelbine for HER2-Positive Early Breast 1198-1207. [PMID: 17317830](https://pubmed.ncbi.nlm.nih.gov/17317830), [DOI: 10.1158/1078-0432.ccr-06-1304](https://doi.org/10.1158/1078-0432.ccr-06-1304). - Winer E. Adjuvant women Breast Cancer Research 2007, 9: s17. [DOI: 10.1186/bcr1700](https://doi.org/10.1186/bcr1700). Ponte PR, Gross Connaughton MJ, Hassinger J. Implementing an interdisciplinary governance model in a comprehensive cancer center. Oncology Nursing 2007, 34: 611-6. [PMID: 17573318](https://pubmed.ncbi.nlm.nih.gov/17573318), Vredenburgh J, Winer E, Hortobagyi G, Muss H, Sartor C, Rubin E, Hall R, Holland R, Cocquyt V, Rosti G, Fiorentini G, Blondeel P, Avisar E, Doraiswamy P, Hurley J, Abernethy A, Crews J, Jorda M, Velasquez M, Yepes M, Angulo A, Bennett C, Takita C, Kharfan-Dabaja M, Morgensztern D, Heros D, Roman E, Negret L, Lopes G, Rosado M, Fein S, De Cesare T, Abdullah S, Ayala E, Sanchez O, Silva C, Gonzalez E, Brenner J, Silva J, Caldera H, Padmanabhan, Moreno S, Ceballos - Mayer E, Winer E. Aromatase Inhibitors for Breast Cancer Treatment and Prevention 2007, 159-174. [DOI: 10.3109/9781420019940.014](https://doi.org/10.3109/9781420019940.014). [Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342](http://www.ncbi.nlm.nih.gov/pubmed/17129383)Harris LN, Broadwater G, Lin Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing M, Winer E, Partridge A. Menopausal-type symptoms in young breast cancer 17: 1777-1782. [PMID: 16971671](https://pubmed.ncbi.nlm.nih.gov/16971671), [DOI: 10.1093/annonc/mdl299](https://doi.org/10.1093/annonc/mdl299). [Estrogen-Receptor Chemotherapy for Patients With Node-Positive Breast Cancer](https://doi.org/10.1097/01.ogx.0000234789.05150.7c)Berry D, Cirrincione C, Henderson I, Citron M, Budman D, Goldstein L, Martino S, Perez E, Muss H, Norton L, Hudis C, Winer E. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer Obstetrical effect of paclitaxel, dose density and trastuzumab](https://doi.org/10.1016/j.fertnstert.2006.07.514)Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. P-166 Chemotherapy-related amenorrhea in premenopausal women with breast cancer: The effect of paclitaxel, dose density and trastuzumab Fertility And Sterility [DOI: cancer: NCCN Task Force report and recommendations. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl The effect of paclitaxel or dose density](https://doi.org/10.1200/jco.2006.24.18_suppl.10506)Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density Journal Of Clinical Oncology 2006, breast cancer (MBC): A phase I trial](https://doi.org/10.1200/jco.2006.24.18_suppl.10564)Mayer E, Harris L, Partridge A, Gelman R, Schumer S, Comanaru R, Long M, Sampson E, Burstein H, Winer E. Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial Of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors](https://doi.org/10.1200/jco.2006.24.18_suppl.10574)Krop I, Kosh M, Fearen I, Savoie J, Dallob A, Matthews C, Stone J, Winer E, Freedman S, Lorusso P. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors Journal Of Clinical Oncology 2006, 24: 10574-10574. [DOI: 10.1200/jco.2006.24.18_suppl.10574](https://doi.org/10.1200/jco.2006.24.18_suppl.10574). [Superiority of measuring response of metastatic brain tumors](https://doi.org/10.1200/jco.2006.24.18_suppl.1542)Kilpatrick M, Linn N, Smith J, Winer E, Bullitt E, Carey L, Ewend M. Superiority of bi-dimensional measurements compared to RECIST in measuring response of metastatic brain tumors Journal Of Clinical Oncology 2006, 24: 1542-1542. [DOI: 10.1200/jco.2006.24.18_suppl.1542](https://doi.org/10.1200/jco.2006.24.18_suppl.1542). - Lin N, Carey L, Liu M, Younger J, Come S, Bullitt E, Van Den Abbeele A, Li X, Hochberg F, Winer E. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer Journal Of Clinical Oncology 2006, 24: 503-503. [DOI: 10.1200/jco.2006.24.18_suppl.503](https://doi.org/10.1200/jco.2006.24.18_suppl.503). - Partridge A, Wolff A, Marcom P, Kaufman P, Moore C, Lake D, Fleming G, Rugo H, Collyar D, Winer E. Study participants' perceptions of the process and impact of receiving results of N9831 Journal Of Clinical Oncology 2006, 24: 518-518. [DOI: 10.1200/jco.2006.24.18_suppl.518](https://doi.org/10.1200/jco.2006.24.18_suppl.518). [Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience](https://doi.org/10.1200/jco.2006.24.18_suppl.559)Muss H, Berry D, Cirrincione C, Budman D, Henderson I, Citron M, Norton L, Winer E, Hudis C. Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The 2006, 24: 559-559. [DOI: 10.1200/jco.2006.24.18_suppl.559](https://doi.org/10.1200/jco.2006.24.18_suppl.559). [The impact of an exercise intervention on body composition, fat distribution, and weight in breast cancer survivors](https://doi.org/10.1200/jco.2006.24.18_suppl.590)Ligibel J, Chen W, Keshaviah A, Adloff K, Partridge A, Salinardi T, Winer E. The impact of an exercise intervention on body composition, fat distribution, and weight in breast cancer survivors Journal Of Clinical Oncology 2006, 24: 590-590. Burstein H, Winer E. Use of experimental therapy outside of clinical trials among U.S. oncologists Journal Of Clinical Oncology The study](https://doi.org/10.1200/jco.2006.24.18_suppl.650)Burstein Keshaviah A, Baron A, Hart R, Lambert-Falls R, Marcom P, Gelman R, Winer E. Trastuzumab chemotherapy for HER2+ breast 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer](https://doi.org/10.1200/jco.2006.24.18_suppl.674)Naughton M, Gu L, Wang X, Seidman A, Winer E, Kornblith A. Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast 674-674. [DOI: 10.1200/jco.2006.24.18_suppl.674](https://doi.org/10.1200/jco.2006.24.18_suppl.674). [The impact of tumor receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with earlystage RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806](http://www.ncbi.nlm.nih.gov/pubmed/16773437)Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H, for the Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 Breast Cancer Research And Treatment 2006, and Leukemia Group B Breast Committee: Decades of Progress and Plans for the Future Clinical Cancer Research 2006, 12: 3576s-3580s. [PMID: 16740788](https://pubmed.ncbi.nlm.nih.gov/16740788), [DOI: 10.1158/1078-0432.ccr-06-9016](https://doi.org/10.1158/1078-0432.ccr-06-9016). [Inadvertent Use of Aromatase in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons](http://www.ncbi.nlm.nih.gov/pubmed/16800976)Burstein H, Mayer E, Partridge A, O'Kane H, Litsas G, Come S, Hudis C, Goldstein D, Muss H, Winer E, Garber J. Inadvertent Use of Aromatase Inhibitors in Patients with Breast Cancer with Residual Ovarian Function: Cases and Lessons Clinical Breast Cancer 2006, 7: 158-161. [PMID: 16800976](https://pubmed.ncbi.nlm.nih.gov/16800976), [DOI: 10.3816/cbc.2006.n.026](https://doi.org/10.3816/cbc.2006.n.026). [Estrogen-Receptor Status and Chemotherapy for Patients With Node-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16609087)Berry DA, Cirrincione C, Henderson IC, Citron ML, DR, Goldstein LJ, Martino S, Winer EP. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Task Force Report: Adjuvant Therapy for Breast Cancer. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 1: s1-26. [PMID: 16507275](https://pubmed.ncbi.nlm.nih.gov/16507275), [DOI: 10.6004/jnccn.2006.2001](https://doi.org/10.6004/jnccn.2006.2001). - Winer E. Should there be guidelines for the treatment of metastatic breast cancer: the U.S. perspective European Journal Of Cancer Supplements 2006, 4: 179. [DOI: 10.1016/s1359-6349(06)80458-1](https://doi.org/10.1016/s1359-6349(06)80458-1). [Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement](http://www.ncbi.nlm.nih.gov/pubmed/16467115)Come SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement Clinical Cancer Research 2006, to Underuse of Surveillance Mammography Among Breast Cancer Survivors Journal 85-94. MG, Zeng D, Winer EP, Carey LA, Smith JK. Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Treatment of Postmenopausal Women with Early Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/19803930)Ligibel JA, Winer EP. Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer Women's Health 2006, 2: 89-97. [PMID: 19803930](https://pubmed.ncbi.nlm.nih.gov/19803930), [DOI: 10.2217/17455057.2.1.89](https://doi.org/10.2217/17455057.2.1.89). [Early Breast Cancer (Stage I Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer](https://doi.org/10.1007/978-3-540-28266-2_17)Krop I, Winer E. Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer 2006, 327-348. [DOI: 10.1007/978-3-540-28266-2_17](https://doi.org/10.1007/978-3-540-28266-2_17). - Lin NU, Gelman R, Winer EP. Dose Density in Breast Cancer: A Simple Message? Journal Of The National Cancer EP. Standards for follow-up care of patients with breast The Breast 2005, 14: 500-508. [PMID: 16288876](https://pubmed.ncbi.nlm.nih.gov/16288876), [DOI: 10.1016/j.breast.2005.09.001](https://doi.org/10.1016/j.breast.2005.09.001). - Kornblith AB, Regan MM, Kim Y, Greer G, Parker B, Bennett S, Winer E. Cancerrelated communication between female patients and male partners scale: a study CA, Kulke MH, Fuchs CS. Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy Journal Of Every-2-Week Adjuvant Breast Cancer Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/16293865)Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy 8340-8347. [PMID: postmenopausal women: a therapeutic advance but many unresolved questions](http://www.ncbi.nlm.nih.gov/pubmed/16457700)Ligibel JA, Winer EP. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions Breast Cancer Research 2005, 7: 255. [PMID: radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/16243442)Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer International Journal Of Radiation Oncology Biology Physics 2005, 64: 496-504. [PMID: 16243442](https://pubmed.ncbi.nlm.nih.gov/16243442), [DOI: 10.1016/j.ijrobp.2005.07.975](https://doi.org/10.1016/j.ijrobp.2005.07.975). [Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret](http://www.ncbi.nlm.nih.gov/pubmed/16242898)Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret Patient Education And Counseling 2005, 63: 104-109. [PMID: 16242898](https://pubmed.ncbi.nlm.nih.gov/16242898), [DOI: 10.1016/j.pec.2005.09.006](https://doi.org/10.1016/j.pec.2005.09.006). [Quality of life among patients with Stage II and III breast carcinoma randomized to receive highdose chemotherapy with autologous bone marrow support or intermediatedose chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/16118805)Peppercorn J, Herndon J, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E, Group T. Quality of life among patients with Stage II and III breast carcinoma randomized to receive highdose chemotherapy with autologous bone marrow support Society for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16157938)Lyman GH, Giuliano AE, Somerfield AB, AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Journal HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/16150805)Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based Suppression for Breast Cancer: An Effective Treatment in Search of a Home Journal Of Clinical Oncology A Analysis](http://www.ncbi.nlm.nih.gov/pubmed/15998905)Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis [PMID: 15998905](https://pubmed.ncbi.nlm.nih.gov/15998905), [DOI: 10.1200/jco.2005.02.964](https://doi.org/10.1200/jco.2005.02.964). - Partridge Wong J, Knudsen K, Gelman R, Sampson E, Gadd M, Bishop K, Harris J, Winer E. Offering participants results of a clinical trial: sharing results of a negative study American Journal Of Ophthalmology 2005, 139: 1153. [DOI: 10.1016/j.ajo.2005.04.010](https://doi.org/10.1016/j.ajo.2005.04.010). - Peppercorn J, Blood E, Winer E, Partridge A. Pharmaceutical involvement in breast cancer clinical trials Journal Of Clinical Oncology 2005, 23: 6057-6057. [DOI: 10.1200/jco.2005.23.16_suppl.6057](https://doi.org/10.1200/jco.2005.23.16_suppl.6057). [Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG](https://doi.org/10.1200/jco.2005.23.16_suppl.620)Citron M, Berry D, Cirrincione C, Livingston R, Gradishar W, Perez E, Muss H, Norton L, Winer E, Hudis C. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, [DOI: 10.1200/jco.2005.23.16_suppl.620](https://doi.org/10.1200/jco.2005.23.16_suppl.620). [Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V](https://doi.org/10.1200/jco.2005.23.16_suppl.687)Partridge A, Gelber S, Gelber R, Goldhirsch A, Winer E. Delayed premature menopause following chemotherapy for early stage breast cancer: Long-term results from IBCSG Trial V Journal 10.1200/jco.2005.23.16_suppl.687](https://doi.org/10.1200/jco.2005.23.16_suppl.687). [Optimizing women with early stage breast cancer: A decision analysis for biological subsets of tumors](https://doi.org/10.1200/jco.2005.23.16_suppl.529)Burstein H, Winer E, Kuntz K, Weeks J, Punglia R. Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors Journal Of Clinical Oncology 2005, 23: 529-529. [DOI: 10.1200/jco.2005.23.16_suppl.529](https://doi.org/10.1200/jco.2005.23.16_suppl.529). [Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342](https://doi.org/10.1200/jco.2005.23.16_suppl.545)Harris L, Perou C, Szallasi Z, Eklund A, Carter You F, Broadwater G, Monovich L, Winer E, Erlander M, Ellis M. Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342 HER2 extracellular domain of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840](https://doi.org/10.1200/jco.2005.23.16_suppl.558)Seidman A, Broadwater G, Carney W, Dressler L, Berry D, Norton L, Hudis C, Winer E, Ellis M, Harris L. Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): Winer E, Stark N, Weeks JC, Paskett E. Economic outcomes of breast cancer survivorship: CALGB study 79804 Breast Cancer [DOI: Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. Journal Of The National Comprehensive Cancer Network 2005, 3: 238-89. [PMID: 16002000](https://pubmed.ncbi.nlm.nih.gov/16002000), [DOI: 10.6004/jnccn.2005.0015](https://doi.org/10.6004/jnccn.2005.0015). - Thompson D, O'Sullivan A, Stokes M, Montoya E, Earle C, Winer E, Kulig K, Weinstein M. PCN13 SURVIVAL AND COST FOLLOWING BREAST CANCER RECURRENCE: ESTIMATES FROM SEER-MEDICARE DATA Value In Health 2005, 8: 347. [DOI: 10.1016/s1098-3015(10)62919-1](https://doi.org/10.1016/s1098-3015(10)62919-1). - Partridge AH, Winer EP. Fertility After Breast Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L, B F. Adjuvant Chemotherapy in Older and Younger Women With Lymph Node-Positive Breast Cancer K, Gelman R, Sampson E, Gadd M, Bishop KL, Harris JR, Winer EP. Offering participants results of a clinical trial: sharing results of a negative study The Lancet 2005, HER2: That Is Weeks JC. Patient Utilities for Advanced 2005, 43: 173-181. [PMID: 15655431](https://pubmed.ncbi.nlm.nih.gov/15655431), [DOI: 10.1097/00005650-200502000-00011](https://doi.org/10.1097/00005650-200502000-00011). [Prognosis after local conservative surgery and radiation for early-stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/15667952)Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer International Journal Of Radiation Oncology 61: 348-357. [PMID: 15667952](https://pubmed.ncbi.nlm.nih.gov/15667952), [DOI: 10.1016/j.ijrobp.2004.06.011](https://doi.org/10.1016/j.ijrobp.2004.06.011). [The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries](http://www.ncbi.nlm.nih.gov/pubmed/15693926)Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E. The association of ambulatory care with breast cancer stage at diagnosis among medicare beneficiaries Journal Of General Internal Medicine 2005, 20: 38-44. Jahanzeb M, Venook AP, KM, Rivera JA, Dibella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in Phase I/II clinical anthracyclines and other systemic therapies in the management of advanced breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/15717740)Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Shapiro CL, Park JW, Colbern GT, AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer Seminars In Oncology 2004, 31: Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004](http://www.ncbi.nlm.nih.gov/pubmed/15545664)Winer Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004 Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP. Web-Based Survey of Fertility Issues in Young Women With Breast Cancer Journal Of Clinical Oncology with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15342805)Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer New England Journal Of Medicine 2004, 351: 971-977. [PMID: for therapy in breast cancer: Small molecule tyrosine kinase inhibitors Breast weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC](https://doi.org/10.1200/jco.2004.22.14_suppl.512)Seidman A, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Norton L, Winer E, Hudis C. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 10.1200/jco.2004.22.14_suppl.512](https://doi.org/10.1200/jco.2004.22.14_suppl.512). Burstein H, Overmoyer Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Winer E. Rebeccamycin analog for refractory breast cancer: a randomized phase II Journal 22: 547-547. [DOI: 10.1200/jco.2004.22.14_suppl.547](https://doi.org/10.1200/jco.2004.22.14_suppl.547). Blood Dees C, Kaelin C, Weeks J, Emmons K, Winer E. Accuracy of risk perceptions of women with ductal carcinoma in situ Journal Of Clinical Oncology 2004, [DOI: 10.1200/jco.2004.22.14_suppl.6034](https://doi.org/10.1200/jco.2004.22.14_suppl.6034). Sampson E, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer E. Fertility outcomes in young women with breast cancer: A Web-based survey Journal Of Clinical Oncology cancer subjects with visceral disease](https://doi.org/10.1200/jco.2004.22.14_suppl.628)Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral Clinical Oncology 2004, 22: 628-628. [DOI: 10.1200/jco.2004.22.14_suppl.628](https://doi.org/10.1200/jco.2004.22.14_suppl.628). [The predictive value of and on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342](https://doi.org/10.1200/jco.2004.22.14_suppl.9562)Lin Broadwater G, Dressler L, Schnitt S, Lara J, Bleiweiss I, Ngo T, Miron A, Winer E, Harris L. The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from 9840: of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC](https://doi.org/10.1200/jco.2004.22.90140.512)Seidman A, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Norton L, Winer E, Hudis C. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 10.1200/jco.2004.22.90140.512](https://doi.org/10.1200/jco.2004.22.90140.512). Burstein H, Overmoyer Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Winer E. Rebeccamycin analog for refractory breast cancer: a randomized phase II Journal 22: 547-547. [DOI: 10.1200/jco.2004.22.90140.547](https://doi.org/10.1200/jco.2004.22.90140.547). Blood Dees C, Kaelin C, Weeks J, Emmons K, Winer E. Accuracy of risk perceptions of women with ductal carcinoma in situ Journal Of Clinical Oncology 2004, [DOI: 10.1200/jco.2004.22.90140.6034](https://doi.org/10.1200/jco.2004.22.90140.6034). Sampson E, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer E. Fertility outcomes in young women with breast cancer: A Web-based survey Journal Of Clinical Oncology cancer subjects with visceral disease](https://doi.org/10.1200/jco.2004.22.90140.628)Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral Clinical Oncology 2004, 22: 628-628. [DOI: 10.1200/jco.2004.22.90140.628](https://doi.org/10.1200/jco.2004.22.90140.628). [The predictive value of and on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342](https://doi.org/10.1200/jco.2004.22.90140.9562)Lin Broadwater G, Dressler L, Schnitt S, Lara J, Bleiweiss I, Ngo T, Miron A, Winer E, Harris L. The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from Piccart M, Winer E. Introducing Breast Cancer Research's updates on clinical trials Breast Cancer Research 2004, [PMCID: PMC468662](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC468662), [DOI: 10.1186/bcr810](https://doi.org/10.1186/bcr810). [Failure in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342](http://www.ncbi.nlm.nih.gov/pubmed/15169793)Winer EP, Berry DA, Woolf S, Duggan D, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342 10.1200/jco.2004.08.048](https://doi.org/10.1200/jco.2004.08.048). [Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants](http://www.ncbi.nlm.nih.gov/pubmed/15100341)Partridge AH, Hackett N, Blood E, Gelman R, Joffe S, Bauer-Wu S, Knudsen K, Emmons K, Collyar D, Schilsky RL, Winer EP. Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants Journal Of The National Cancer Institute 2004, 96: 629-632. Therapy for Metastatic Breast Cancer: A C, Hudis C, Norton L, Winer E, Gradishar W, Davidson N, Martino S, Livingston R, Ingle J, Carpenter J, Hurd D, Holland J, Smith B, Sartor C, Leung E, Abrams J, Schilsky R, Muss H. In Reply: Journal Partridge AH, Winer EP. Long-Term Complications of Adjuvant Chemotherapy for Early Stage Breast Cancer Breast Disease 2004, 21: 55-64. [PMID: 15687723](https://pubmed.ncbi.nlm.nih.gov/15687723), [DOI: 10.3233/bd-2004-21108](https://doi.org/10.3233/bd-2004-21108). [Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. Journal Of Clinical 817-825. late effects of treatment and surviorship issues in early-stage breast carcinoma Seminars In Oncology 2003, cancer](https://doi.org/10.1016/s1359-6349(03)90429-0)Harris Kuter I, Borges V, Kaelin C, Bellon Preoperative trastuzumab and active regimen for Her2 3+/FISH+stage II/III breast cancer European Journal Of Cancer Supplements 1: s121. [DOI: 10.1016/s1359-6349(03)90429-0](https://doi.org/10.1016/s1359-6349(03)90429-0). [Trastuzumab breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.](http://www.ncbi.nlm.nih.gov/pubmed/12885806)Burstein HJ, Harris LN, breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. Journal Of perceptions and decisionmaking among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses](http://www.ncbi.nlm.nih.gov/pubmed/12833555)Bluman LG, Rimer BK, Sterba Clark S, Borstelmann N, Iglehart JD, Winer EP. Attitudes, knowledge, risk perceptions and decisionmaking among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and as Treatment for Refractory Breast Cancer: A Phase II Study Breast Cancer Research Treatment 2003, 79: 391-397. [PMID: 12846423](https://pubmed.ncbi.nlm.nih.gov/12846423), [DOI: for metastatic breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/12784331)Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumabbased therapy for metastatic assessment working group update: use of aromatase inhibitors in the adjuvant setting.](http://www.ncbi.nlm.nih.gov/pubmed/12732612)Winer EP, C, AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. Journal Clinical Oncology Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. Journal Of Clinical Oncology 2003, inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. Journal Of The National Comprehensive Cancer Network 2003, 1: 215-21. [PMID: 19768880](https://pubmed.ncbi.nlm.nih.gov/19768880), [DOI: PK, Winer EP. Do Patients Participating in Clinical Trials Want to Know Study Results? Journal Of The National Cancer Institute 2003, of oral bexarotene for patients with metastatic breast cancer. Journal two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12637464)Buzdar A, O'Shaughnessy J, Booser DJ, Pippen PN, Peterson P, AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. Journal Of Clinical Avorn J. ABSTRACTS REPRINTED FROM JOURNAL OF CLINICAL scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.](http://www.ncbi.nlm.nih.gov/pubmed/12668651)Citron ML, Berry DA, Cirrincione C, Hudis Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study](http://www.ncbi.nlm.nih.gov/pubmed/12506169)Burstein HJ, Harris LN, Gelman R, RL, CA, J, Winer Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study Journal Of [PMID: 12506169](https://pubmed.ncbi.nlm.nih.gov/12506169), [DOI: 10.1200/jco.2003.03.124](https://doi.org/10.1200/jco.2003.03.124). [Second on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.](http://www.ncbi.nlm.nih.gov/pubmed/12538498)Come SE, Buzdar Davidson VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clinical Cancer Research 2003, 9: 443s-6s. [PMID: 12538498](https://pubmed.ncbi.nlm.nih.gov/12538498). - Ligibel JA, Winer EP. Clinical inhibitors. Cancer 2003, 9: 473s-9s. [PMID: 12538503](https://pubmed.ncbi.nlm.nih.gov/12538503). 10.1007/0-387-22621-4_34](https://doi.org/10.1007/0-387-22621-4_34). Avorn J, Wang P, E. RESPONSE: Re: Adherence to Therapy With Oral Antineoplastic Agents Journal Of The National Cancer Institute 2002, 94: [DOI: 10.1093/jnci/94.21.1652-a](https://doi.org/10.1093/jnci/94.21.1652-a). - DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. Journal Of Clinical Oncology 2002, 20: 34s-8s. the splitters take technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Journal technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.](http://www.ncbi.nlm.nih.gov/pubmed/12149307)Chlebowski Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase 363-365. [PMID: 12117402](https://pubmed.ncbi.nlm.nih.gov/12117402), [DOI: 10.1001/jama.288.3.363](https://doi.org/10.1001/jama.288.3.363). [2002 the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology*](http://www.ncbi.nlm.nih.gov/pubmed/12065567)Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology* Journal Of Clinical BRCA Testing: Does Tailoring Make a Difference? Genetic Winer EP. Adherence to Therapy With Oral Antineoplastic Agents Journal Of The National Cancer Institute 2002, as firstline therapy of metastatic breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/11815957)Harris Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, Winer E, Group T. Liposomeencapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as firstline therapy [Side Effects Therapy in Women With Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/11773307)Partridge A, Burstein H, Winer E. Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage New cytotoxic agents and schedules for advanced breast In 2001, E. New cytotoxic agents and schedules for advanced breast cancer Seminars In Oncology 2001, 28: 28: 32-40. [DOI: 10.1053/sonc.2001.26436](https://doi.org/10.1053/sonc.2001.26436). [Knowledge, Satisfaction, and Perceived Cancer Risk among Women Diagnosed with Ductal Carcinoma In Situ](http://www.ncbi.nlm.nih.gov/pubmed/11559456)Bluman L, Borstelmann N, Rimer B, Iglehart J, Winer E. Knowledge, Satisfaction, and Perceived Cancer Risk among Women Diagnosed with Ductal Carcinoma In Situ Journal Of Women's Health 2001, metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/11352965)Burstein H, Kuter I, Campos S, Gelman R, Tribou L, Parker L, Manola J, Younger J, Matulonis U, Bunnell C, Partridge A, Richardson P, Clarke K, Shulman L, Winer E. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast 11352965](https://pubmed.ncbi.nlm.nih.gov/11352965), [DOI: 10.1200/jco.2001.19.10.2722](https://doi.org/10.1200/jco.2001.19.10.2722). [Changes in body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.](http://www.ncbi.nlm.nih.gov/pubmed/11331316)Demark-Wahnefried W, Peterson B, Winer E, Marks L, Aziz N, Marcom P, Blackwell K, Rimer B. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. Journal Of IIIII breast cancer](https://doi.org/10.1016/s0959-8049(01)81029-7)Burstein H, Harris L, Kaelin Parker L, Kuter I, Gadd M, Borges V, Bunnell C, Smith B, and paclitaxel (P) for HER2-overexpressing (HER2+) stage IIIII breast cancer Of Cancer 2001, 37: s146. 10.1016/s0959-8049(01)81029-7](https://doi.org/10.1016/s0959-8049(01)81029-7). trastuzumab in patients with advanced breast cancer](https://doi.org/10.1016/s0959-8049(01)81204-1)Theodoulou M, Campos S, Welles L, Batist G, Winer E, Hudis C. Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer European Journal Of Cancer 2001, 37: s195. [DOI: 10.1016/s0959-8049(01)81204-1](https://doi.org/10.1016/s0959-8049(01)81204-1). - Baidas S, Winer E, Fleming Harris L, Pluda J, Crawford J, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson, Hawkins M, Lippman M, Hayes D. Phase II Evaluation Of Thalidomide In Patients With Metastatic Breast Cancer Journal Of The Peripheral Nervous System 2001, 6: 65-66. [DOI: 10.1046/j.1529-8027.2001.01008-20.x](https://doi.org/10.1046/j.1529-8027.2001.01008-20.x). - Partridge A, Bunnell C, Winer E. Quality of Life Issues Among Women Undergoing High-Dose Chemotherapy for Breast Cancer Breast Disease 2001, 14: 41-50. 15687635](https://pubmed.ncbi.nlm.nih.gov/15687635), [DOI: Farrar ML, Somlo R, Ward JH, Winer EP, Wolff A. 11195418](https://pubmed.ncbi.nlm.nih.gov/11195418). - Burstein HJ, Winer EP. Primary Care for Survivors of Breast Cancer New England Journal Of Medicine 2000, 343: 1086-1094. [PMID: 11027744](https://pubmed.ncbi.nlm.nih.gov/11027744), [DOI: 10.1056/nejm200010123431506](https://doi.org/10.1056/nejm200010123431506). Harris L, Pluda J, Crawford J, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson M, Hawkins M, Lippman M, Hayes D. Phase II evaluation of thalidomide in patients with metastatic breast cancer. Journal Winer E. Letter to the Editor Clinical Breast Cancer 2000, 1: 164-165. [PMID: 11899655](https://pubmed.ncbi.nlm.nih.gov/11899655), [DOI: 10.1016/s1526-8209(11)70117-3](https://doi.org/10.1016/s1526-8209(11)70117-3). - Clark N, Regan K, Winer E, Rimer B, Skinner C. Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2 Journal Of 10.1023/a:1009463905057](https://doi.org/10.1023/a:1009463905057). [Dexrazoxane and of chemotherapy and radiotherapy protectants: a critique.](http://www.ncbi.nlm.nih.gov/pubmed/10784645)Hellmann K, Hensley N, Pfister D. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. Journal E, Skinner C, Futreal P, Culler D, Calingaert B, Clark S, Marcom P, Iglehart J. Testing for Hereditary Breast and Ovarian Cancer in the Southeastern United States Annals Of Surgery 2000, Parker L, Bunnell C, Scheib R, Matulonis U, Garber J, Clarke K, Shulman L, Winer E. Docetaxel administered on a weekly basis for metastatic breast cancer. Journal Of group considerations of patients and oncological providers](http://www.ncbi.nlm.nih.gov/pubmed/10767748)Speice J, Harkness J, Laneri H, Frankel R, Trief P, Finkel J, Spira J, Greenberg D, Rowland J, Holland J. Involving family members in cancer care: focus group considerations of patients and versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/10679652)Dawson N, Conaway M, Halabi S, Winer E, Small E, Lake D, Vogelzang N. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma Cancer 2000, 88: 825-834. [PMID: 10679652](https://pubmed.ncbi.nlm.nih.gov/10679652), [DOI: 10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n](https://doi.org/10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n). [American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.](http://www.ncbi.nlm.nih.gov/pubmed/10506637)Hensley M, Schuchter L, Lindley C, Meropol N, Cohen G, Broder G, Gradishar W, Green D, Langdon R, Mitchell R, Negrin R, Szatrowski T, Thigpen J, VonHoff D, Wasserman T, Winer E, Pfister D. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. Journal study of Doxil and vinorelbine men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.](http://www.ncbi.nlm.nih.gov/pubmed/10561316)Kantoff P, Halabi S, Conaway M, Picus J, Kirshner Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical C, Iglehart J, Prosnitz L. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. Journal [PMID: 10334532](https://pubmed.ncbi.nlm.nih.gov/10334532), a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642.](http://www.ncbi.nlm.nih.gov/pubmed/10334524)Costanza M, Weiss R, Henderson I, Norton L, Berry D, Cirrincione C, Winer E, Wood W, Frei III E, McIntyre O, Schilsky R. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B Hochster H, Chang A, Adamkiewicz B, White R, McGuirt C. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older Annals Of Oncology 1999, 10: 397-402. (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182](https://doi.org/10.1097/00005392-199904010-00708)Kantoff P, Halabi S, Conaway M, Picus J, Kirshner Hars V, Trump D, Winer E, Vogelzang N. HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF 1999, 161: 176.. [DOI: 10.1097/00005392-199904010-00708](https://doi.org/10.1097/00005392-199904010-00708). [Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.](http://www.ncbi.nlm.nih.gov/pubmed/10071299)Bluman L, Rimer B, Berry D, Borstelmann N, Iglehart J, Regan K, Schildkraut J, Winer E. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. Journal 10.1200/jco.1999.17.3.1040](https://doi.org/10.1200/jco.1999.17.3.1040). [Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support](http://www.ncbi.nlm.nih.gov/pubmed/10335560)Winer E, Lindley C, Hardee M, Sawyer W, Brunatti C, Borstelmann N, Peters W. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow intensity using a daily \u00d7 3 schedule with and without filgrastim in patients with metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/9923543)Havlin K, Ramirez M, Legler C, Harris L, Matulonis U, Hohneker J, Hayes D, Winer E. Inability to escalate vinorelbine dose intensity using a daily \u00d7 3 schedule with and without filgrastim in patients with metastatic breast cancer Cancer 9923543](https://pubmed.ncbi.nlm.nih.gov/9923543), [DOI: 10.1007/s002800050864](https://doi.org/10.1007/s002800050864). [Randomized and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal American Vorozole Study Group.](http://www.ncbi.nlm.nih.gov/pubmed/10458218)Goss PE, Winer EP, Tannock IF, Schwartz on of the North American Vorozole Study Grou L. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. Journal Of Clinical M\u00fcller P, Schildkraut J, Winer E. Modeling Risk of Breast Cancer and Decisions about Genetic Testing 1999, 140: 133-203. [DOI: 10.1007/978-1-4612-1502-8_3](https://doi.org/10.1007/978-1-4612-1502-8_3). - Warmuth M, Bowen G, Prosnitz Chu L, Broadwater G, Peterson B, Leight G, Winer E. Complications of axillary lymph node dissection for carcinoma of the breast Cancer 1998, 83: Berry DA. Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes 10372578](https://pubmed.ncbi.nlm.nih.gov/10372578), Winer E, Berry D, Shildkraut J. Overestimation of Hereditary Breast Cancer Risk Annals BRCA2: correlation of mutations with family history and ovarian cancer risk.](http://www.ncbi.nlm.nih.gov/pubmed/9667259)Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal Of Clinical Oncology 1998, E, Tremont S, Lindley C. Cancer Pain Survey Patient-Centered Issues in Control Journal Of Pain And Symptom Management 1998, 15: 275-284. R, Trief P, Finkel J, Spira J, Holland J, Greenberg D, Rowland J. Delivering bad news: the importance of involving family members Patient Education And Counseling 1998, 34: s5-s6. [DOI: 10.1016/s0738-3991(98)00058-5](https://doi.org/10.1016/s0738-3991(98)00058-5). [Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/9552041)Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. Journal Of Clinical E, Bluman L, Lerman C. Informed Consent for BRCA1 and BRCA2 Breast C, Iglehart J, Berry D. P53 Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis European Journal Of Cancer 1998, 34: s26. [DOI: 10.1016/s0959-8049(97)89271-4](https://doi.org/10.1016/s0959-8049(97)89271-4). [796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support](https://doi.org/10.1016/s0169-5002(97)80173-0)Crawford J, Blackwell S, Shoemaker D, Pupa M, Mulhausen T, Herndon J, Winer E, Flynn J, Dempsey H. 796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with Lung Cancer 1997, 18: 205. [DOI: 10.1016/s0169-5002(97)80173-0](https://doi.org/10.1016/s0169-5002(97)80173-0). [Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.](https://doi.org/10.1097/01893697-199715030-00018)DemarkWahnefried W, Hars V, Conaway, Havlin K, Rimer B, McElveen G, Winer E. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Rehabilitation Oncology 1997, 15: 21. [DOI: 10.1097/01893697-199715030-00018](https://doi.org/10.1097/01893697-199715030-00018). [Pharmacokinetics and all-trans acid metastatic breast cancer: a phase L, Warmuth M, Petros W, Winer E. Pharmacokinetics and impact of all-trans retinoic acid in metastatic breast cancer: a phase II K, Rimer B, Winer E. Genetic Testing for Susceptibility to Breast Cancer: Findings from Women's Focus Groups Journal Of Women's Health 1997, 6: 317-327. [PMID: 9201666](https://pubmed.ncbi.nlm.nih.gov/9201666), [DOI: 10.1089/jwh.1997.6.317](https://doi.org/10.1089/jwh.1997.6.317). [Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/9129482)Demark-Wahnefried W, Hars V, Conaway, Havlin K, Rimer B, McElveen G, Winer E. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy American Journal Of Clinical Nutrition 1997, 65: 1495-1501. WINER E. Weight Gain in Women Diagnosed with Breast Cancer Journal Of The Academy Of Nutrition And Dietetics 1997, 97: 519-529. Winer E. A Review of Hereditary Breast Cancer: From Screening to Risk Factor Modification The American Journal Of Medicine 1997, 102: 407-415. [PMID: 9217624](https://pubmed.ncbi.nlm.nih.gov/9217624), [DOI: 10.1016/s0002-9343(97)00093-4](https://doi.org/10.1016/s0002-9343(97)00093-4). Sanchez J, Schildkraut J, Winer E. Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History Journal Of The National Cancer Institute 1997, 89: 227-237. [PMID: 9017003](https://pubmed.ncbi.nlm.nih.gov/9017003), [DOI: 10.1093/jnci/89.3.227](https://doi.org/10.1093/jnci/89.3.227). 10.1007/978-1-4757-2705-0_20](https://doi.org/10.1007/978-1-4757-2705-0_20). C, Rimer B, Georgiade G. Factors Contributing to Patient Satisfaction with Breast Reconstruction Using Silicone Gel Implants Plastic & Reconstructive Surgery 1996, 97: 1420-1426. [PMID: EP. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. The Infusional 1996, S, Winer Vogel Laufman Hutchins B, D, J, J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast vinorelbine (Navelbine) in the treatment of advanced breast cancer. Seminars 1995, 22: 72-8; discussion 78-9. oral vinorelbine in patients with solid tumors.](http://www.ncbi.nlm.nih.gov/pubmed/8083697)Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas SE, Ettinger DS. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. Journal Of Clinical bone marrow Oncology 1994, C, Holmes V, Rimer BK. Silicone controversy: a survey of women with breast cancer and silicone implants. Journal Of The National Cancer Institute 1993, 85: BK. Why women gain weight with adjuvant chemotherapy for breast cancer. Journal Of Clinical Oncology 1993, marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/8501500)Peters W, Ross M, Vredenburgh J, Meisenberg B, Marks L, Winer E, Kurtzberg J, Bast R, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal Of Oncology phase I trial in combination with vinblastine.](http://www.ncbi.nlm.nih.gov/pubmed/1359155)Trump DL, Smith DC, Ellis PG, Rogers MP, Schold a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. Journal Of The National Cancer Institute DC, Schold SC, Rogers MP, Winer EP, Fine RL, of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a 1992, 52: 2456-9. [PMID: 1533174](https://pubmed.ncbi.nlm.nih.gov/1533174). - Brizel D, Winer E, Prosnitz L, Scott J, Crawford J, Moore J, Gockerman J. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy International Journal Of Radiation Oncology Biology Physics 1990, Cadman E. The use of adjuvant chemotherapy for breast cancer in a community practice. Connecticut Medicine 1985, 49: 281-5. [PMID: 3839177](https://pubmed.ncbi.nlm.nih.gov/3839177). - Breast CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 1st, suite ANew Haven, CT 06511 - Breast CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl "}